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Abstract 
The use of in vitro assays to study membrane fusion events has been instrumental in 
discovering the molecular requirements of membrane fusion. The processes involved in 
phagosome-lysosome fusion are not clear. Some intracellular pathogens, such as 
Rhodococcus equi, are able to prevent phagosome-lysosome fusion. Thus, this study 
aimed to develop an in vitro phagosome-lysosome fusion assay to better understand the 
fusion of these two organelles and to understand the molecular mechanisms behind R. 
equi pathogenesis. 
Transfer of biotin-conjugated horseradish peroxidase (biotin-HRP) from lysosomes to 
streptavidin-bead containing phagosomes (sBCPs) was used to measure organelle fusion. 
A protocol for the purification of lysosomes from J774.2 mouse macrophages was 
developed using superparamagnetic iron oxide nanoparticles (SPIONs). Lysosomes were 
enriched with LAMP1 and devoid of EEA1. Biotin-HRP from lysosomes could be detected 
and was able to bind to sBCPs in a binding assay. A protocol for the purification of sBCPs 
from J774.2 cells was also developed. Phagosomes were enriched with LAMP1 and 
contained Rab5, Rab7 and EEA1. Fusion between organelles, in cytosol and in the 
presence of an ATP regenerating system, was not detected and may have been disrupted 
by factors present in pig brain cytosol used to support the vesicle fusion.  
R. equi virulence depends a 90 Kb plasmid harbouring several virulence-associated 
proteins (Vaps). Only one of these, VapA, is essential for virulence but R. equi may have 
additional virulence factors. To identify these potential additional R. equi genes, a R. equi 
gene library was expressed in yeast which were then screened for membrane trafficking 
defects. The screen failed to yield any potential R. equi virulence factors that disrupted 
membrane trafficking in yeast. In a targeted approach, recombinant VapA when fed to 
cells, induced swelling of mammalian cell lysosomes and late endosomes. This activity 
was conferred by the C-terminal core of VapA. VapA induced LAMP1 expression 
suggesting lysosome dysfunction. The effects of VapA were not seen with other R. equi 
Vap proteins.  
This thesis presents the framework for further developing an in vitro phagosome-lysosome 
fusion assay. Secondly, this work builds on our understanding of how R. equi uses VapA 
to survive intracellularly. 
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Chapter 1: Introduction 
1.1 The endocytic pathway 
Intracellular membranes allow the partitioning of cellular components into 
membrane-bound compartments allows for their specialisation for different cell 
functions. Differences in the protein and lipid compositions of such intracellular 
compartments are key for their interaction and function. The plasma membrane is 
the surface at which the cell senses and communicates with its environment. 
Thus, the composition of the plasma membrane is highly regulated. Endocytosis is 
a general term used to described the internalisation of extracellular fluid, particles, 
plasma membrane receptors and solutes through the invagination of the plasma 
membrane. Conversely, exocytosis is the process by which vesicles fuse with the 
plasma membrane and expel their contents into the extracellular environment. In 
endocytosis, part of the plasma membrane is deformed inwards forming a vesicle 
which pinches off and seals through the active process of membrane fission. This 
nascent organelle is termed the early endosome (EE) and will contain a vast range 
of material, including nutrients, signalling receptors, receptor-ligand complexes, 
solutes, fluid, lipids, membrane proteins, bacteria, viruses, cell debris and 
extracellular matrix components. Early endosomes are key sorting stations of the 
cell. It is here that these different cargo are either recycled back to the plasma 
membrane or further trafficked along the endocytic pathway for degradation in the 
lysosome. Typically, 0.5 - 1.8 fold of the plasma membrane is internalised and 
returned to the cell surface per hour (Steinman et al., 1983) and in macrophages, 
the volume of incoming vesicles is 10 times larger than the volume of lysosomal 
compartments (Steinman et al., 1976). Clearly, there must be extensive regulation 
of endocytosis and return of material to back to the plasma membrane if the cell is 
to maintain the correct size and composition. 
The early endosome undergoes extensive remodelling within minutes of its 
formation. This includes the acquisition and removal of membrane proteins, lipids 
and cytoplasmically associated proteins such as Rab GTPases and tethering 
factors such as the class C core endosome vacuole tethering (CORVET) complex 
(Balderhaar et al., 2013). This confers specific functions onto the maturing 
endosome allowing cargo recycling to be kept spatially and temporally separate 
from degradation of macromolecules. A schematic representation of endosome 
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maturation is shown in figure 1.0.  Key regulators of early endosome maturation 
include the GTPase RAB5 and other factors such as its effector protein VPS34. 
During the transition to a late endosomal configuration the EE membrane begins 
to bud inwards forming intraluminal vesicles (ILVs) that contain ubiquitinated 
membrane proteins that have been targeted for degradation (Scott et al., 2014). 
This function is performed by a series of oligomeric protein complexes known as 
endosomal sorting complexes required for transport (ESCRT) proteins (Schuh and 
Audhya, 2014). Concomitantly, Rab5 and its effectors are exchanged for Rab7 
and a different set of effector proteins and lipids such as Rab-interacting lysosomal 
protein (RILP), Rubicon and the HOPS complex (Cantalupo et al., 2001, Sun et 
al., 2010, Balderhaar and Ungermann, 2013). This allows the progression of the 
EE to a late endosome also known as a multivesicluar body (MVB). Early 
endosomes maintain a peripheral location within the cell (dependent on cell type) 
whereas late endosomes begin to move along microtubules towards the 
perinuclear region of the cell where they encounter lysosomes (Loubery et al., 
2008). LEs transiently interact with lysosomes in a series of rapid “kiss and run” 
fusion events and eventually fully fuse with lysosomes to form hybrid organelles or 
endolysosomes (Storrie and Desjardins, 1996). Endolysosomes are thought to be 
distinct from dense core/primary lysosomes, as they do not appear in the same 
fractions as primary lysosomes in isopycnic centrifugation gradients (Bright et al., 
1997). Finally, lysosomes are reformed from hybrid organelles in a process of 
membrane retrieval and the removal and recycling of mannose 6-phosphate 
receptors (M6PRs) back to the Golgi (Luzio et al., 2003). 
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Fig. 1.0 Schematic representation of endosome maturation. The formation of early 
endosomes begins with the invagination of the plasma membrane to partition part of the 
extracellular milieu into a membrane-bound compartment called the early endosome (EE). 
The EE undergoes rapid membrane remodelling and acquires proteins and lipids that 
regulate this process, such as the GTPase RAB5, the lipid phosphatidylinositol 3-
phosphate (PtdIns[3]P) and tethering factors such as early endosomal antigen 1 (EEA1). 
As the EE matures it loses its association with early effectors and acquires proteins such 
as RAB7 and mannose-6-phosphate receptors (M6PRs) that confer a late endosomal 
identity. The late endosome (LE) then fuses with the lysosome to form an endolysosome, 
where it acquires lysosomal hydrolases and membrane proteins such as LAMP1. Finally, 
membrane is retrieved from the endolysosome to reform primary lysosomes.     
Clearly there must be extensive regulation of these processes. However, this 
regulation is susceptible to manipulation by intracellular pathogens (Gruenberg 
and van der Goot, 2006) and genetic deficiencies in genes controlling endocytic 
process can result in a wide range of pathologies (Maxfield, 2014). The stages of 
endosome maturation and pathogen manipulation of intracellular membrane 
trafficking are discussed in greater detail below.  
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1.1.1 Formation of the early endosome 
The invagination and subsequent fission of the plasma membrane to form an early 
endosome is an active process that is highly regulated. Membrane fission is an 
energetically unfavourable reaction, as the removal of one membrane into two is 
counteracted by strong hydrophobic forces that try and maintain the lipid 
membrane structure (Frolov and Zimmerberg, 2010). This is achieved by range of 
fission machinery that acts to overcome this energy barrier and facilitate 
membrane fission. These include clathrin-mediated and clathrin-independent 
mechanisms (Mayor and Pagano, 2007, Doherty and McMahon, 2009). 
Within minutes of early endosome formation proteins associate with the 
cytoplasmic face of the endosome membrane. These proteins are necessary for 
recycling of the endosome contents and remodelling of the endosome membrane 
which define its identity and function. One of these proteins that is associated with 
the early endosome is RAB5. Rabaptin-5, a RAB5 effector protein that that 
promotes the GEF activity of Rabex-5 (Horiuchi et al., 1997), is essential for 
endosome fusion (Stenmark et al., 1995). Rabaptin-5 forms a complex with 
another Rab5 effector, Rabex-5, which acts to catalyse Rab5 nucleotide exchange 
(Horiuchi et al., 1997). After it is activated by Rab5, the Rabaptin-5-Rabex-5 
complex drives its own recruitment to the endosomal membrane and establishes a 
feedback loop whereby GTP associated Rab5 promotes further Rab5 recruitment 
(Lippe et al., 2001) which may help to promote clusters of active Rab5 forming on 
the endosome. Active Rab5 recruits effector proteins such as VPS34/p150 to the 
endosomal membrane (Murray et al., 2002). VPS34 is a phosphatidylinositol 3-
kinase (PI[3]K) that generates phosphoinositide 3-phosphate (PtdIns[3]P) 
(Christoforidis et al., 1999), a key lipid of early endosomal membranes. The 
importance of this lipid is shown in Vps34 knockout mice that display a range of 
defects including disrupted endocytic and autophagic degradation, as well as heart 
and lung problems (Jaber et al., 2012). EEA1 is a large (170 kDa) tethering factor 
that contains two Rab5 binding sites (Callaghan et al., 1999, Simonsen et al., 
1998, Lawe et al., 2000) and a Fab1, YOTB, Vac1 and EEA1 (FYVE) domain 
(Stenmark et al., 1996) that is critical for Rab5 binding (Lawe et al., 2000). EEA1 
binds to PtdIns[3]P lipids on the endosomal membrane and forms a molecular 
complex with Rabaptin-5, Rabex-5 and N-ethylmaleimide-sensitive factor (NSF). 
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This complex then interacts with the soluble-NSF attachment protein receptor 
(SNARE) protein, Syntaxin 13, which may help to drive vesicle fusion (McBride et 
al., 1999). Thus, the generation of different lipids and the recruitment of fusion 
proteins allows the early endosome to interact with other endocytic compartments. 
This is essential for the retrieval of membrane proteins and receptors that need to 
be redistributed to the plasma membrane. 
1.1.2 Sorting of early endosomal cargo 
Early endosomes fuse with each other and pre-existing sorting endosomes. The 
EE contents are either destined for degradation (via lysosomes), rapid retrieval to 
the plasma membrane, or delivery to the endocytic recycling compartment (ERC). 
The mildly acidic pH of the early endosome causes the dissociation of some 
receptor-ligand complexes, allowing receptors to be reused (Mukherjee et al., 
1997). There are two main routes for the sorting of endosomal cargo back to the 
cell surface, a fast and a slow route. Using fluorescent lipid analogues, Hao and 
Maxfield (2000) showed approximately 50 % is returned to the plasma membrane 
within 1-2 minutes suggesting a rapid recycling mechanism. The remaining 50 % 
is returned to the cell surface after 12 min and is trafficked via the ERC. The ERC 
is a tubular compartment that often resides near the Golgi and is associated with 
microtubules (Yamashiro et al., 1984). It is hypothesised that the majority of early 
endosomes mature to form the late endosomes, whereas endosomal tubules form 
ERCs. Transport between the early endosome and ERC may prevent the 
degradation of cargo and most proteins trafficked to the ERC normally return to 
the plasma membrane (Maxfield and McGraw, 2004). Sorting in the ERC is also 
controlled by Rab GTPases, in particular, Rab11. Overexpression of Rab11 in 
HeLa cells disrupted the localisation of the transferrin receptor, which accumulates 
in the ERC (Wilcke et al., 2000) and altered the location of the ERC in the cell 
(Grant and Donaldson, 2009). The exact mechanisms behind Rab11 regulation of 
the ERC are not clear (Horiuchi et al., 1997). 
1.1.3 Late endosome formation 
Following sorting of the contents of the early endosome, the EE begins to mature 
to a late endosome. This is characterised by a series of changes that alters the 
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identity and function of the early endosome and results in a more degradative 
organelle. Soluble cargo that remains at this stage is destined for degradation, 
although retrograde trafficking from the LE to the Golgi has been described. The 
most well characterised examples of retrograde transport are the trafficking of the 
vps10 receptor in yeast (Valls et al., 1987, Cooper and Stevens, 1996, Seaman et 
al., 1997) and mannose 6-phosphate receptors in mammalian cells (Geuze et al., 
1985, Hirst et al., 1998, Diaz and Pfeffer, 1998). This is mediated by the retromer 
complex which is essential for the retrieval of these receptors (Seaman et al., 
1997(Arighi et al., 2004). Retrograde trafficking is also regulated by Rab9, which is 
able to stimulate the transport of MPRs from late endosomes to the trans Golgi 
network (TGN) in a cell free system (Lombardi et al., 1993) and is required for late 
endosome stability (Ganley et al., 2004).  
1.1.4 The Rab5-Rab7 conversion 
Although Rab5 is associated with the EE it must be removed if endosomal 
maturation is to progress, since expression of a constitutively active form of Rab5 
prevents the maturation of the early endosome (Rink et al., 2005) and results in 
the formation of giant organelles that take on characteristics of both early and late 
endosomes (Hirota et al., 2007). GTP-locked Rab5 expression also affects 
lysosome biogenesis and reduces the amount of lysosomes found in dense 
fractions on Percoll gradients (Rosenfeld et al., 2001). For endosomes to mature 
Rab5 must be replaced with Rab7, a dynamic process referred to as the Rab 
conversion or Rab switch (Rink et al., 2005). This is essential to redefine the 
composition of the early endosome to a late endosome by the removal of Rab5 
effectors and the acquisition of Rab7 effectors and other late endosome/lysosome 
associated proteins. As previously described, a Rab5 feedback promotes the 
generation of Rab5 domains on endosomal membranes. Rab5 must be displaced 
and its GTP hydrolysis activity enhanced to promote its own inactivation. One 
model proposes that Rab5 recruits Rab7, which inactivates and supresses Rab5 
activity through a “cut off switch” whereby accumulation of Rab7 reaches a critical 
threshold upon which Rab5 is replaced. Thus, Rab5 is able to facilitate its own 
removal to allow endosomal progression (Del Conte-Zerial et al., 2008). The Rab 
conversion is necessary for the Rab7-mediated recruitment of fusion machinery so 
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that late endosomes can only fuse homotypically with other late endosomes or 
heterotypically with lysosomes. 
1.1.5 Intraluminal vesicle formation 
As the EE matures the surface invaginates to form intraluminal vesicles (ILVs). 
This results in the extracellular domain of membrane proteins being exposed to 
hydrolytic enzymes within the endolysosome and allows for their degradation. This 
process is essential for the sequestering and degradation of signalling receptors 
and is an important mechanism of downregulating cell signalling (Dobrowolski and 
De Robertis, 2012). Late endosomes containing ILVs are also known as a multi-
vesicular bodies (MVBs). This membrane invagination is achieved through the 
actions of a series of protein complexes termed the endosomal sorting complexes 
required for transport (ESCRT) complexes. There are 5 main ESCRT complexes, 
(ESCRT 0, I, II, III and the VPS4 ATPase complex) that each have distinct roles in 
ILV formation (Schmidt and Teis, 2012b). ESCRT 0 is a heterodimer composed of 
two subunits; HRS and STAM1 (Vps27 and Hse1p in yeast). Proteins that are 
ubiquitinated are recognised by this complex and are targeted to ILVs for 
degradation. The ESCRT 0 complex recognises ubiquitin motifs through VHS 
(Vps27p/Hrs/STAM) domains and is recruited to the endosome membrane through 
binding of its FYVE to PtdIns[3]P (Bilodeau et al., 2002). Interaction of the ESCRT 
0 FYVE domain and PtdIns[3]P is essential for recruitment of ESCRT 0 which 
accumulates in the cytoplasm if this domain is mutated (Urbe et al., 2000). ESCRT 
I is a hetero-tetramer composed of TSG101 (vps23), VPS28, VPS37A-C (vps37) 
and MBV12A/MVB12B (Mvb12), known as Vps23, Vps28, Vps37 and Mvb12 in 
yeast, respectively (Kostelansky et al., 2007, Katzmann et al., 2001, Morita et al., 
2007). ESCRT I is recruited from the cytoplasm to the endosomal membrane by 
ESCRT 0 (Ren and Hurley, 2011). ESCRT I also recognises ubiquitinated cargo 
and forms a rigid stalk-like structure that may act to regulate the spacing of other 
ESCRT components and participate in the mechanical aspects of membrane 
remodelling (Kostelansky et al., 2007). ESCRT II is composed of VPS36/EAP45, 
VPS22 (also known as SNF8) and two VPS25/EAP20 proteins, know as Vps36, 
Vps22 and Vps25 in yeast respectively (Babst et al., 2002b). One VPS25 protein 
associates with either VPS36 or VPS22, resulting in a characteristic Y-shaped 
complex (Hierro et al., 2004). VPS36 contains a GRAM-like ubiquitin-binding in 
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EAP45 (GLUE) domain that simultaneously binds ubiquitin, PtdIns[3]P (Slagsvold 
et al., 2005) and ESCRT I via VPS28 (Gill et al., 2007). ESCRT II is required to 
recruit ESCRT III machinery to the endosome membrane. The VPS25 subunit of 
ESCRT II induces a conformational change in the ESCRT III subunit VPS20, 
which then serves as a nucleation point for the assembly of the full ESCRT III 
complex (Teis et al., 2010). ESCRT III is also a hetero-oligomeric complex formed 
from a core of CHMP4 (Snf7 in yeast), along with CHMP6 (Vps20), CHMP2 (Vps2) 
and CHMP3 (Vps24). These four subunits are joined by three accessory proteins, 
CHMP1 (Did2), CHMP5 (Vps60) and Ist1 (Schmidt and Teis, 2012a). ESCRT 
complexes 0, I and II form stable cytoplasmic complexes, whereas ESCRT III 
polymerises from cytoplasmic monomers and only transiently associates with 
endosomes (Henne et al., 2011). ESCRT III has two distinct subcomplexes; 
CHMP4 and CHMP6 bind to the endosomal membrane via a myristoyl group on 
CHMP6. The VPS4 subcomplex then associates with the endosome and allows 
the recruitment of additional proteins (Babst et al., 2002a). CHMP4 is present in 
the highest concentrations in the cytoplasm and the other subunits of the complex 
act to polymerise CHMP4 (Teis et al., 2008). ESCRT III is widely accepted as 
being the main complex responsible for the actual formation of ILVs from 
membrane invaginations and their eventual release into the lumen of the MVB. 
The mechanisms behind this have yet to be elucidated (Schuh and Audhya, 2014). 
The VPS4 complex is the fifth complex of the ESCRTs. VPS4 is a type I AAA-
ATPase and forms a complex with its co-factor LIP5 (VtA1 in yeast). The ESCRT 
III protein VPS2 is needed along with CHMP1A (Did2 in yeast) to recruit VPS4 to 
the ESCRT III complex (Nickerson et al., 2006). The Vps4 complex is assembled 
as two hexameric rings with a central pore. CHMP1A binding to VPS4 activates 
this complex and enhances the ATPase activity of VPS4 (Azmi et al., 2006). Vps4 
then uses the energy from ATP hydrolysis to drive the disassembly and recycling 
of ESCRT III components, pulling each subunit through the Vps4 ring (Odorizzi, 
2015). Vps4 also participates in membrane neck constriction during ILV budding 
(Adell et al., 2014). This is hypothesised to shorten the membrane neck of the 
forming ILV and be a possible mechanism to facilitate membrane scission 
(Saksena et al., 2009). Alternatively, Vps4 may alter the conformational state of 
the ESCRT III proteins to induce membrane scission (Hanson et al., 2008). Thus, 
the ESCRT proteins act in a highly regulated manner target membrane proteins for 
degradation. This process is also interestingly, independent of other endosomal 
 28 
maturation events. Over expression of constitutively active Rab5 does not block 
ILV formation (Wegner et al., 2010) and the vacuolar ATPase (vATPase) is not 
required for ILV biogenesis (Vaccari et al., 2010). Rab7 is not essential for ILV 
formation (Vanlandingham and Ceresa, 2009) but the Rab7 effector Rab-
interacting lysosomal protein (RILP) may facilitate ILV formation as in the absence 
of RILP, ILV numbers are reduced (Progida et al., 2007). Figure 1.2 depicts the 
activity of ESCRTs 0, I, II and III and figure 1.3 shows the activity of the Vps4-Vta1 
complex. 
 
Fig. 1.1. Schematic representation of the ESCRT machinery in intraluminal vesicle 
formation in yeast. ESCRT 0 (brown) initiates the formation of intraluminal vesicles 
(ILVs) by binding to ubiquitinated membrane proteins. ESCRT I (green) associates with 
ESCRT 0 (via the Vps27 subunit) and also binds to ubiquitinated cargo. ESCRT II (blue) 
subunit Vps36 interacts via a GLUE domain with ESCRT II Vps28, ubiquitinated cargo 
and phosphatidylinositol 3-phosphates (PtdIns[3P). Vps25 then serves as a nucleation 
point for the formation of ESCRT III (yellow/orange) which drives inward vesiculation of 
the endosomal membrane. Figure reproduced with permission from (Schmidt and Teis, 
2012b). 
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Fig. 1.2. Schematic representation of the Vps4-Vta1 complex in ESCRT III 
disassembly and ILV formation in yeast. The ESCRT-III subunits Vps24 and Vps2 
terminate assembly of the ESCRT-III filaments (orange) on the endosome surface. Vps2 
together with Did2, Ist1 and Vps60 build a recruitment complex for the AAA-ATPase Vps4 
and its cofactor Vta1. Once assembled, the Vps4 complex (pink) catalyses disassembly of 
the ESCRT-III filament in an ATP-driven reaction. ESCRT-III disassembly terminates each 
round of the MVB pathway, which results in the generation of a cargo-laden 25 nm MVB 
vesicle (50 nm in human cells). Figure and figure legend reproduced with permission from 
(Schmidt and Teis, 2012b). 
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1.1.6 Late endosome acidification  
As the late endosome matures the endosome lumen becomes more acidic. The 
pH of the early endosome is between 6.8 and 6.1 but this drops to 6.0-4.8 as the 
endosome matures (Maxfield and Yamashiro, 1987). This pH drop is essential for 
the proper function of lysosomal enzymes which only operate within a narrow 
range of pH values. The progressive acidification also allows the dissociation of 
receptors and their soluble cargoes.  
This acidification is also manipulated by some bacterial toxins and viral proteins 
which only become active when they are trafficked to EEs, LEs or lysosomes. For 
example, the anthrax toxin protective antigen (PA) is only able to form pores in 
membranes at < pH 6.0 (Koehler and Collier, 1991, Mercer et al., 2010). Similarly, 
endocytosed influenza viral particles require a drop in pH to induce a 
conformational change in the hemagglutinin fusion peptide to facilitate fusion with 
the endosome membrane (Bullough et al., 1994, Durrer et al., 1996). The task of 
acidifying endocytic vesicles is performed by the vacuolar ATPase (vATPase). 
This is a large protein complex that is separated into two domains. The ~650 kDa 
V1 domain is located on the cytoplasmic face of the vesicle membrane and the 
~260 kDa V0 domain is embedded in the membrane. V1 is composed of eight 
subunits (A-H) and is responsible for the ATPase activity of the pump (Forgac, 
2007). V0 in yeast contains 6 subunits (a, b, c, c’ and c’’), whereas c’’ is substituted 
for Ac45 in higher eukaryotes (Supek et al., 1994). The V0 domain is responsible 
for the using the energy of ATP hydrolysis to translocate protons across the 
endosomal membrane to generate a proton gradient. Acidification is regulated by 
the association and dissociation of the vATPase subunits with membrane lipids, as 
well as the different in abundances of the V1 on early and late endosomal 
membranes (Lafourcade et al., 2008). Alternatively, differential expression of 
vATPase isoforms with different proton translocation efficiencies can determine 
the extent to which a membrane-bound compartment acidifies (Kawasaki-Nishi et 
al., 2001). 
Currently, there is some controversy regarding the requirement of the vATPase for 
vesicle fusion. It was hypothesised that vacuole acidification is essential for 
vacuole fusion (Ungermann et al., 1999) and in vitro studies of yeast vacuole 
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fusion suggested that that the V0 subunit is essential for vacuole fusion (Baars et 
al., 2007). The V0 was also suggested to participate in membrane fusion by 
generating a fusion pore (Strasser et al., 2011). However, it is difficult to separate 
requirement for the acidification of the vacuole or the physical presence of the V0 
subunit, as vacuoles of yeast lacking V0 do not acidify. More recently, it was 
demonstrated that it is actually the acidification of the vacuole that is needed for 
membrane fusion, rather than the vATPase per se (Coonrod et al., 2013). Yeast 
vacuoles with a mutant vATPase that lacked a proton translocation function could 
not fuse and vacuole fusion could be rescued through vacuole acidification by an 
exogenous H+ translocating inorganic pyrophosphatase (Coonrod et al., 2013). 
Similarly, in macrophages the vATPase was shown not to be essential for late 
endosome/lysosome fusion, but interestingly, pharmacological disruption leading 
to an increase in lysosome pH did not prevent lysosome fusion (Kissing et al., 
2015). Thus the exact relationship between endosome/vacuole acidification and 
membrane fusion has yet to be fully understood. 
1.1.7 The role of lipids in endosome maturation  
As previously discussed, integral membrane proteins and cytoplasmic effector 
proteins must be removed and exchanged for those that confirm a late endosomal 
identity. The same is true for membrane lipids. Phosphatidylinositides are lipids 
present in low levels in endocytic membranes (Di Paolo and De Camilli, 2006)   
The main lipids that contribute to endosomal identity are PtdIns[3]P and 
phosphatidylinositol 3,5-bisphosphate (PtdIns[3,5]P2), which are associated with 
early and late endosomes/lysosomes respectively (Li et al., 2013). The synthesis 
of these lipids is performed in their subcellular location allowing strict regulation of 
compartment identity (De Matteis and Godi, 2004). The division of different lipid 
species between endocytic vesicles allows the recruitment of vesicle-specific 
effector proteins.  
VPS34 forms a protein complex with other proteins that regulate its kinase activity. 
These include p150 (Vps15 in yeast) and Beclin-1 (Vps30 in yeast), which form a 
core complex that associates with another protein, UVRAG (Funderburk et al., 
2010, Itakura et al., 2008, Thoresen et al., 2010). UVRAG is an activator of the 
HOPS complex, but is sequestered by the RAB7 effector, Rubicon. Thus, upon the 
 32 
switch from RAB5 to RAB7, RAB7 competes with UVRAG for binding to Rubicon, 
causing UVRAG to become released and free to interact with the HOPS complex 
(Sun et al., 2010). Moreover, VPS34 and p150 also bind to inactive RAB7, 
suggesting that RAB7 is able to inhibit VPS34 activity and stop the production of 
PtdIns[3]P (Stein et al., 2003). This intimately links the activation of RAB7 with the 
generation of lipids of the late endosomal membrane. PtdIns[3,5]P2 is synthesised 
by phosphatidylinositol 3-phosphate 5-kinase (PIKfyve, Fab1p in yeast) which 
uses PtdIns[3]P as a substrate to generate PtdIns[3,5]P2 (Sbrissa et al., 1999). 
PIKfyve knockouts are embryonically lethal (Ikonomov et al., 2011) demonstrating 
that this kinase is essential. PtdIns[3]P must first be dephosphorylated to be used 
as a substrate by PIkfyve. This is performed by a family of 3-phosphatases, the 
myotubularins (Robinson and Dixon, 2006), mutations in which are linked to X-
linked neuromuscular disorders and Charcot-Marie-Tooth disease type 4B (Begley 
and Dixon, 2005). Overexpression of myotubularins results in disrupted late 
endosome to lysosome trafficking suggesting that these proteins are also 
important in endosomal maturation events (Tsujita et al., 2004). The production of 
PtdIns[3,5]P2 is a prerequisite for LE/lysosome acidification in lower eukaryotes 
but the situation in yeast and mammals is not so clear (Ho et al., 2015, de Lartigue 
et al., 2009). PIKfyve inhibition in macrophages has recently been shown to 
disrupt phagosome acquisition of lysosomal proteins LAMP1 and cathepsin D but 
acidification appeared unaffected (Kim et al., 2014). PIKfyve also actives ion 
channels on late endosomal membranes. For example, the calcium channel 
TRPML1 is activated by PtdIns[3,5]P2 (Dong et al., 2010) and the lysosomal two 
pore channel TPC-2 (also a calcium channel) is activated by PtdIns[3,5]P2. As 
calcium is known to regulate lysosome fusion (Pryor et al., 2000, Hay, 2007) this 
may be a mechanism by which PIKfyve regulates LE fusion. Some PtdIns[3,5]P2 
binding proteins have been identified including sorting nexin (SNX) 1 (Carlton et 
al., 2004), which is part of the retromer complex and VPS24 (Whitley et al., 2003), 
which is part of the ESCRT machinery. It is likely that other PtdIns[3,5]P2 binding 
proteins will be found that may be involved in endosome maturation. Other lipids 
are also important in endosome maturation. Bis-(monoacylglycero) phosphate, 
also known as lysobisphosphatidic acid (BMP/LBPA, hereon referred to as LBPA), 
is also found on late endosome/lysosomes (Piper and Katzmann, 2007), but in 
greater abundance than phosphaditylinositides. The presence of LBPA in 
membranes promotes inward budding of acidic liposomes in vitro and this 
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invagination process is controlled in vivo by ALIX (bro1 in yeast), a cytosolic 
protein involved in MVB biogenesis (Matsuo et al., 2004)  
1.2 Lysosomes 
1.2.1 Characteristics of lysosomes 
Lysosomes are the terminal compartment in the endocytic pathway and are the 
degradative organelles of the cell. Lysosomes have key roles in membrane 
trafficking, including endocytosis, exocytosis, autophagy and phagocytosis but 
also have other roles such as membrane repair (Reddy et al. 2001). The primary 
role of lysosomes is to degrade the soluble cargo that they receive via fusion with 
late endosomes. Lysosomes contain around 60 acid hydrolyses which degrade a 
diverse range of molecules, including lipids, proteins and carbohydrates (Schulze 
et al. 2009). These enzymes operate within the low pH of the lysosome (4.5-5.0) 
which is maintained the vATPase proton pump (Mellman et al., 1986). By 
sequestering these degradative hydrolases into the lysosome the cell is able to 
regulate the digestion of macromolecules and provide an optimal environment for 
their degradation. This also prevents degradation of the cell itself. If lysosome 
membrane integrity is disrupted the enzymes become inactive in the more alkaline 
cytoplasm. 
Lysosomes appear as dense bodies and are often seen in close apposition to the 
cell nucleus. The size and shape of lysosomes varies between cell types but they 
are generally spherical and 0.5-1 µm in diameter (Mellman et al., 1986). The 
membrane of the lysosome is around 7-10 nm thick (Saftig et al., 2010) and is 
characterised by the presence membrane proteins such as LAMP1 and LAMP2, 
as well as lipids such as LBPA, which is also found in late endosome membranes 
(Kobayashi et al., 1998). There are at least 100 known lysosomal membrane 
proteins (Schroder et al., 2010) with LAMPs, CD-63 and lysosomal integral 
membrane protein (LIMP)-2, amongst the most abundant (Eskelinen et al., 2003). 
Lysosomal membrane proteins are also heavily glycosylated on their lumenal 
domains which is hypothesised to prevent degradation of the lysosome membrane 
by resident hydrolases (Schwake et al., 2013). 
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1.2.2 Lysosomal storage disorders 
Deficiencies in lysosomal hydrolases and lysosomal associated proteins can 
cause a lysosomal storage disease (LSD) either through accumulation of a 
substrate, or perturbation in a related biochemical pathway (Dierks et al. 2009). 
This ultimately disrupts lysosomal function resulting in a wide variety of clinical 
manifestations that includes, but is not limited to; neurological problems, kidney 
damage, blindness and premature death (Ballabio & Gieselmann 2009). Individual 
LSDs are themselves quite rare, but together they are estimated to occur in 1 in 
every 5,000 live births, with the true figure probably higher due to misdiagnosed or 
undiagnosed cases (Fuller et al., 2006). LSDs are almost all due to deficiencies in 
lysosomal hydrolases but there are a few that are caused by deficiencies in non-
enzymatic lysosomal membrane proteins. Thus, the study of LSDs can offer 
insights into lysosome physiology (Platt et al., 2012). As lysosomes play a key role 
in degrading macromolecules, disruption of enzyme activity can result in the 
accumulation of substrates within lysosomes. When lysosomes accumulate high 
levels of substrates this can have a secondary effect and result in the inhibition of 
an further enzymes that are not mutated or genetically deficient. For example, the 
protein degradative capacity of lysosomes in fibroblasts from 
mucopolysaccharidoses I and VI and GM-1 gangliosidosis is disrupted despite 
these cells not suffering from a protease deficiency (Kopitz et al., 1993). 
Lysosomes are an integral part of the autophagy process, of which there are three 
distinct mechanisms of autophagy; macroautophagy, microautophagy and 
chaperone-mediated autophagy (CMA), all of which require lysosomes (Boya et al., 
2013). The rate of lysosome-autophagosome fusion is reduced in most LSDs 
(Ballabio and Gieselmann, 2009). For example, autophagosome-lysosome fusion 
is perturbed in mucolipidosis type III A and multiple sulfatase deficient mouse 
embryonic fibroblasts (Fraldi et al., 2010). The impact of LSDs on microautophagy 
are not clear, despite a recent report that a mouse model of Pompe disease had 
impaired microautophagy (Takikita et al., 2009). CMA is also affected in some 
lysosomal storage disorders. CMA is the direct targeting of cytoplasmic proteins to 
the lysosome for degradation. Substrates are recognised and bound by heat shock 
cognate protein of 70 kDa (hsc70) which delivers proteins to the lysosome surface. 
The hsc70-substrate complex then binds to LAMP-2A and the substrate is 
unfolded and translocated across the lysosome membrane, assisted by a 
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lysosomal form of hsc70 (lys-hsc70) that is present in the lysosome lumen 
(Kaushik and Cuervo, 2008). Danon disease is caused by mutations in LAMP-2A 
and results in defective CMA (Fidzianska et al., 2007). CMA is also affected in 
mucolipidosis type IV. The transient receptor potential mucolipin (TRPML1) 
associates with hsc70 and hsc40 on the lysosomal membrane and might be a 
regulator of CMA. TRPML1 is mutated in mucolipidosis type IV and patients with 
this disease have decreased CMA (Venugopal et al., 2009). Given the role of 
lysosomes in pathogen destruction, it is not surprising that some LSD patients 
have defective clearance of infections. Gaucher disease is caused by a deficiency 
in glucocerebrosidase leading to an accumulation of glucosylceramide in 
macrophages, also called “Gaucher cells” (Platt et al., 2012). Gaucher cells have 
impaired bactericidal activity (Marodi et al., 1995) and non-pathogenic bacteria can 
cause infections in Gaucher patients (Castaneda et al., 2008). These examples 
demonstrate the importance of correct lysosomal function in a variety of different 
cellular processes and cell types.  
1.2.3 Lysosome-endosome fusion 
The final step in endosome maturation is fusion between late endosomes and 
lysosomes, forming a hybrid organelle/endolysosome. This is critical for the 
delivery of lysosomal hydrolases into the acidic lumen of the late endosome. 
Fusion between LEs and lysosomes (and between any two membranes) can be 
described in three stages; vesicle docking, trans-SNARE formation and finally full 
fusion.  
As described previously, the exchange of Rab5 for Rab7 and its effector proteins 
is necessary for late endosome maturation and for LE-lysosome fusion. A complex 
consisting of SAND-1 (Mon1 in yeast) and CCZ-1 has been suggested to act as a 
switch in this process The SAND-1/CCZ-1 complex is able to bind to active Rab5, 
PtdIns[3]P, bind Rab7, remove Rabex-5 from endosomal membranes and interact 
with the HOPS complex (Poteryaev et al., 2010). This allows SAND-1/CCZ-1 to 
couple the removal of Rab5 and the recruitment of Rab7, along with the HOPS 
complex to initiate vesicle tethering and promote vesicle fusion. Additionally, it has 
been shown in yeast that Mon1-Ccz1 functions as a GEF for Rab, promoting the 
exchange of GDP for GTP and thereby activating Rab7 (Nordmann et al., 2010). 
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In mammalian cells SAND1/CCZ-1 has also been shown to be a RAB7 GEF 
(Kinchen and Ravichandran, 2010) and this role has been confirmed in 
Arabidopsis thaliana (Cui et al., 2014). 
The HOPS complex is a oligomeric protein tethering complex consisting of 6 
subunits, Vps41, Vps18, Vps39, Vps11, Vps16 and Vps33. Consistent with a role 
in mediating membrane fusion between Rab7 positive compartments, the HOPS 
complex is able to bind Rab7 through Vps39 and Vps41 at either ends of the 
complex with a SNARE binding domain (Vps39) between the two (Brocker et al., 
2012). The HOPS complex has been shown to have affinity for different 
phosphatidylinositide lipids including PtdIns[3]P and PtdIns[3,5]P2 (Stroupe et al., 
2006). It is interesting that SAND-1/Ccz1 can bind both PtdIns[3]P and the HOPS 
complex (Poteryaev et al., 2010). Moreover, the interplay between the Rab7 
effector Rubicon and UVRAG, an activator of the HOPS complex (Sun et al., 
2010) may be a mechanism that links Rab conversion with tethering between LEs 
and lysosomes. 
Once LEs-lysosomes have been brought together in close proximity there must be 
correct SNARE pairing if membrane fusion is to proceed. SNAREs (soluble NSF-
attachment protein receptor, where NSF stands for N-ethylmaleimide-sensitive 
factor) are a group of proteins that act as docking and fusion machinery between 
lipid membranes and drive fusion between them. SNAREs are identified by a 60-
70 amino acid heptad repeat called a SNARE motif (Fasshauer et al., 1998a). 
Most SNAREs have a C-terminal transmembrane domain that is connected to the 
SNARE motif by a short flexible linker (Jahn and Scheller, 2006). Monomeric 
SNARE proteins are unstructured but when present in the correct combination, 
four SNARE proteins assemble into a intertwined coiled-coil structure that is 
extremely stable (Fasshauer, 2003). Within the central hydrophobic core of the 
complex there are conserved residues – three glutamines and one arginine. These 
are used to divide the SNARE proteins into two groups, Q-SNAREs containing 
glutamine and R-SNARES containing arginine (Fasshauer et al., 1998b). SNAREs 
on opposing membranes then interact to form the helical bundle that brings vesicle 
membranes in close apposition. Although it has not been proven, it is widely 
accepted that this is most likely the driving force behind membrane fusion (Chen 
and Scheller, 2001). The SNARES are thought to “zip” together from their N-
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terminal ends and that the formation of this extremely stable complex pulls the 
membranes together, excluding water molecules and allowing mixing of the 
hydrophobic lipid layers (Sutton et al., 1998). However, there are also reports that 
suggest SNAREs are not the final step in membrane fusion. Disruption of SNARE 
formation with a blocking antibody has been reported not to affect vacuole content 
mixing in a cell-free yeast vacuole system (Ungermann et al., 1998). An alternative 
hypothesis is that SNAREs may be involved in vesicle docking which may cause 
lysosomal calcium release. This is sensed by the calcium binding protein 
calmodulin, which binds tightly to vacuole membranes and could trigger mixing of 
the lipid bilayers (Peters and Mayer, 1998, Schekman, 1998). Finally, cis SNARE 
complexes must be dissociated if SNARES are to be reused in additional rounds 
of vesicle fusion. This process requires the ATPase NSF and α-SNAP (soluble 
NSF attachment protein) to disassemble SNARE bundles back into individual 
monomers (May et al., 2001). In the mammalian endosomal system, evidence for 
the identity of the SNAREs necessary for LE-Lysosome or lysosome-lysosome 
fusion has come from an in vitro fusion study (Pryor et al., 2004). This determined 
that Syntaxin 7, Vti1b and Syntaxin 8 form the Q a/b/c SNAREs and that Vamp7 
and Vamp8 are the R-SNAREs that mediate heterotypic fusion (between late 
endosomes and lysosomes) or homotypic fusion (between two lysosomes), 
respectively (Pryor et al., 2004). 
Interestingly, in vitro studies of yeast vacuole fusion have also demonstrated a 
proof reading ability of the HOPS complex which recognises incorrect SNARE 
pairings and inhibits vacuole fusion (Starai et al., 2008). Sec1/Munc18 (SM) 
proteins are essential for vesicle fusion and interact with cognate SNARE proteins 
to accelerate vesicle fusion (Yu et al., 2013). The HOPS subunit Vps33 itself is an 
SM protein that binds to SNARE bundles (Lobingier and Merz, 2012). However, 
the proof reading ability of the HOPS complex is conferred by the complex as a 
whole, not via Vps33 alone (Starai et al., 2008). HOPS itself does not promote 
trans SNARE formation but ensures that SNARE assemble in the proper 3Q:1R 
configuration (Solinger and Spang, 2013). This provides an additional layer of 
regulation in ensuring fusion only occurs between correctly paired vesicles and 
suggests the HOPS complex participates in the fusion reaction. 
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1.2.4 Lysosome biogenesis 
Clearly lysosome homeostasis is essential for proper cell function. While there is 
still some debate as so whether newly formed lysosomes are synthesized de novo 
or made by retrieving membrane from other organelles, studies in recent years 
have shed light on the mechanisms behind lysosome biogenesis. 
In a study of the promoter region of lysosomal genes, it was found that many 
shared a 10 bp palindromic repeat (GTCACGTGAC) that was present either as a 
single or in tandem repeats. This motif was named the coordinated lysosomal 
expression and regulation (CLEAR) element. It was subsequently shown that the 
transcription factor EB (TFEB) binds to this element and regulates lysosomal gene 
expression. TFEB belongs to the MiT/TFE subfamily of basic helix-loop-helix 
(bHLH) transcription factors (Steingrimsson et al., 2004).  Over expression of this 
protein in HeLa cells led to an upregulation of mRNA of lysosomal genes as well 
as an increase in the number of lysosomes (Sardiello et al., 2009). TFEB directly 
regulates the expression of 471 genes encoding lysosomal hydrolases, membrane 
proteins, autophagy genes and non-enzymatic proteins associated with lysosome 
biogenesis (Palmieri et al., 2011). TFEB also regulates the expression of some 
non-lysosomal genes. These include N-acetylglucosamine-1-phosphotransferase 
(GlcNAc-P) and members of the biogenesis of lysosome related organelles 
complex (BLOC) family, BLOC1-3 and Hermansky-Pudlak syndrome genes (HPS) 
HPS1, HPS3 and HPS5 (Palmieri et al., 2011). GlcNAc-P is responsible for adding 
mannose 6-phosophate residues to lysosomal hydrolases in the Golgi. Mutations 
in this enzyme which prevent it from recognising lysosomal enzymes cause the 
lysosomal storage disorder mucolipidosis IIIC (pseudo-Hurler polydystrophy 
(Raas-Rothschild et al., 2000). Similarly, mutations in HPS genes causes 
Hermansky-Pudlak syndrome in which patients are deficient in lysosome-related 
organelles such as melanocytes and platelet granules (Nazarian et al., 2003). 
Some of these TFEB regulated genes, such as UVRAG, are involved in autophagy 
and lysosome biogenesis (Liang et al., 2006). TFEB has also shown to be a 
regulator of autophagy, providing a link between autophagy and lysosome 
biogenesis (Settembre et al., 2011). Recently, it has been demonstrated that 
TFEB is a master regulator of proteostasis and that its upregulation in Gaucher 
disease fibroblasts helped to increase folding and activity of a mutated lysosomal 
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hydrolase suggesting TFEB could be used as a therapeutic target in lysosomal 
diseases (Song et al., 2013). It has also been reported that some lysosomal genes 
implicated in lysosomal storage disorders are also under the control of circadian 
rhythms which may have important implications in enzyme replacement therapy 
(ERT) used to treat these conditions (Mazzoccoli et al., 2015).    
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1.3 Phagocytosis 
Macrophages and other immune cells eliminate foreign particles and invading 
microorganisms by internalising them into a membrane bound organelle called the 
phagosome (Vieira et al., 2002). The phagosome matures through a series of 
sequential interactions with endocytic organelles and eventually fuses with the 
lysosome. This process is highly analogous to endosome maturation and involves 
many of the same regulatory and effector proteins (Fig. 1.4). 
 
Fig. 1.3 Schematic representation of phagosome maturation. Phagocytic cells 
internalise microbes or foreign particles into membrane bound compartments called 
phagosomes (early phagosome). The early phagosome undergoes extensive membrane 
remodelling and acquires proteins and lipids that regulate this process, such as the 
GTPase Rab5 the lipid phosphatidylinositol 3-phosphate (PI3P) and tethering factors such 
as early endosomal antigen 1 (EEA1). As the early phagosome matures to a late 
phagosome, it loses its association with early effectors and acquires proteins such as 
Rab7, mannose 6-phosphate receptors (M6PRs) and the vATPase proton pump. The late 
phagosome then fuses with the lysosome to form a phagolysosome, where it acquires 
lysosomal hydrolases and membrane proteins such as LAMP1. Finally, membrane is 
retrieved from the phagolysosome in a process of lysosome reformation. 
 41 
1.3.1 Initiation of phagocytosis 
Phagocytic cells can be loosely classified as being professional, paraprofessional, 
or non-professional phagocytes, based upon their high, medium or low phagocytic 
capacity, respectively (Rabinovitch, 1995). For simplicity, only professional 
phagocytic cells of the immune system (such as macrophages) will be discussed 
further. The initiation of phagocytosis is very much dependent upon the particle or 
microbe being internalised but begins with the interaction of a ligand and cognate 
receptor present on the cell surface. These ligands are present on the surface of 
the bacteria or particle being internalised or on cells of the body that need to be 
cleared, such as phosphatidylserine present on the surface of apoptotic cells (Wu 
et al., 2006). Given the vast array of particles or microbes that cells could 
encounter there are a wide range of receptors that recognise different ligands. In 
the case of bacteria or other microbes, pattern-recognition receptors (PPRs) 
interact with pathogen-associated molecular patterns (PAMPs) which are present 
on the surface of the phagocytic particle (Janeway, 1992). These can include 
molecules such as mannans present in the yeast cell wall which are recognised by 
mannose receptors (Ezekowitz et al., 1990). Other ligands include the 
lipopolysaccharides (LPS) of Gram negative bacteria, that is recognised by the 
CD14 receptor (Schiff et al., 1997) or lipoteichoic acids of Gram-positive bacteria 
recognised by the CD204 receptor (Thomas et al., 2000). These are known as 
non-opsonic phagocytic ligands as they are present on the surface of the 
phagocytic particle. Alternatively, host-derived proteins may coat the pathogen or 
particle being internalised which is termed opsonic phagocytosis (Aderem and 
Underhill, 1999). The most well studied opsonic ligands are immunoglobulin G 
(IgG) and complement factor C3bi. IgG antibodies display specificity towards 
particular surface epitopes and are recognised by Fcγ receptors of which there are 
6 in humans; FcγRI, FcγRIIA, FcγRIIB, FcγRIIC, FcγRIIIA and FcγRIIIB (Freeman 
and Grinstein, 2014). In contrast, C3bi binds non-discriminately to the surface of 
foreign particles and is recognised by the complement receptor CR3 (Wright et al., 
1987). Crosstalk and synergy between different phagocytic receptors that 
recognise the same ligand further complicates the understanding of phagocytic 
processes (Aderem and Underhill, 1999). Upon ligand binding, signalling cascades 
are initiated that result in the recruitment of the cytoskeleton and other 
components such as GTPases, protein kinases, phospholipases and motor 
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proteins to the site of phagocytosis (Freeman and Grinstein, 2014). This results in 
the internalisation of the phagocytic particle. 
1.3.2 Parallels to endosome maturation 
Phagocytic maturation has many parallels to endosome maturation but it is 
important to remember that the receptors used to initiate phagocytosis may 
influence the progression and maturation of phagosomes differently. Immediately 
after the sealing of the phagosome its membrane composition is much like that of 
the plasma membrane. The phagosome at this stage posses no microbiocidal 
activity and must be modified to achieve this. This maturation depends on 
interactions with early endosomes and eventually late endosomes and lysosomes, 
resulting in the formation of the phagolysosome which has the degradative 
capacity needed to digest the contents of the phagosome (Vieira et al., 2002). 
Interactions between phagosomes and endocytic organelles becomes apparent 
immediately after phagosome formation (Pitt et al., 1992, Mayorga et al., 1991) 
and has been recapitulated  in vitro (Jahraus et al., 1998, Desjardins et al., 1994, 
Desjardins et al., 1997). The selective nature of phagosome interactions with early 
endosomes mirrors in vitro homotypic endosome fusion (Mills et al., 1998). 
Although a lot is understood about endosome maturation the molecular 
mechanisms behind phagosome maturation are not as well characterised. Despite 
this, the molecular events behind phagosome maturation are likely to mirror those 
in endosome maturation. Early phagosomes acquire early endosomal markers 
such as Rab5 (Duclos et al., 2000) and EEA1 (Pitt et al., 1992, Fratti et al., 2001). 
These are important in phagosome maturation as persistence of Rab5 on the 
phagosomes of Mycobacterium tuberculosis  (M. tuberculosis) and loss of Rab5 
on the phagosomes of Legionella pneumophila (L. pneumophila) prevents their 
maturation (Clemens et al., 2000).   
1.3.3 The Rab conversion in phagosome maturation 
The RAB5-RAB7 conversion is likely to play a key role in phagosome maturation 
but this has not yet been proven. In mammalian cells, RAB5 has been shown to be 
recruited to phagosomes in a manner that requires active PI[3]PK, but the 
recruitment of RAB5 was not essential for the appearance of RAB7 on phagosome 
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membranes (Vieira et al., 2003). RAB7 itself however is not sufficient for fusion 
between phagosomes and lysosomes (Vieira et al., 2003). RAB7 is likely to play a 
role in linking phagosomes to the actin cytoskeleton and trafficking them towards 
lysosomes, a process mediated by its effector protein RILP (Harrison et al., 2003). 
However, Rab7 has been shown to be important in both early and late phagosome 
maturation in Dictyostelium (Rupper et al., 2001), suggesting that these 
mechanisms may differ slightly in higher and lower eukaryotes. The HOPS 
complex, a Rab7 effector, is another likely candidate in phagosome maturation. In 
C. elegans, the HOPS subunit Vps41 is thought to have a role in removing Rab5 
from phagosomes and functions before Rab7 acquisition by phagosomes. In the 
same study it was shown that RNAi knockdown of the HOPS complex subunits 
prevented phagosome maturation (Kinchen et al., 2008).  
1.3.4 The role of protein sorting in maturing phagosomes 
Akin to recycling in early endosomes, components of the plasma membrane have 
been shown to be recycled from phagosomes. Rab coupling protein (RCP) 
interacts with both Rab11 and Rab4 to regulate membrane recycling from 
phagosomes (Damiani et al., 2004). Furthermore, the loss of plasma membrane 
components (such as Fcγ receptors) from late phagosomes has been suggested 
to be due to recycling from phagosomes (Pitt et al., 1992). 
The role of intraluminal vesicle formation in phagosome maturation is not clear but 
may be of importance. ILV formation is regulated by the ESCRT proteins. The M. 
tubercuolosis effector proteins EsxH, binds to the ESCRT protein Hrs. 
Furthermore, EsxH forms a complex with another effector protein, EsxG, to disrupt 
ESCRT function and prevent bacterial delivery to the lysosome (Mehra et al., 
2013). In yeast, expression of the L. pneumophila effector protein VipA, disrupts 
ILV formation by binding to Bro1 (Franco et al., 2012). Bro1 is the yeast orthologue 
of ALIX, a protein involved in MVB formation (Odorizzi, 2006). LBPA is thought to 
have a role in ILV formation. LBPA is present in phagosomal membranes (Vieira et 
al., 2003) and is able to promote inward budding of pure liposomes in vitro 
(Matsuo et al., 2004). LBPA also has a role in cholesterol transport from late 
endosomes (Kobayashi et al., 1999). Moreover, in macrophages where cholesterol 
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transport was pharmacologically inhibited, phagosome-lysosome fusion was 
impaired (Huynh et al., 2008).  
1.3.5 The involvement of SNARES in phagosome maturation 
As with late endosome-lysosome fusion, the fusion between phagosomes and 
lysosomes is likely to be mediated by SNAREs. In vitro LE/lysosome fusion 
involves the Q-SNAREs Syntaxin7, Vti1b and Syntaxin 8 and the R-SNARE 
Vamp7 or Vamp8 (LE-lysosome and lysosome-lysosome fusion respectively) 
(Pryor et al., 2004). It is likely that these proteins are involved in phagolysosome 
formation and Vti1 and Vamp7 have been found on Dictyostelium phagosomes 
(Gotthardt et al., 2002). Syntaxins 2, 3 and 4 have also been found on 
macrophage phagosomes (Hackam et al., 1996) and SNAP-23 (also a SNARE 
protein) has been found in phagosome membranes and is implicated in 
phagosome maturation (Sakurai et al., 2012). Syntaxin 7 and 13 have been found 
on phagosomes, although Syntaxin 13 is associated more with recycling 
compartments and is rapidly removed from phagosome membranes (Collins et al., 
2002). Recombinantly produced SNARE proteins lacking transmembrane domains 
(solSNARES) cannot support vesicle fusion reactions but inhibit them by binding to 
SNAREs present on vesicle membranes. In an in vitro phagosome-lysosome 
fusion assay, a combination of solSNARES Syntaxin 7, Vti1b and Syntaxin 8 were 
able to inhibit fusion reactions suggesting these SNARES are involved in 
phagosome-lysosome fusion (Becken et al., 2010). 
1.3.6 Phagosome acidification 
As with endosome maturation, the pH of the phagosome decreases as it matures. 
The most commonly used marker of a functional phagosome is this drop in pH as 
it allows lysosomal hydrolases to become active, facilitating the digestion of 
phagocytosed particles (Kinchen and Ravichandran, 2008). This is performed by 
the vATPase which is rapidly recruited to phagosomes after their formation (Pitt et 
al., 1992). The acidic pH of the phagolysosome also supports the generation of 
reactive oxygen species (ROS), such as nitric oxide, which is particularly 
damaging to pathogens and is a key part of innate immunity (Kotsias et al., 2013). 
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In Dictyostelium the vATPase appears to be delivered to the phagosome through 
fusion with vATPase containing endosomes (Clarke et al., 2002). In mammalian 
cells this is not so clear, as the vATPase is synthesised in the Golgi and is 
delivered to the phagosome along with cathepsins (Fratti et al., 2003). The 
vATPase has also been shown to be retrieved from phagosome membranes 
during exocytosis (Clarke et al., 2010).   
1.2.7 LAMP proteins and phagosome maturation 
LAMP1 and LAMP2 are heavily glycosylated integral membrane proteins with 
currently undefined functions, but LAMP2 has recently been shown to be involved 
in chaperone mediated autophagy (Eskelinen et al., 2003). Loss of both LAMP1 
and LAMP2 results in embryonic lethality in mice. In LAMP1-/- and LAMP2-/- mouse 
embryonic fibroblast model, it was shown that these proteins were required for 
phagosome maturation. While phagocytic uptake in these cells proceeded as 
normal, phagosomes failed to acquire Rab7 and accumulated the early 
phagosomal lipid PtdIns[3]P (Huynh et al., 2007).   
Clearly there is much overlap between the molecular mechanisms governing 
phagosome and endosome maturation events. Phagosome maturation is highly 
regulated and disruption of this regulation can prevent the interaction between 
phagosomes and lysosomes. The proteins that regulate these processes are often 
targetted by the effector proteins produced by intracellular pathogens.   
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1.4 Pathogen manipulation of intracellular membrane traffic 
Intracellular pathogens by their definition must be able to modulate or disrupt host 
cell defences if they are to survive intracellularly. Once phagocytosed, a bacteria is 
destined for destruction in the lysosome unless it escapes into the host cell 
cytoplasm or is able to disrupt events in membrane trafficking that arrest 
phagosome maturation. For a pathogen to be successful, it must be able to avoid 
the immune system of its host. It is striking however, that some bacteria actually 
seek out host immune cells and actively encourage their uptake into the host cell. 
This may seem counterintuitive, but the intracellular lifestyle has several 
advantages. Firstly, by being intracellular a pathogen is afforded protection from 
the rest of the immune system and avoids circulating antibodies and humoral 
factors. Secondly, the phagosome provides a replicative niche with a supply of 
nutrients for bacterial growth. Thirdly, it may allow dissemination of the pathogen 
throughout the rest of the host and in some cases can facilitate transmission 
between hosts. The intracellular niche is one that is intriguing, but can also shed 
light on the mechanisms that underlie host cell biology. By studying intracellular 
pathogens and understanding how they manipulate host cells it is possible to 
unravel novel mechanisms in membrane trafficking and other cellular functions. 
To prevent delivery to the lysosome a pathogen could opt to escape the 
phagosome and reside in the host cell cytoplasm. This would also prevent the host 
cell from presenting foreign bacterial or viral peptides from the endosomal system 
on the cell surface via MHC class II molecules (Roche and Furuta, 2015), leading 
to the T-Cell activation and induction of host cell apoptosis (Mogensen, 2009). 
However, immune surveillance of the cytoplasm is carried out by specialised 
cytosolic PPPs such as retinoid acid-inducible gene I-like receptors (RLRs) (Loo 
and Gale, 2011) which recognise viral RNA and nucleotide-binding oligomerization 
domain-like receptors (NLRs) which recognise bacterial ligands (Franchi et al., 
2009). Activation of these receptors induces a cascade of proinflammatory 
cytokines and chemokines which can activate the inflammasome and induce host 
cell death (Latz et al., 2013). Furthermore, host cell autophagic machinery can 
induce autophagosome formation around cytosolic bacteria, leading to their 
sequestration and eventual delivery to the lysosome, a process which has recently 
been termed xenophagy (Bauckman et al., 2015). Some intracellular bacteria such 
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as Shigella have adapted to a cytoplasmic lifestyle and actively downregulate 
autophagy to avoid this (Ogawa et al., 2005). 
A prerequisite of being an intracellular pathogen is the production of proteins or 
lipids that interfere with host cell function. If a pathogen is within a phagosomal 
compartment then effector proteins or lipids must either exert their effect from 
within the phagosome or they must be actively translocated across the 
phagosome membrane where they become active in the cytoplasm. The latter is 
achieved by secretion systems. These are specialised bacterial protein complexes 
that are responsible for exporting a variety of virulence proteins outside of the 
bacterial cell. Two of these secretion systems, the type III secretion system (T3SS) 
and type IV secretion system (T4SS) are unique in that they span both the 
bacterial cell envelope and host cell membranes (Costa et al., 2015). Many 
intracellular bacterial use these systems to deliver many different effector proteins 
into the host cell cytoplasm. For example, Legionella pneumophila is thought to 
have over 300 different effector proteins that it uses to disrupt host cell function 
(Segal, 2013). Bacterial effector proteins effect phagosome maturation by 
interacting with many different regulators of membrane trafficking, including Rab 
and Rho GTPases, phosphoinositide lipids, multisubunit tethering complexes and 
the actin cytoskeleton (Ham et al., 2011).  While there are many intracellular 
bacteria, the classical and most well studied include Salmonella, Legionella, 
Yersinia, Leishmania, Shigella, Chlamydia and Mycobacterium species (Hueck, 
1998). 
1.4.1 Salmonella 
Salmonella enterica is a Gram-negative facultative intracellular pathogen that has 
over 2500 different serovars and causes a variety of pathologies ranging from 
gastroenteritis to systemic typhoid fever (Coburn et al., 2007). Salmonella is 
phagocytosed and resides within the Salmonella containing vacuole (SCV). 
Salmonella uses a variety of T3SS substrates to regulate the fusion of this 
compartment with early and late endosomes, but it remains unclear whether or not 
the SCV also fuses with lysosomes (Knodler and Steele-Mortimer, 2003). The 
SCV has been shown to acidify (Rathman et al., 1996), acquire lysosomal proteins 
such as LAMPs (Steele-Mortimer et al., 1999) but does not acquire mannose 6-
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phosphate receptors and cathepsin delivery to the SCV is delayed (Garcia-del 
Portillo and Finlay, 1995).  
The effector protein SopB is a phosphatidylinositol phosphatase (PI-P) that has 
multiple roles in host cell invasion and maturation of the SCV. SopB catalyses the 
hydrolysis of PtdIns(4,5)P2 present on the cell surface. This promotes bacterial 
uptake at the site of SCV formation by promoting membrane fission through 
reorganisation of the actin cytoskeleton (Hernandez et al., 2004, Terebiznik et al., 
2002). By hydrolysing PtdIns[4,5]P2  SopB indirectly recruits RAB5 to the SCV 
surface by maintaining high levels of PtdIns[3]P. This in turn recruits the Rab5 
effector VPS34 which increases PtdIns[3]P levels further. Low levels of 
PtdIns(4,5)P2 reduces the negative charge on the SCV membrane preventing the 
recruitment of RAB35 and RAB23 to the SCV and inhibiting SCV-lysosome fusion 
(Mallo et al., 2008). A schematic of this is depicted in figure 1.5.  
A characteristic of SCVs is the formation of Salmonella induced filaments (Sifs). 
These are tubular protrusions of the SCV that contain LAMP1, the vATPase and 
LBPA and so are thought to be of late endocytic origin (Srikanth et al., 2011). The 
effector protein SifA is essential for tubulation of the SCV. SifA binds to the kinesin 
binding protein SKIP (Diacovich et al., 2009). The correct position of the SCV and 
the formation of SifA filaments/tubules is essential for bacterial replication and 
maintaining the integrity of the SCV (Ham et al., 2011). The SCV also moves 
along microtubules towards the microtubule organising centre (MTOC). This 
process requires the recruitment of the RAB7 effector RILP and the dynein motor 
complex by the effector SseF, which acts with SifA and SseG to regulate the 
juxtanuclear positioning of the SCV (Abrahams et al., 2006).  
Interestingly, Salmonella may also modulate host cell-gene expression. The 
effectors SptP and SspH1 are involved in the downregulation of interleukin-8. 
Moreover, SspH1 enters the nucleus and disrupts NF-κB-dependent gene 
expression. This suggests that the suppression of inflammation is crucial for 
Salmonella infections (Haraga and Miller, 2003). 
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Fig. 1.4 Modulation of the SCV by SopB. Salmonella actively translocates the type III 
secretion substrate SopB, from the Salmonella-containing vacuole (SCV) into the host cell 
cytoplasm. SopB is a phosphatidylinositol phosphatase (PI-P) that hydrolyses 
phosphatidylinositiol 4,5,bis-phosphate (PI(4,5,)P2) to phosphatidylinositol 3-phosphate 
(PI(3)P). This has the effect of recruiting RAB5 which in turn recruits its effector protein 
phosphatidylinositol 3-phosphate- kinase (PI(3)PK). This generates more PI(3)P. The 
decrease in PI(4,5,)P2 levels on the SCV membrane reduces the negative charge on the 
membrane surface, preventing the association of RAB35 and RAB23 on the SCV and 
inhibiting SCV-lysosome fusion. 
1.2.5 Mycobacterium tuberculosis 
Mycobacterium tuberculosis (M. tuberculosis) is a Gram-positive bacterium that 
resides inside alveolar macrophages and causes tuberculosis. M. tuberculosis 
arrests phagosome maturation at an early endosomal stage and is positive for 
RAB5 and does not fuse with the lysosome (Kumar and Valdivia, 2009). The 
mycobacterial cell wall is composed of unique lipids such as mannose-capped 
lipoarabinomannan (ManLAM) and trehalose dimycolate (Meena and Rajni, 2010). 
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ManLam is of particular interest due to the fact that it mimics host cell 
phosphatidylinositol and is a potent inhibitor of phagosome maturation. The 
SNARE Syntaxin 6 interacts with EEA1, which is recruited to phagosome 
membranes by the binding of its FYVE domain to PtdIns[3]P (Simonsen et al., 
1999). ManLam insertion into the phagosome membrane prevents association of 
Syntaxin 6. This subsequently blocks membrane trafficking between the Golgi and 
the Mycobacterium phagosome which prevents delivery of LAMPs, lysosomal 
hydrolases and the vATPase (Fratti et al., 2003). 
The secreted effector protein SapM is also involved in intracellular survival of M. 
tuberculosis (Fig. 1.6). SapM is an acid phosphatase that converts PtdIns[3]P to 
PtdIns. The phagosomes of live Mycobacterium continuously remove PtdIns[3]P 
whereas  phagosomes of dead Mycobacterium do not  (Vergne et al., 2005). This 
prevents the association of PtdIns[3]P-interacting proteins necessary for 
phagosome maturation such as EEA1. When added to an in vitro fusion assay, 
SapM was shown to inhibit late endosome-phagosome fusion (Vergne et al., 
2005). Another M. tuberculosis effector protein, Protein tyrosine phosphatase A 
(PtpA) has been shown to be involved in preventing phagosome-lysosome fusion. 
The HOPS complex is a key regulator of SNARE formation and is necessary for 
fusion with the lysosome. When PtpA binds to the HOPS subunit VPS33, resulting 
it its dephosphorylation and inactivation, subsequently preventing phagosome-
lysosome fusion (Bach et al., 2008). Interestingly, PtpA has also been shown to 
have a second function in arresting phagosome acidification. PtpA binds to subunit 
H of the vATPase. The HOPS complex is recruited to the vATPase where PtpA is 
then able to dephosphorylate VPS33 and disrupt the interaction between HOPS 
and the proton pump (Wong et al., 2011). Intriguingly, M. tuberculosis has no 
known means of translocating effector proteins across the phagosomal membrane 
into the host cell cytoplasm. Despite this, effectors such as SapM and PtpA clearly 
have their targets in the cytoplasm. While PtpA has been detected in immuno-
electron microscopy and western blot analysis of macrophages (Bach et al., 2008), 
the mechanisms behind which M. tuberculosis effector proteins reach the cytosol 
remains elusive (Wong et al., 2013). A similar Gram-positive pathogen 
Rhodococcus equi (R. equi) also resides intracellularly in alveolar macrophages. 
R. equi arrests phagosome maturation at the early endosomal stage but the 
mechanisms by which it does so are unclear (Fernandez-Mora et al., 2005).  
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Fig. 1.5 SapM disruption of phagosome maturation. SapM is an acid phosphatase 
secreted by Mycobacterium tuberculosis that crosses the phagosomal membrane 
(through a currently unknown mechanism) and is active in the host cell cytoplasm. M. 
tuberculosis phagosome acquire RAB5 and its effector VPS34, a phosphatidylinositol 3-
phosphate kinase (PI(3)PK). Production of PI(3)P is essential for phagosome maturation 
and fusion with the lysosome. SapM converts phosphatidylinositol 3-phosphate (PI(3)P) to 
phosphatidylinositol (PI) which prevents the acquisition of the PI(3)P binding protein EEA1 
which is needed for maturation of the phagosome. 
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1.5 Rhodococcus equi 
1.5.1 Rhodococcus equi 
Rhodococcus equi, first identified almost 90 years ago (Magnusson, 1923), is a 
Gram-positive mycobacterium found in the soil. Rhodococcus equi grows on a 
variety of substrates forming mucoid salmon-pink colonies after several days of 
growth. The genus is comprised of more than 40 species which are used in a 
range of biotechnological applications such as the biodegradation of hydrophobic 
and organic compounds (Larkin et al., 2005). R. equi is the only pathogenic 
Rhodococcus species and is a cause of pneumonia in new born foals up to 6 
months of age but also causes a similar disease in humans (Prescott, 1991). 
Transmission of infection is thought to occur through inhalation of contaminated 
dust or soil particles (Muscatello et al., 2006). R. equi shares some similarities with 
M. tuberculosis such as production of mycolic acid cell wall components (Sutcliffe, 
1998) and causes a similar disease pathology (Yamshchikov et al., 2010). 
Incidence of R. equi disease has been increasingly reported in the literature and R. 
equi may be becoming an emerging pathogen (Weinstock and Brown, 2002). R. 
equi is a substantial economic impact to the equine industry (Muscatello, 2012) 
and is estimated to cost around $2-4 million annually in Australia (Muscatello et al., 
2006). However, the precise worldwide economic cost to the equine industry and 
the healthcare industry is not known.  
1.5.2 Taxonomic status of R. equi 
Currently, there is some controversy regarding the naming of R. equi. Although 
almost every research publication uses the term R. equi, the original description of 
the bacteria was termed Corynebacterium equi (Magnusson, 1923). However, it 
was reported that R. equi should be reclassified as Corynebacterium hoagii 
(Goodfellow and Alderson, 1977). This should take precedence over the name 
Rhodococcus equi as the naming of Corynebacterium hoagii  occurred before that 
of Rhodococcus equi (Tindall, 2014). The situation is further complicated by the 
proposed renaming of Rhodococcus equi to Prescottia equi (in honor of the 
substantial contribution to the R. equi field by John Prescott) and subsequent 
revision of Prescottia to Prescottella (Jones et al., 2013, Goodfellow et al., 2015). 
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Subsequently, there has been much confusion regarding the appropriate naming 
of this bacterium.  
1.5.3 Infection of horses 
Foals aged up to 6 months appear to be susceptible to R. equi infections and the 
mortality rate if left untreated can be as high as 80 %. This is reduced to around 
12 % with antibiotic therapy (von Bargen and Haas, 2009). In horses, R. equi 
causes severe lung abscesses with the formation of granulomas and an influx of 
immune cells into the lungs. More rarely, the infection can also spread to the 
intestines (Prescott, 1991). 
1.5.4 Human infections of R. equi 
The first reported case of R. equi infection in humans was of a man receiving  
immunosuppressive therapy (Golub et al., 1967) and it is thought that transmission 
in humans may be due to exposure to R. equi  through contact with infected 
animals (Weinstock and Brown, 2002). R. equi is an increasingly reported 
zoonosis of immunocompromised patients, such as AIDS patients (Samies et al., 
1986, Shin et al., 1999, De Nardi et al., 2011, Topino et al., 2010) and organ 
transplant patients (Guerrero et al., 2011, Hayes et al., 2011, Munoz et al., 2008). 
Infection in healthy individuals is rare (Hondalus, 1997) but the outcome can be 
fatal in the immunocompetent, even with adequate treatment (Gabriels et al., 
2006). Mortality rates among the immunocompromised varies from 25%-55%, 
compared to 11 % in the immunocompetent (Kedlaya et al., 2001). Compromised 
cellular immunity is associated with an increase in morbidity in R. equi infections, 
as shown by experiments with T-cell deficient and severe combined 
immunodeficient (SCID) mice which are particularly susceptible to R. equi infection 
(Nordmann et al., 1992, Yager et al., 1991). Treatment of R. equi is with antibiotic 
therapy, but this is difficult due to the low in vivo uptake of these drugs (Berghaus 
et al., 2013) Antibiotic resistance in R. equi has also been reported (Cisek et al., 
2014). 
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1.5.5 Virulence of Rhodococcus equi 
R. equi has been shown to survive and replicate in vitro, within mouse 
macrophages (Hondalus and Mosser, 1994) and human alveolar epithelial cells 
(Ramos-Vivas et al., 2011). Maturation of the Rhodococcus containing phagosome 
(RCV) is arrested after the early endosome stage and RCVs do not fuse with 
lysosomes (Fernandez-Mora et al., 2005). However, it has been reported that 
while R. equi was unable to prevent phagosome-lysosome fusion, the resulting 
hybrid organelle was not as acidic as that of phagolysosomes containing avirulent 
R. equi strains (Toyooka et al., 2005). As such, is it currently not clear how R. equi 
is able to survive intracelluarly. R. equi shares many similarities to M. tuberculosis  
as demonstrated by the similarities in their disease pathologies. Both have mycolic 
acids in the cell wall and sequencing analysis of 1417 R. equi sequences showed 
that 799 (47%) shared homology with genes in M. tuberculosis. These included 
genes for metabolism, lipid biosynthesis, iron acquisition and virulence (Rahman 
et al., 2003). It may be possible to understand M. tuberculosis infection by 
studying the mechanisms by which R. equi survives inside cells. 
The susceptibility of new-born foals to R. equi infection is likely to be due a variety 
of factors, such as the immaturity of their immune system and the decline of 
maternal antibodies. However, R. equi clearly must have virulence factors that 
allow its persistence in the immunocompetent human host. The main focus of 
current research is on the 90Kb virulence plasmid that virulent R. equi strains 
possess, which allows the expression of Virulence associated proteins (Vaps). The 
virulence plasmid contains 64 open reading frames (ORFs). 22 have homology to 
genes of a known function and 3 have homology to genes of unknown function in 
other species. The plasmid also contains a 27.5kb pathogenicity island (PI) 
containing 7 Vap genes all of which have a high degree of homology in their C-
terminus regions to VapA (Takai et al., 2000).  Expression of the Vaps is induced 
when R. equi is exposed to low pH (pH 5.0) (Benoit et al., 2001), H2O2 (Benoit et 
al., 2002) and when cultured at 37 ºC (Byrne et al., 2001). These conditions mimic 
the acidic pH, reactive oxygen species (ROSs) and the higher temperature of the 
macrophage phagosome. These genes are indeed upregulated when R. equi is 
grown inside macrophages (Rahman et al., 2005). Strains which do not posses the 
plasmid are avirulent in a mouse model of virulence (Takai et al., 1996), but 
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addition of constitutively expressed VapA to an plasmid cured strain is not 
sufficient to rescue the full virulent phenotype (Giguere et al., 1999). This suggests 
VapA is not the only virulence factor that R. equi utilises for intracellular survival 
and potential there are chromosomal genes that facilitate persistence. 
1.5.6 Putative virulence factors 
R. equi has several mycobacterial gene families that may have roles in virulence. 
These include three mammalian cell entry (mce) gene clusters and an ESX gene 
cluster, which may have role in mycobacterial pathogenesis (Letek et al., 2010). In 
Mycobacterium, the ESX gene clusters are type VII secretion systems (T7SS) that 
secrete virulence factors (Feltcher et al., 2010). Whether these factors are 
important in R. equi pathogenesis is not clear. R. equi also possess membrane 
damaging toxins such as cholesterol oxidase and a potential phospholipase. 
However, it was recently shown that cholesterol oxidase (ChoE) was not essential 
for intracellular survival of R. equi (Pei et al., 2006). R. equi also has genes with 
homology to M. tuberculosis effector proteins PtpA and PtpB. Similarly, R. equi 
has a gene with homology to M. tuberculosis nucleoside-diphosphate kinase (Ndk) 
which interferes with GTPase function to prevent phagosome maturation (Sun et 
al., 2013). It is not known if these proteins are produced by R. equi or have a role 
in virulence. Other putative virulence factors include the lipids produced by R. 
equi. In a study of R. equi mutants that could not stop their delivery to the 
lysosome, it was found that the length of mycolic acid chains on the bacterial cell 
surface is particularly important for virulence (Sydor et al., 2013). 
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1.6 Research Aims 
Lysosomes have multiple roles in cell functions and in particular in the clearance 
and degradation of pathogenic bacteria. The molecular mechanisms behind 
phagosome-lysosome fusion are not clear and currently there is no suitable means 
of assaying phagosome-lysosome fusion in vitro. The use of in vitro assays in 
understanding fusion events has several advantages. Firstly, the specific 
conditions of vesicle fusion can be easily altered to examine the effect on 
membrane fusion e.g. temperature, salt concentration, etc. Secondly, cell-free 
assays allow membrane fusion to be studied in isolation from the other processes 
of the cell which could influence the results or make their interpretation difficult. 
Finally, specific inhibitors can be used to disrupt the activity of a single protein e.g 
the production of PtdIns[3]P by PtdIns[3]P-kinase can be disrupted by wortmannin. 
The use of in vitro assays of vesicle fusion have been invaluable in the dissection 
of the molecular requirements these events.  Examples of these include fusion at 
the Golgi (Balch and Rothman, 1985, Balch et al., 1987) and fusion of liposomes 
to understand SNARE function (Schuette et al., 2004). In vitro fusion of lysosomes 
and late endosomes resulting in hybrid organelle formation has also been studied 
and shown to require NSF, ATP, physiological temperature, cell cytosol and the 
activity of a Rab GTPase (Mullock et al., 1998). However, there is only one report 
of in vitro phagosome-lysosome fusion (Becken et al., 2010). Thus, the first aim of 
this research is: 
i) develop an in vitro phagosome-lysosome fusion assay to determine the 
molecular requirements behind phagosome-lysosome fusion. 
 Some intracellular pathogens manipulate their trafficking to the lysosome to reside 
within a modified phagosomal compartment. In the case of R. equi, the molecular 
mechanisms behind intracellular persistence and disruption of membrane 
trafficking are not known. Thus, the second aim of this research is: 
ii) Unravel the molecular mechanisms that R. equi uses to survive intracellularly. 
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Chapter 2: General Materials and Methods 
2.1 Chemicals 
All chemicals unless otherwise stated, were of analytical grade and were 
purchased from Sigma or Fisher. 
2.2 Antibiotics  
Stocks of antibiotics were made by dissolving the required amount antibiotic in 
water unless otherwise stated. All stocks were stored at  -20 ºC unless otherwise 
stated. Ampicillin was made at 100 mg/ml in H2O and used at 100 µg/ml. 
Chloramphenicol was made as a 25 mg/ml stock in absolute ethanol and used at 
25 µg/ml. Kanamycin was made at 40 mg/m in H2O and used at 40 µg/ml. 
Gentamycin was made at 20 mg/ml in H2O and used at 150 µg/ml or 10 µg/ml. 
Hygromycin B was stored at 4 ºC as a 50 mg/ml stock (Roche) and used at 100 
µg/ml. 
2.3 Bacterial and yeast culture and media 
All bacterial media was purchased from Oxoid or Formedium, and all yeast media 
was purchased from Formedium, UK, unless otherwise stated. 
All autoclaving was performed at 121 oC at 38.4 psi for 28 min. Bacterial media 
was made as follows: Lysogeny broth (LB), was made by dissolving 10 g of  NaCl, 
10 g of tryptone, and 5 g of yeast extract in 1 L of ddH2O and autoclaved. For LB 
agar, 15 g of agar was added per litre. Brain heart infusion (BHI, Sigma, UK) broth 
was prepared by dissolving 37 g of premade media in 1 L of ddH2O. BHI agar 
(Sigma, UK) was prepared by dissolving 52 g in 1 l ddH2O. SOC media was 
prepared by dissolving 20 g of tryptone, 5 g of yeast extract, 5 ml of 2 M MgCl2 
and 0.5 g of NaCl in 1 l of ddH2O and autoclaving.  After autoclaving the media, 20 
ml of 1 M glucose (sterile filtered) was added. 2TY broth was made by dissolving 
16 g of tryptone, 5 g of NaCl, and 10 g of yeast extract in 900 ml of ddH2O. The pH 
was adjusted to 7.0 with 5 M NaOH, volume made to 1 L, and the media 
autoclaved. 
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All yeast media were made as per the manufacturer’s instructions: For YEP broth, 
30 g of premade YEP (Formedium, Cat # CCM0402) was dissolved in 1l ddH2O. 
For YPD broth, 50 g of premade YDP (Formedium, Cat # CCM0202) was 
dissolved in 1 L ddH2O and then autoclaved. For Synthetic depleted (SD) - ura 
media, 6.9 g of yeast nitrogen base, and 1926 mg of Kaisers dropout mix (– uracil) 
was dissolved in 1 L of ddH2O and autoclaved. Synthetic complete (SC) media 
was made by dissolving 6.9 g nitrogen base and 2002 mg of Kaisers’ complete 
dropout mix in 1 L ddH2O and autoclaved. Agar plates were made by adding agar 
to 1.5 % (w/v) to the required media where appropriate. Sterile glucose or fructose 
(from a 40 % w/v stock) was added to all yeast media after autoclaving, to a final 
concentration of 2 % (v/v) . All bacterial cultures were grown at 37 oC in LB (with 
antibiotics where appropriate) with shaking, unless otherwise stated. R. equi was 
grown in BHI at 30 oC with shaking unless otherwise stated. All yeast were grown 
in non selective media (YEP or YPD, with glucose as the carbon source or 
fructose as the carbon source where CPY-invertase secretion was to be assayed) 
or selective media (SD-Ura) at 30 ºC with shaking, unless otherwise stated.  
2.4 Mammalian cell culture 
All mammalian cell culture (for J774.2, Raw 264.7, NRK, and HeLa cells) was 
performed as following unless otherwise stated. Cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10 % (v/v) FBS, 2 mM 
glutamine and 1 % (v/v) penicillin-streptomycin (10 U/ml and 10 µg/ml 
respectively) in a humidified 5 % CO2 atmosphere at 37 ºC. Where antibiotic 
selection was required, media was supplemented with Hygromycin B (Roche, 50 
µg/ml from a 50 mg/ml stock). 
2.5 DNA extractions 
2.5.1 Plasmid DNA Minipreps from bacteria 
DNA plasmids were routinely extracted from 7.5 ml overnight cultures using the 
Qiagen mini prep kit as per the manufacturers’ instructions. For low copy plasmids, 
the volumes of buffers P1, P2, and P3 were doubled. Where the volume of 
bacterial lysate exceeded the capacity of the column, the remainder was passed 
through the same column.  
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2.5.2 Plasmid DNA Midipreps from bacteria 
DNA plasmids were routinely extracted from 50 ml overnight cultures using the 
Qiagen Midi prep kit as per the manufacturers’ instructions with the following 
modifications. At the final elution step, 500 µl of TE was used to elute DNA, and 
the eluate was passed through the filter disc a second time. 
2.6 DNA electrophoresis 
Agarose gels were prepared by dissolving 0.5- 2.0 % (w/v) agarose in 75 ml in 
TAE buffer (40 mM Tris, 20 mM Acetic acid, 0.5 mM EDTA, pH 8) by heating in a 
microwave until dissolved. Either ethidium bromide (diluted 1:1000 from a 10 
mg/ml stock) or Sybr Safe, used at 1:10,000 (Invitrogen) was added to the melted 
agarose and gently mixed. DNA was electrophoresed at 60 V for approximately 1 
h. DNA was visualised using UV light (ethidium bromide) or a blue light box (Sybr 
Safe), and images captured using a Syngene gel imager and Genesnap software. 
2.7 Purification of PCR products 
PCR products were electrophoresed using an appropriate percentage agarose gel 
containing Sybr Safe DNA stain (1:10,000). DNA bands were visualised on a blue 
light box, and excised from the gel using a sterile scalpel blade. DNA was purified 
from gel slices using the Qiagen gel purification kit, as per the manufacturer’s 
instructions, with the following modifications: 600 µl of buffer QC was used 
regardless of gel slice size, and 200 µl of isopropanol was added to the dissolved 
agarose gel slice. 
2.8 DNA restriction digests. 
All restriction digests were performed in a total volume of 40 µl unless otherwise 
stated. All digests were carried out in 0.5,1, 1.5 or 2 X KGB buffer (10 X KGB, 1 M 
glutamic acid (monopotassium salt), 250 mM Tris acetate, pH 7.6, 100 mM 
magnesium acetate, 0.5 mg/ml bovine serum albumin, 5 mM β-mercaptoethanol), 
depending on the dilution of KGB that gave the highest activity for a particular 
restriction enzyme (McClelland et al., 1988). For plasmid digests, 1 µg of plasmid 
DNA was incubated with 1 µl of the appropriate restriction enzyme for a minimum 
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of 45 min at the appropriate temperature. For overnight digests, a further 1 µl of 
restriction enzyme was added after a 2 h incubation. Digested DNA was analysed 
by gel electrophoresis (section 2.6) and DNA was gel-purified where appropriate 
using a Qiagen gel extraction kit (section 2.7) as per the manufacturer’s 
instructions. 
2.9 Polymerase chain reaction (PCR) 
All PCRs was performed in a Biorad PTC-200 DNA engine cycler unless otherwise 
stated.  
2.9.1 Generation of PCR products for cloning 
For the generation of high-fidelity PCR products for cloning, reactions were set up 
as follows: PCR reactions were performed in a total volume of 50 µl, containing 
37.5 µl of ultrapure 18 Ω H2O,  5 µl of 10X pfu polymerase buffer, 0.5 µl of dNTPs 
(final concentration of 100 µM each of dATP, dTTP, dCTP and dGTP from a 10 
mM stock), 2.5 µl each of forward and reverse primers (final concentration of 0.5 
µM from a 10 µM stock), and 1.0 µl of pfu polymerase (2.5 units). The mixture was 
vortexed, and approximately 10 ng of template DNA was added to the tube, which 
was vortexed again. The PCR programme used for pfu polymerase was as 
follows: template denaturation was performed for 45 seconds at 94 ºC followed by 
primer binding for 45 seconds at 50 ºC (unless otherwise stated). Extension was 
performed for 72 ºC for 1 min per Kb of template length. These steps were 
repeated for a further 29 cycles, with a final extension at 72 ºC for 10 min. 
2.9.2 General PCR 
For general PCR reactions where high-fidelity amplification of the PCR product 
was not required, reactions were set up as follows: All reactions were performed in 
a final volume of 20 µl and contained 11.2 µl of 18 Ω ddH2O, 4 µl of 5X Go Taq 
Flexi polymerase buffer, 0.4 µl of dNTPs (final concentration of 100 µM each from 
a 10 mM stock), 1 µl each of forward and reverse primers (final concentration of 
0.5 µM from a 10 µM stock), 1.2 µl of 25 mM MgCl, and 1.0 µl of Go Taq 
polymerase (1.0 unit). The mixture was vortexed, and approximately 10 ng of 
template DNA was added to the tube, which was vortexed again. The PCR 
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programme used for Taq polymerase was as follows: DNA was denatured at 95 ºC 
for 1 min followed by primer annealing at 50 ºC for 1 min. This was followed by 
extension at 74 ºC for 1 min (per 1 Kb of product). This was performed for 29 
cycles followed by a final extension at 72 ºC for 10 min. 
2.9.3 Colony PCR screening of transformed bacteria 
Colony PCR screening of transformed E.coli colonies was performed as follows: 
bacteria were lifted from an agar plate and spotted onto a fresh plate using a 
sterile pipette tip. The remainder of the colony was added to a PCR reaction as 
section 2.9.2 instead of template DNA. 
2.9.4 Colony PCR screening of R. equi 
For colony PCR of R. equi colonies, template DNA was generated as follows. 
Single colonies of R. equi were resuspended in 20-30 µl of sterile ddH2O and 
heated to 95 ºC for 15 min. The sample was then briefly centrifuged to pellet cell 
debris and 1 µl was taken for use as template DNA. 
2.9.5 Colony PCR screening of transformed yeast 
For colony PCR of yeast, template DNA was generated as follows. Single colonies 
were resuspended in sterile 0.2 % (w/v) SDS and heated to 95 ºC for 15 min. The 
sample was then briefly centrifuged to pellet cell debris and 1 µl was taken for use 
as template DNA. 
2.10 Ethanol precipitation of DNA 
DNA solutions were concentrated by ethanol precipitation. A volume of 3 M 
sodium acetate, pH 5.5, equal to that of 1/10th of the DNA solution was added and 
mixed by inverting the tube several times. 2-3 volumes of 100 % ice-cold ethanol 
was added and mixed gently by inversion to precipitate the DNA. DNA was 
pelleted at 16,000 x g in a microcentrifuge at 4 ºC for 15 min. The supernatant was 
discarded and the pelleted washed with 500 µl of 70 % ethanol (prechilled to -20 
ºC). The solution was centrifuged again for 2 min, and the supernatant carefully 
discarded. The pellet was air dried at room temperature for 10 min, and 
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resuspended in an appropriate volume of TE (10 mM Tris, pH 8.0, 1 mM EDTA). 
DNA was then stored at – 20 ºC until further use.  
2.11 PCR product insertion into vectors 
PCR products were recombined into linearised vectors using In-Fusion HD cloning 
kits (Clontech) as per the manufactuerer’s instructions.  
2.12 Generation of detergent soluble lysates 
Tissue culture cells were rinsed once with phosphate buffered saline (PBS) and 
then cells were scraped into in ice-cold cell lysis buffer (0.15 M NaCl, 20 mM Tris-
HCl, pH 8.0, 2 mM EDTA, 1 % (v/v) NP-40) with EDTA-free protease inhibitors 
(Roche). The lysate was incubated at 4 ºC for 15 min and then centrifuged at 
16,000 x g for 10 min at 4 ºC. Detergent-soluble lysates were retained for 
experiments. 
2.13 Bicinchoninic acid (BCA) protein assay 
Estimation of protein concentrations was carried out using the Pierce Bicinchoninic 
acid assay kit, in a 96 well microplate (Corning NY) as per manufacturer’s 
instructions. 5 µl of 0.2 M NaOH was added to 5 µl of the protein sample. Where 
the concentration of protein was measured, dilutions of protein samples were 
performed with ddH2O where appropriate. A standard curve of 0 - 10 µg was 
prepared using a stock of 1 mg/ml BSA in 0.1 M NaOH. 200 µl of BCA working 
reagent was added to each well and incubated at 37 oC for approximately 30 min. 
The absorbance was read at 570nm on a plate reader. 
2.14 SDS PAGE 
Protein samples to be resolved by gel electrophoresis were prepared by adding  
Laemmli sample buffer (3 X stock 188 mM Tris pH 6.8, 6 % (w/v) SDS, 30 % (v/v) 
glycerol, and 0.03 % (w/v) Bromophenol blue) and heating at 95 oC for 5 min. 
Samples were resolved using discontinuous polyacrylamide gels (lower resolving 
gel and upper stacking gel) using the Bio-Rad minigel apparatus (Mini-PROTEAN 
Tetra cell). Resolving gels were made with acrylamide (Protogel, National 
Diagnostics) at concentrations between 7.5 % (v/v) and 15 % (v/v) using resolving 
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gel buffer (final concentration 0.375 M Tris-HCl, pH 8.8, 0.2 % (w/v) SDS), plus 
ammonium persulfate (APS) at a final concentration of 0.05 % (v/v) and TEMED at 
a final concentration of 0.05 % (v/v).  Stacking gels were made with acrylamide at 
a final concentration of 7.5 % (v/v) plus stacking gel buffer (final concentration 
0.125 M Tris-HCl, pH 6.8, 0.2 % (w/v) SDS). Ammonium persulfate (APS) was 
added to a final concentration of 0.05 % (v/v) and TEMED was added to a final 
concentration of 0.05 % (v/v). Protein samples were resolved at 200 V until the 
bromophenol blue dye front had eluted from the bottom of the gel, or as 
appropriate. A protein ladder (Precision Plus Kaleidoscope ladder, Biorad), was 
used to estimate the molecular mass of proteins. Both the anode and cathode 
running buffer was 25 mM Tris, 0.1 % (w/v) SDS, 192 mM glycine.  For the 
visualisation of proteins using Coomassie staining, gels were rinsed once with 
ddH2O and incubated with Coomassie stain in destain (0.2 % (w/v) Coomassie 
Blue in 10 % glacial acetic acid (v/v), 30 % (v/v) methanol) for 5 min on a shaking 
platform. Gels were rinsed once with destain (30 % methanol, 10 % acetic acid)  to 
removed excess stain, and left in destain for 30 min or until protein bands were 
visible. 
2.15 Western blotting 
Proteins were transferred to nitrocellulose membranes using the iBlot system 
(Invitrogen) as per the manufacturer’s instructions. Alternatively proteins were 
transferred to nitrocellulose membranes equilibrated in transfer buffer  (48 mM 
Tris, pH 8.8, 39 mM glycine, 20 % (v/v) methanol, 0.0375 % (w/v) SDS) using a 
Pharmacia Biotech Nova blot semi-dry transfer apparatus at 1 mA/cm2 for 1.5 h. 
Transferred proteins were visualised by incubating membranes with Ponceau S 
(0.2 % Ponceau S in 3% (w/v) trichloroacetic acid) for 10 seconds and removing 
excess stain with copious amounts of ddH2O. Membranes were then blocked in 
either 5 % (w/v) semi-skimmed milk or 5 % (w/v) BSA in TBS (100 mM NaCl, 10 
mM Tris-HCl, pH 7.4) + 0.1 % (v/v) Tween-20 (TBST) for 30 min at room 
temperature or overnight at 4 oC. Membranes were probed with primary antibodies 
in 5 % (w/v) milk or 5 % (w/v) BSA TBST for 1 h at room temperature or 4 oC 
overnight. Membranes were then washed with TBST (3 x 5 minute washes) and 
incubated with horseradish peroxidase conjugated secondary antibodies in milk or 
 64 
BSA at room temperature for 30 min. Membranes were washed a further 3 times 
with TBST and then proteins were visualised using ECL reagent (Amersham). 
2.16 Immunofluorescence  
Cells were rinsed once with Dulbecco’s PBS (Sigma) and fixed as follows. For 
methanol fixation, cells were incubated at  -20 ºC for 5 min with methanol that was 
prechilled to -20 ºC. Methanol was then removed and coverslips left to air dry and 
stored at 4 ºC overnight, or processed immediately. For formaldehyde fixation, 
cells were rinsed with PBS and fixed for 20 min in 4 % formaldehyde in PBS. The 
formaldehyde was removed and coverslips incubated in 50 mM NH4Cl in PBS for 
10 min. Coverslips were stored in this solution for up to a week at 4 ºC, or 
processed immediately. After fixation, cells were permeabilised (where 
appropriate) in 0.2 % (w/v) BSA, 0.05 % (v/v) Saponin, in PBS, for 10 min. All 
further washes and antibody dilutions were carried out in BSA/Saponin/PBS (BSP) 
solution, unless otherwise stated. For permeabilisation and cytosol extraction of 
cells before fixation, coverslips were treated as follows: coverslips were rinsed 
once with cytosol extraction buffer (CEB, 25 mM HEPES-KOH, pH 7.4, 25 mM 
KCl, 2.5 mM magnesium acetate, 5 mM EGTA (sodium free), 150 mM potassium 
glutamate (monopotassium L- glutamic acid) ) and then incubated in CEB 
containing 0.05 % (w/v) saponin for 30-60 seconds. Cells were then immediately 
fixed with 4% formaldehyde solution. In all cases, coverslips were incubated in 
primary antibody diluted in BSP for 1 h at room temperature, by inverting the 
coverslips into drops of antibody solution on a strip of parafilm (25-30 µl for 10 mm 
round coverslips, 70-80 µl for 22 mm coverslips). Coverslips were washed 3 x 5 
min (minimum) with approximately 1 ml of BSP. Coverslips were then incubated 
with Alexa fluorophore-conjugated secondary antibodies (diluted 1:300 in BSP) for 
30 min, followed by a further 3 x 5 min washes with 1 ml of BSP. For visualisation 
of DNA, 4',6-diamidino-2-phenylindole (DAPI), was included in the final wash 
(used at 1 µg/ml from a 10 mg/ml stock). Coverslips were rinsed once in distilled 
water, blotted dry, and mounted onto slides with MOVIOL 4-88 containing 2.5 % 
(w/v) DABCO (1,4-diazobicyclo [2,2,2]-octane). MOVIOL was prepared as follows: 
2.4 g of MOVIOL 4-88 (Calibiochem) was added to 6 g of glycerol and 6 ml of 
ddH2O and was mixed on a rotating wheel at room temperature for several hours. 
12 ml of 0.2 M Tris (pH 8.5) was added, and the solution heated to 50 ºC for 10 
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min with occasional mixing. After the MOVIOL had dissolved, the solution was 
clarified by centrifugation at  5,000 x g for 15 min, then DABCO was added to 
2.5 % (w/v). The solution was then aliquoted into air tight tubes and stored at – 20 
ºC for long term storage.  
2.17 Image acquisition 
Slides were viewed on a Zeiss LSM 880 Axio Observer.Z1  inverted confocal laser 
microscope running Zen software (2015) or a Zeiss LSM 510 meta Axioplan 2M 
upright confocal laser microscope running Zen software (2009, Carl Zeiss Ltd, 
Germany). Live-cell imaging was performed on a Andor Revolution XD spinning 
disk Axiovert 200M confocal microscope running Andor IQ software (2009), with 
the microscope stage contained within a sealed chamber preheated to 37 ºC. Gain 
and laser powers were set accordingly. All images are single slices or maximum-
intensity Z projections unless otherwise stated. Post-acquisition image processing 
was performed using ImageJ software (Schneider et al., 2012) 
2.18 Fusion protein production 
2.18.1 Fusion protein test production 
Recombinant GST-Myc-VapA and Myc-VapA-His6 fusion proteins were expressed 
in E.coli expression strain BL21 (DE3) pLysS as follows. For initial test production, 
10 ml of LB (plus the appropriate selective antibiotics) was inoculated with a single 
bacterial colony and grown overnight at 37 ºC with shaking at 450 rpm. The 
overnight starter culture was diluted 1:500 into 10 ml of LB and grown at 37 ºC 
with shaking until OD600 0.6-2.0. 5 ml of this culture was then transferred to a new 
tube. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to the remaining 5 
ml, to a final concentration of 0.2 mM. Both cultures were incubated for 4 h. 40 µl 
was taken from each culture for -/+ IPTG samples to be analysed by SDS-PAGE. 
The induced culture was pelleted at 2,465 x g for 10 min at 4 º C. The pellet was 
resuspended in 1 ml bacterial lysis buffer (1 % (v/v) Triton X-100, 1 mg/ml 
lysozyme, 2 mM MgCl2, 1 U/ml DNAse, in PBS) with protease inhibitors (Roche). 
The resuspended bacteria were frozen at -20 ºC. The lysate was defrosted and 
then centrifuged at 16,000 x g for 20 min at 4 ºC in a microcentrifuge. 8 µl of the 
supernatant was taken to represent a detergent-soluble protein sample. The pellet 
 66 
was resuspended in 100 µl of Laemmli sample buffer and 1 µl used to represent 
an insoluble protein sample. 
2.18.2 Large scale fusion protein production 
For large scale production, fusion proteins were grown in 2 x 600 ml of LB or 2TY 
broth as follows: 7.5 ml of LB (plus the appropriate selective antibiotics) was 
inoculated with a single bacterial colony and grown overnight at 37 ºC with 
shaking. The next day, starter cultures were diluted 1:500 into a total volume of 
600 ml LB or 2TY broth, and grown at 37 ºC until an OD600 of 0.6 - 2.0 was 
obtained. Protein production was induced with IPTG to a final concentration of 0.2 
mM, and cultures grown for a further 4 h. The bacteria were pelleted at 2,645 x g 
for 15 min at 4 ºC. The cell pellet was resuspended in 10 ml of bacterial lysis 
buffer (1 % (v/v) Triton X-100, 1 mg/ml lysozyme, 2 mM MgCl2, 1 U/ml DNAse, in 
PBS) with protease inhibitors (Roche), and frozen at -20 ºC overnight. The cell 
pellet was defrosted on ice and centrifuged at 47,800 x g in a Sorvall SS34 rotor 
for 20 min at 4 ºC. For GST fusion proteins, the supernatant was incubated with 1 
ml (packed volume) of glutathione sepharose (GE healthcare) for 1 h at 4 ºC with 
gentle rotation. The sepharose beads were then collected and washed with 3 x 20 
ml of wash buffer (1 % (v/v) Triton X-100 in PBS). GST/GST-fusion proteins were 
eluted with 20 ml elution buffer (50 mM Tris, pH 8.0, 10 mM reduced glutathione), 
and 1 ml fractions collected to determine which fractions the proteins were in. 
Fractions were analysed by spotting 1 µl of each fraction onto 3M chromatography 
paper, which was dried, and then stained with Coomassie stain to see which 
fractions the protein was in. These fractions were then analysed by SDS-PAGE. 
The eluted proteins were then pooled and dialysed extensively into PBS at 4 ºC for 
2 days and stored at -20 ºC until needed. For the purification of His6-tagged 
proteins, cell pellets were processed as above. The soluble supernatant was 
incubated with 134 µl (packed volume) of His-Select resin (Sigma) for 1-2 h at 4 ºC 
with gentle rotation. The beads were washed with 3 x 20 ml wash buffer (10 mM 
imidazole, 0.3 M NaCl, 50 mM Na2HPO4, pH 8.0). Proteins were eluted with 20 ml 
elution buffer (250 mM imidazole, 0.3 M NaCl, 50 mM Na2HPO4, pH 8.0) and 1 ml 
fractions collected. Fractions were analysed by spotting 1 µl of each fraction onto 
3M chromatography paper and analysed by SDS-PAGE as previously described. 
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The eluted proteins were then pooled and dialysed extensively into PBS at 4 ºC for 
2 days and stored at -20 ºC until needed.  
2.19 Immunoprecipitation of proteins 
2.19.1 Antibody purification 
Antibodies raised against a myc epitope were purified from 9E10 mouse 
Hybridoma (Developmental studies Hybridoma bank, University of Iowa, USA) cell 
culture supernatants as follows: cells were brought up from liquid nitrogen stocks 
and cultured in Iscove’s modified Dulbecco’s medium (IMDM, Sigma UK) 
containing 1 % (v/v) penicillin-streptomycin (10 U/ml and 10 µg/ml respectively), 
and 10 % (v/v) Ultra-Low IgG FCS (Thermo). After several days of growth, the 
cells were resuspended in 12 ml of IMDM and 3 ml of Ultra-low IgG FCS. The cells 
were seeded into the lower chamber of a 1 L CELLine disposable bio-reactor 
(Integra, Switzerland). 1 L of serum-free Hyclone ADCF-MAb media (GE 
healthcare, USA) containing 5 % regular FCS was added to the top chamber of 
the bioreactor. After approximately 16 days of continuous culture the cells were 
removed from the bottom chamber and pelleted. The supernatant (containing 
secreted α-myc antibodies) was collected and sterile filtered. ¼ of the cells were 
then used to reseed the flask. 
2.19.2 Antibody coupling 
The IgG-containing supernatants were dialysed extensively against PBS at 4 ºC 
for 2 days Antibodies were covalently coupled to Amino-link beads using the 
Pierce Direct Co-IP kit as per the manufacturer’s instructions. Amino-link beads 
were first washed extensively with PBS. 1 µg of antibody was covalently coupled 
to 1 µl (packed volume) of Amino-link beads, by the addition of 3 µl of 5 M 
NaCNBH4, per 200 µl volume (sepharose and antibody). The suspension was 
rotated gently at 4 ºC for 1-2 h. The beads were gently pelleted at 3,300 x g, and 
washed 3 times with 1 M Tris-HCl, pH 8.0. 0.5 ml of the Tris solution was added 
per 500 µl of packed resin, and then 3 µl of 5 M NaCNBH4 was added per 200 µl 
total volume (sepharose and Tris). The beads were further rotated for 15 min at 
room temperature and then washed 3 times with PBS. The beads were then 
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washed 6 times with 1 M NaCl, followed by 3 washes with PBS. An equal volume 
of mammalian cell lysis buffer (0.15 M NaCl 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 
1 % (v/v) NP-40) was added to create a 50 % slurry, and the resin was stored at 4 
ºC until further use. 
2.19.2 Immunoprecipitation  
Immunopreciptation experiments were performed as follows: Flp In HeLa cells 
expressing Myc-VapA (under the control of an inducible promoter) were induced 
by the addition of 1 µg/ml doxycycline for 16 h. Flp In HeLa cells (not expressing 
any exogenous proteins) were used as a control for non-specific protein 
interactions. Cells were washed once with ice cold PBS and resuspended in 
mammalian cell lysis buffer (0.15 M NaCl, 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1 
% (v/v) NP-40) with protease inhibitors. The lysate was incubated on ice for 15 
min, and then centrifuged at 13,200 x g at 4 ºC for 15 min. The pellet was 
discarded and BCA assay used to estimate the protein concentration of the 
supernatant. The lysate was precleared (to reduce non specific protein binding), 
by incubation (for 1-2 h at 4 ºC with gentle rotation) with a volume of inert control 
sepharose resin equal to that of α-Myc resin. The beads were pelleted and the 
precleared lysate incubated with α-Myc resin at a ratio of 1 mg of lysate per 20 µl 
(packed volume) of α-Myc resin (40 mg lysate, 1600 µl of packed resin). This was 
incubated at 4 ºC for 1-2 h with gentle rotation. The supernatant was removed and 
the beads washed 5 times with 20 ml of lysis buffer. Proteins were eluted by the 
addition of 1 ml of 10 mM Na2HPO4, pH. 7.4, followed by 1 ml of Pierce low pH 
IgG elution buffer. Beads were then incubated with 3 ml of IgG elution buffer for 10 
min at room temp, and then with a further 5 ml for 10 min. 10 ml of eluate was then 
concentrated to 160-200  µl by placing the eluate into a Slide-A-Lyzer cassette 
(3,500 MWCO, Pierce) and then placing the cassette onto Aquacide (a 
hygroscopic powder) for ~ 10 h. 3X Laemmli sample buffer (with 10 % (v/v) β - 
mercaptoethanol) was added and protein samples resolved on a 8-15 % SDS 
PAGE gel run at 12 mA for 16 h (using a BioRad Protean II XL cell). Gels were 
then silver stained using a Pierce silver stain kit as per the manufacturer’s 
instructions.  
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2.20 β-Hexosaminidase Assay 
3-25 µl of sample was incubated with 100 µl of substrate solution (100 mM Citrate 
buffer pH. 5.0 (74 mM Sodium citrate, 37 mM citric acid), 0.5 mM 4-
methylumbelliferyl-2-acetamido-2-deoxy-𝛃-D-glucopyranoside, 0.27 M sucrose) for 
exactly 3 min (samples were added at regular timed intervals). The reaction was 
stopped with 1 ml of 1 M Na2CO3. The estimation of lysosomal latency was 
calculated by assaying the activity of the lysosomal enzyme β-Hexosaminidase, in 
the presence and absence of 0.1 % (v/v) Triton X-100 detergent. Samples were 
measured in a Lumina fluorescence spectrophotometer (Thermo Scientific) at 360 
nm excitation and 443 nm emission. The % latency/intactness of lysosomes was 
calculated as follows: 
β-hex (AU) with Triton X-100 – β-hex (AU) without Triton X-100         X 100 
                                       β-hex (AU) with Triton X-100   
2.1 Antibodies 
The primary and secondary antibodies used in this study are listed in table 2.0 
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Primary Antibodies 
Cat. No. Source Target Target Species 
Dilution 
W.B. IF 
N/a Dr Ashley Toyne LAMP1 Hu   1:1000 
1D4B DSHB LAMP1 Mu 
1:500-
1:5000 
1:500-
1:1000 
C45B10 Cell signalling Tech. EEA1 Mu/Rat/Hu 1:1000   
C8B1 Cell signalling Tech. Rab5 Mu/Rat/Hu 1:1000   
D95F2 Cell signalling Tech. Rab7 Mu/Rat/Hu 1:1000   
DM1A Sigma-Aldrich α-tubulin n/a 1:1000   
610978 
BD Transduction 
Labs GRP78 Hu/Rat/Mu 1:250   
C10456 
BD Transduction 
Labs EEA1 Hu 1:5000   
EPR7691 Santa Cruz cdM6PR Mu/Hu/Rat 1:1000   
EPR6599 Santa Cruz ciM6PR Mu/Hu/Rat 1:1000   
9E10 DSHB myc Myc epitope 1:200 1:200 
VapA Dr.Albert Haas  VapA R. equi 1:1000 1:500 
1001 Prof. J.P. Luzio ciM6PR Rat   1:1000 
 6217 Prof. J.P. Luzio Syntaxin 7 Rab 1:200   
N/a Dr Katherine Bowers PHO8/ALP S. cerevisiae 1:50   
580 Cambridge Lgp110 Rat 1:1000   
MA1-21315 ThermoFisher 6x His n/a 1:1000 1:1000 
8738 Cambridge ciM6PR Rat 
1:1000 - 
1:200 
1:1000 - 
1:200 
MA1-164 ThermoFisher Lgp120 Hu/Mu/Rat 1:500   
Secondary Antibodies/other 
Cat. No. Source Antigen Label Dilution W.B. IF 
405210 BioLegend Biotin 
Streptavidin 
HRP 
1:10,000-
1:40,000   
A9169 Sigma Aldrich α-Rab IgG HRP 1:8000   
A9044 Sigma Aldrich α-Mu IgG HRP 1:8000   
A9542 Sigma Aldrich α-Rat IgG HRP 1:8000   
A21424 ThermoFisher α-Mu IgG AF 555   1:300 
A11029 ThermoFisher α-Mu IgG AF 488   1:300 
A21429 ThermoFisher α-Rab IgG AF 555   1:300 
A11034 ThermoFisher α-Rab IgG AF 488   1:300 
A21434 ThermoFisher α-Rat IgG AF 555   1:300   
Table 2.0 Source and details of antibodies used in this study.  Hu; human, Mu; 
mouse, Rab; rabbit, W.B; western blot, IF; immunofluorescence, AF; Alexa fluor, IgG; 
immunoglobulin G. 
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Chapter 3: Development of an in vitro phagosome-
lysosome fusion assay 
3.1. Lysosome purification 
3.1.1 Introduction 
To set up an in vitro phagosome-lysosome fusion assay, it is necessary to purify 
both phagosome and lysosomes from cells The purification of these lysosomes 
requires a protocol that isolates functional lysosomes, and with a marker that can 
be used to asses fusion. The challenge in purifying endocytic organelles has led to 
the development of a wide range of novel strategies, each with their own 
advantages and disadvantages, which are discussed below. Obtaining fractions 
with a high degree of purity can be cumbersome and time consuming. Lysosomes 
were traditionally isolated by isopycnic centrifugation on sucrose gradients 
(Novikoff et al., 1956, De Duve et al., 1955), but these typically produced 
lysosomal fractions containing contamination from the endoplasmic reticulum 
(ER), peroxisomes and mitochondria, which have overlapping densities in sucrose 
gradients (Beaufay, 1969, Graham, 2001). Furthermore, the density of the 
lysosomes are altered on a sucrose gradient by the efflux of water from the 
lysosomes, since they are subjected to the osmotic stress of the hyperosmotic 
sucrose centrifugation medium. This may render the lysosomes abnormal or non-
functional. Purification by centrifugation is further complicated by the heterogeneity 
of the lysosomal population resulting in subpopulations of lysosomes which display 
different densities (Pertoft et al., 1978). Alternative purification methods include 
altering the density of lysosomes by loading them with a substrate such as Triton 
WR 1339 (Wattiaux et al., 1963),  iron (Glaumann et al., 1975), or gold (Henning 
and Plattner, 1974). However, these methods involve the pre-treatment of animals, 
and significantly alter the lysosome rendering it abnormal (Wattiaux et al., 1978). 
For example, Triton WR 1339 loading results in different enzyme activities 
(Plattner et al., 1975) membrane characteristics compared to normal lysosomes 
(Weglicki et al., 1973). A centrifugation technique using Metrizamide (a medical 
contrast agent used in imaging) allowed better separation of lysosomes from 
mitochondria (Wattiaux et al., 1978). However, the development of newer contrast 
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agents halted the production of Metrizamide, rendering it impractical for long term 
use in lysosome isolation. While better than sucrose, Metrizamide still exerts 
osmotic effects on organelles at densities above 1.2 g/ml (Castle, 2004).  
Lysosomes can also be purified magnetically using superparamagnetic iron oxide 
nanoparticles (SPIONS, Walker, 2015). These are small (<100 nm) iron oxide 
(Fe2O3 or Fe2O4) particles coated in inert and biocompatible polymers, such as 
dextran, which have wide ranging biomedical applications (Wahajuddin and Arora, 
2012). Unlike ferromagnetic materials (those which retain magnetic properties in 
the absence of a magnetic field), SPIONS display magnetic properties, but only 
when in the presence of an externally applied magnetic field (Dave and Gao, 
2009). Colloidal-iron dextran (FeDex) has previously been used to isolate 
lysosomes and other endocytic organelles from a variety of cell types (Rodriguez-
Paris et al., 1993, Diettrich et al., 1998, Becich and Baenziger, 1991, Cardoso et 
al., 2009, Duvvuri et al., 2004). This method can also be used to purify lysosomes 
from the cells of patients with lysosomal storage diseases (LSDs), where the 
abnormal composition of the lysosomes makes purification by density gradient 
centrifugation impractical (Diettrich et al., 1998). Furthermore, the pH of isolated 
lysosomes has been reported to be between 4-6, indicating pH gradients of 
isolated organelles can be retained and that they remain functional (Satori et al., 
2011). FeDex purified organelles are less likely to be contaminated with 
mitochondria or peroxisomes as these organelles would not be labelled during the 
purification protocol. The study of lysosomes in different pathologies is a wide 
ranging field that encompasses many different cell and tissue types. Because of 
this there are numerous publications describing protocols for purification of 
lysosomes that have been heavily optimised for a particular purpose. 
Subsequently, different protocols accept differing levels of contamination from 
other subcellular organelles, or do not require the lysosomes to be intact. 
For an in vitro fusion assay utilising lysosomes from macrophages, there is a 
requirement for an optimised method of isolating lysosomes that is rapid, simple, 
and yields lysosomes that have a high degree of latency. To purify lysosomes, 
cells must first be fractionated in order to separate out the different organelles. 
This must be conducted carefully and optimised depending on the organelle being 
purified, the cell type, and the final use of the organelles. For example, a 
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purification method that yields 90 % of a cell’s lysosomes, but renders them 
broken and non-functional, is of no use if the final application requires intact 
lysosomes capable of fusing with other membranes. Such a protocol would be 
more suited for applications not requiring intact lysosomes, e.g. proteomic 
analysis. Many techniques have been used to disrupt cells, including physical 
disruption (ball-bearing homogenisation, (Balch and Rothman, 1985), passage 
through high-gauge needles, nitrogen cavitation (Kelly et al., 1989), a French 
press, chemical lysis, sonication etc. These all have advantages and 
disadvantages. For example, passage through a needle is widely used to disrupt 
cells, but some cell types remain refractory to this method of fractionations (such 
as J774.2 macrophages, data not shown). Nitrogen cavitation is a rapid, gentle, 
fractionation method that uses nitrogen gas pressure to lyse cells. Unlikely other 
physical disruption methods (such as ball bearing homogenisation), nitrogen 
cavitation does not generate localised friction or heat, which can lead to sample 
degradation. Nitrogen cavitation has been used for lysosome purification (Gottlieb 
and Adachi, 2000, Graves et al., 2008, Sparrow et al., 2008, Ghislat et al., 2012). 
This chapter describes development of a lysosome purification protocol for J774.2 
mouse macrophages, based upon the isolation of colloidal iron dextran-containing 
Dictyostelium lysosomes (Rodriguez-Paris et al., 1993). In brief, J774.2 cells are 
pulse chased with colloidal iron dextran (FeDex), before a gently lysis by nitrogen 
cavitation. A post-nuclear supernatant (PNS) is generated from the lysate, which is 
then applied to a iron column held within a magnetic field. The magnetic field 
retains the iron-containing lysosomes, which are then washed of label-free 
organelles and cell debris. The column is then removed from the magnetic field to 
allow the elution of the lysosomes. In order to use these organelles in an in vitro 
fusion assay, it was important to optimise the protocol to give a high yield of intact 
organelles. Thus, the following experiments were performed with the aim of 
optimising the isolation of a sufficient quantity of intact lysosomes.  
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3.1.2 Lysosome purification specific methods 
3.1.2.1 Colloidal Iron Dextran (FeDex) 
Colloidal iron dextran was made as previously described (Rodriguez-Paris et al., 
1993). Briefly, 5 ml of 1.2M FeCl2 and 5 ml 1.8 M Fe2Cl3 were mixed in a beaker 
and 5 ml of 30 % (v/v) NH4OH was added drop wise, whilst stirring. The precipitate 
was collected on a large permanent magnet and washed once with 5 % (v/v) 
NH4OH and twice with ddH20. Washing was performed by removing the magnet, 
thoroughly resuspending the precipitate, then re-gathering the precipitate using the 
magnet and disposing of the supernatant. The precipitate was resuspended in 40 
ml of 0.3M HCl and stirred. After 30 min, 2 g of dextran (Mr ~ 40,000) was added 
and quickly dissolved, followed by stirring for 40 min. The colloidal solution was 
then dialysed extensively against ddH2O for 2 days at 4 ºC. Large aggregates 
were removed by centrifugation at 26,800 x g for 15 min at 4 ºC in a Sorvall SS-34 
rotor. The supernatant was sterile filtered through a 0.22 µm filter and stored at 4 
ºC for up to 2 months. 
3.1.2.2 Lysosome purification using superparamagnetic iron particles (SPIONS) 
This is the final protocol used to isolate lysosomes. Section 3.3 describes how this 
method was developed. This protocol has been published in: Subcellular 
Fractionation. A laboratory manual. Cold Spring Harbour Protocols 2015 
(Purification of lysosomes using supraparamagentic iron oxide nanoparticles 
(SPIONS). A.P.Rofe and P.R. Pryor) 
J774.2 macrophages were seeded at 6 - 8 x106 cells per 10 cm tissue culture dish 
(Starstedt) in DMEM and cultured overnight. The next day the tissue culture media 
was replaced with FeDex diluted 1:20 in DMEM for a 1 h pulse. FeDex containing 
media was removed and the cells were washed carefully 3 times with warm 
DMEM to remove any remaining extracellular FeDex. Cells were then incubated in 
DMEM for a 2 h chase. The cells were then scraped and pelleted at 1000 x g for 3 
min, washed once in PBS, and resuspended in 1 ml of STM fractionation buffer 
(250 mM sucrose, 10 mM TES (2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl] 
amino] ethanesulfonic acid), pH 7.4, 1 mM MgCl2). Routinely, between 20 and 40 
x 106 cells were resuspended in 1 ml of STM. Cells were fractionated in a nitrogen 
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cavitation vessel (Parr Instrument Company, IL USA, model number Q913534). 
The pressure vessel was prechilled to 4 ºC on ice, and cells were placed under 
pressure for 5 min at 250 psi. The lysate was then eluted into a 50 ml tube with a 
parafilm splash guard. A post-nuclear supernatant (PNS) was generated by 
centrifugation of the lysate at 800 x g for 5 min at 4 ºC. The PNS was then applied 
to a MACS cell column (Miltenyi Biotech, Cat # 130-042-202) held within a 
magnetic MiniMACS separator (Miltenyi Biotech) that had been previously 
equilibrated with 3 ml of ice cold STM buffer. A 23G needle was used to reduce 
the flow rate of the PNS. The PNS was reapplied to the column twice more. The 
column was washed with 3 ml of STM and then removed from the MiniMACS 
separator. FeDex containing lysosomes were then eluted from the column directly 
into an ultracentrifuge tube using 3 ml of STM. The lysosome-containing solution 
was then centrifuged at 37,500 x g for 15 min at 4 ºC in a Beckman TLA-110 rotor. 
The supernatant was discarded and the lysosomal pellet resuspended in 
appropriate volume of STM for subsequent experiments.  
3.1.2.3 Purification of lysosomes by isopycnic centrifugation 
A 4 ml cushion of 45 % (w/v) Nycodenz was loaded into a Beckman Quick-seal 
centrifuge tube at 1 ml/min. 30ml of a 1-22 % (w/v) Ficoll gradient was layered on 
top and left at 4 ºC overnight to settle. The next day, 20 x 106 J774.2 cells were 
fractionated at 250 psi for 5 min on ice in 1 ml of homogenisation buffer (HB, 10 
mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2). Three separate lysates were 
pooled to give a total of 60 x106 cells. 900 µl of restoration buffer (RB, 500 mM 
sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) was added to the lysate and gently 
mixed. The lysate was made to a final volume of 6 ml with STM, and loaded on top 
of the gradient. The centrifuge tube was heat sealed and centrifuged at 241,830 x 
g in a VTi50 rotor, for 1 h at 4 ºC with slow acceleration and deceleration (3 min). 1 
ml fractions were collected from the bottom of the gradient at 1 ml/min at 4 ºC 
using a fraction collector. 25 µl of each fraction was assayed for β-hexosaminidase 
activity, and the refractive index of each fraction was measured on a 
refractometer. Equal volumes (180 µl) of each fraction were analysed by western 
blotting.  
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3.1.3 Results 
3.1.3.1 Purification of lysosomes using superparamagnetic iron 
oxide nanoparticles (SPIONS) 
The purification of lysosomes using colloidal iron dextran (FeDex) had previously 
been used in the Pryor lab. However, it required extensive modification and 
optimisation to purify lysosomes for use in a fusion assay. The variables that were 
investigated will be discussed further, but included:  
- the use of ball bearing homogenisation or nitrogen cavitation to disrupt cells. 
- varying the concentration and the pulse/chase times of FeDex used in lysosome 
purification.  
- changing the osmolarity of the fractionation buffer. 
- changing the number of cells fractionated and the confluency of cells. 
- biochemical characterisation of purified lysosomes. 
This method was used as the starting point for lysosome purification. Lysosomes 
were purified from J774.2 macrophages and samples taken at each stage of the 
purification protocol. Samples were biochemically analysed by western blot for 
lysosomal (Lysosome-associated membrane protein 1, LAMP1) and cytoskeletal 
(α-tubulin) markers (Fig. 3.0 A), and assayed for the activity of the lysosomal 
enzyme β−hexosaminidase (Fig. 3.0 B) in order to monitor the enrichment of 
lysosomal material. The final lysosome fraction showed increased levels of 
LAMP1, and decreased levels of α-tubulin compared to the other fractions. The 
final fraction was enriched with lysosomal material as shown by the average 12.4-
fold increase in the activity of β-hexosaminidase (β-hex) relative to the starting 
fraction. However, this was highly variable, with the fold increase ranging from 3.3 
to 36.7. The average latency of these final lysosomal fractions was 42.8 % and the 
average recovery was 5.58 % (data not shown). Thus, the purification protocol 
was further optimised to improve the latency and recovery of lysosomes. 
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Fig. 3.0 Analysis of lysosomes purified using FeDex. A. J774.2 cells were incubated 
with colloidal-iron dextran (FeDex) diluted 1:20 in DMEM for 6 h followed by a chase with 
DMEM for 18 h. The cells were then scraped and resuspended in 1 ml of ice cold HB 
buffer (10 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) for 10 min on ice. Cells were 
then homogenised by 40 passes of a ball bearing homogeniser with a clearance of 6 µm. 
The lysate was restored to 250 mM sucrose by the addition of an equal volume of 
restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) and then 
centrifuged at 1,500 x g for 10 min at 4 ºC to generate a post-nuclear supernatant (PNS). 
The PNS was applied to a cell column held within a magnetic field. The flow through was 
collected, and the column washed with 3 ml of STM buffer (250 mM sucrose, 10 mM TES, 
pH 7.4, 1 mM MgCl2). The column was removed from the magnetic field, and lysosomes 
eluted with 3 ml of STM. Lysosomes were pelleted by centrifugation at 104,000 x g for 15 
min at 4 ºC, and resuspended in 100 µl of STM using a 1 ml dounce homogeniser.  
Samples were taken of the starting material (Total), PNS, column flow through (Flow), and 
the final lysosome eluate (Lys). Samples were analysed by western blotting using α- 
LAMP1 (lysosome-associated membrane protein 1) and α-α tubulin antibodies. 5 µg of 
protein was loaded per lane. Western blotting is representative of 4 separate experiments. 
B. 5 µl of each of the fractions in A. were assayed for the activity of the lysosomal enzyme 
β-hexosaminidase (β-hex) as previously described in section 2.20. The amount of (β-hex) 
activity (AU) per µg of protein of each fraction was determined and normalised to the 
activity of the total fraction. Data are means ± SEM and were analysed by one-way 
ANOVA (n=4). 
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3.1.3.2 Optimisation of FeDex purification protocol 
The conditions used to fractionate cells can vary greatly depending upon the 
downstream application of the subcellular fractions. Previous studies in the Pryor 
lab had demonstrated that smaller ball bearing sizes gave better lysosomal latency 
values. As intact lysosomes were required, the size of the ball bearing used to 
homogenise cells was changed to see if it would improve the latency and recovery 
of lysosomes (Fig. 3.1). Cells were fractionated with 40 passes of an 8.012 mm or 
8.014 mm ball bearing (8 µm and 6 µm clearance, respectively) and FeDex-
labelled lysosomes purified from the post-nuclear supernatant. Changing ball 
bearing size did not significantly affect lysosome latency (p = 0.721) or recovery (p 
= 0.444), and the latency and recovery was poor for both ball bearing sizes 
(latency ≤ 50 %, recovery ≤ 10 %).  
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Fig. 3.1. Homogenisation of J774.2 cells using two different sized ball bearings. 
J774.2 macrophages were pulsed for 6 h with FeDex diluted 1:20 followed by a FeDex-
free chase for 16 h in order to label lysosomes. The cells were then scraped and 
resuspended in 1 ml of ice cold HB buffer (10 mM sucrose, 10 mM TES, pH 7.4, 1 mM 
MgCl2) for 10 min on ice. Cells were then homogenised by 40 passes of a ball bearing 
homogeniser with a clearance of 6 µm (8.014 mm ball bearing) or 8 µm (8.012 mm ball 
bearing). The lysate was restored to 250 mM sucrose by the addition of an equal volume 
of restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) and was 
centrifuged at 1,500 x g for 10 min at 4 ºC to generate a post-nuclear supernatant (PNS). 
The PNS was applied to a cell column held within a magnetic field. The flow through was 
collected, and the column washed with 3 ml of STM buffer (250 mM sucrose, 10 mM TES, 
pH 7.4, 1 mM MgCl2). The column was removed from the magnetic field, and lysosomes 
eluted with 3 ml of STM. Lysosomes were pelleted by centrifugation at 104,000 x g for 15 
min at 4 ºC, and resuspended in 100 µl of STM using a 1 ml dounce homogeniser. 
Lysosomal latency was calculated by calculating the activity of the lysosomal enzyme β-
hexosaminidase (β-hex) in the presence and absence of detergent (as described in 
section 2.20). The same assay was used to determine the recovery of lysosomal material 
from the starting material. Data are means ± the range and were analysed by an unpaired 
t-test (n=2). 
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To determine if the poor latency and recovery was due to the protocol, or a 
particular trait of J774.2 cells, an alternative cell line, RAW 246.7 were fractionated 
using the same protocol. RAW 246.7 cells are a macrophage-like cell line used in 
studies of phagocytosis (Anand et al., 2008, Rogers and Foster, 2007, Nakanishi-
Matsui et al., 2012), signal transduction (Zhu et al., 2006), and cell migration 
(Murray et al., 2013). These cells are used partly because they have a flattened 
morphology and have a less extensive cytoskeleton (N. Signoret, personal 
communication, Oct 2011). This may mean that there is less association between 
lysosomes and the cytoskeleton in these cells, making it easier to recover 
lysosomes. For optimisation experiments, the latency and recovery of lysosomes 
in the PNS was first determined to quickly assess whether or not a particular 
variable had made a significant change to lysosome latency or recover. The 
lysosome purification protocol was performed on RAW 264.7 cells, but with 
additional FeDex concentrations. This was done to determine if RAW 264.7 cells 
were suited to this method, and secondly, to determine if altering FeDex 
concentration had an effect on lysosome purification (Fig. 3.2 A). FeDex was 
diluted 1:20. 1:50 or 1:100, and the latency of lysosomes in the PNS ranged from 
68 % - 82 %. However, no clear trend in the latency of lysosomes in the PNS was 
seen as the FeDex concentration was varied. The recovery of lysosomes in the 
PNS ranged from 17 % - 58 % and appeared to follow a downward trend as the 
amount of FeDex was increased. This was most likely due to the increased density 
of FeDex-filled lysosomes, when FeDex was incubated with cells at a higher 
concentration. As these latency and recovery values in the PNS were high, 
lysosomes were then purified fully from RAW 264.7 cells with FeDex diluted 1:20 
or 1:100 to see if the same would be true for purified lysosomes. These values 
were chosen as they were the highest and lowest concentrations of FeDex used 
previously. The latency and recovery of lysosomes purified from these cells was 
then determined (Fig. 3.2 B&C). The latency of lysosomes purified using FeDex at 
1:20 was 43.6 % compared to 48.1 %. The recovery of purified lysosomes was 
4.46 % (FeDex 1:20) compared to 22.5 % (FeDex 1:100). The low latency was 
mostly likely due to damage to the lysosomes when resuspending them using the 
dounce homogeniser. Alternatively, this may have been due to the FeDex 
damaging the lysosomes, as iron oxidation products can be particularly damaging 
to lysosomes (Kurz et al., 2011) Some FeDex-containing lysosomes were 
probably lost during the centrifugation step used generate the post-nuclear 
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supernatant, as the FeDex would increase the density of the lysosomes. The PNS 
would also contain FeDex-free lysosomes that would not be pelleted out during the 
PNS spin. This may account for the high latency seen in the PNS compared to the 
lower latency seen in the final fraction, as unlabelled, intact lysosomes, would be 
present in the PNS but not in the final fraction. 
 
Fig. 3.2. Purification of lysosomes from RAW 264.7 macrophages. A. RAW 264.7 
cells were incubated with colloidal-iron dextran (FeDex) (at the concentrations indicated) 
in DMEM for 6 h followed by a chase with DMEM for 18 h. The cells were then scraped 
and resuspended in 1 ml of ice cold HB buffer (10 mM sucrose, 10 mM TES, pH 7.4, 1 
mM MgCl2) and incubated on ice for 10 min. The cells were then homogenised by 40 
passes of a ball bearing homogeniser with a clearance of 6 µm. The lysate was restored 
to 250 mM sucrose by the addition of an equal volume of restoration buffer (490 mM 
sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) and centrifuged at 1,500 x g for 10 min at 4 ºC 
to generate a post-nuclear supernatant (PNS). 5 µl of the PNS was assayed for the 
activity of the lysosomal enzyme β-hexosaminidase (β-hex) as previously described in 
section 2.20. The amount of (β-hex) activity was used to determine the latency and 
recovery of lysosomes in the PNS. B&C. Lysosomes were purified from RAW 264.7 cells 
as per the method described in the figure legend of Fig. 3.1, but with FeDex dilutions of 
1:20 and 1:100. The purified lysosomes were then subjected to β-hexosaminidase (β-hex) 
assay to calculate the latency (B) and recovery (C) of lysosomes (n=1). 
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Given that lysosome recovery from RAW cells dropped when FeDex concentration 
was increased it was decided to see if the same trend would be true for J774.2 
cells (Fig. 3.3 A). Indeed, the latency of lysosomes in the PNS did not vary greatly 
between the FeDex concentrations used (87.3 % 1:100 FeDex compared to 80.1 
% 1:20 FeDex). However, as seen previously with the RAW cells, there was 
downward trend in the recovery of lysosomes in the PNS (46 % 1:100 FeDex 
compared to 8.5 % 1:20 FeDex). 
The latency and recovery of lysosomes did not differ greatly between J774.2 cells 
or RAW 264.7 cells but there was the potential for improvement. As such, it was 
decided to investigate if alternative fractionation methods would leave more 
lysosomes intact. Ball bearing homogenisation places cells under high shear 
forces, resulting in the release of the cytoplasm and organelles. However, the 
amount of force applied during each stroke can vary due to its manual operation. 
This can result in high variation between experiments and between users. 
Furthermore, the mechanical stress and friction placed on the sample generates 
localised increases in temperature, which can result in sample degradation. In 
contrast, nitrogen cavitation places the sample under high pressure with nitrogen 
gas, which dissolves in the cell. When the pressure is released, the gas expands 
and gently stretches the cell membrane, causing it to rupture and release the 
cellular contents. This method has several advantages that make it particularly 
attractive. As the cell lysate is saturated with inert nitrogen gas, it provides 
excellent protection against oxidative damage, and also does not change the pH of 
the fractionation media. This property also prevents the sample being damaged by 
increases in temperature, as the adiabatic expansion of the gas cools the sample 
(Simpson, 2010). Furthermore, as there are no limitations to the fractionation 
buffer that can be used, this reduces the manipulation of the sample, and does not 
require additional reagents to be added during the protocol. The fractionation is 
also uniform, as the nitrogen gas is applied evenly across the sample. Nitrogen 
cavitation has been used to isolate polyribosomes (Dowben et al., 1968), 
microsomal fractions, (Short et al., 1972), mitochondria (Gottlieb and Adachi, 
2000), and endosomal vesicles (Lamb et al., 2012). Consequently, it was 
investigated if nitrogen cavitation could be used to optimise lysosome purification. 
J774.2 cells were pulse-chased with varying dilutions of FeDex and were 
fractionated at 500 psi for 5 min (Fig. 3.3 B). 
 83 
 
Fig. 3.3 The effect of FeDex concentration on latency and recovery of FeDex-
labelled lysosomes in J774.2 cells. J774.2 macrophages were pulsed for 6 h with 
FeDex at varying concentrations, followed by a FeDex-free chase for 16 h in order to label 
lysosomes. The cells were then scraped and resuspended in 1 ml of ice cold HB buffer 
(10 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) for 10 min on ice. Cells were then 
homogenised by 40 passes of a ball bearing homogeniser (A) with a clearance of 6 µm 
(8.014 mm ball bearing) or lysed by nitrogen cavitation (B) at 500 psi for 5 min at 4 ºC. In 
both cases, the lysate was restored to 250 mM sucrose by the addition of an equal 
volume of restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) and was 
centrifuged at 1,500 x g for 10 min at 4 ºC to generate a post-nuclear supernatant (PNS). 
The PNS was subjected to β-hexosaminidase (β-hex) assay in the presence and absence 
of detergent (as described in section 2.20) to calculate the latency and the recovery of 
lysosomes in the PNS (n=1). 
Unlike ball bearing homogenisation, when nitrogen cavitation was used to lyse the 
cells, there was a slight downward trend in lysosomes latency in the PNS as 
FeDex concentration was increased. Latency using FeDex at 1:100 was 80 % 
FeDex 1:100 compared to 62.7 % when the FeDex was used at  1:20. As with 
previous experiments, as the FeDex concentration was increased there was a 
downward trend in lysosome recovery in the PNS. Latency was 23.7 % when the 
FeDex was used at 1:100, compared to 7.9 % when the FeDex was used at 1:20. 
Despite this experiment only being performed once and the latency and recovery 
values of lysosomes in the PNS of cells broken by nitrogen cavitation appearing to 
be slightly less compared to ball bearing homogenisation, the use of the nitrogen 
bomb was further optimised. The justification for this decision was that it was 
 84 
hypothesised that (along with the previously discussed advantages), nitrogen 
cavitation would be a more consistent and reproducible method of cell disruption 
compared to ball-bearing homogenisation. Secondly, J774.2 cells were incubated 
in a hypotonic buffer (HB) to facilitate cell disruption with the ball-bearing 
homogeniser. With nitrogen cavitation, this step was not necessary, thus cutting 
the protocol time down further. The nitrogen pressure vessel also could 
accommodate sample volumes of > 30 ml, without changing the parameters of cell 
disruption (i.e. cell breakage remains constant regardless of the volume of the 
sample used). With the ball bearing homogeniser, using larger sample volumes 
required the use of larger syringes that needed more force to pass the sample 
through the chamber. This would in turn increase the pressure within the 
homogenisation chamber. Using larger samples with the ball bearing homogeniser 
would alter the parameters previously optimised. As such, the nitrogen cavitation 
protocol might have been easier to optimise and improve upon, and so was taken 
forward. 
The next variables investigated were the pressure used to lyse cells and the time 
under pressure (Fig. 3.4). J774.2 cells were lysed by nitrogen cavitation at 500 psi, 
1000 psi, 1500 psi or 2000 psi, and the lysosomal latency and recovery in the PNS 
was determined by β-hexosaminidase assay (Fig. 3.4 A). The latency of 
lysosomes in the PNS did not vary significantly between the different pressures 
tested (p=0.841). There appeared to be a slight upward trend in the recovery of 
lysosomes in the PNS, but this was only measured once. In contrast, there was a 
clear downward trend in both the latency and recovery of lysosomes in the PNS of 
cells as the time under pressure was increased (Fig. 3.4 B). After 5 min under 
pressure (500 psi) the latency and recovery of lysosomes in the PNS was 51.2 % 
and 47.7 % respectively. After 30 min, this had decreased to 25.3 % and 21.4 % 
respectively. It was observed that using pressure above 1000 psi resulted in 
violent elution of the sample and resulted in excessive frothing of the sample. 
Therefore, the pressure was kept below 500 psi for further experiments. Increasing 
the time under pressure resulted in a decrease in both the latency and recovery of 
lysosomes in the PNS. As such, cells were subjected to high pressure for only 5 
min in further experiments to improve lysosome recovery. 
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Fig. 3.4. Optimisation of cell disruption using nitrogen cavitation. A. J774.2 
macrophages were scraped into 1 ml of ice cold HB buffer (10 mM sucrose, 10 mM TES, 
pH 7.4, 1 mM MgCl2) and placed under nitrogen gas pressure at different pressures for 5 
min at 4 ºC. The lysate was restored to 250 mM sucrose by the addition of an equal 
volume of restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2). A post-
nuclear supernatant (PNS) was generated from the lysate by centrifugation at 1,500 x g 
for 10 min at 4 ºC. B. As in A, except cells were placed under pressure at 500 psi for the 
times indicated, at 4 ºC. The PNS from both A&B was subjected to β-hexosaminidase (β-
hex) assay in the presence and absence of detergent (as described in section 2.20) to 
calculate the latency and the recovery of lysosomes in the PNS (A - latency data are 
means ± the range of two experiments, and were analysed by one-way ANOVA. Recovery 
values in A are from a single experiment. B - n=1). 
For the previous experiments, J774.2 cells were incubated on ice in a hypotonic 
homogenisation buffer (HB) for 10 min to allow the cells to swell and become 
easier to homogenise. As such, it was decided to investigate whether it was 
necessary to incubate cells in HB for longer periods of time when using nitrogen 
cavitation at two different pressures (Fig. 3.5). Cells were incubated on ice for 
increasing lengths of time (5 min to 30 min) and disrupted at 500 psi (Fig. 3.5 A) or 
250 psi (Fig. 3.5 B) for 5 min. The latency of lysosomes in the PNS of cells 
incubated on ice for increasing lengths of time did not vary greatly whether cells 
were fractionated at 500 psi (61.2 % to 67 %) or at 250 psi (71.9 % to 73.4 %). 
When cells were disrupted at 500 psi, the incubation on ice did not appear to 
change recovery of lysosomes in the PNS (53% to 62 %). When cells were 
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disrupted at 250 psi, there appeared to be a slight downward trend in recovery, 
with recovery dropping from 68.1 % (0 min on ice) to 42.9 % (20 min on ice). 
Although there was no clear trend in these results, it was decided to disrupt cells 
at 250 psi for further experiments as this made the elution of the sample from the 
nitrogen bomb much gentler with less frothing of the lysate and loss of the sample. 
Elution from the pressure vessel was also difficult to safely control at higher 
pressures, and disruption of subcellular organelles has been reported to occur at 
1000 psi (Gottlieb and Adachi, 2000).   
 
 
Fig. 3.5. The effect of incubating cells in a low osmolarity before nitrogen cavitation 
at 500 or 250 psi. J774.2 cells were incubated in a hypotonic buffer (10 mM sucrose, 10 
mM TES, pH 7.4, 1 mM MgCl2) and incubated on ice for increasing lengths of time. Cells 
were then placed under nitrogen gas pressure at 500 psi (A) or 250 psi (B) for 5 min at 4 
ºC. The lysate was restored to 250 mM sucrose by the addition of an equal volume of 
restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) A post-nuclear 
supernatant (PNS) was generated from the lysate by centrifugation at 1,500 x g for 10 min 
at 4 ºC. The PNS was subjected to β-hexosaminidase (β-hex) assay (as described in 
section 2.20) to calculate the latency and the recovery of lysosomes in the PNS (n=1).  
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The number of cells fractionated in an experiment was also an important 
consideration. For ball bearing homogenisation, changing the cell number would 
have altered the viscosity of the cell suspension and changed the shear forces 
placed upon the sample. Changing the cell number would have changed the ratio 
of buffer : cell. This would have resulted in a different osmolarity for each sample 
and would likely influence the outcome of the homogenisation. In contrast, 
nitrogen cavitation places each cell under the exact same gas pressure, so the 
fractionation should be equal across the entire sample. As such, the nitrogen 
cavitation should give similar results regardless of the number of cells fractionated. 
To investigate this, cells were fractionated in HB buffer at 250 psi for 5 min at 3, 
6,12, or 24 x 106 cells/ml (Fig. 3.6) and the latency and recovery of lysosomes in 
the PNS calculated using β-hexosaminidase assay. There was no significant 
difference in lysosome latency or recovery in the PNS when cells were lysed at 
different cell densities (p = 0.783 and p = 0.496, respectively). Despite the 
previous optimisations to the protocol, both the lysosome latency and recovery 
were poor, with latency ranging from 45 % to 54 % and recovery ranging from 56.7 
% to 70.6 %. 
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Fig. 3.6. The effect of cell number on lysosome latency and recovery in the PNS of 
cells fractionated by nitrogen cavitation. J774.2 macrophages were resuspended at 
3,6,12, or 24 x 106 cells in 1 ml of HB buffer (10 mM sucrose, 10 mM TES, pH 7.4, 1 mM 
MgCl2) and lysed by nitrogen gas at 250 psi for 5 min at 4 ºC. The lysate was restored to 
250 mM sucrose by the addition of an equal volume of restoration buffer (490 mM 
sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2) and a post-nuclear supernatant (PNS) was 
generated from the lysate by centrifugation at 1,500 x g for 10 min at 4 ºC. The PNS was 
subjected to β-hexosaminidase (β-hex) assay in the presence and absence of detergent 
(as described in section 2.20) to calculate the latency and the recovery of lysosomes in 
the PNS. Data are means ± SEM and were analysed by one-way ANOVA (n=6).   
As cell number had no significant effect on latency or recovery, 20 x106 cells /ml 
were used as experimentally, this number of cells was easier to deal with. As a 
large degree of variability in the latency and recovery of lysosomes was seen in all 
previous experiments, the experimental protocol as it stood was repeated several 
more times to determine whether the variability was an inherent property of the 
cells used, or whether experimental variance was the cause of variability. 20 x 106 
cells were incubated in 1 ml of HB for 10 min at 4 ºC. The cells were then 
disrupted at 250 psi for 5 min at 4 ºC, and a PNS generated. The latency and 
recovery of lysosomes in the PNS was calculated in 6 independent experiments 
(Fig. 3.7 A). The recovery and latency of lysosomes further purified from the PNS 
of two of these experiments was also calculated (Fig. 3.7 B). Encouragingly, the 
average latency and recovery of lysosomes in the PNS of cells fractionated using 
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nitrogen cavitation in HB was much higher than previous experiments (81.2 % and 
73.7 % respectively). However, the average latency and recovery of the final 
lysosomal fraction was 34.3 % and 4.3 % respectively (Fig. 3.7 B). The drop in 
latency and recovery from the PNS to the final lysosome fraction most likely was a 
result of damage to the lysosomes while pelleting and resuspending them. These 
values were also lower than the latency and recovery values seen for lysosomes 
purified using ball-bearing homogenisation, from J774.2 and RAW 264.7 cells (Fig. 
3.1; J774.2 ~50 % latency  and ~10 % recovery & Fig. 1.2; 48 % latency, 22 % 
recovery). Despite this, further optimisation experiments were performed using the 
nitrogen cavitation, as the latency and recovery values of lysosomes from the 
original protocol had room for improvement, and use of the nitrogen bomb was 
simpler than the ball bearing homogeniser. 
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Fig. 3.7 Latency and recovery of lysosomes in the PNS and final lysosome fractions 
of cells fractionated by nitrogen cavitation. 20 x 106 J774.2 cells were pulse chased 
with FeDex diluted 1:20 for 6 h followed by a 16 h chase in FeDex-free media. The cells 
were then scraped and resuspended in 1 ml of ice cold HB buffer (10 mM sucrose, 10 mM 
TES, pH 7.4, 1 mM MgCl2) for 10 min on ice. Cells were then lysed by nitrogen cavitation 
at 250 psi for 5 min at 4 ºC. The lysate was restored to 250 mM sucrose by the addition of 
an equal volume of restoration buffer (490 mM sucrose, 10 mM TES, pH 7.4, 1 mM 
MgCl2) and was centrifuged at 1,500 x g for 10 min at 4 ºC to generate a post-nuclear 
supernatant (PNS). The PNS was applied to a cell column held within a magnetic field. 
The flow through was collected, and the column washed with 3 ml of STM. The column 
was removed from the magnetic field, and lysosomes eluted with 3 ml of STM. Lysosomes 
were pelleted by centrifugation at 104,000 x g for 15 min at 4 ºC, and resuspended in 100 
µl of STM. Lysosomal latency and recovery of lysosomes in the PNS (A n=6) and final 
lysosome fraction (B n=2) was determined by calculating the activity of the lysosomal 
enzyme β-hexosaminidase (β-hex) in the presence and absence of detergent (as 
described in section 2.20). All data are means ± SEM. 
One possibility for the variation seen could have been due to the homogenisation 
buffer used. Restoration buffer was added to the lysates to restore them to 250 
mM sucrose (300 mOsm) in order to return the buffer to an osmolarity close to that 
of mammalian cells (280 mOsm). Lysosome integrity may have been affected by 
incomplete mixing of the two buffers. As such, it was investigated whether lysing 
cells directly into an osmotically balanced buffer (STM), could improve lysosome 
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latency and recovery. 20 x106 cells were fractionated at 250 psi for 5 min in either 
1 ml of HB or STM buffers (Fig. 3.8), and the latency and recovery of lysosomes in 
the PNS was determined. There was no statistically significant difference between 
latency (Fig. 1.8 A p = 0.187) and recovery (Fig. 1.8 B p = 0.136) when using HB 
or STM. The average latency in the PNS was 61.7 % (HB) and 71.5 % (STM), and 
the average recovery in the PNS was 53.8 % (HB) and 37.4 % (STM). As there 
was no significant difference between the two buffers, it was decided to use STM 
for further experiments in order to reduce the need to manipulate the sample 
through adding additional buffers and mixing. Removing this step also removed 
another possible source of variability between experiments. 
 
Fig. 3.8. Lysosome latency and recovery in the PNS of cells fractionated in HB and 
STM buffers. 20x106 J774.2 macrophages were resuspended in either 1 ml of hypotonic 
HB buffer (10 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2, 38 mOsm) or osmotically 
balanced STM (250 mM sucrose, 10 mM TES, pH 7.4, 1 mM MgCl2, 300 mOsm). Cells 
were then lysed by nitrogen cavitation at 250 psi for 5 min at 4 ºC (cells lysed in HB were 
restored to 300 mOsm by the addition of an equal volume of restoration buffer). A post-
nuclear supernatant (PNS) was generated from the lysate by centrifugation at 1,500 x g 
for 10 min at 4 ºC The PNS was assayed for the activity of the lysosomal enzyme β-
hexosaminidase in order to calculate the lysosomal latency (A) and recovery (B) of 
lysosomes in the PNS. Data are means ± SEM. Data were analysed by two-tailed t-test 
(n=6). 
To ensure that the previous results seen were consistent and would not be 
dramatically different when STM buffer was used instead of HB, it would have 
been necessary to repeat these experiments using STM. However, due to time 
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constraints, cell number was considered to be the variable that most likely could 
have affected lysosome integrity when using STM instead of HB.  To test this, 
J774.2 cells were lysed at different cell numbers (Fig. 3.9 A). It has previously 
found that some cell types stiffen with passage number (Berdyyeva et al., 2005), 
or may produce more cytoskeletal proteins such as α-actin (Kato et al., 2008). 
Lysosome number may also increase with cell age and confluency (Thoene, 
1992). As the growth state of the cells may have affected the efficiency of 
lysosome purification, the number of days the cells seeded for before fractionation 
was also investigated (Fig. 3.9 B). Changing cell number had no effect of 
lysosome latency (p = 0.501) or recovery (p = 0.831). Similarly, seeding cells for 
increasing lengths of time before cell lysis had no effect on latency (p = 0.101) or 
recovery (p = 0.963). 
 
Fig. 3.9 The effect of cell number and cell age on lysosome latency and recovery. A. 
Increasing numbers of J774.2 macrophages were fractionated in 1 ml of STM at 250 psi 
for 5 min at 4 ºC in a nitrogen pressure vessel. A post-nuclear supernatant (PNS) was 
generated from the lysate by centrifugation at 1,500 x g for 10 min at 4 ºC. The PNS was 
assayed for the activity of the lysosomal enzyme β-hexosaminidase in order to calculate 
the lysosomal latency and recovery (n=6). B. Cells were cultured for different lengths of 
time before they were resuspended at 20 x 106 cells in 1 ml of STM and were subjected to 
the same experimental protocol as in A. The latency and recovery of lysosomes was 
calculated by β-hexosaminidase assay (n=2). Data are means ± SEM and were analysed 
by one-way ANOVA. 
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The centrifugation speed and duration used to generate a PNS from the cell lysate 
was also considered. Lysosomal density increases with iron accumulation and can 
be correlated with the degree and duration of iron exposure (Dimitriou et al., 
2000). It was hypothesised that once lysosomes reach a particular density through 
the accumulation of FeDex, they can be pelleted at relatively low centrifugation 
speeds. Secondly, FeDex-containing organelles may be denser than non-labelled 
lysosomes, and a slower centrifugation speed may have resulted in less FeDex-
labelled lysosomes being pelleted along with cellular debris during the PNS spin 
(Fig. 3.10). To investigate this cells were fractionated in STM for 5 min at 250 psi 
and the lysates centrifuged at 800 x g for 5 min or 1500 x g for 10 min at 4 ºC. The 
latency (Fig. 3.10 A) and recovery (Fig. 3.10 B) in the PNS was then measured by 
β-hexosaminidase assay. There was no significant difference between 
centrifugation conditions on lysosome latency (p = 0.325). While it appeared that 
there was a slight drop in recovery at 1,500 x g compared to 800 x g this was no 
statistically significant (p = 0.402). Subsequently, post-nuclear supernatants were 
generated at 800 x g for 5 min to reduce the protocol length further. 
 
Fig. 3.10. The effect of different centrifugation conditions upon lysosome latency 
and recovery in a post-nuclear supernatant.  20 x106 J774.2 cells were fractionated in 
1 ml of STM buffer at 250 psi for 5 min at 4 ºC. The lysate was then  centrifuged at 800 x 
g for 5 min or 1500 x g for 10 min at 4 ºC to generate a post-nuclear supernatant (PNS). 
The latency (A) and recovery (B) in these PNS samples was then calculated by β-
hexosaminidase assay. Data are means ± SEM and were analysed by un-paired t-test 
(n=2). 
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3.1.3.3 Determining the minimum pulse and chase time needed to 
purify lysosomes 
It was previously seen that increasing the concentration of FeDex used to 
magnetically label lysosomes, resulted in a drop in recovery when using HB buffer 
(Fig. 3.2 & 3.3). The effect of FeDex using STM buffer was also investigated (Fig. 
3.11 A). J774.2 cells were pulsed with increasing amounts of FeDex diluted 1:20, 
1:50, 1:100 and 1:200 and the FeDex labelled lysosomes were isolated. FeDex 
concentration did not significantly affect lysosome latency (p=0.986) or recovery 
(p=0.933) in the final lysosome fraction, and FeDex was used at 1:20 for further 
experiments. Next, in order to improve lysosome purification and reduce the 
protocol length as much as possible, the length of the FeDex pulse required to 
label lysosomes was determined (Fig. 3.11 B) J774.2 cells were pulsed with 
FeDex (1:20) for 1 h, 2 h, 4 h, or 6 h followed by a 16 h chase period with FeDex-
free media. FeDex-labelled lysosomes were isolated magnetically and the latency 
and recovery was determined by β-hexosaminidase assay. The latency of 
lysosomes followed a significant downward trend as the length of the FeDex pulse 
was increased (p = 0.032). The recovery also followed a downward trend, but this 
was not significant (p = 0.423). Encouragingly, the latency for 1 h pulse was 79 %, 
with a recovery of 7.2 %, indicating that a shorter pulse time may result in more 
intact lysosomes with a reasonable recovery. Thus, a 1 h pulse of FeDex diluted 
1:20 was sufficient to purify lysosomes and gave the highest latency and recovery. 
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Fig. 3.11. The effect of FeDex concentration and pulse length on latency and 
recovery of FeDex-purified lysosomes. A. J774.2 macrophages were given a 6 h pulse 
of FeDex at increasing concentrations, followed by a 16 h chase in FeDex free media. The 
cells were then resuspended in 1 ml of STM buffer and lysed by nitrogen cavitation at 250 
psi for 5 min at 4 ºC. The lysate was centrifuged at 800 x g for 5 min at 4 ºC to generate a 
post-nuclear supernatant (PNS). The PNS was applied to a cell column held within a 
magnetic field. The flow through was discarded, and the column washed with 3 ml of 
STM. The column was removed from the magnetic field, and lysosomes eluted with 3 ml 
of STM. Lysosomes were pelleted by centrifugation at 104,000 x g for 15 min at 4 ºC, and 
resuspended in 100 µl of STM. FeDex-labelled lysosomes were assayed for the activity β-
hexosaminidase in order to calculate the lysosomal latency and recovery. Data are means 
± SEM and were analysed by one-way ANOVA (n=3). B. J774.2 macrophages were 
pulsed with FeDex (1:20) for increasing amounts of time, followed by a 16 h chase in 
FeDex free media. FeDex labelled organelles were then magnetically isolated as 
described in (A) and the latency and recovery determined by β-hexosaminidase assay. 
Data are means ± SEM and were analysed by one-way ANOVA (n=2). 
To reduce the protocol length further still, we sought to determine the minimum 
time required for all endocytosed FeDex to reach the terminal lysosomal 
compartment. J774.2 cells were given a 1 h pulse of FeDex and chased with 
FeDex-free media for 0, 30, 60, or 120 min (Fig. 3.12). Lysosomes were then 
magnetically isolated and probed for different markers of the endocytic pathway. 
Early endosomal antigen 1 (EEA1) and Rab5 were used as early endosomal 
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markers, Rab7 as a marker of late endosomes, and Lysosome associated 
membrane protein 1 (LAMP1) as a marker of lysosomes. The level of 
contamination with the cytoskeleton was determined by blotting for α-tubulin. In 
order to compare the levels of early and late endocytic markers, samples were first 
normalised to the activity levels of the lysosomal enzyme β-hexosaminidase. 
Levels of early endosomal antigen 1 (EEA1) dropped rapidly between 0 and 30 
min chase and were almost absent after 120 min. The levels of LAMP1 were 
equivalent between all samples within an experiment, indicating that the loading of 
samples normalised to β-hexosaminidase activity can be used to normalise 
amounts of lysosomal material between samples. The levels of α-tubulin were 
similar between all chase times. The late endosomal marker Rab7 dropped 
steadily from 0 min to 120 min. Similarly, levels of the early marker endosomal 
marker Rab5 dropped from 60 min. After 120 min, endocytic compartments had 
high levels of LAMP1 and negligible levels of EEA1, Rab5 and Rab7. This was 
similar between three separate experiments. Therefore, a 1 h pulse and 2 h chase 
was deemed sufficient to purify terminal lysosomal compartments. 
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Fig. 3.12. Western blot analysis of magnetically purified endocytic compartments. 
J774.2 macrophages were given a 1 h pulse of FeDex diluted 1:20 followed by a chase 
with FeDex free media of 0,30,60,or 120 min. FeDex-labelled endocytic compartments 
were then magnetically isolated as described in Fig. 3.11. Purified organelles were 
subjected to western blotting for EEA1 (early endosomal antigen 1), LAMP1 (Lysosome 
associated membrane protein 1), α-tubulin, Rab7 and Rab5. Samples were normalised to 
levels of the lysosomal enzyme β-hexosaminidase in order to compare the levels of early 
and late endocytic markers relative for an arbitrary amount of lysosomal material. Data are 
results of three individual experiments (1,2,3), with blotting for EEA1 performed twice, 
Rab7 twice, and Rab5 once. 
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3.1.3.4 Purification of lysosomes using density centrifugation. 
A major disadvantage of purifying lysosomes by density centrifugation is the 
amount of time the purification takes, as well as the inherent disadvantages of the 
centrifugation media used. As a more rapid lysosome purification protocol had 
been optimised, that was much quicker than centrifugation, it was decided to 
compare the purity of lysosomes isolated by both protocols (Fig. 3.13 & 3.14). 
Lysosomes were purified from J774.2 mouse macrophages on a 1-22% Ficoll 
density gradient (Fig. 3.13), in order to compare the level of contamination (of 
other subcellular fractions), relative to lysosome fractions purified using the FeDex 
protocol. J774.2 cells were lysed in STM by nitrogen cavitation at 250 psi for 5 min 
at 4 ºC and the lysate centrifuged to generate a post-nuclear supernatant (PNS). 
The PNS was loaded onto a 1-22 % Ficoll gradient, and centrifuged for 1 h in a 
vertical rotor to reduce the centrifugation time. 1 ml fractions were collected using 
a fraction collector and analysed by both enzymatic assay (Fig. 3.13 A) and 
western blotting (Fig. 3.13 B) to determine where lysosomes were on the gradient. 
There was a peak of β-hexosaminidase starting at fraction 3 and finishing at 
fraction 11. This peak was only visible when detergent was used to lyse lysosomal 
membranes, indicating intact lysosomes had been purified, and that the enzymatic 
activity was not due to the presence of free enzyme. Indeed, a second peak of β-
hexosaminidase activity was seen from fractions 17-21, which did not increase 
when detergent was used in the β-hexosaminidase assay. This is indicative of free 
enzyme present in the soluble fraction. The average latency of lysosomes in 
fractions 7-15 was 78 %. The western blotting also corresponded to the results of 
the enzymatic assay. LAMP1 was detected most strongly in fractions 7-13, and 
was largely absent from lighter fractions on the gradient. Contamination of the 
endoplasmic reticulum (ER) was determined by the levels of glucose-regulated 
protein,78 kDa (GRP78). A small amount of GRP78 was detected in fraction 7, but 
the majority was found at the lighter end of the gradient in fractions 21-29. 
Similarly, no α-tubulin was detected in the lysosomal fractions, but was detected in 
fractions 23-29. Syntaxin 7 was detected as soon as fraction 7, but the highest 
amounts were detected in fractions 13-19. This is not surprising, as Syntaxin 7 is 
required for late endosome-lysosome fusion and would be present on some 
lysosomal membranes (Mullock et al., 2000).  
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Fig. 3.13. Purification of lysosomes by isopycnic centrifugation. A. 60 x106J774.2 
cells were lysed in 3 ml of STM by nitrogen cavitation at 250 psi for 5 min at 4 ºC. The 
lysate was centrifuged at 800 x g  for 5 min at 4 ºC to generate a post-nuclear supernatant 
(PNS). The PNS was then loaded onto a 1-22% Ficoll gradient and centrifuged in a 
Beckman Vti50 vertical rotor for 1 h at 50,000 rpm. 1 ml fractions were collected and 
subjected to β-hexosaminidase assay in the presence or absence of detergent. The 
refractive index of each fraction was also measured. B. Equal volumes of the fractions of 
the gradient in A were western blotted for markers of lysosomes (LAMP1), endoplasmic 
reticulum (GRP78), cytoskeleton (α-tubulin), and late endosomes/lysosomes (Syntaxin 7) 
(n=1). 
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Lysosomes were purified using isopycnic centrifugation (fractions 5-9) or magnetic 
isolation, and were then analysed for contamination of other subcellular fractions 
(Fig. 3.14). Lysosomes were purified on a 1-22 % Ficoll gradient, or by the FeDex 
protocol (using either nitrogen cavitation or ball bearing homogenisation to 
generate a PNS). Lysosomes were subjected to western blotting using antibodies 
against LAMP1, GRP78 and α-tubulin All lysosome fractions were positive for 
LAMP1, with lysosomes purified by ball bearing homogenisation having the 
highest amounts, followed by purification by density centrifugation. All fractions 
were contaminated with similar levels of endoplasmic reticulum, as judged by the 
levels of GRP78. However, lysosomes purified by ball bearing homogenisation 
had no contamination of α-tubulin. Small amounts of α-tubulin were present in 
lysosomes purified by density centrifugation and nitrogen cavitation.  
 
Fig. 3.14. Western blot analysis of lysosomes purified using three different 
purification protocols. J774.2 cells were pulse-chased with FeDex and were 
fractionated by nitrogen cavitation (N2) or with a ball bearing homogeniser (Ball bearing). 
FeDex labelled endocytic compartments were then magnetically isolated as previously 
described. Alternatively, J774.2 cells were fractionated by nitrogen cavitation and 
lysosomes purified using isopycnic centrifugation on a 1-22 % Ficoll gradient (gradient) as 
per Fig. 1.13. Purified lysosomes were subjected to western blotting for lysosomal 
(LAMP1), ER (GRP78), and cytoskeletal (α-tubulin) markers. 5 µg of protein was loaded 
protein per lane of an SDS PAGE minigel (n=1). 
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While the lysosomes purified using nitrogen cavitation had less LAMP1 and more 
α-tubulin, the final protocol was quicker than isopycnic centrifugation, and simpler 
than ball bearing homogenisation. Thus the final protocol for purifying lysosomes 
was a 1h pulse of FeDex (1:20) followed by a 2 h chase. The total length of time 
from fractionation to a final eluate was approximately 3h 40 min – 4 h. The length 
of time to generate a lysosomal fraction using centrifugation was approximately 3-
4 h, but required the setting up of the gradient the day before the experiment, and 
would result in a lysosome fraction containing Ficoll, which would require 
additional steps to remove it. 
3.1.4 Lysosome purification - Discussion 
Lysosome purification can be difficult and time consuming, and often requires the 
use of high speed centrifuges to separate lysosomes from other subcellular 
fractions by isopycnic centrifugation. Obtaining lysosome fractions free from 
impurities and in enough quantity for downstream applications is challenging. 
Monitoring the purification itself routinely requires enzymatic assays to determine 
levels of contamination and enrichment of lysosomes, which again are time 
consuming and results in less of the sample available for further experiments. 
Importantly, these methods are not necessarily optimised to ensure lysosomes 
remain intact.  As we wished to use lysosomes in an in vitro fusion assay, they 
need to be intact to ensure the assay would be efficient as possible. Therefore a 
quicker, simpler method, that was optimised to purify intact lysosomes would be 
extremely beneficial. As such, we sought to investigate the variables that may 
improve upon established methods to magnetically isolate lysosomes. 
While there are many published protocols for lysosome purification, they can 
require extensive optimisation for a particular cell or tissue type. For a fusion 
assay in particular, the purification protocol must be gentle enough to result in a 
final lysosome fraction that contains a large proportion of intact lysosomes. These 
lysosomes must also remain fusogenic and behave similarly in vitro to those in 
vivo. Thus, ligands or compounds introduced into lysosomes to aid in there 
purification must not interfere with lysosome function. The isolation of lysosomes 
from Dictyostelium discoideum (Rodriguez-Paris et al., 1993), was adapted to 
J774.2 cells, a mouse macrophage cell line. This method was chosen over other 
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lysosome purification protocols, as it allowed rapid isolation of lysosomes and was 
already an established method in the laboratory. 
To begin with, cells were pulsed for 6 h with colloidal-iron dextran (FeDex), which 
was chased to the lysosome by a 16 h chase in FeDex-free media. Lysosome 
purification was monitored by western blot (Fig. 3.0 A) and β-hexosaminidase (β-
hex) assay (Fig. 3.0 B). The final lysosomal fraction showed an enrichment of the 
lysosomal marker LAMP1, relative to the starting material. This was confirmed by 
the result of the enzymatic assay, which showed an average 12.4 fold increase in 
β-hex activity per µg of protein in the lysosome fraction compared to the total. The 
drop in β-hex activity in the post-nuclear supernatant compared to the total, 
suggests that a proportion of lysosomes are pelleted with nuclei and other cell 
debris during the PNS spin. This was supported by the western blot data, which 
showed that the level of α-tubulin was significantly lower in the lysosomal fraction 
compared to the total and PNS fractions. As lysosomes are linked to microtubule 
filaments (Wubbolts et al., 1999), and lysosome trafficking within the cell is 
dependant on microtubules (Matteoni and Kreis, 1987), this suggests that purified 
lysosomes were released from their contacts with the microtubule cytoskeleton, 
whereas pelleted lysosomes were not. While, these experiments demonstrated 
that the protocol was able to purify lysosomes from J774.2 cells effectively, the 
average latency of lysosomes over 5 experiments was only 44.5 %. Therefore, 
alternative cell disruption methods, and a wide range of variables were 
investigated to try and improve lysosome latency and recovery.  
3.1.4.1 Cell line used  
Initially, cells were broken open to release lysosomes by ball-bearing 
homogenisation. It was reasoned that using a smaller ball bearing to homogenise 
cells may have reduced the shear forces placed upon the sample and thus 
improved the latency and recovery of lysosomes (Fig. 3.1). However, when this 
was tested, the latency and recovery of final lysosome fractions was not 
significantly affected, and the latency and recovery of lysosomes was still poor. To 
determine whether this was due to the cell line or due to the experimental protocol, 
an alternative mouse macrophage cell line (RAW 264.7) was also investigated. 
Secondly, testing this cell line before optimising the protocol further would prevent 
 103 
a lengthy repeat of optimisation experiments should the cell line have been 
changed at a later time. The suitability of RAW 264.7 cells was investigated, and 
additionally, the concentrations of FeDex used were also tested (Fig. 3. 2 A-C). 
While the latency and recovery of lysosomes in the PNS of RAW 264.7 cells 
looked promising, the latency and recovery values of lysosomes in the final 
fractions were no better than those obtained from J774.2 cells. It was observed 
that the recovery was 5-fold higher for lysosome purified using FeDex at 1:100 
compared to 1:20 (22.5 % compared to 4.4 % respectively).  
As the lysosome latency and recovery in the PNS of RAW 264.7 looked promising, 
lysosomes were then purified fully from these cells to determine whether the final 
lysosomal fraction would also have high latency and recovery values. However, 
the latency and recovery of lysosomes purified from RAW 264.7 cells did not differ 
greatly from the latency and recovery of lysosomes purified from J774.2 cells (Fig. 
3.1). RAW 264.7 cells were investigated, as they reportedly have less cytoskeleton 
which may have made lysosome purification easier. However, no evidence was 
found that lysosomes purified from these cells had less α-tubulin associated with 
them, than those from J774.2 cells (data not shown). J774.2 cells also did not 
require an additional trypsin digest step to remove the cells from the tissue culture 
dishes, and such using them would make the protocol simpler.  
3.1.4.2 FeDex concentration 
When FeDex concentration in RAW 264.7 cells was increased, a downward trend 
was seen in lysosome latency and recovery (Fig. 3.2). This was not specific to this 
cell line or cell lysis method, as the same trend was seen in J774.2 cells whether 
they were broken open using ball-bearing homogenisation or nitrogen cavitation 
(Fig. 3.3). When this experiment was repeated multiple times (n=3) however, there 
was no significant change in lysosome latency (p = 0.986) or recovery (0.933) in 
the PNS of J774.2 cells  (Fig. 3.11).  
3.1.4.3 Different buffers and incubation on ice 
It was previously found in the Pryor lab that J774.2 cells are particularly refractory 
to homogenisation by passage through low gauge needles, and ball bearing 
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homogenisation (data not shown). To homogenise cells using ball bearing 
homogenisation, requires that cells are incubated in a hypotonic buffer (HB, 10 
mOsm) on ice for 10 minutes to allow the cells to swell and become easier to 
disrupt. It was hypothesised that incubating the cells in HB buffer for increasing 
amounts of time may increase the amount of osmotic swelling and could increase 
the recovery of lysosomes. However, no clear trend was seen for lysosomal 
latency or recovery in post nuclear supernatants of cells disrupted at 500 psi or 
250 psi (Fig. 3.5). Moreover, lysates from cells lysed in HB needed to be restored 
to mammalian osmolarity (approximately 280 mOsms, (Waymouth, 1970) with 
restoration buffer. It was possible that lysosomes were partially protected from 
osmotic shock within the cell. Upon fractionation and release into the buffer, 
lysosomes would have been placed under osmotic stress until the osmolarity was 
restored. This would not be an issue if cells were lysed directly into an iso-osmotic 
buffer (STM, 300 mOsm). However, there was no significant difference in 
lysosome latency (p = 0.187) or recovery (p = 0.136) in the PNS when cells were 
fractionated in HB or STM (Fig. 3.8). Taken together, these data suggest that the 
buffer composition does not directly affect the efficiency of nitrogen cavitation per 
se. Despite these results, further optimisations were performed in STM in order to 
reduce the manipulation of the sample and reduce another potential source of 
variation. 
3.1.4.4 FeDex pulse and chase times  
The aim of optimising the protocol was not only to obtain intact lysosomes suitable 
for the fusion assay, but also to make the protocol as short as possible. This would 
also help to minimise any potential effects on lysosome integrity from iron 
accumulation. Therefore we aimed to determine the minimum amount of time 
needed for cells to endocytose enough FeDex to purify endocytic compartments. 
Cells were pulsed with FeDex at 1:20 for varying lengths of time followed by a 16 h 
chase in FeDex-free media (Fig. 3.12 B), the minimum length of the FeDex pulse 
needed to purify lysosomes was determined experimentally. A 1 h pulse was 
sufficient to purify FeDex-labelled organelles, and decreasing the length of the 
pulse improved the viability and integrity of the lysosomes (Fig. 3.11). Next, the 
shortest time necessary to chase FeDex from earlier endocytic compartments to 
the lysosome was determined. Cells were pulsed for 1 h with FeDex before a 
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label-free chase of 0, 30, 60, or 120 min (Fig. 3.12). Purified lysosomes were then 
subjected to western blot for the cytoskeletal, early endosome, late endosome and 
lysosomal markers. One problem with loading samples normalised to the same 
protein concentration, is that it is not clear how much early, late and lysosomal 
compartments contribute to the total protein.  For example, if early endosomes are 
relatively devoid of protein compared to lysosomes, then loading equal amounts of 
protein of the two samples may result in large amounts of contaminating proteins 
being detected. This would be an artefact of loading large amounts of protein, 
rather than the actual content of those fractions. Furthermore, endosomes are very 
heterogeneous, and not all endocytic vesicles will mature at the same rate. As 
such, loading samples normalised to protein gives an average representation of 
the population of vesicles in the cell. Therefore, samples were normalised to the 
activity of the lysosomal hydrolase β-hexosaminidase, in order to load equal 
amounts of lysosomal material and compare the relative amounts of early and late 
endocytic material. This was confirmed by western blotting, which showed that 
LAMP1 levels remained constant between samples. When cells were pulsed with 
FeDex without a label-free chase, the entire endocytic pathway was purified as 
shown by the presence of EEA1, Rab5, Rab7 and LAMP1. After 30 min chase, 
levels of EEA1 significantly dropped and remained constant at 60 min and 120 min 
chase. Rab5 dropped slightly, and Rab7 was still present, indicating FeDex 
reaches late endosomes after 30 min. Levels of Rab7 and Rab5 continued to drop 
and were at their lowest levels at 120 min. This is consistent with the transition 
from a late endocytic compartment to a terminal lysosome, which is devoid of 
M6PR, Rab5 and Rab7 (Chavrier et al., 1990, Rabinowitz et al., 1992). However, 
J774.2 cells do not express high levels of cation-independent mannose-6-
phosphate (ciM6PR) receptor (Gabel et al., 1983). The absence of blots for 
ciM6PR represents the low expression and the lack of a suitable antibody. 
Purifying a truly lysosomal fraction with no earlier endocytic organelles is 
particularly challenging, due to the highly dynamic and asynchronous nature of the 
endocytic pathway. Although a 120 min chase is sufficient to purify a pool 
consisting largely of terminal lysosomes, the detection of Rab5 and Rab7 indicates 
co-purification of some Rab5 positive early vesicles, as well as Rab7 positive 
vesicles such as endolysosomes (Humphries et al., 2011). As expected, α-tubulin 
was associated with purified vesicles at all time points. Endocytic vesicles interact 
with microtubules via specific motor proteins which are involved in intracellular 
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trafficking (Bananis et al., 2004, Loubery et al., 2008, Hunt et al., 2013), and the 
positioning of early endosomes, late endosomes and lysosomes is dependant on 
proper microtubule function (Matteoni and Kreis, 1987). 
These results are in agreement with previous data, where magnetic endocytic 
vesicles isolated from HeLa cells showed an enrichment for EEA1 and Rab5 after 
30-45 min internalisation, and maximum enrichment of Rab7 and LAMP1 at 90 -
180 min. Interestingly, EEA1 was absent after 180 min while Rab5 was not, 
suggesting Rab5 may associate with a small population of late endocytic 
compartments (Loubery et al., 2008). Furthermore, western blots of endocytic 
vesicles isolated using paramagnetic iron particles showed an increase in LAMP1, 
and decrease in Rab5 and Rab7 after a 120 min label-free chase. This was 
accompanied by an increase in lysosomal enzyme activity, which was also 
observed when lysosomes were isolated using FeDex (Becken et al., 2010). Rab5 
was also found to be associated with lysosomes purified from J774A.1 cells 
(Jahraus et al., 1998), and was detected by western blot on isolated late 
endosomes and lysosomes (Tjelle et al., 1996). Thus, while thought to be enriched 
on early endosomal membranes, Rab5 may also be associated with late endocytic 
organelles. The difference in the rate at which endocytic markers are acquired and 
lost is likely due to differences in experimental methods and the fact that the 
dynamics of endosome maturation differs between professional phagocytic cells 
and other cell types. Despite these minor differences, it is clear that lysosomes 
and other endocytic organelles can be magnetically purified from cells. By 
characterising the fractions isolated using a panel of organelle markers and 
monitoring the acquisition of lysosomal enzymes, it is possible to determine the 
pulse/chase times needed to isolated an specific population of organelles from a 
particular cell type.  
3.1.4.5 General considerations using FeDex 
For many variables, lysosome latency and recovery in the PNS was measured 
rather than the final lysosome fraction. If a particular variable greatly reduced 
latency and recovery in the PNS, there would be little use in determining the 
latency and recovery of the final lysosomal fraction. A caveat to this approach 
could be that if FeDex labelled organelles are pelleted during the PNS spin due to 
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and increase in their density, then the PNS values for latency and recovery do not 
represent all FeDex-labelled organelles. For example, if when using FeDex at 
1:100, the lysosomes do not become dense enough to pellet during the PNS 
generation whereas those labelled with 1:20 FeDex do, the PNS values for the 
latter would only represent unlabelled lysosomes. However, the latency and 
recovery values for final lysosomal fractions are most likely accurate, as unlabelled 
organelles are not retained on the magnetic column. 
Lysosomal membranes are damaged by lipid peroxidation by OH • radicals, a 
product of Haber-Weiss reactions catalysed by iron (Mak and Weglicki, 1985). 
Indeed, iron accumulation renders the lysosome extremely fragile (Peters and 
Seymour, 1976), and isolating iron-containing lysosomes can be particularly 
difficult due to their fragility (Selden et al., 1980). However, iron-containing 
lysosomes are more normal in size than those purified using other ligands such as 
Triton WR-1339 (Glaumann et al., 1975), and have been purified with a recovery 
of 15-20 % and 60 fold enrichment of lysosomal enzyme activity relative to the 
starting material. Furthermore, some cell types are likely to be more susceptible to 
iron-induced damage than others. In one report, lysosomes isolated from rat 
hepatocytes using iron had a latency of 46 % compared to the control (78 %) 
(Myers et al., 1991). Lysosomal pH was increased and membrane fluidity was 
found to be decreased, which may have had serious consequences for vesicle 
fusion. Indeed, yeast mutants defective for membrane fusion at the vacuole can be 
pharmacologically rescued by the addition of chlorpromazine, which increases 
membrane curvature and fluidity (Karunakaran and Fratti, 2013).  This suggests 
iron-containing lysosomes may not function as normal. Moreover, these 
lysosomes were abnormally shaped, larger, and increased in number. Indeed, the 
latter may be a response to lysosomal dysfunction, as lysosome biogenesis is 
upregulated when lysosomal function is impaired (Sardiello et al., 2009). Further 
work could include analysing FeDex-treated cells to determine if the levels of 
LAMP proteins increases, which may indicate if FeDex impairs lysosome function. 
This may not be necessary however, as FeDex-containing vesicles have been 
successfully used in an in vitro vesicle fusion assay indicating they remain 
fusogenic (Becken et al., 2010), but is something that should be considered. 
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3.1.4.6 Density centrifugation  
The purification of lysosomes using FeDex was compared to those isolated using 
density centrifugation. A PNS was generated from J774.2 cells, which was 
fractionated on a continuous 1-22% Ficoll gradient (Fig. 3.15). There were two 
peaks of β-hexosaminidase activity detected throughout the gradient, one at the 
dense end of the gradient (50,960 β-Hex AU), and the other at the lighter end 
(27,000 β-Hex AU). The first peak was only detectable upon the release of 
membrane bound enzyme from detergent-lysed organelles, indicating the 
purification of intact compartments. The addition of detergent to the fractions 
corresponding to the second peak only slightly increased enzyme activity, 
indicating that the peak to corresponded to free enzyme and broken organelles. 
The membrane bound activity was associated with lysosomal and late endosomal 
markers (LAMP1 and Syntaxin 7 respectively), indicating this to be a 
lysosomal/late endosomal fraction. However, the bulk of Syntaxin 7 was detected 
in lighter fractions. The lysosomal fraction was also devoid of α-tubulin and had a 
low amount of the ER marker glucose-regulated protein of 78 kDa (GRP78). While 
in this instance, the lysosomal fraction was relatively pure, the setup and 
centrifugation is still lengthy and cumbersome. The removal of the Ficoll 
centrifugation media also adds and additional step needed to purify lysosomes for 
use in an in vitro assay. As such, gradients may be an attractive option for 
obtaining fractions for use in proteomic and biochemical studies, but for a fusion 
assay where degradation of a marker is a potential problem, speed is preferable. 
Peripheral membrane proteins that are transiently associated with the cytoplasmic 
face of endocytic vesicles may also be lost from lysosomal fractions during high 
speed centrifugation. 
Lysosomes purified on a gradient or by magnetic isolation, were compared by 
western blotting (Fig. 3.16) Magnetically isolated organelles were first fractionated 
by nitrogen cavitation or ball bearing homogenisation. All lysosome samples were 
LAMP1 positive, with those purified using the ball bearing having the most LAMP1. 
Nitrogen cavitation had the least amount of LAMP1. All samples were positive for 
GRP78 and α-tubulin was detected in lysosomal fractions purified by on a gradient 
and using nitrogen cavitation, but not by ball-bearing homogenisation. These 
differences most likely reflect the different isolation methods used. The lysosomes 
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purified from the gradient and by ball-bearing homogenisation appeared to be 
more enriched for LAMP1 and have less α-tubulin associated with them than those 
purified using nitrogen cavitation. However, for the purposes of the fusion assay 
one of the aims of optimisation was to reduce the protocol length in order to 
reduce any potential degradation of ligands by lysosomal proteases. While 
gradient purification can produce high quality, latent lysosomes, there are some 
disadvantages. Firstly, the gradients may require large numbers of cells. The 
purification of lysosomes using FeDex could be performed on a single tissue 
culture dish of cells. Secondly, gradients are time consuming. Although the 
centrifugation time can be reduced by using a vertical rotor, the set up of the 
gradient and removal and analysis of fractions is itself time consuming. Thirdly, the 
centrifugation media necessary to purify lysosomes may result in irreversible 
damage to organelles through osmotic effects, which may in turn reduce organelle 
densities and alter the resolution of the gradient. Although more modern 
centrifugation mediums such as Nycodenz, Ficoll or Metrizamide do not exert 
osmotic pressure on lysosomes to the extent that traditional sucrose gradients do, 
they may still exert significant osmolarity at densities used to purify organelles. For 
example, Nycodenz and Metrizamide are only at mammalian cell osmolarity at 
densities below 1.2 mg/ml which is below that of many organelles (Castle, 2004). 
With FeDex purification the lysosomes can be kept in an isoosmotic buffer for the 
entire protocol. Moreover, FeDex purified lysosomes can easily be transferred to a 
different buffer, whereas those purified on a gradient must be extensively dialysed 
if the centrifugation medium needs to be removed.  
3.1.4.7 Homogenisation methods 
Others have reported that nitrogen cavitation is a preferred method of cell 
disruption when trying to obtain intact lysosomes (Kaushik and Cuervo, 2009, 
Koga et al., 2011). Mechanical rupture was found to damage lysosomes and 
release lysosomal enzymes, which was minimal when cells were fractionated by 
nitrogen cavitation (Klempner et al., 1980). Similarly, (Gottlieb and Adachi, (2000), 
found that nitrogen cavitation resulted in little outer membrane damage to purified 
mitochondria, whereas homogenisation resulted in significant damage. Ball-
bearing homogenisation may also be a suitable method for releasing lysosomes 
from cells. However, nitrogen cavitation was chosen as a preferred method with 
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J774.2 cells, as it did not require the use of different buffers, or a 10 minute pre-
incubation of the sample on ice before cells were broken open. The nitrogen bomb 
could handle much larger sample sizes (30 ml compared to 1 ml for the ball-
bearing homogeniser), meaning the protocol could be more easily adapted should 
a large number of cells be required. 
3.1.4.8 Final Conclusions 
These experiments have resulted in the development of a robust and rapid method 
to purify lysosomes from J774.2 cells, which remain intact and suitable for use in a 
fusion assay. In summary, the final protocol gave lysosomes with an average 
latency of ~80 % and a recovery of ~7 %. The time take to purify lysosomes using 
SPIONs (including a 3 h pulse- chase with FeDex), was around 3 h 40 min – 4 h in 
total. This protocol could also be easily altered to purify endocytic compartments of 
different ages, For example, a shorter pulse period and no chase would result in 
the purification of early endosomes rather than late endosomes and lysosomes. 
This method could also be used to purify lysosomes for other uses, such as 
proteomic analysis or purification of pathogen-containing compartments. 
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3.2 Phagosome purification 
3.2.1 Introduction 
To analyse phagosome-lysosome fusion, or understand how intracellular 
pathogens are able manipulate the phagosomal compartment, it necessary to 
isolate phagosomes from cells. For an in vitro phagosome-lysosome fusion assay, 
phagosomes also need to be purified. Phagosomes can be purified using similar 
techniques to lysosome purification. Purification of phagosomes is often carried 
out by allowing cells to internalise synthetic particles such as latex beads. This 
allows easy purification following cell fractionation, since latex beads will float on 
top of density gradients, allowing a simple one-step gradient to be performed 
(Weisman and Korn, 1967). Magnetic particles are even easier to purify and can 
simply be pulled out of a cell lysate using a strong magnet. Furthermore, other 
compounds or markers can be introduced to the cells at different time points to the 
study the kinetics of phagosome maturation. These methods are not without some 
disadvantages. Changing the properties of the phagosome to aid in its purification, 
will likely change the very properties of the phagosomes which one is trying to 
study. For example, latex bead phagosomes are often used as they allow for easy 
purification on one-step sucrose gradients (Desjardins and Griffiths, 2003, 
Desjardins et al., 1994b).  However, latex beads have a particularly hydrophobic 
surface chemistry, which is likely to influence the maturation of these phagosomes 
(Oh and Swanson, 1996). Bacterial surface chemistry also effects phagosome 
maturation. For example, the cell wall of Mycobacterium species is particularly 
hydrophobic due to its high lipid content. This results in the phagosome membrane 
surrounding the bacterium very tightly, which has been hypothesised to prevent it 
from effectively maturing and fusing with lysosomes (Rhoades and Ullrich, 2000). 
Indeed, particle surface chemistry can influence the interaction of phagosomes 
with lysosomes (Thiele et al., 2003). So, while they are an attractive model system 
to study phagosome maturation, the data acquired through their use likely 
describes latex bead-phagosome maturation, but not necessarily that of 
phagosomes in general or those containing bacteria with a different surface 
chemistry (Luhrmann and Haas, 2000). Despite these limitations, latex beads are 
a very popular method of purifying phagosomes (Garin et al., 2001, Desjardins 
and Griffiths, 2003, Rabinowitz et al., 1992, Reiner, 2009). 
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Phagosomes containing bacteria have been isolated using density gradient 
centrifugation (Luhrmann and Haas, 2000, Kühnel et al., 2006). However, these 
methods are time consuming and laborious, due to the gradients that need to be 
set up and multiple centrifugation steps. These methods have some of the same 
problems associated with lysosome purification, such as the detrimental osmotic 
effects of the centrifugation media used. Isolation of phagosomes containing 
magnetic bacteria is an alternative method of phagosome purification (Lonnbro et 
al., 2008, Steinhauser et al., 2013). Alternatively, magnetic bead containing 
phagosomes have been successfully purified from cells in multiple studies 
(Manoury, 2013, Arora et al., 2000, Thi et al., 2012, Ramachandra and Harding, 
2000). Isolation of magnetic bead phagosomes is rapid, as they can be removed 
quickly from a lysate and washed thoroughly on a strong magnet. Furthermore, 
cells that do not contain any beads are not co-purified. However, one 
disadvantage is that unbroken cells containing magnetic beads are also isolated, 
which is not desirable for some applications, e.g. western blotting. Furthermore, 
the fractionation method used to generate a cell lysate can damage the 
phagosomes, resulting in organelles that are not intact. As such, we sought to 
optimise this system for J774.2 cells, in order to purify streptavidin-bead containing 
phagosomes that were intact, for use in the in vitro fusion assay.   
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3.2.2 Phagosome-specific methods 
3.2.2.1 Phagosome purification 
This is the final protocol used to purify phagosomes. Section 3.7 describes how 
this method was developed. This protocol has been published in: Subcellular 
Fractionation. A laboratory manual. Cold Spring Harbour Protocols 2015 (Isolating 
Phagosomes from Tissue Culture Cells. P.R. Pryor and A.P.Rofe).  
J774.2 cells were seeded at 1 x 106 cells per well in 6 well plates. An additional 
well was seeded to perform cell number counts. The next day, cells were counted 
and prechilled to 4 ºC for 15 min in binding media (RPMI pH 7.4, 0.2 % (w/v) BSA, 
10 mM HEPES). Binding media was replaced with binding media containing 
streptavidin-coated magnetic microspheres (ProMag 3 series, Bangs Labs IN, 
USA) to a multiplicity of infection (MOI) of 3. Cells were incubated at 4 ºC for 1 h to 
allow the beads to bind, and then washed gently 3 times with ice cold PBS to 
remove unbound beads. Cells were incubated with DMEM (prewarmed to 37 ºC) 
to allow beads to be internalised. After an appropriate amount of time (25 min for 
fusion assay phagosomes), cells were scraped and rapidly cooled to 4 ºC by 
pelleting the cells at 1000 x g for 5 min at 4 ºC, and resuspending in PBS 
prechilled to 4 ºC. The cell pellet was resuspended in 1 ml of STM and incubated 
on ice for 10 min. The cells were then homogenised by 20 passages through a ball 
bearing homogeniser with an 8 µm clearance, at 4 º C. The homogenate was 
incubated on a DynaMag-2 magnet (Invitrogen) for 5 min on ice and the 
supernatant discarded. The phagosome pellet was gently resuspended in 1 ml of 
ice-cold STM. The washes were repeated twice more and the phagosomes were 
resuspended in STM. For characterisation of phagosomes by western blotting, 
phagosomes were normalised to OD600, 𝛃-Hexosaminidase activity or protein 
levels. For the latter, phagosomes beads were resuspended in an appropriate 
volume of modified RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1 % (w/v) 
deoxycholate, 1 % (v/v) Triton X-100, 0.2 % (v/v) NP-40). Beads were vortexed 
vigorously, pelleted in a microcentrifuge, and the supernatant transferred to a fresh 
tube. A BCA protein assay was then performed on the supernatants. 
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3.2.3 Results 
3.8.1 J774.2 cells internalise more beads as MOI is increased 
Firstly, the uptake of 3 µm beads by J774.2 cells was investigated, as 1- 3 µm 
particles had been proposed as the optimal particle size for phagocytosis, (Paul et 
al., 2013), which is the average size of many water and airborne pathogens and 
may represent a conserved mechanism for phagocytosis of particles of this size 
(Champion et al., 2008). J774.2 cells were seeded onto glass coverslips and an 
appropriate number of beads added to give a multiplicity of infection (MOI) of 3 or 
10, as this is a commonly used number for infection assays and phagosome 
studies. Where appropriate, beads were centrifuged onto cells at 50 x g for 5 min 
to determine whether centrifugation increased the efficiency of bead uptake. Cells 
were incubated for a further 45 min to allow uptake and internalisation, and then 
washed with PBS (to remove extracellular beads) and chased for 1 h in bead free 
media. Cells were fixed and immunolabelled with α-LAMP1 antibodies followed by 
α-mouse Alexa Fluor 555 IgG, to distinguish between internal and external beads 
(Fig. 3.15 A). Internal beads were found to be surrounded by a LAMP1 positive 
membrane, indicating that the beads were most likely in a late phagocytic 
compartment. The corresponding Brightfield image showed that external beads 
could be found on top of cells or in close association with them, but were not 
surrounded by a LAMP positive membrane (white asterisks). A bead was scored 
as internal only if it was surrounded by a LAMP positive membrane. The average 
percentage of internalised beads was 43 % and 62 % for an MOI of 3 (not 
centrifuged and centrifuged respectively), and 61 % and 54 % for an MOI of 10 
(not centrifuged and centrifuged respectively). Overall, there was a significant 
difference in the number of internalised beads between conditions (Fig. 3.15 B p = 
0.0003). Centrifugation significantly increased the number of internalised beads 
when an MOI of 3 was used (p = <0.05) but not when an MOI of 10 was used. This 
may have been because at an MOI of 10 without centrifugation, enough beads 
make contact with the cells to be internalised and reach the capacity of that cell, 
whereas at an MOI 3, centrifugation increases the number of beads a cell makes 
contact with and subsequently internalised. There was a significant difference (p = 
<0.05) between the number of internalised beads using an MOI of 3 and an MOI of 
10 when beads were allowed to settle onto cells. When beads were centrifuged 
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onto cells at an MOI of 3 or 10, there was no significant difference between the 
numbers of internalised beads (p = >0.05). At an MOI of 3, centrifuging beads onto 
cells increases the amount of uptake, but at an MOI of 10, centrifugation makes no 
difference to bead uptake. The average number of beads per cell was 2.29  and 
1.75 for an MOI of 3 (not centrifuged and centrifuged respectively), and 3.77 and 
3.59 for an MOI of 10 (not centrifuged and centrifuged respectively Fig. 3.15 C). 
There was a significant increase in the number of beads per cell when using an 
MOI of 10 compared to an MOI of 3 (p = <0.0001). Centrifuging beads onto cells 
did not increase the average number of beads per cell at either MOI. Cells were 
also scored for the numbers of internal beads (Fig. 3.15 D). The number of cells 
with 1 to 3 internalised beads was 94.3 % and 89.8 % (MOI:3, not centrifuged, and 
centrifuged respectively) and 55.3 % and 65.4 % (MOI:10 not centrifuged, and 
centrifuged respectively). The percentage of cells with between 4 and 6 beads was 
10.2 % and 5.7 % for an MOI of 3 (not centrifuged and centrifuged respectively). 
No cells with an MOI of 3 had more than 6 internalised beads, regardless of 
centrifugation conditions. At an MOI of 10, 34 % and 27.5 % of cells had between 
4 and 6 internalised beads (not centrifuged and centrifuged respectively). 8 % and 
6.4 % of cells had between 7 and 10 internalised beads (not centrifuged and 
centrifuged respectively), and 2.7 % and 0.7 % of cells had more than 11 
internalised beads (not centrifuged and centrifuged respectively). The highest 
number of beads seen inside a single cell was 16 beads (data not shown).  
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Fig. 3.15 Internalisation of magnetic beads by J774.2 cells. J774.2 cells were seeded 
onto glass coverslips. 3 µm magnetic beads were added to the cells at an MOI of 3 or 10. 
Beads were left to settle onto cells, or were centrifuged at 50 x g for 5 min. The cells were 
incubated for a further 45 min and then washed 3 x with PBS. After a further 1 h chase at 
37 ºC, cells were fixed and processed for confocal microscopy using α-LAMP1 antibodies 
to visualise phagosomal membranes. A. Representative confocal image of J774.2 cells 
immunolabelled with α-LAMP1 antibodies. Scale bar 10 µm. Asterisks show external 
beads associated with cells. B For each condition, beads were scored as being internal 
(surrounded by a LAMP1 positive membrane) or external, as judged by the corresponding 
Brightfield image. Data were analysed by one-way ANOVA. C. Average number of beads 
per cell for each condition. Data are means ± the range and were analysed by One-Way 
ANOVA. D. Histogram showing the distribution of numbers of internalised beads (as a 
percentage of the total number of internalised beads) for each condition tested. 300-600 
cells were counted per condition, with an average of 1500 beads counted per condition 
(n=1).  
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3.2.3.2 Purification of latent phagosomes from J774.2 cells. 
It was clear from these data that J774.2 cells would readily phagocytose magnetic 
beads and that at an MOI of 10, centrifugation was not necessary. Next, the 
purification of these phagosomes was optimised to try and yield intact 
phagosomes. While an MOI of 10 resulted in greater bead uptake, an MOI of 3 
was used for the optimisation experiments to reduce the amount of beads used in 
each experiment. Given that characterising the phagosomes by western blotting 
would also have required large amounts of sample, using an MOI of 10 for the 
experiments would have been prohibitively expensive. Secondly, beads were 
centrifuged onto cells (where appropriate) to try and synchronise bead uptake. 
Cells were pulse-chased with beads which were then released from cells by 
nitrogen cavitation (Fig. 3.16). The latency of phagosomes purified using nitrogen 
cavitation at 250 psi for 5 min was low, at only 24.8 %. When the time under 
pressure was dropped to 1 minute, this increased phagosome latency slightly to 
34.9 %, but this was not significant (p = 0.391). As nitrogen cavitation did not 
appear to be an appropriate method for phagosome purification, phagosomes 
were released from cells using a ball-bearing homogeniser to see if this would 
improve latency (Fig. 3.17). Both different ball-bearing sizes, and the number of 
passes used, was investigated. When cells were broken open using 40 passes the 
latency was slightly higher than nitrogen cavitation over the range of ball bearing 
sizes tested (30 % - 42 %). This was significantly (p = 0.0008) improved by 
reducing the number of passes from 40 to 20, which gave a much better latency 
over a range of ball bearing sizes (73 % to 85 %). The size of the ball bearing 
used did not significantly affect phagosome latency (p = 0.477). Phagosomes 
continued to be purified from cells using 20 passes and a 8.008 mm ball bearing. 
When the homogenisation was monitored under a light microscope, it became 
apparent that not all of the cells were broken open. While this would not interfere 
with the fusion assay, it was necessary to determine if these unbroken cells 
skewed the results of the β-Hexosaminidase assay and over estimated 
phagosome latency. The contribution of unbroken cells to the β-hexosaminidase 
assay was calculated by determining the AU of activity from a known number of 
cells (Table 3.1). This resulted in a slight (10 %) overestimation of phagosome 
latency. Despite this, phagosome latency was for the most part high (> 70 %). 
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Fig. 3.16 Latency of phagosomes purified from J774.2 cells using a nitrogen bomb. 
J774.2 cells were pulsed with 3 µm magnetic beads at an MOI of 3 for 45 min, washed 
three times with PBS to remove extracellular beads and incubated for 1 h at 37 ºC. Cells 
were scraped and resuspended in 1 ml of STM and phagosomes released from cells by 
nitrogen cavitation at 250 psi for 1 min (n=4) or 5 min (n=2) at 4 ºC. The latency of the 
purified phagosomes was then measured by β-hexosaminidase assay. Data are means ± 
SEM and were analysed by t-test. 
 
Fig. 3.17 Latency of phagosomes purified from J774.2 cells using ball-bearing 
homogenisation. J774.2 cells were incubated with 3 µm magnetic beads as per the 
figure legend of Fig. 3.16. Phagosomes were released from cells by 20 (n=3) or 40 (n=2) 
passes of a ball bearing homogeniser with different sized ball bearings. Phagosomes 
were then isolated on a magnet and washed three times with STM. The latency of the 
purified phagosomes were then measured by β-hexosaminidase assay. Data are means ± 
SEM and were analysed by two-way ANOVA. 
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  Ball bearing size (mm) 
  8.008 8.010 8.012 8.014 
- Triton 489 562 719 312 
+ Triton 3591 3354 2707 1599 
Latency (%) 86 83 73 80 
  
Unbroken Cells per µl of 
phagosomes 474.00 396.00 380.00 88.00 
No. of cells per assayed β-
Hex sample 
2370 1980 1900 440 
β−Hex AU overestimation per 
sample 1635 1366 1311 304 
Adjusted + Triton value 1956 1988 1396 1295 
Adjusted Latency (%) 75 72 48 76 
Difference (%) 11 11 25 4 
Average difference (%) 12.75 
 
Table 3.0 Contribution of unbroken cells to the results of phagosome β-
Hexosaminidase assay. Phagosomes were purified as previously described at the 
latency determined by β-Hexosaminidase assay. To determine the contribution that 
unbroken cells made to the + Triton sample, the indicated number of cells were subjected 
to β-Hexosaminidase assay to determine the amount of fluorescence (AU) from unbroken 
cells. The number of unbroken cells was then estimated by placing some of the 
phagosome sample on a haemocytometer and counting the unbroken cells. The number 
of unbroken cells per sample was multiplied by the AU per cell to give the contribution 
(AU) that unbroken cells made to the assay. These values were then subtracted from the 
+ TX sample and the adjusted phagosome latency was determined.  
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3.2.3.2 Characterisation of magnetic bead-phagosomes  
Next, phagosomes were biochemically analysed in order to be sure of purifying 
late phagosomes, rather than early phagosomes or fully mature phagolysosomes. 
J774.2 cells were equilibrated in binding media for 15 min at 4 ºC to cool the cells 
and stop phagocytosis in order to try and synchronise bead uptake. 3 µm beads 
were centrifuged onto cells for 5 min at an MOI of 3, and left to bind for 1 h at 4 ºC. 
Unbound beads were then removed by three washes with ice cold PBS. The PBS 
was replaced with DMEM preheated to 37 ºC to warm the cells and the cells were 
cultured at 37 ºC and bead internalisation allowed to proceed for varying amounts 
of time. This resulted in phagosomes of different ages, which were then purified 
and characterised. Initially, phagosomes were allowed to mature for 1 h before 
isolation and analysis by western blotting (Fig. 3.18 A). EEA1 and Rab5 were used 
as markers of early phagosomes, and LAMP1 and Rab7 as markers of late 
phagosomes. The level of cytoskeletal contamination was monitored by blotting for 
α-tubulin. All markers probed (except Rab7) were detected on phagosomes from 
10 min. The levels of EEA1, LAMP1, Rab5 and Rab7 remained low until 45 min 
where a large increase was seen. EEA1 and Rab7 then showed a slight drop from 
45-60 min. Except for 0 min, the level of α-tubulin was approximately the same for 
all time points. There was a sharp increase in the level of β-hexosaminidase 
activity between 30 min and 45 min, which remained high at 60 min (Fig. 3.18 B). 
The experiment was then repeated twice more with increasing time points in order 
to determine the reproducibility of the protocol. Phagosomes were purified as 
before, but at times ranging from 0 h to 4 h (Fig. 3.19). EEA1 was detected on 
phagosomes from 20 min and was present on phagosomes up to 4 h (Fig. 3.19 
A&B), where a large drop was observed (Fig. 3.19 B). LAMP1 increased to its 
highest levels between 80 min and 180 min. The levels of Rab5 and Rab7 were 
not significantly different between the different time points in either experiment. As 
seen previously, α-tubulin was associated with phagosomes at all time points. In 
contrast to the first experiment there was no lag in the increase of   hex activity, 
which steadily increased as the maturation time increased. Based upon previously 
published data (Pitt et al., 1992, Mayorga et al., 1991, Desjardins et al., 1994b) 
and as a result of our data, we concluded that 25 min - 30 min phagosomes are 
likely to beginning to interact with lysosomes (as judged by the presence of Rab7 
and LAMP1), but had not formed mature phagolysosomes, as there was no sharp 
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increases in β-hexosaminidase activity. However, from 60 min – 120 min, the 
increase in LAMP1 and β-hexosaminidase appeared to mirror each other, 
suggesting that phagosomes of these ages may indeed be reaching lysosomes. 
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Fig. 3.18 Characterisation of magnetic bead-phagosomes purified from J774.2 
macrophages. A. J774.2 cells were equilibrated in binding media (RPMI containing 10 
mM HEPES, pH 7.5, 0.2 % (w/v) BSA) for 15 min at 4 ºC to cool the cells and stop 
endocytosis in order to try and synchronise bead uptake. 3 µm beads were centrifuged 
onto cells for 5 min at an MOI of 3, and left to bind for 1 h at 4 ºC. Unbound beads were 
then removed by three washes with ice cold PBS. The PBS was replaced with DMEM 
preheated to 37 ºC to warm the cells and the cells were cultured at 37 ºC and bead 
internalisation allowed to proceed for the times indicated. The cells were immediately 
placed on ice for 15 min, and then scraped into 1 ml of ice cold STM. Phagosomes were 
released from cells by 20 passes of a ball-bearing homogeniser with a clearance of 12 
µm. Phagosomes were collected on a magnet, washed three times with STM, and then 
resuspended in 100 µl of STM. Phagosomes were then probed by western blotting for 
different endocytic and cytoskeletal markers. Samples were normalised to bead OD600. B. 
The activity of the lysosomal enzyme β-hexosaminidase was determined for each sample 
and normalised to bead OD600 (n=1).  
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Fig. 3.19 Characterisation of magnetic bead-phagosomes of 0 - 4 h purified from 
J774.2 macrophages. Magnetic bead-phagosomes of varying ages (0-100 min A., 0-240 
min B.) were purified from J774.2 cells as per the figure legend of Fig. 3.18. Purified 
phagosomes were then probed by western blotting for different endocytic and cytoskeletal 
markers. Samples were normalised to bead OD600.C & D. The activity of the lysosomal 
enzyme β-hexosaminidase was determined for each sample in A & B, respectively, and 
normalised to bead OD600. 
Due to the variability seen between phagosome isolations, and the possibility that 
not all phagosomes had matured after 4 h chase, the experiment was repeated a 
final time with phagosomes matured for 25 min, 4 h or 24 h. Samples were also 
normalised to OD600, protein concentration, or the activity of the lysosomal enzyme 
β-hexosaminidase (Fig. 3.20). The levels of EEA1 were highest between 4 h and 
24 h, regardless of normalisation method. Similarly, the highest amounts of 
LAMP1 detected on phagosomes were at 4 h and 24 h in all normalisations. Rab7 
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was detected at highest levels at 24 h when samples were normalised to β-
hexosaminidase, but there was no significant difference between time points in the 
remaining samples. A similar pattern was seen for Rab5, but a slight peak was 
seen at 4 h when samples were normalised to protein levels. Levels of α-tubulin 
were the same between all time points and normalisations. The β-hexosaminidase 
activity of phagosomes normalised to protein, revealed that there was no 
significant difference between samples. However, when normalised to OD600, β-
hexosaminidase activity increased from 25 min to 4 h, with a sharp increase from 
4 h to 24 h.  As a result of these data, 25 min phagosomes were chosen as the 
ideal age for the fusion assay, as these most likely represent phagosomes that 
were capable of interacting with lysosomes, but the majority had not undergone 
full maturation to a phagolysosomal state. 
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Fig. 3.20. Characterisation of magnetic bead containing-phagosomes normalised to 
β-Hexosaminidase activity, optical density, or protein concentration. Phagosomes of 
different ages were purified from J774.2 cells as per the figure legend of Fig. 3.18. A. 
Samples were normalised to OD600, protein concentration, or the activity of the lysosomal 
enzyme β-hexosaminidase, and probed by western blotting (W.B.) for markers of the 
endocytic pathway. B. The levels of β-hexosaminidase of the samples in A, normalised to 
OD600 (closed circles) or protein concentration (open circles) (n=1). 
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In summary, the final phagosome purification protocol was as follows: cells were chilled to 
4 ºC for 15 min in binding media. Beads were centrifuged onto cells at an MOI of 3 at 4 
ºC, and left for 1 h to bind to cells. Unbound beads were then washed with ice-cold 
binding media, and the media replaced with DMEM pre-warmed to 37 ºC. The 
phagosomes were then allowed to mature for 25 min, before cells were scraped into cold 
PBS and pelleted. The cells were resuspended in 1 ml of STM and homogenised with 20 
strokes of a ball bearing homogeniser with a clearance of 12 µm. The homogenate was 
then placed into a rack attached to a strong magnet to collect the phagosomes. The 
supernatant was discarded, and the phagosomes resuspended again in 1 ml of STM. This 
process was repeated three times to wash the phagosomes, which were then typically 
resuspended in 100 µl of STM. Phagosomes were typically around 70 % intact, with some 
unbroken cells (containing beads). Phagosomes were typically enriched for LAMP1, but 
other endocytic markers could also be detected. The recovery of phagosomes was not 
calculated. 
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3.2.4 Phagosome purification - Discussion 
3.2.4.1 J774.2 cells internalise more beads as MOI is increased 
Immunofluorescence analysis revealed that the bead-containing phagosomes 
appeared to be surrounded by a LAMP1 positive membrane, indicating that 
LAMP1 may have started to be incorporated into the phagosomal membrane. The 
caveat to this however, is that the volume of the cytoplasm of J774.2 cells is small. 
As such, was difficult to resolve a LAMP1 compartment from lysosomes in close 
apposition to internalised beads. The Z-stack images showed that the beads did 
appear to be completely surrounded by a LAMP1 membrane, and most likely were 
internalised (Fig. 3.15 A) 
The percentage of internalised beads increased as more beads were used at an 
MOI of 3 but not 10. Centrifugation also increased the uptake of beads, but only at 
an MOI of 3. This may indicate that enough beads settle onto cells at an MOI of 
10, and that the limit to uptake was the capacity of the cell to take up beads, rather 
than the availability of beads (3.15 B). For an MOI of 3 or 10, it would be likely that 
the percentage of internalised beads could be improved by ensuring cells were 90-
100 % confluent, thus reducing the number of beads that land on non-confluent 
cells. The average number of beads per cell did not differ when beads were 
centrifuged onto cells, but a significant increase was seen when a higher MOI was 
used (Fig. 3.15 C). This suggests that centrifugation increases the number of cells 
that phagocytose beads, but does not increase the number of beads that become 
internalised. Increasing the MOI also had the effect of increasing the number of 
cells containing more than 1-3 beads (Fig. 3.15 D). At an MOI of 3, only  ~ 10 % of 
cells containing beads only had more than 3 beads per cell, but at an MOI of 10, 
this increased to ~ 35 %. Thus, increasing the MOI increases the numbers of cells 
containing beads, and the numbers of cells containing more than 3 beads.  
The maximum number of beads seen within a single cell was 16, which may not 
be surprising give the propensity of this cell line to engulf particles more than 5.5 X 
their resting surface area (Lam et al., 2009). These data indicate significant 
heterogeneity in a macrophage population, with regards the extent to which they 
phagocytose particles. Although this experiment was only performed once, it was 
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clear that J774.2 cells would be suitable for phagosome purification. A higher MOI 
was hypothesised to result in a heterogeneous phagosome population than a 
lower MOI. A group of cells that have only one particle to internalise and delivery 
to the lysosome would most likely have enough free membrane to do so. A group 
of cells with some having one particle to phagocytose, but the rest having 3 or 4, 
would most likely result in the delay of phagocytosis for some of the particles, 
while membrane has to be synthesised de novo or recovered from other 
organelles, resulting in a mixed population of phagosomes of different states.  
Other phagosome purification protocols either do not take into account the 
importance of MOI when trying to synchronise cells, or they do not mention that 
they have done so. Clearly, the number of particles an individual cell has to 
internalise can have a great effect on the rate at which the phagosomes mature 
and is something that may need to be studied in greater detail.  
3.2.4.2 Purification of latent phagosomes 
Next, phagosome purification was optimised to yield intact phagosomes for use in 
the fusion assay. Cells were allowed to phagocytose beads, and were disrupted by 
nitrogen cavitation (Fig. 3.16) at 250 psi for 1 min or 5 min. The mean latency of 
the phagosomes was 35 % and 25 % respectively. This is in stark contrast to the 
latency of lysosomes purified by nitrogen cavitation. The poor latency may be due 
to increased fragility of phagosomes containing large solid particles. Both the 
membrane and lumenal contents of vesicles containing soluble cargo would be 
compressed under pressure. The membrane of phagosomes with insoluble 
contents (that do not compress easily) may be placed under increased pressure. 
For example, if the surface of the magnetic beads is not uniform and contains 
sharp or rough edges, this may provide a weak point in the membrane causing it 
to rupture. Phagosomes have previously been purified from cells using nitrogen 
cavitation (Lonnbro et al., 2008). However, the study used magnetically labelled-
bacteria rather than an inorganic non-aqueous particle. Furthermore, the latency of 
the phagosomes purified was only 35 %. This may indicate that nitrogen cavitation 
in general is not an ideal method for purifying phagosomes. Next, cells were 
fractionated using 40 passes of a ball bearing homogeniser with different sized ball 
bearings (Fig. 3.17). Phagosome latency was low (42 %), and, there was a slight 
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downward trend when ball bearing size was increased. However, phagosome 
latency was significantly improved when only 20 passes was used to homogenise 
cells. There was no clear trend in phagosome latency when the ball bearing size 
was increased regardless of the number of passes. The range of latency for 20 
passes was 71 % - 85 %, compared to 30 % - 41 % for 40 passes. Therefore, 
phagosomes continued to be purified from cells using an 8.008 mm ball bearing 
with 20 passes of the homogeniser. While the sample contained unbroken cells 
(as judged by monitoring the homogenate under a light microscope), these were 
deemed not to be a significant problem (Table 3.0). The number of unbroken cells 
counted did not alter the results of the β-hexosaminidase assay by more than an 
average of ~12.75 %. Unbroken cells would most likely not be an issue for the 
fusion assay, as they would not be able to participate in any fusion events.  
3.2.4.3 Characterisation of magnetic bead-phagosomes  
With regards to western blotting, one must assume that the same level of 
unbroken cells was present in all samples. Therefore, any contamination is 
present in all samples, and when analysed by western blot all samples should be 
the same. The fact that the levels of the markers analysed differed between 
phagosomes of different ages, indicates the changes are real and not due to 
sample contamination. Levels of contaminating proteins should not change, as 
they are present throughout each sample and do not participate in phagosome 
maturation (Rogers and Foster, 2007). Phagosome characterisation is not a trivial 
task. While the synchronisation of a cell population can be achieved, it is not 
possible to synchronise the process of phagocytosis. Within a cell population, and 
even within a single cell, phagosomes will mature at different rates due to the 
highly dynamic and heterogeneous nature of the endocytic and phagocytic 
pathway (Griffiths, 2004). The situation is further complicated by the nature of the 
particle(s) being phagocytosed, and the differing rates of phagocytosis between 
cells types. Much of the data obtained on phagosome maturation has been 
collected from many different lines of enquiry involving many cells types and 
different methods (Pitt et al., 1992, Duclos et al., 2000, Zimmerli et al., 1996, 
Manoury, 2013, Desjardins et al., 1994b, Garin et al., 2001). Therefore, proposed 
rates of phagosome maturation can only be taken as rough estimates. The fusion 
assay required phagosomes which remain fusogenic with lysosomes, but which 
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had not undergone fusion with the lysosome and reached a phagolysosomal 
endpoint. With that in mind, it was important to characterise the composition of 
phagosomes isolated from J774.2 cells.  
Phagosomes were characterised using a panel of markers, including early 
phagosomal (EEA1, Rab5), late phagosomal (Rab7) phagolysosomal (LAMP1), 
and cytoskeletal (α-tubulin) components. In all experiments, cells were incubated 
with beads at 4 ºC in order to synchronise binding to the cells. A chase period 
began with the addition of media warmed to 37 ºC, and phagosomes were isolated 
at varying time points.  The kinetics of phagosome maturation were examined from 
0-60 min (Fig. 3.18), 0-100 min/0- 4h (Fig. 3.19) and 25 min to 24 h (Fig. 3.20). 
EEA1 was detected on phagosomes on all phagosomes regardless of age. Rab5 
was detected at 10 min, but was also present on phagosomes from all time points 
and experiments. Rab5 is found on early endosomes and is involved in regulating 
homotypic endosome fusion (Hutagalung and Novick, 2011, Gorvel et al., 1991) 
EEA1 is a Rab5 effector, that binds activated Rab5 via two spatially separated 
domains (Simonsen et al., 1998, Callaghan et al., 1999), and is thought to act as a 
tether to bring endosomal membranes in close apposition in order for fusion to 
occur (Christoforidis et al., 1999). Despite the huge volume of information 
regarding the role of Rabs in endosome fusion and maturation, comparatively little 
is known about the roles of these proteins in phagosome maturation. Phagosome 
maturation is often thought to be analogous to endosome maturation, but many 
questions remained unanswered. Despite this, both Rab5 and EEA1 have been 
shown to be important in early phagosome maturation events. Rab5 is present on 
phagosomal membranes (Gutierrez, 2013) and regulates transient fusion events 
between phagosomes and endosomes (Duclos et al., 2000). The fact that many 
intracellular pathogens manipulate the function and distribution of Rab5 on 
phagosomal membranes, underlines its importance in phagosome maturation. 
Legionella penumophilia specifically excludes Rab5 from the phagosome 
membrane to prevent maturation. In contrast, Rab5 persists on the Mycobacterium 
tuberculosis containing-phagosome membrane, delaying the acquisition of 
proteins required for the maturation of the phagosome (Clemens et al., 2000). 
Moreover, M.tuberculosis phagosomes do not acquire EEA1 and microinjection of 
anti-EEA1 antibodies into macrophages delayed the acquisition of late endocytic 
markers onto latex bead phagosomes (Fratti et al., 2001). This can be in part, 
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attributed to the M.tuberculosis toxin lipoarabinomannan (LAM), that disrupts the 
production phosphatidylinositol-3-phosphate (PI3P) on phagosomal membranes, 
(Vergne et al., 2003). EEA1 to binds to PI3P on membranes via its FYVE domain 
(Lawe et al., 2000), and the inhibition of PI3P production by the PI3-kinase 
inhibitor wortmannin, reduces the recruitment of EEA1 to phagosome membranes 
(Vieira et al., 2001). Thus, any disruption to the localisation of Rab5 or EEA1 on 
phagosome membranes will result in retarded phagosome maturation.Rab7 and 
LAMP1 were found on almost all phagosomes. However, the changes in LAMP1 
levels between time points were more substantial. This was the same for the 
levels of β-hexosaminidase, which increased over time in all experiments and 
were always at their highest points at the longest time points in each experiment.  
A prerequisite of progression from an early endosome to a late endosome, is the 
removal of Rab5 the recruitment of Rab7 (Rink et al., 2005, Poteryaev et al., 2010) 
and its effector proteins (Zhang et al., 2009). The same Rab conversion may be 
necessary for phagosome maturation. The recruitment of Rab7 is required for 
phagosome maturation in Dictyostelium (Rupper et al., 2001), but its presence 
alone is insufficient to allow phagosome progression (Vieira et al., 2001). Rab7 
effector proteins such as Rab-interacting lysosomal protein (RILP) (Jordens et al., 
2001), and the HOPS complex (Balderhaar and Ungermann, 2013) are 
conceivably involved in phagosome maturation, but this has yet to be confirmed. 
Furthermore, it has been suggested that the Rab5 to Rab7 switch is regulated on 
M.tuberculosis phagosomes by Rab22a (Roberts et al., 2006). Interestingly, the 
gram-positive bacterium Tropheryma whipplei (the causative agent of Whipple’s 
disease) has been reported to survive in a Rab5 and Rab7 positive compartment. 
This demonstrates that it is possible to find both these GTPases residing 
concomitantly on the same intermediate compartment (Mottola et al., 2014). 
Clearly, Rab7 is central to phagosome maturation but the exact mechanisms by 
which it functions remain to be elucidated.  
Rab7 was detected on phagosomes as early as 20 min (Fig. 3.18), which may be 
indicative of an early to late phagosome transition. However, Rab7 has also been 
shown to accumulate on the phagosome membrane in as little as ten minutes, and 
this recruitment preludes any drop in phagosome pH and subsequent maturation 
(Harrison et al., 2003). Thus the presence or absence of Rab7 on its own is not a 
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sufficient criterion by which to class an organelle as a late phagosome. LAMP1 
was detected on phagosomes as early as 10 min, with the largest increase seen at 
45 min. This is in agreement with Pitt et al., (1992) who found that when using 
J774.2 E cells, formaldehyde fixed Staphylococcus aureus containing 
phagosomes acquired late endocytic markers (Cathepsin D, the mannonse-6-
phosphate receptor (M6PR), β-glucuronidase and the vATPase proton pump), 
within 7 minutes of phagosome creation. This indicates that some phagosomes 
rapidly begin to acquire components of the late endocytic pathway. However, the 
authors reported that the absence of a drop of M6PR at the latest time point 
indicated that phagosomes either cannot recycle the receptor, or do not progress 
to a phagolysosomal state within the maximum time point observed (18 min). 
Interestingly, the presence of LAMP1 and detectable levels of β-hex activity at 
early time points may indicate some phagosomes rapidly interact with late 
endocytic compartments. Indeed, in vivo, 5 nm gold particles were observed to be 
transferred from late endosome/lysosomes to S.aureus containing-phagosomes 
within 10 min of phagosome formation (Mayorga et al., 1991), demonstrating that 
some but not all phagosomes follow the same rate of maturation. As with Rab7, 
the caveat to this is that the transfer of a single membrane marker cannot be used 
to define the formation of the phagolysosome. 
Finally, we decided to compare 25 min phagosomes, with those isolated at 
extended time points (4 h & 24 h, Fig. 3.20). Samples were normalised to β-
hexosaminidase activity (AU), bead OD600, and protein concentration in order to 
characterise phagosomes. Normalising to β-hex shows the relative contribution of 
early endocytic markers when an equal amount of “phagolysosomal” material is 
loaded. Bead OD600 shows the “average profile” of all the phagosomes isolated 
from cells at a particular time point, while loading by protein normalises all the 
samples to the protein content in a phagosome sample. When loaded by β-hex, 
EEA1 was present to a greater extent in 4 h phagosomes, compared to 25 min 
and 24 h. 25 min phagosomes overall had less LAMP1, Rab5 and Rab7. This data 
was mirrored by the β-hex assay (Fig. 3.20 B), which showed that 25 min 
phagosomes had low levels of β-hex activity compared to those at 4 h and 24 h, 
indicating 25 min phagosome had not yet acquired large amounts lysosomal 
enzymes. Rab5 was found on 25 min phagosomes, with higher levels on 4 h and 
24 h phagosomes. The presence of LAMP1 and Rab7 at 25 min indicates some 
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interactions with late endocytic compartments. These interactions increase as the 
phagosomes were matured for longer periods of time, as levels of both these 
markers increased.  
While the presence of Rab5 on late phagosomes is unexpected, it has also been 
found to be present on latex bead phagosomes even after 25 h maturation 
(Jahraus et al., 1998). Therefore, this marker may never fully be lost from purified 
phagosome preparations. Alternatively, the levels of EEA1 and Rab5 proteins may 
be a reflection of contamination of the phagosomes with unbroken cells containing 
magnetic beads. However, this is unlikely, as the levels of the markers analysed 
change at different time points, rather than remaining constant. Similarly, EEA1 
and Rab5 may be present due to contamination by other endocytic organelles. It is 
reasonable to assume that some fragments of other organelles co-purify with 
phagosomes, e.g. trapped in the actin cytoskeleton surrounding the phagosomes 
(Rogers and Foster, 2007). Although the ability of phagosomes to fuse with early 
endosomes rapidly declines as they age (Desjardins et al., 1997, Jahraus et al., 
1998), this does not rule out the possibility that a small proportion of phagosomes 
may interact with early endosomes. Alternatively, early markers found in late 
phagosome samples may be due the creation of nascent phagosomes after the 
start of the chase period. The ability of a cell to internalise particles is limited by 
the amount of membrane it has available to facilitate phagocytosis. A cell with 
beads attached to the cell surface may internalise one or two, but cannot 
internalise the remaining beads until more membrane becomes available, either 
through remodelling of existing membrane or membrane biogenesis. Thus, within 
an individual cell there may be phagosomes of different ages with different 
membrane proteins (Griffiths, 2004). 
Unsurprisingly, it was found that α-tubulin was associated with phagosomes at all 
time points in all experiments (Figs. 3.18 - 3.20). Early phagosomes display a 
preference for the plus end of microtubules and are trafficked to from the cell 
periphery to the perinuclear region, a movement which is disrupted by microtubule 
disrupting drugs nocodazole and taxol (Blocker et al., 1998). Phagosomes have 
been shown in vitro to move along microtubules via kinesin and dynein motor 
proteins (Blocker et al., 1997), and the transfer of membrane or fluid phase 
markers from lysosomes to phagosomes is inhibited by microtubule 
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depolymerisation (Desjardins et al., 1994b, Blocker et al., 1996). Rab-interacting 
lysosomal protein (RILP), is able to interact with active Rab7, the HOPS complex, 
and (indirectly) with microtubules (van der Kant et al., 2013), thus linking 
lysosomes to microtubules. A requirement for both Rab7 and RILP has been 
shown for phagosome maturation through tubules that extend along microtubules 
and allow interactions between phagosomes and lysosomes (Harrison et al., 2003) 
Transport of both organelles along microtubules is necessary for phagolysosome 
formation, as they must be brought in close proximity to allow membrane fusion to 
occur. The interaction between phagosomes and the cytoskeleton is one that has 
been exploited by intracellular pathogens. Listeria monocytogenes effector ActA 
activates the actin related protein complex Arp2/3 in order to promote the 
polymerisation of actin comet tails on the bacteria, in order to propel it throughout 
the cytoplasm and invade neighbouring cells (Radhakrishnan and Splitter, 2012). 
Actin is also the target of several pathogens. The lipophosphoglycan (LPG) 
present on the surface of the intracellular parasite Leishmania donovani, is thought 
to recruit F-actin to the phagosome, physically preventing it from interacting with 
endosomes/lysosomes (Holm et al., 2001). Legionella penumophilia effector 
protein VipA has been demonstrated to nucleate actin without any additional host 
factors. This results in disrupted host actin dynamics and may help prevent fusion 
of the Legionella-containing vacuole (LCV) with the lysosome. Finally, Salmonella 
has a unique way of manipulating the host cell cytoskeleton, to gain entry into the 
cell and then prevent its delivery to the lysosome. Firstly, SopE promotes 
membrane ruffling and actin rearrangement to gain accelerated entry into the host 
cell. Subsequently, SptP then promotes the disassembly of actin, thus disrupting 
the trafficking of the Salmonella vacuole to the lysosome (Kubori and Galan, 
2003). Other cytoskeletal proteins have been found on phagosomes. Actin binding 
proteins annexin I (Kaufman et al., 1996), annexin II, IV, α-actinin and α-tubulin 
were found to be enriched on phagosomes (Desjardins et al., 1994a). As these 
binding proteins can interact with the actin cytoskeleton, this suggests that these 
could be possible mechanisms by which phagosome movement, (and subsequent 
maturation), is coupled to the movement of these organelles within the cell. 
Phagosome maturation is also highly dependant on interactions with the 
cytoskeleton. The movement of phagosomes away from the cell periphery may be 
analogous to the movement of lysosomes towards the nucleus, and may involve 
similar molecular mechanisms. Lysosomes typically display a perinuclear 
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distribution which is dependent upon microtubules (Swanson et al., 1987, Matteoni 
and Kreis, 1987) and their coupling to microtubules by motor proteins (Burkhardt 
et al., 1997) and cargo adaptors such as RILP (Cantalupo et al., 2001) and HSP6 
(Li et al., 2014). Actin filaments and microtubules have also been shown to act 
together to transport lysosomes within the cell (Cordonnier et al., 2001). 
Taken together, these data indicate that the purified phagosomes display a large 
degree of heterogeneity. This is due to the inability to synchronise the rate of 
uptake of the phagocytic probe by the cells. While it is possible to initiate 
phagocytosis at the same time, it is not possible to control how many beads, or 
how quickly individual cells internalise them. This is further complicated by the 
dynamic nature of phagosome maturation, and within an individual cell, 
phagosomes are likely to mature at different rates. Emans et al., (1996) showed 
that latex bead phagosomes (LBPs) displayed a cyclical nature of phosphorylation. 
LBPs isolated at 12 h displayed a significant decrease in in vitro phosphorylation 
compared to 2 h or 24 h phagosomes. A large number of lysosomal genes have 
recently been shown to display circadian rhythmicity (Mazzoccoli et al., 2015) and 
organelle remodelling may be under the control of circadian rhythms. Thus, it is 
possible that phagosomes may also oscillate, and phagosomes may be in different 
signalling states when isolated at different times. Furthermore, phagosomes 
isolated from RAW 264.7 cells were shown to have several markers that displayed 
a biphasic profile of abundance on phagosomes that was shown not to be due to 
nonsynchronous phagosome maturation (Rogers and Foster, 2007). Indeed, the 
pH of phagosomes can vary greatly (5.5-7.5), even within individual cells (Bouvier 
et al., 1994). As such, it must be accepted that the purified sample represents this 
entire range of phagosomes, and can only be enriched for a certain state (e.g. late 
phagosomes), rather than be a homogeneous preparation. Phagosomes are 
extremely complex organelles. In J774.2 cells alone, phagosomes most likely have 
over 1000 proteins, with roughly half of these remaining unidentified (Garin et al., 
2001). The composition while similar, differs between phagosomes containing 
different cargo and even between similar cells types. For example, the phagosome 
proteome of the macrophage-like cell line RAW 264.7, and bone marrow-derived 
macrophages (BMDM) has been shown to be significantly different. Furthermore, 
the phagosomes of BMDMs mature considerably faster than that of the RAW cell 
line (Guo et al., 2014).  Pathogen manipulation of membrane trafficking further 
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complicates what is already a difficult pathway to study. Therefore, the 
characterisation of phagosomes based upon the detection of a handful of 
membrane markers (that have other roles not limited to phagosome maturation), 
must be taken lightly. This paradigm must be accepted when working with these 
organelles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 137 
3.3 Phagosome-lysosome fusion in vitro 
3.3.1 Introduction 
An advantage of studying vesicle fusion in vitro is that it is possible to specifically 
study the interaction of donor and acceptor organelles and the conditions that 
facilitate fusion between them. In in vivo systems, the overall complexity of the 
cell, the possibility of off-target effects, and compensatory mechanisms may allow 
vesicle fusion to continue when a particular condition is altered. This means it can 
be difficult to interpret results of such experiments. A cell-free assay allows the 
study of the interactions between specific vesicles under specific conditions, at a 
molecular level. 
Previous vesicle fusion assays have been invaluable in addressing the 
requirements of vesicle fusion in vitro. These include transport between Golgi 
stacks (Balch et al., 1987, Rothman, 1987), transport between the endoplasmic 
reticulum and the Golgi (Barlowe, 1997), endosome fusion (Gorvel et al., 1991), 
endosome-lysosome fusion (Mullock et al., 1989), and SNARE-mediated liposome 
fusion (Schuette et al., 2004). These include factors such as cytosol, physiological 
temperature, and the presence of ATP/GTP, (Mullock et al., 1989, Becken et al., 
2010, Mullock et al., 1998, Ward et al., 1997) which have been shown to be 
essential for vesicle fusion. However, only one such study to date, has attempted 
to dissect the fusion of phagosomes and lysosomes in vitro (Becken et al., 2010). 
However, this study is not without some caveats. Firstly, it measures the 
colocalisation of fluorescently labelled lysosomes and phagosomes. However, 
colocalisation cannot distinguish between vesicle tether and true fusion. The study 
uses FRET to demonstrate that vesicle fusion occurs, but does not use this 
measurement for every experiment. Secondly, it does not measure the intactness 
of the compartments being used and cannot rule out that the FRET signal seen 
was due to content mixing of leaky organelles rather than true fusion.  
3.3.1.1 Phagosome-lysosome membrane fusion 
The fusion of phagosomes with other endocytic organelles is crucial for their 
maturation. Nascent phagosomes mature through the addition and removal of 
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membrane proteins and other components by fusion with early and late 
endosomes, and finally, with lysosomes to form phagolysosomes (Vieira et al., 
2002). Thus, membrane fusion must be tightly regulated in order for the correct 
vesicles to be targetted to the maturating phagosome. The fusion of intracellular 
vesicles is driven by several molecular complexes, which provide the energy 
required to overcome the energy barrier of lipid membrane fusion, but also confer 
specificity to interactions. SNARE (soluble NSF [N-ethyl-maleimide-sensitive 
fusion protein] attachment receptor protein) proteins have been demonstrated to 
be involved in almost all cellular membrane trafficking events so far. SNAREs are 
designated as being (arginine containing) R-SNAREs, or (glutamine-containing) Q-
SNAREs, based upon the presence of these highly conserved residues 
(Fasshauer et al., 1998). SNAREs have been shown to be the minimal proteins 
required for membrane fusion (Weber et al., 1998), and may also help to provide a 
layer of specificity to the pairing of donor and acceptor vesicles (Sollner et al., 
1993), along with Rab GTPases and other tethering factors. 
3.3.1.2 Principle of the in vitro phagosome-lysosome fusion assay 
In order to study the fusion of the phagosome and lysosome in vitro, two protocols 
were developed for the purification of these two organelles. A schematic 
representation of the fusion assay is shown in figure 3.21. Briefly, FeDex and 
biotin-HRP filled lysosomes are mixed in vitro with magnetic streptavidin bead-
containing phagosomes. Fusion is enhanced by the addition of cytosol and an 
ATP regenerating system. To prevent binding of biotin-HRP to streptavidin 
phagosomes where the membrane integrity is compromised, the assay is 
performed in the presence of saturating amounts of biotinylated lysine (biocytin), to 
mop up any biotin binding sites on the beads. After fusion has proceeded, the 
bead containing phagolysosomes are collected on a magnet, lysed with detergent 
and washed thoroughly. The amount of HRP activity is then assayed using Amplex 
Red (AR) reagent to quantify the amount of fusion.  
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Fig. 3.21. Schematic representation of in vitro phagosome-lysosome fusion. 1. 
Biotin-HRP filled lysosomes are magnetically isolated using FeDex as previously 
described. Streptavidin bead containing phagosomes are also purified magnetically as 
previously described. The two organelles are then mixed in vitro. Fusion is enhanced by 
the addition of cytosol and an ATP regenerating system. To prevent binding of biotin-HRP 
to streptavidin phagosomes where the membrane integrity is compromised, the assay is 
performed in the presence of saturating amounts of biotinylated lysine (biocytin), to mop 
up and biotin binding sites on the beads. 2. Fusion is allowed to proceed, and the bead 
containing phagolysosomes are collected on a magnet, lysed with detergent and washed 
thoroughly. 3.The amount of HRP activity is then assayed using Amplex Red (AR) reagent 
to quantify the amount of fusion. 
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3.3.1.3 Amplex Red reaction 
Amplex Red is a non-fluorescent and colourless compound that is used as a 
reagent for the measurement of H2O2. Amplex Red reacts with H2O2 in a 1:1 
stoichiometry (Fig. 3.22). The reaction is catalysed by horseradish peroxidase 
(HRP), to form the highly fluorescent oxidation product, Resorufin, which is excited 
at 568 nm and emits at 581 nm (Zhou et al., 1997). Amplex Red is highly sensitive 
and can detect concentrations of H2O2  as low as 50 nM, or HRP concentrations as 
low as 1 x 1-5 U/ml (Thermo fisher product data sheet). Amplex Red has been 
used in a variety of different assays to measure HRP activity (Bulina et al., 2006, 
Nakanaga et al., 2007, Castello et al., 2007) 
 
Fig. 3.22. Oxidation of Amplex Red to form Resorufin. Horseradish peroxidase (HRP) 
catalyses de-N-acetylation and oxidation of Amplex Red (Non-fluorescent) to Resorufin 
(Highly fluorescent) in a 1:1 stoichiometry.  
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3.3.2 Fusion assay specific methods 
3.3.2.1 Detection of biotin-HRP using Amplex Ultra Red 
To detect lysosomal biotin-HRP, lysosomes were purified from J774.2 cells as per 
the FeDex protocol (section 3.2.2) but with the following changes. Biotin-HRP 
(Invitrogen, catalogue number P-917) was added to the FeDex-containing tissue 
culture media to a final concentration of 0.5 mg/ml. Lysosomes were then purified 
as previously described. HRP-containing lysosomes were then assayed for HRP 
using Amplex Ultra Red (AR) reagent (Invitrogen, catalogue number A36006). In 
the presence of HRP, Amplex Red reacts (in a 1:1 stoichiometry) to produce a red 
oxidation product, Resorufin (excitation and emission maxima of 571 nm and 585 
nm respectively, (Zhou et al., 1997). Lysosomes or phagosome beads were 
resuspended in RIPA buffer or STM containing 0.1 % (v/v) Triton X-100 and plated 
in duplicate into the wells of a black flat-bottomed microplate (Nunc). 50 µl - 150 µl 
of AR working reagent was then added immediately to each sample using a 
multichannel pipette. 
Amplex red working reagent was prepared as follows: One vial of Amplex Ultra 
Red (1 mg) was dissolved in 389 µl of DMSO (dimethyl sulfoxide) to give a final 
concentration of 8.6 mM. 20 mM H2O2 was prepared fresh by adding 3 µl of 30 % 
(w/w) H2O2 in 977 µl of ice-cold STM or RIPA buffer. 50 µl of 8.6 mM Amplex Red, 
and 500 µl of 20 mM H2O2 were added to 4.45 ml of STM or RIPA buffer (giving a 
final concentration of 86 µM Amplex Red and 2 mM H2O2). Samples were 
measured in a BMG Polarstar plate reader preheated to 37 ºC with an excitation 
wavelength of 541 nm and emission read at 590 nm. Fluorescence measurements 
were taken every minute for 30 min, with the gain set appropriately between 
experiments (for the majority of experiments, this was 1800). Where appropriate, 
blank values were subtracted from data, and data were plotted at a point when the 
production of fluorescent resorufin was still occurring. 
3.3.2.2 Isolation of pig brain cytosol 
Fresh pig brains were finely minced and snap frozen in liquid nitrogen and stored 
at -80 ºC until required. Approximately 4 g of pig brain was partially defrosted and 
resuspended in 3 ml of ice-cold STKM (250 mM sucrose, 10 mM TES, pH 7.4, 1 
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mM MgCl2, 25 mM KCl). Brain tissue was homogenised on ice with three strokes 
of a Potter-Elvehjem homogeniser (with the pestle attached to a household drill 
rotating at 1000 rpm). The homogenate was then centrifuged at 104,300 x g , for 
15 min at 4 ºC. The supernatant was adjusted to approximately 3 ml with STKM 
and passed through an Econo-Pac 10DG disposable chromatography column 
(BioRad). The cytosol was eluted from the column with 4 ml of STKM, snap frozen 
in liquid nitrogen, and stored at -80 ºC. The protein concentration was typically 5-
10 mg/ml. Pig brain cytosol for use in the fusion assay was prepared a maximum 
of one day before the assay. 
3.3.2.3 In vitro phagosome-lysosome fusion assay 
This is the protocol as it currently stands. Section 3.13 shows the development of 
this assay protocol. 
Lysosomes were purified from four 10 cm tissue cultures dishes of J774.2 cells as 
previously described with the following changes. Cells were pulse-chased with 
FeDex diluted 1:20 in DMEM, with the addition of 0.5 mg/ml biotin conjugated – 
HRP. Lysosomes were eluted from the iron column with 1 ml of pig brain cytosol. 
Streptavidin-bead phagosomes were prepared as previously described, except 
phagosomes were resuspended in 200 µl of  pig brain cytosol. All samples were 
set up on ice in prechilled tubes. 25 µl of lysosomes and 25 µl of phagosomes 
were added to each tube. To reduce the background signal from damaged 
organelles, 25 µl of biocytin (25 µg/ml biotinylated lysine in STKM) or 25 µl STKM 
was added. Where appropriate, 25 µl of an ATP regenerating system (10 µl of 4 
mg/ml creatine kinase in PBS, 10 µl of 261.2 mg/ml creatine phosphate in PBS, 
2.5 µl of 50 mM ATP, and 2.5 µl of 50 mM GTP) or 25 µl of PBS was added to 
each tube. Fusion was allowed to proceed for 30 min on ice or in a 37 ºC water 
bath. After 30 min, tubes were plunged into ice-cold water.100 µl of 2 X RIPA 
buffer was added to each tube, which was vortexed and incubated on ice for 15 
min. The streptavidin beads were collected on a magnet, washed three times with 
1 X RIPA, and resuspended in 50 µl of RIPA buffer. Biotin-HRP bound to the 
beads was detected using Amplex Ultra Red, as previously described.  
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3.3.3 Results 
3.3.3.1 Biotin-HRP can be detected in lysosomes 
An inherent problem with studying lysosomes is that the hydrolytic enzymes they 
contain are able to degrade ligands or markers that are delivered to the lysosome. 
For the fusion assay, biotin-HRP needed to be detectable in FeDex-purified 
lysosomes. To test this, lysosomes were purified from cells incubated with biotin-
HRP and were assayed with Amplex Red to determine if an HRP signal could be 
detected. 4x10 cm tissue culture dishes of J774.2 cells were incubated with 0.5 
mg/ml biotin-HRP in DMEM containing FeDex (1:20) for 1 h followed by a 
HRP/FeDex-free chase for 2 h (Fig. 3.23). As a control, the same number of cells 
were subjected to the same protocol without biotin-HRP. Lysosomes were 
magnetically isolated, and assayed for the presence of HRP using Amplex Ultra 
Red reagent  (AR). 
A fluorescent signal (above that of the highest volume of control lysosomes), was 
detectable when AR was incubated with biotin-HRP containing lysosomes for all of 
the volumes of lysosomes tested (25 µl to 0.19 µl). Control lysosomes did not 
produce a fluorescent signal when incubated with AR, indicating that they do not 
react with Amplex Red. For lysosomes containing biotin-HRP, the rate of resorufin 
production increased over time and was dependent on the volume of HRP-
lysosomes.  After 10 min (Fig. 3.22) the highest amount of fluorescence seen in 
the samples with the highest amounts of lysosomes. 25 µl (2650 AU) was lower 
than 12.5 µl (3040 AU) but this was most likely experimental error. After 30 min 
the signal from 25 and 12.5 µl of biotin-HRP lysosomes decreased negligibly 
(2553 AU and 2915 AU). However, the signal from lower volumes of lysosomes 
increased. For example, at 10 min 1.56 µl gave a signal of 906 AU, which 
increased to 1832 AU after 30 min. Control lysosomes (containing no biotin HRP) 
did not give a signal at either 10 min or 30 min, indicating they did not react with 
Amplex Red. These data indicate that give enough time, small amounts of biotin-
HRP can react with Amplex Red to give a much larger signal. Thus, 30 min 
endpoints were not suitable for the fusion assay, and it was decided that all data 
needed to be collected when the rate of resorufin production was linear and before 
the Amplex Red became a limiting factor in the samples with higher amounts of 
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HRP. The plateau of fluorescence seen with the highest volume of lysosomes 
(12.5 µl) was probably due to the depletion of AR substrate. If this was the case 
then all samples, given enough time, would eventually reach the same endpoint. 
Although, at 37 ºC, this would accelerate the rate at which H2O2 decomposes to 
water and singlet O2. It is also possible that the production of resorufin from 
Amplex Red is self-quenching at high concentrations. Thus, large amounts of HRP 
give lower fluorescence signals than samples that have lower amounts of HRP. 
 
Fig. 3.23. Detection of biotin-HRP from FeDex-purified lysosomes. 4x10 cm tissue 
culture dishes of J774.2 cells were incubated with 0.5 mg/ml biotin-HRP in DMEM 
containing FeDex (1:20) for 1 h followed by a HRP/FeDex-free chase for 2 h As a control, 
the same number of cells were subjected to the same protocol without biotin-HRP. 
Lysosomes were isolated from cells as previously described lysosomes, and resuspended 
in a final volume of 100 µl of STM containing 0.2 % (v/v) Triton X-100. Serial dilutions of 
control or HRP lysosomes were performed in a 96 well plate (in duplicate), and 50 µl of 
Amplex Red (AR) reagent was used to assay for HRP. The fluorescence signal was read 
every minute for 30 min at 37 ºC. Data are means ± range of fluorescence values after 10 
min or 30 min (Excitation wavelength 541 nm, emission wavelength 590 nm). Data are the 
results of one experiment, with the same trend seen in two separate experiments.  
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3.3.3.2 Transfer of biotin-HRP from lysosomes to phagosomes 
can be detected in a mixing assay 
The previous experiment showed that biotin-HRP was detectable within lysosomes 
from cells incubated with biotin-HRP but not control cells. However, it was possible 
that the biotin could have been degraded in the lysosome and be unable to bind to 
the beads. Similarly, the streptavidin on beads could be degraded in the 
phagosomes, rendering the beads unable to bind biotin-HRP. To ensure that this 
was not the case a mixing assay was performed. This would also demonstrate that 
the mixing of the two organelles would give a detectable signal that could be 
blocked by the addition of biotinylated-lysine (biocytin) and finally, determine the 
lowest volume of phagosomes that could be used for an assay (Fig. 3.24). Briefly, 
HRP lysosomes were purified from 4x10 cm dishes of J774.2 cells and 
resuspended in 120 µl of STM containing Triton-X 100 at 0.2 % (v/v) to lyse 
lysosomal and phagosomal membranes. Phagosomes were purified from a 
second batch of cells, and again lysed in Triton X-100. Briefly, phagosomes were 
isolated from one 6-well plate of cells at an MOI of 3 (approximately 100 µl of 
beads). One half of the purified phagosomes were incubated in STM (unblocked) 
and the other half in STM containing 5 µg/ml biocytin for 30 min on ice. Biocytin 
will compete with biotin-HRP for streptavidin binding sites on the bead 
phagosomes, thus blocking the signal. 3 µl of lysosomes were then incubated with 
doubling dilutions of phagosomes for 15 min at room temperature with rotation, to 
allow the HRP to bind to the beads. Beads were then isolated, washed, and 
assayed for HRP activity using AR.  The fluorescence signal after 10 min from 3 µl 
of lysosomes was 25563 AU (data omitted from the graph for brevity). At 10 min, 
the largest fluorescence signal was seen with unblocked phagosomes was 5410 
A.U and the highest HRP signal obtained from blocked phagosomes was 610 A.U. 
The percentage of the total fluorescence signal (from 3 µl of lysosomes) for 
blocked phagosomes was 2.4 %, 3 %, 0.54 %, 0.68 %, 0.94 %, 0.23 %, 0.36 %, 
and 0.16 % (dilution 1-8 respectively).  The percentage of the total fluorescence 
signal for unblocked phagosomes was 23 %, 16.6 %, 7.2 %, 5.6 %, 0.8 %, 0.4 %, 
0.6 %, and 0.31 % (dilution 1-8 respectively). In general, the HRP signal dropped 
with each subsequent dilution of phagosomes (both blocked and unblocked). This 
experiment showed that the limiting factor in the fusion assay would most likely be 
the phagosomes. Only 2.5 % of the total volume of lysosomes were used for each 
 146 
phagosome sample, yet over 75 % of the total HRP signal remained unbound. 
However, this may have been due to the fact that mixing of phagosomes and 
lysosomes was only performed for 15 min. If this incubation time was increased, it 
would be likely that the total percentage of HRP recovered would increase, giving 
a better estimation of the number of phagosomes needed to bind all of the 
available HRP. Approximately 100 µl of stock beads were used to purify 
phagosomes in this experiment. As this sample was split in half (blocked and 
unblocked) and then diluted, the lowest amount of beads where an HRP signal 
was detectable in this experiment was approximately 12.5 µl. 
 
Fig. 3.24 In vitro phagosome-lysosome mixing A. Biotin-HRP containing lysosomes 
were purified from 4x10 cm tissue culture dishes of J774.2 cells and resuspended in 120 
µl of STM + 0.2 % (v/v) T X-100. Streptavidin bead phagosomes were purified from a 
different batch of J774.2 cells as described in previously (approximately 100 µl of beads). 
Phagosomes were then incubated with (open bars) or without 5 µg/ml biocytin (closed 
bars) to block biotin binding sites on damaged phagosomes. Doubling dilutions of 
phagosome samples (1-8) were incubated with 3 µl of HRP-lysosomes for 15 min at room 
temperature with rotation. The beads were retrieved on a magnet, washed three times 
with STM and the amount of bound HRP assayed using 50 µl of Amplex Red. The 
fluorescence signal was read every minute for 30 min at 37 ºC. Data are means ± range 
of fluorescence (AU) after 10 min when the fluorescence signals were still increasing 
(n=1). 
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3.3.3.3 HRP binding to streptavidin beads can be blocked by 
biocytin 
Previous data indicated that biotin-HRP was not degraded sufficiently in 
lysosomes to be undetectable and that binding to beads could still occur after the 
beads had been passed through cells. To be sure that the HRP signal was bona 
fide binding of biotin-HRP to biotin binding sites, rather than a non-specific 
interaction, the binding of HRP was blocked by titrating increasing amounts of 
biocytin. The streptavidin beads were capable of binding 0.44 µg of FITC-biotin 
per mg of beads (6.824 x 10-10 moles of FITC-biotin per mg of spheres). 20 µl of 
beads was roughly 200 µg in mass, which gave a binding capacity of 1.36 x 10-10 
moles of FITC-biotin. Substituting in the estimated molecular weight of biotin-HRP 
(476.31 g/mole), this gave a bead binding capacity of 6.47 x 10-8 g (65 ng) of 
biotin-HRP per 20 µl of beads. Substituting in the molecular weight of biocytin 
(372.48 g/mole), 1.36 x 10-10 moles of biocytin, 50.65 ng of biocytin can bind to 20 
µl of beads. Thus, 20 µl of beads (not incubated with cells) were added to 0.5 ml of 
STM containing a saturating amount of biotin-HRP (65 ng) plus biocytin at 0, 6.25, 
12.5, 25, 50, 100, or 500 ng/ml (Fig. 3.25). Samples were incubated for 30 min, 
washed with RIPA buffer and then assayed for HRP activity using Amplex Red.  
The signal decreased as the amount of biocytin was increased. The total 
fluorescence signal from 65 ng of biotin-HRP alone (no beads) was 31453 AU. 
The highest bead signal was seen with 0 ng/ml biocytin (21528 AU, 68.4 % of the 
total) and the lowest signal was detected at 100 ng/ml (2548 (8.1 % of the total). 
When the data was normalised so that 0 ng/ml = 100 % binding, and 500 ng/ml = 
0 % binding), then the percentage of biotin-HRP bound to the beads was as 
follows; 87.3 % (6.25 ng/ml), 81.6 % (12.5 ng/ml), 61.5 % (25 ng/ml), 44 %, (50 
ng/ml), and 1.8 % (100 ng/ml). 500 ng/ml gave no increase in signal for the 
duration of the time course (30 min). Therefore, for further experiments, 500 ng/ml 
(250 ng absolute amount) was deemed sufficient to block the binding of biotin-
HRP to 20 µl of beads.  
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Fig. 3.25. Biotin-HRP binding can be blocked by biocytin. 20 µl of streptavidin beads 
were incubated with 0.5 ml STM containing biocytin at the indicated concentrations and 65 
ng of biotin-HRP, for 30 min at room temperature. The beads were then isolated, washed 
three times with RIPA buffer, and resuspended in 50 µl of RIPA buffer. HRP activity was 
then detected using 50 µl of Amplex Red reagent using a plate reader heated to 37 ºC. 
The graph shows fluorescence after 10 min while the fluorescent signal was still 
increasing. Data is representative of a single experiment that was repeated twice. 
3.3.3.4 J774.2 cell lysate does not interfere with HRP binding  
As HRP-containing lysosomes and bead-containing phagosomes for the fusion 
assay were purified from J774.2 cells, it was important to ensure that any cellular 
debris carried over from washing the organelles did not react with the Amplex Red 
reagent to give a fluorescence signal. To test this, 20 µl of beads were incubated 
with a J774.2 cell lysate equivalent to that of the number of cells 20 µl of 
phagosomes would be purified from, i.e., for the phagosome purification, 20 µl of 
beads were incubated with approximately 4x106 cells. Cells were lysed in cell lysis 
buffer and a detergent soluble lysate was made (as previously described). 20 µl of 
beads were incubated with or without 500 ng/ml biocytin, and then washed. 
Unblocked and blocked beads were then incubated with biotin-HRP or J774.2 cell 
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lysate (Fig. 3.26). The beads were then washed, and assayed for HRP activity. To 
demonstrate that any fluorescence seen was due to the binding of biotin-HRP, 
beads were incubated with or without biocytin to show that binding could be 
blocked. Indeed, there was no change in fluorescence (over 30 min) when beads 
were pre-incubated with biocytin and then incubated with biotin-HRP (919 AU) 
When blocked and unblocked beads were incubated with J774.2 cell lysate, the 
fluorescence signal remained constant, (J774 blocked 717 AU, J774.2 unblocked 
756 AU), and below that of beads incubated with biocytin (HRP blocked). Similarly, 
a J774.2 cell lysate gave no fluorescence signal above that of the blocked beads 
(159 AU). The fluorescence signal after 10 min from the HRP control was 13150 
AU. The fluorescence signal of the unblocked beads after 10 min was 51 % of this 
(6750 AU). This dropped to 6.9 % when beads were blocked with biocytin 
beforehand, but given that this signal did not change over the course of the assay 
(30 min), it is likely to be background noise. Overall, these data indicate that the 
J774.2 cell lysate does not react with Amplex Red to give a fluorescence signal, or 
it does not stick to the beads/is sufficiently removed when the beads are washed. 
Therefore, any fluorescence signal seen when assaying beads using Amplex Red 
is due to the presence of bound biotin-HRP alone. 
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Fig. 3.26. J774.2 cell lysate does not produce a fluorescent signal when assayed 
with Amplex Red. 20 µl of streptavidin beads were either incubated with 0.5 ml STM 
(unblocked) or STM containing 500 ng/ml biocytin (blocked) for 15 min at room 
temperature. Beads were then washed 3 times with STM, and incubated with 65 µl of 
biotin-HRP in STM (1 µg/ml), plus 225 µl of STM, or 290 µl of a J774.2 cell lysate for 30 
min at room temperature. Beads were then washed three times with RIPA buffer, and 
bound HRP activity assayed using Amplex Red. As a control, 65 µl of 1 µg/ml biotin-HRP, 
and 50 µl of J774.2 cell lysate were also assayed Data are fluorescent signals after 10 
min while the fluorescence signal was still increasing (n=1).  
3.3.3.5 Determining the maximum signal obtainable from 
streptavidin beads 
Based upon previous fusion assays (Becken et al., 2010, Mullock et al., 1998, 
Mullock et al., 1989, Ward et al., 1997, Jahraus et al., 1998) the amount of vesicle 
fusion was likely to only be 5-10 % of the total obtainable signal. To maximise the 
sensitivity of the assay and see such low rates of fusion, it was necessary to 
determine the amount of biotin-HRP needed to saturate 20 µl of streptavidin beads 
(arbitrary volume of beads). This was previously calculated to be 65 ng. However, 
the binding of biotin-HRP to the beads was routinely performed for 30 min in 0.5 
ml volumes. When using biotin-HRP at 130 ng/ml (65 ng per 0.5 ml), 30 min was 
 151 
not long enough to saturate beads. To try and saturate the beads within this time 
frame, 20 µl of beads were incubated with increasing amounts of biotin-HRP in 
STM for 30 min at room temperature, washed, and then assayed for bound HRP 
with AR (Fig. 3.27 A&B). The fluorescence signal continued to increase as the 
concentration of biotin-HRP was increased, up to 1000 ng/ml (Fig. 3.27 A). The 
highest amount of fluorescence was seen at 1000 ng/ml (9540 AU), followed by 
500 ng/ml (7340 AU), 125 ng/ml, (6000 AU), 250 ng/ml (5460), 62.5 ng/ml (2890 
AU), 31.25 ng/ml (1990 AU), 15.6 ng/ml (1150 AU) and 7.8 ng/ml (446 AU). As no 
plateau in fluorescence was observed, the experiment was repeated using higher 
concentrations of biotin-HRP (1000-5000 ng/ml, Fig. 3.27 B). The highest amount 
of fluorescence was seen at 2000 ng/ml (12,500 AU), followed by 1000 ng/ml 
(11,700 AU), 500 ng/ ml (10,760), 3000 ng/ml, (10,400 AU), 5000 ng/ml (9740), 
4000 ng/ml (9730), 250 ng/ml (8190 AU) and 125 ng/ml (4,800 AU). Given that the 
fluorescence did not differ greatly from 500-5000 ng/ml, it was concluded that 0.5 
ml of 500 ng/ml biotin-HRP was probably sufficient to saturate 20 µl of beads in 30 
min, but it was not clear if the beads were saturated or if the Amplex Red substrate 
itself was limiting. It was important to test this to ensure that the assay reagent 
was not limiting in the fusion assay. To test this, 20 µl of beads were saturated 
with biotin-HRP (0.5 ml of 500 ng/ml) for 30 min at room temperature. The beads 
were then washed and assayed with 50, 100, 150, 200, or 250 µl of Amplex Red 
(Fig. 3.28). Increasing the volume of Amplex Red by 5-fold did not result in a 5-fold 
increase in fluorescence. After 10 min, the fluorescence of samples incubated with 
50 µl of Amplex Red was 55 % of the signal from 250 µl of Amplex red. 150 µl of 
AR gave 85 % of the signal seen from 250 µl.  Doubling the volume of Amplex 
Red substrate did not result in a doubling of fluorescence, indicating resorufin 
production was not limited by the availability of the substrate, but possibly by the 
rate at which HRP could catalyse the production of resorufin. Alternatively, the rate 
of production may have altered as the amount of H2O2 was depleted. For further 
experiments, 150 µl of assay reagent was used as it was thought that this would 
be a sufficient volume to not be a limiting factor. However, as long as the 
fluorescence signals were measured at a point when the signal was still increases 
(i.e. before all of the substrate was used up) then the volume of assay reagent 
would not matter as long as it was the same for all samples used. 
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Fig. 3.26 Saturation of streptavidin beads with biotin-HRP. 20 µl of streptavidin beads 
were incubated with 0.5 ml of STM containing biotin-HRP at the concentrations shown 
(ng/ml) for 30 min at room temperature. The beads were washed three times with RIPA 
buffer, and the level of biotin-HRP bound to the beads determined by Amplex Red assay 
using a plate reader preheated to 37 ºC. A&B show the results of independent 
experiments over two different ranges of biotin-HRP concentrations. Data are 
fluorescence taken at 5 min when the fluorescence of the samples was still increasing. 
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Fig. 3.28. Increasing the volume of Amplex Red increases the fluorescence signal. 
20 µl of streptavidin beads were saturated with 0.5 ml of STM containing 500 ng/ml biotin-
HRP. Beads were then washed three times and assayed with the indicated volumes of 
Amplex Red. Samples were adjusted to 250 µl by the addition of RIPA buffer. As a 
control, 20 µl of beads were incubated in STM alone (Beads only). Data are means ± the 
range, with each data point plotted as a % of the signal seen from 250 µl of Amplex Red 
in that experiment. 
3.3.3.6 Determining the volume of lysosomes needed to saturate 
streptavidin beads 
To ensure the conditions for the fusion assay produce the maximum chance of 
detecting a fusion signal, it was necessary to determine the volume of biotin-HRP 
containing lysosomes that were needed to saturate 20 µl of streptavidin beads 
(having determined the maximum single from 20 µl of beads incubated with biotin-
HRP directly). This was necessary to ensure that the volume of lysosomes used in 
the fusion assay would not be a limiting factor. J774.2 cells were seeded at 8x106 
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per dish (2 dishes) and cultured for 48 h. Cells were then incubated with 0.5 mg/ml 
biotin-HRP in FeDex (1:20) containing DMEM for 1 h, rinsed three times with PBS, 
then incubated with DMEM for a further 2 h. Control cells were incubated with 
FeDex containing DMEM only. The cells were lysed and lysosomes purified using 
the previously described method. Lysosomes were eluted in 1 ml of STM and 
Triton X-100 added to a final concentration of 0.1 % to lyse lysosomal membranes. 
20 µl of beads were then incubated with 2.5, 5, 10, 25, 50, or 100 µl of HRP-
containing or control lysosomes for 30 min. Beads were then washed and assayed 
for HRP activity using Amplex Red (Fig. 5.29).   
The maximum fluorescence from the control and lysosomes containing HRP was 
also determined. As seen previously, control lysosomes did not give a 
fluorescence signal above that of the background (and as such have been omitted 
from the graphs for brevity). The maximum signal obtainable from 20 µl of beads 
saturated with HRP after 10 min was 16,700 AU. The lowest volume of HRP-
containing lysosomes where a fluorescence signal could be detected was 10 µl. 
100 µl of biotin-HRP lysosomes gave a fluorescence signal of 14,200, suggesting 
that 100 µl of lysosomes almost contained enough HRP to saturate the bead 
control (at 30 min, the 100 µl of lysosomes gave a fluorescence signal above that 
of the bead control). However, the fluorescence from beads incubated with 100 µl 
of lysosomes was only 13 % of the total signal (1940 AU). Similarly, beads 
incubated with 10, 25, and 50 µl of lysosomes only gave 33.8 %, 34.7 % and 14.2 
% of the total fluorescence signal from 10, 25, and 50 µl of lysosomes, 
respectively. The fact that the beads did not bind all of the biotin-HRP that was 
present in the lysosome samples may have been due to degradation of the biotin 
part of the biotin-HRP molecule. 
 
 155 
 
Fig. 3.29. Determining the volume of biotin-HRP lysosomes needed to saturate 20 µl 
of streptavidin beads. Biotin-HRP containing lysosomes were purified from 2x10 cm 
dishes of J774.2 cells and resuspended in 1 ml of STM containing 0.1 % (v/v) Triton X-
100. 20 µl of streptavidin beads were incubated for 30 min at 4 ºC with 2.5, 5, 10, 25, 50, 
or 100 µl of HRP-containing lysosomes. The beads were then washed, and assayed for 
HRP activity using 150 µl of Amplex Red (Open bars). The same volume of lysosomes 
were also measured to give a total obtainable signal (Closed bars) For brevity, the signals 
from 2.5 µl and 5 µl of HRP-lysosomes are omitted. As a control, 20 µl of beads saturated 
with biotin-HRP (by incubation with 500 ng/ml biotin-HRP in STM for 30 min) were also 
assayed (hatched bar). Data are fluorescence values after 10 min of incubation with 
Amplex Red, while the fluorescence signal was still increasing (n=1). 
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This experiment was then repeated in order to try and reach a point where HRP-
lysosomes were able to saturate the 20 µl control. This time, 4 dishes of cells were 
used and incubated with FeDex-HRP (or FeDex alone) to increase the amount of 
HRP available to the beads. Lysosomes were eluted in 1 ml of STM. 20 µl of 
beads were then incubated with 5, 10, 20, 25, 100, or 200 µl of FeDex-HRP or 
FeDex lysosomes. To try and increase the amount of HRP binding to the beads, 
the incubation was performed overnight (Fig. 5.30). The previous experiment had 
shown that 100 µl of HRP-lysosomes contained enough HRP to give a signal that 
was close to the saturated bead control. When repeated, 100 µl of lysosomes only 
gave 45.5 % of the control signal, whereas 200 µl of lysosomes gave 96.6 % of 
the saturated bead control. This discrepancy may be due to depletion of the HRP 
from the media after repeated uses (HRP-containing media was filter sterilised and 
reused for further experiments). Incubating the beads with 10 µl of lysosomes 
resulted in a 1.8-fold increase in fluorescence compared to 10 µl of assayed 
lysosomes (600 AU compared to 334 AU). Similarly, 25 µl of lysosomes gave a 
lower signal than beads incubated with the same volume of lysosomes (493 AU 
compared to 1813 AU), and 50 µl of lysosomes gave a slightly smaller 
fluorescence signal compared to 50 µl of beads incubated with lysosomes (3057 
AU compared to 3341 AU). These differences could be due to biological variation 
between experiments in the fluorescence that the control lysosome blank gave. 
Beads incubated with 100 µl of lysosomes gave 66.2 % of the fluorescence from 
100 µl of HRP lysosomes, and beads incubated with 200 µl of lysosomes gave 
31.5 % of the fluorescence from 200 µl of HRP lysosomes. Despite increasing the 
incubation time from 30 min to overnight, the binding of HRP to the beads 
remained roughly 30 % of the total available HRP, which as in previous 
experiments, may be due to degradation of biotin from the HRP conjugate. This 
experiment also differed slightly to the previous experiment, where 100 µl of 
lysosomes was sufficient to saturate 20 µl of beads. Here, 200 µl of HRP-
lysosomes were needed to almost saturate the control beads. This discrepancy 
was probably due to depletion of biotin-HRP from the FeDex media (biotin-HRP 
media was filtered and reused between experiments). Therefore, the reuse of 
media was kept to a minimum where possible.   
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Fig. 3.30. Binding of biotin-HRP from lysosomes to beads overnight. Lysosomes 
were purified from J774.2 cells that were incubated with or without biotin-HRP. 20 µl of 
streptavidin beads were incubated overnight at 4ºC with, 10, 25, 50, 100 or 200 µl of 
control or HRP-containing lysosomes. The beads were then washed, and assayed for 
HRP activity using Amplex Red. For clarity, the fluorescence from non-HRP control 
lysosomes are omitted. 20 µl of beads saturated with biotin-HRP by incubation with 500 
ng/ml HRP is shown (control; hatched bar). Data are fluorescence values after 10 min, 
taken while the fluorescence signal for all samples was still increasing (n=1). 
This experiment was repeated a final time, with beads incubated with 100, 150, or 
250 µl of HRP or control lysosomes overnight (Fig. 3.31). Similar to the previous 
two experiments, only 31.7 % (100 µl) and 34.3 % (150 µl) of the fluorescence 
signal was seen with beads incubated with lysosomes (250 µl of lysosomes were 
not assayed as this exceeded the volume of the 96 well plate). 150 µl of HRP 
lysosomes gave a fluorescence signal of 81.3 % of the saturated bead control. It is 
likely that 250 µl would have exceeded this. Taken together, these data suggest 
that some of the biotin-HRP may be degraded, or unable to bind to streptavidin 
beads after passing through lysosomes.  
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Fig. 3.31. Binding of biotin-HRP from lysosomes to streptavidin beads. Lysosomes 
were purified from J774.2 cells that were incubated with or without biotin-HRP. 20 µl of 
streptavidin beads were incubated overnight at 4ºC with 150, 150 or 250 µl of control or 
HRP-containing lysosomes. The beads were then washed, and assayed for HRP activity 
using Amplex Red. For clarity, the fluorescence from non-HRP control lysosomes are 
omitted. 20 µl of beads saturated with biotin-HRP by incubation with 500 ng/ml HRP is 
shown (control; hatched bar). Data are fluorescence values after 10 min, taken while the 
fluorescence signal for all samples was still increasing (n=1). 
The aim of these experiments was to try and saturate 20 µl of beads with biotin-
HRP, in order to have a set of conditions where control beads could be used to 
determine if the assay was set up optimally. The next experiment was to 
determine the volume of bead containing-phagosomes necessary to establish the 
volume of phagosomes saturated with biotin-HRP that gave a signal equal to that 
of 20 µl of beads saturated with HRP. This would then give a set of conditions 
under which there would be suitable volumes of both phagosomes and lysosomes, 
to maximise the potential of seeing a true fusion signal. Phagosomes were 
isolated using the standard protocol (MOI:3, approximately 14 x 106 cells) and 
resuspended in 100 µl of STM containing 0.1 % (v/v) TX-100. 5, 10, 20, 30, and 35 
µl of phagosomes were incubated with a saturating amount of HRP (500 ng/ml) 
overnight (to maximise binding) and the HRP signal was measured using 150 µl of 
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Amplex Red (Fig. 3.32). An HRP signal was detected from all of the volumes of 
phagosomes used, which increased as more phagosomes were used. The 
fluorescence values (as a percentage of the control) were 1.96 %, 7.32 %, 15.8 %, 
23.3 % and 23.7 % (from 5,10,20,40 and 35 µl of phagosomes, respectively). As 
these phagosomes were unblocked, the total amount of biotin-HRP that could bind 
to these volumes of phagosomes would drop further when biocytin was used  (in 
the fusion assay). Therefore the volume of phagosomes needed to be increased to 
maximise the chance of seeing a fusion signal (given that blocked phagosomes 
would not participate in fusion reactions, and that fusion rates would likely be low). 
As approximately 100 µl of beads were used for each phagosome preparation (1 
6-well plate) around 4 6-well plates worth of phagosomes would have been 
needed to give a signal equivalent to that of the saturated bead control.  
Fig. 3.32. Saturating streptavidin bead-phagosomes with biotin-HRP. Streptavidin 
bead-containing phagosomes were purified from approximately 14 x 106 J774.2 cells as 
described previously. Phagosomes were isolated and resuspended in 100 µl of STM 
containing 0.1 % (v/v) TX-100. 5, 10, 20, 30, and 35 µl of phagosomes were incubated 
with a saturating amount of biotin-HRP (500 ng/ml) overnight (to maximise binding). The 
beads were washed and the amount of biotin-HRP bound to the beads was determined 
using Amplex Red. As a control, 20 µl of beads saturated with biotin-HRP were also 
assayed (control; hatched bar). Data are the fluorescence values of samples after 25 min, 
at which point the fluorescence signals were still increasing (n=1).  
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Previous experiments sought to determine the volumes of lysosomes and 
phagosomes to use in the fusion assay, so that neither component was limiting. 
Around 100 µl of lysosomes were found to have enough biotin-HRP to produce a 
strong signal, but only 1/3rd of this was able to bind to beads. However, if this 1/3rd  
was enough to saturate beads, then the signal would be high enough. Therefore, 
biotin-HRP lysosomes were then mixed with an increased volume of phagosomes 
in a mixing assay, to determine how much lysosomal biotin-HRP could be 
transferred to phagosomes (Fig. 3.33). Phagosomes were purified from 4 x 6-well 
plates of J774.2 cells (approximately 350 µl of beads). 50 % of the sample was 
incubated in STM, and the remaining 50 % was incubated in STM containing 500 
ng/ml biocytin, to block phagosomes and determine how much of the binding 
capacity of the phagosomes would drop when used in the fusion assay. The 
phagosomes were then resuspended in 175 µl of STM containing 0.1 % (v/v) T X-
100 (to lyse organelle membranes), and 25 µl, 50 µl and 100 µl of phagosomes 
were then incubated with biotin-HRP lysosomes (25 µl, 100 µl and 200 µl, 
respectively), overnight at 4 ºC. The beads were recovered on a magnet, washed 
three times with RIPA buffer, and assayed with 150 µl of Amplex Red. As a 
control, 20 µl of HRP saturated beads were also assayed, as were the same 
volumes of lysosomes used in the mixing assay. 25 µl, 100 µl, and 200 µl of 
lysosomes gave fluorescence signals that were 8 %, 28 % and 78 % of the control, 
respectively. This was in agreement with previous experiments. 25 µl of blocked 
phagosomes gave no fluorescence signal, whereas 25 µl of unblocked 
phagosomes gave 3 % of the total possible signal (from 25 µl of lysosomes). 100 
µl of unblocked phagosomes gave 0.4 % of the signal from 100 µl of lysosomes, 
whereas blocked phagosomes gave 7.1 %. The fact that blocked phagosomes 
gave a higher signal indicates that these data are likely to be the result of random 
variation, and are not actually the result of the transfer of biotin-HRP to the beads. 
However, 100 µl of blocked phagosomes gave 1.6 % of the signal from 200 µl of 
lysosomes, which rose to 3.7 % when phagosomes were not blocked, suggesting 
the latency of this preparation was low (43 %). These results also indicate that the 
overall capacity of phagosomes to bind biotin-HRP was very low meaning a very 
large number of beads would be needed for each experiment, which would be 
prohibitively expensive. One way to improve the binding capacity of a phagosome 
preparation would be to increase the uptake of beads. As seen previously, this 
could be achieved by increasing the MOI, but this required yet more beads. 
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Alternatively, the beads could be opsonised with immunoglobulin, to try and 
improve the uptake of beads. 
 
Fig. 3.33. Phagosome-lysosome mixing in vitro. Streptavidin bead phagosomes were 
purified from four 6 well plates of J774.2 cells (MOI of 3 approximately 18 x 106 cells per 
plate). Briefly, beads were centrifuged onto cells at  50 x g for 5 min followed by a 55 min 
incubation at 37 ºC to allow bead uptake. Cells were then washed three times to remove 
unbound beads, and chased for a further 1 h at 37 ºC. Phagosomes were the released 
from cells by ball-bearing homogenisation and purified (as previously described). One half 
of the phagosomes were incubated with STM containing 500 ng/ml biocytin (blocked 
phagosomes) and the other half in STM alone (unblocked phagosomes) for 30 min. Each 
set of phagosomes were washed once more in STM and resuspended in 175 µl of STM. 
Biotin-HRP lysosomes were purified from cells as previously described. The lysosomes 
were eluted into 1 ml of STM, and Triton X-100 added to a final concentration of 0.1 % 
(v/v). The indicated volumes of phagosomes (25 µl, 50 µl and 100 µl) were then incubated 
with biotin-HRP lysosomes (25 µl, 100 µl and 200 µl, respectively), overnight at 4 ºC. The 
beads were recovered, and the captured biotin-HRP assayed using 150 µl of Amplex Red. 
25 µl, 100 µl, and 200 µl of HRP-lysosomes were also assayed. 20 µl of beads saturated 
with HRP were assayed as a control (hatched bar). Data are fluorescence signals after 25 
min, at a point where fluorescence values were still increasing (n=1). 
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To try and increase the uptake of beads and number of phagosomes recovered, 
beads were opsonised with mouse immunoglobulin before centrifuging onto cells 
(Fig. 3.34). 100 µl of beads were incubated with 490 µl of mouse IgG in PBS, 
overnight at 4 ºC to coat the beads in IgG. 100 µl of beads incubated with PBS 
were used as a control. Secondly, the protocol was altered slightly to try and 
increase bead uptake further. Bead uptake was performed for 1 h at 37 ºC, and 
the cells washed three times to remove unbound beads. For this experiment, it 
was accepted that the resulting phagosomes would be different to those previously 
characterised in section 3.7. The cells were then cultured for a further hour, and 
the resulting phagosomes were isolated as previously described. Half of the 
phagosomes were incubated with 500 ng/ml of biocytin for 30 min at room 
temperature. The phagosomes were then incubated overnight at 4 º C with 500 
ng/ml biotin-HRP in STM containing 0.1 % (v/v) T-X100 to lyse phagosomal 
membranes, and allow binding of biotin-HRP. The beads were washed and then 
assayed for bound HRP. 
The fluorescence signal after 10 min from phagosomes from non-opsonised beads 
was approximately 5389 (PBS, - biocytin) and 2481 (PBS, + biocytin) compared to 
11,097 AU (IgG, - biocytin) and 4,777 AU (IgG, + biocytin), for opsonised beads. In 
both cases, blocking the bead-phagosomes with biocytin before incubation with 
HRP, led to a reduction in fluorescence (46 % for non-opsonised beads, and 43 % 
for opsonised beads). This indicated that not all the phagosomes were intact. The 
non-opsonised beads had 13.4 % and 29 % (+/- biocytin respectively) of the 
fluorescence of the control beads, and which increased to 25.7 % and 59.7 % for 
opsonised beads. Thus, opsonisation appeared to increase bead internalisation 
resulting in a 50 % increase in the amount of phagosomes recovered that could 
participate in the fusion assay. There are many different ligands and receptors 
involved in phagocytosis (Kwiatkowska and Sobota, 1999), and internalisation of 
pathogens occurs through a heterogeneous set of mechanisms (Aderem and 
Underhill, 1999). Thus not all phagosomes are created equally. It should be noted 
that altering the pulse and chase time of the phagosomes, is likely to result in a 
change in their composition, especially when using opsonised beads which would 
become phagocytosed through a different set of molecular mechanisms to 
particles not internalised via Fc receptors (Vieira et al., 2002). However, for the 
fusion assay, it was deemed more important to demonstrate that it could work, and 
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that fusion could be detected. The phagosome protocol could then be further 
optimised to purify phagosomes at earlier stages, or characterise the phagosomes 
produced when beads were opsonised and chased for a longer period of time. 
 
Fig. 3.34. The effect of opsonisation on bead uptake and phagosome recovery. 
Streptavidin beads were incubated in PBS or 5 mg/ml mouse IgG in PBS overnight at 4 
ºC. Beads were then centrifuged onto J774.2 cells to promote uptake, and were cultured 
for 1 h at 37 ºC to allow bead binding and internalisation. Cells were washed briefly to 
remove unbound beads, and cultured for a further 1 h. Bead-containing phagosomes were 
purified from cells as previously described, and incubated in 0.5 ml of STM (- Biocytin) or 
STM containing 500 ng/ml biocytin (+ Biocytin). Phagosomes were then washed three 
times with STM, and incubated overnight at 4 ºC in STM containing 0.1 % (v/v) Triton X-
100, and 500 ng/ml biotin-HRP. The beads were then recovered, washed, and bound 
HRP assayed using Amplex Red reagent. 20 µl of beads were saturated with 500 ng/ml 
biotin-HRP were also assayed as a control (hatched bar). Data are fluorescence signals 
after 10 min, at a point where fluorescence values were still increasing (n=1). 
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3.3.3.7 Fusion of lysosomes and phagosomes in vitro 
These experiments had been performed to demonstrate that fusion of lysosomes 
and phagosomes in vitro was feasible. Biotin-HRP from lysosomes was detectable 
using Amplex Red reagent and could bind to phagosomes isolated from cells. The 
binding of biotin-HRP could be blocked with biocytin and the amount of lysosomes 
and phagosomes needed to maximise the potential to see a fusion signal was also 
investigated. The next step was to combine these experiments into a full fusion 
assay. Previous fusion assays described the requirement of cytosol for fusion to 
occur (Jahraus et al., 1998, Mullock et al., 1998). Cytosol was isolated from pig 
brain as described in section 3.12.2. Briefly, 4 g of pig brain (finely minced) was 
homogenised in a Potter-Elvehjem homogeniser in 3 ml of ice cold STKM (250 
mM sucrose, 25 mM KCl, 1 mM MgCl2, 10 mM TES, pH 7.4). The lysate was 
centrifuged at 104,000 x g for 15 min at 4 ºC. To demonstrate an energy 
requirement for the fusion assay, the cytosol was depleted of ATP and GTP by 
passing the lysate through a PD10 de-salting column. The cytosol was eluted from 
the column with 4 ml of ice cold STKM and snap frozen in liquid nitrogen, before 
storage at – 80 ºC. The protein concentration of cytosol used for the fusion assay 
was 4.25 mg/ml. 
Biotin-HRP lysosomes were purified from four 10 cm tissue culture dishes of cells 
as previously described, but were eluted from the cell column using 1 ml of pig 
brain cytosol. Phagosomes were isolated as previously described, with some 
changes. Briefly, 800 µl of beads were opsonised in 5 mg/ml mouse IgG in PBS 
overnight at 4 ºC. 100 µl of beads was then centrifuged onto cells of a 6 well plate 
(8 in total) and the cells were then cultured at 37 ºC for 1 h. After washing to 
remove unbound beads, the cells were cultured for a further hour to allow 
internalisation and phagosome maturation. The cells were then resuspended in 8 
ml of ice cold STM and homogenised using a ball-bearing homogeniser as 
previously described. Phagosomes were washed three times in STM and 
resuspended in a final volume of 1 ml of pig brain cytosol. The fusion assay was 
then set up in duplicate as follows: All reactions were set up in 0.5 ml Eppendorf 
tubes on ice. 60 µl of phagosomes were added to each tube, followed by either 60 
µl of 2000 ng/ml biocytin in STKM (500 ng/ml final concentration) or PBS. 60 µl of 
biotin-HRP lysosomes were added next, and finally 60 µl of an energy 
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regenerating system (per 25 µl: 2.5 µl ATP (50mM), 2.5 µl GTP (50 mM), 10 µl of 
creatine kinase (4 mg/ml in PBS stock), 10 µl of creatine phosphate (261.2 mg/ml 
in PBS stock). The fusion assay was assembled as per table 3.1, the tubes gently 
vortexed, and then incubated for 90 min at 37 ºC in a water bath, or on ice. After 
90 min, the tubes were placed on ice and 240 µl of 2X RIPA buffer (0.4 % (v/v) 
NP-40, 2 % (v/v) TX-100, 2 % (w/v) deoxycholate, 300 mM NaCl, 100 mM Tris, pH 
7.5, plus protease inhibitors) was added. The tubes were incubated on ice for 15 
min, and then washed three times with 1 x RIPA buffer. The beads were then 
resuspended in 100 µl of RIPA buffer and assayed with 150 µl of Amplex Red (Fig. 
3.35). The following controls were also set up: 20 µl of beads and 60 µl of 
phagosomes were incubated with 0.5 ml of 500 ng/ml biotin-HRP in STM. 60 µl of 
biotin-HRP lysosomes were also assayed to give the maximum obtainable signal 
obtainable from the lysosomes. 60 µl of cytosol was also assayed, as it had 
previously been seen that pig brain cytosol reacts with Amplex Red to give a 
strong fluorescence signal (data not shown). 
 
Table 3.1. Components of the in vitro lysosome-phagosome fusion assay. The 
fusion assay was assembled on ice as per the table above. 60 µl of phagosomes were 
added to each tube, followed by 60 µl of 2000 ng/ml biocytin in STKM (500 ng/ml final 
concentration) or PBS. 60 µl of biotin-HRP lysosomes were added next, and finally 60 µl 
of an energy regenerating system or PBS, was added where appropriate to give a final 
volume of 240 µl.  
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The total obtainable fusion signal was represented by conditions 5 & 6 (37 ºC no 
biocytin), as without biocytin, there should be maximal binding of biotin-HRP from 
lysosomes to the streptavidin beads. Moreover, conditions 5 & 6 should have the 
same levels of HRP activity. This would then be followed by 3 & 4 (37 ºC + 
biocytin) which would be the signal from fusion of phagosome and lysosomes. 
Lastly, conditions 1 & 2 (4 ºC + biocytin), would represent the background signal. 
Thus, 5 & 6 should always be higher than 3 & 4, which should be higher than 1 & 2 
if fusion has occurred. In all cases, the fluorescence signal was above the 
background, but was very low (127 to 418 AU) when compared to the highest 
obtainable signal (100 % fusion, represented by the phagosomes + HRP control), 
which was approximately 18,900 AU.  The highest to lowest fluorescent signals 
were as follows; 3,5,1,4,6,2. The low signals and the fact that the control 
conditions (5 & 6) did not yield a signal suggested that the signals were just 
background noise and no fusion or HRP binding had occurred. The phagosome + 
HRP control gave a large fluorescence signal almost equal to that of the 20 µl 
HRP-saturated control (18,900 AU compared to 23,700 AU). This indicated that 
the phagosomes used in the assay were still capable of binding biotin-HRP, and 
that the HRP binding capacity of the phagosomes used in the assay was large. 
The lysosome signal (with pig brain cytosol signal subtracted as a blank) was 
much lower than expected, possibly as a result of biotin-HRP degradation in 
lysosomes. However, there was still a reasonable signal (6,090 AU), and even if 
the fusion rate was only 10 % (600 AU), then this should still have been 
observable. These data are confusing, as even in the absence of any fusion signal 
whatsoever, the lysis of phagosomes and biotin-HRP lysosomes in the absence of 
any biocytin to block binding (conditions 5 & 6) should have resulted in the binding 
of HRP to the beads. The lack of any such signal suggested that something in the 
assay was possibly inhibiting the binding of HRP to the beads. This could have 
been temperature but previous experiments had demonstrated that biotin-HRP 
could be transferred to beads at 4 ºC and besides, conditions 5 & 6 were 
incubated at 37 ºC. The other possibility was that the cytosol used for the fusion 
assay somehow interfered with the binding of biotin-HRP to the beads. Thus, this 
was subsequently investigated to see if this was the cause of the problem. 
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Fig. 3.35. Characterisation of in vitro lysosomes-phagosome fusion assay. The 
transfer of biotin-HRP from lysosomes to streptavidin bead containing-phagosomes was 
monitored in an in vitro lysosome-phagosome fusion assay. The assay was assembled as 
per table 3.1. Fusion was allowed to proceed on ice or at 37 ºC for 90 min before the 
tubes were placed on ice. An equal volume of 2X RIPA buffer was added to each tube 
and samples were incubated on ice for 15 min. The beads were then recovered, washed 
three times with 1X RIPA buffer and the amount of bound HRP (as a measure of fusion) 
was determined by Amplex Red assay. The following controls were also included (A). 20 
µl of beads saturated with biotin-HRP (Control), 60 µl of biotin-HRP lysosomes (Lys) 20 µl 
of beads incubated with 60 µl of biotin-HRP lysosomes (Beads + Lys) and 60 µl of 
phagosomes incubated with biotin-HRP (Phagosomes + HRP). B shows the fluorescence 
signals from the different conditions used in the fusion assay. Data are means of 
duplicates ± the range. Data are fluorescence values after 20 min at a point when the 
fluorescence of each sample was still increasing (n=1). 
 168 
3.3.3.8 Pig brain cytosol interferes with biotin-HRP binding to 
beads 
The previous data were puzzling, as in the controls used for the fusion assay, the 
transfer of biotin-HRP to beads was prevented.  A key difference in the fusion 
assay experiment (Fig. 3.35) compared to the mixing assay (Fig. 3.24), was that it 
was carried out in the presence of pig brain (PB) cytosol, which may have 
interfered with binding. This was then investigated. 20 µl of beads were incubated 
with or without biocytin for 30 min to give blocked and unblocked beads. These 
beads were then incubated in either STM, J774.2 cytosol, or PB cytosol, for 30 
min at room temperature. Both J774.2 and PB cytosol were normalised to protein 
concentration and were used at the same concentration as in the fusion assay 
(4.25 mg/ml). The beads were then extensively washed and incubated with 0.5 ml 
of 500 ng/ml biotin-HRP for 30 min at room temperature. The beads were washed 
again and the bound HRP assayed using Amplex Red (Fig. 3.36). 
The total amount of fluorescence in the saturated bead control after 10 min was 
27,266 AU. The total fluorescence seen with 20 µl of (unblocked) beads was 
20,020 AU (73 %) of this, most likely representing loss of beads from the multiple 
washing steps (control beads were only subjected to a single round of washes). 
Thus, in this case, it is more appropriate to use the (unblocked) beads sample as a 
control for the total signal possible. When blocked beads were incubated with 
J774.2 cytosol, or PB cytosol the fluorescence signal was low (1061 AU and 801 
AU) and comparable to that of blocked beads (820 AU). This suggests that pre –
blocked beads incubated in cytosol do not give an appreciable fluorescence 
signal. Unblocked beads incubated with J774.2 cytosol and then biotin-HRP gave 
a fluorescence signal of 21,255 AU (106 % of the unblocked beads sample, or 78 
% of the control beads). In contrast, unblocked beads incubated with PB cytosol 
and then biotin-HRP gave a fluorescence signal of 12,288 AU (61 % of the 
unblocked beads sample, or 45 % of the control beads). 120 µl of J774.2 and PB 
cytosol were also assayed, as 120 µl was the volume of cytosol used in the fusion 
assay. J774.2 cytosol gave a fluorescence signal of 1091, compared to 9582 AU 
for PB cytosol. The J774.2 cytosol was slightly above that of the background 
signal (blocked beads 801 AU) but the PB cytosol gave a clear signal. These data 
suggest that i) a factor in pig brain cytosol (but not in J774.2 cytosol of the same 
protein concentration) blocks binding of biotin-HRP to beads and ii) pig brain 
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cytosol reacts with Amplex Red reagent, and J774.2 cytosol does not. Thus, this 
could explain why no binding of biotin-HRP was seen the in the fusion assay 
control conditions. 
 
Fig. 3.36. Pig brain cytosol interferes with biotin-HRP binding with streptavidin 
beads. 20 µl of streptavidin beads were incubated in either 0.5 ml of STM or 0.5 ml of 
STM containing biocytin at 500 ng/ml. The beads were washed three times with STM and 
incubated in either 0.5 ml of STM, J774.2 cytosol (4.25 mg/ml) or pig brain (PB) cytosol 
(4.25 mg/ml) for 30 min at room temperature. The beads were washed three times with 
STM, and incubated with 0.5 ml of STM containing biotin-HRP at a final concentration of 
500 ng/ml, for 30 min at room temperature. The beads were washed three times with 
RIPA buffer and bound HRP assayed using Amplex Red. 120 µl of J774.2 or PB cytosol 
were also assayed (red bars). 20 µl of beads saturated with HRP were included as a 
control (hatched bar). Data are fluorescence values after 10 min at a point when the 
fluorescence of each sample was still increasing (n=1). 
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3.3.4 Phagosome-lysosome fusion - Discussion 
3.3.4.1 Principle of the fusion assay 
For the fusion assay, it was necessary to have a suitable system to report the 
fusion of phagosomes and lysosomes. The principle of the assay was to measure 
the transfer of one marker to another, as a quantification of vesicle fusion. Other 
assays based up confocal microscopy report vesicle fusion as having occurred 
when separate fluorescent markers present in the two organelles co-localise 
(Becken et al., 2010). However, this method cannot distinguish between two 
vesicles that have fused, tethered, or are just within close proximity to one 
another. This is because the resolution of the light microscope is 200-350 nm, in 
that range. Alternatively, the colocalisation of the two markers could be monitored 
by FRET (Förester resonance energy transfer), to measure the transfer of energy 
from an excited donor fluorophor to another acceptor molecule. This is an 
attractive method, as the maximum distance over which FRET can occur is 
approximately 10 nm (Stryer, 1978). This would therefore allow the distinction 
between real fusion events and vesicle tethering. However, this method requires 
that the fluorphores remain intact after delivery to the lysosome and phagosomes. 
It can also be pH sensitive, which could be a potential problem due to the low pH 
of the lysosome, and the change in pH when vesicles fuse. However, this 
approach has been successfully used to study retrograde transport of molecules 
from lysosomes to late endosomes in vivo (Kaufmann et al., 2009). This method 
would also require the use of a confocal microscope, which would increase the 
cost of the assay. Using a simple enzyme-based assay that can be measured in a 
plate reader significantly reduces the costs associated with performing multiple 
experiments. 
Horseradish peroxidase is widely used enzyme that uses hydrogen peroxide to 
oxidise a wide variety of substrates (Veitch, 2004). One potential problem with 
delivering compounds to the lysosome is that they are exposed to the low pH and 
hydrolytic enzymes which may degrade them. Horseradish peroxidase (HRP) 
however, is relatively resistant to lysosomal degradation (Graham and Rickwood, 
1997). Moreover, biotin-conjugated HRP binds extremely strongly to streptavidin 
beads due to the high affinity interaction between these two molecules (biotin-
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streptavidin Kd ~ 10-14 M, (Dundas et al., 2013), making it a suitable system to 
report vesicle fusion. Moreover, biotin-avidin binding has been successfully used 
in other fusion assays (Jahraus et al., 1998, Mullock et al., 1998, Mullock et al., 
1994). 
The purification of biotin-HRP containing lysosomes using superparamagnetic iron 
particles was shown to be a viable method of lysosome purification (Fig. 3.23) 
While it is possible that the toxic effects of iron accumulation could result in 
lysosomal damage, this method has previously been used to purify lysosomes for 
use in a fusion assay (Becken et al., 2010). As discussed previously, the choice of 
system for phagosome purification such as an inert latex bead, or a heat-killed 
bacterium, would influence the properties of the resulting phagosome. For 
example, the receptors and pathways used to internalise a large particle (such as 
a 3 µm magnetic bead) are likely to differ slightly from those used to phagocytose 
a opsonised bacterium. This may result in different maturation rates, phagosome 
compositions and differences in the ability to fuse with other endocytic 
compartments. However, the molecular machinery needed for vesicle fusion would 
remain the same. For this assay, magnetic beads were chosen due to their ease 
of purification from a cell lysate. This method requires no centrifugation steps on 
gradients (as with latex beads), and is very rapid – phagosomes are simply 
resuspended in a wash buffer multiple times, and can easily be transferred from 
one buffer to another. These phagosomes were also characterised by western 
blotting and were shown to have late endocytic and lysosomal markers, as well as 
increased lysosomal enzyme activity. Therefore, the components of the fusion 
assay were sufficiently characterised and purified, to begin to assemble the 
complete assay. 
3.3.4.2 Biotin-HRP from lysosomes could be detected using Amplex Red 
While lysosomes were easily purified, it was not clear whether biotin-HRP could be 
detected after passing through lysosomes. Thus, purified lysosomes were tested 
to determine whether Amplex Red was sensitive enough to detect HRP activity 
(Fig. 3.23). Indeed, a fluorescence signal was seen when biotin-HRP lysosomes 
were incubated with Amplex Red, indicating that sufficient biotin-HRP remained 
non-degraded to give a signal. Control lysosomes did not produce a fluorescence 
 172 
signal. This indicates that the fluorescence was a direct result of HRP activity, and 
not endogenous activity from lysosomal enzymes. Additionally, lysosomal material 
does not autofluoresce at the wavelengths used in the assay. The lowest volume 
of lysosomes where an increase in fluorescence was seen was 0.2 µl, which was 
1/500th of the total volume of lysosomes purified. Thus, Amplex Red could be used 
to detect very low amounts of HRP activity from purified lysosomes. 
3.3.4.3 Biotin-HRP from lysosomes can still bind to beads from phagosomes 
Although biotin-HRP activity could be detected in purified lysosomes it was 
necessary to check biotin-HRP could still bind to streptavidin beads after they had 
passed through cells. Both the biotin and streptavidin had the potential to be 
degraded and unable to bind each other. To test this, phagosomes and lysosomes 
were mixed together in the presence of detergent to lyse lipid membranes and 
allow biotin-HRP to bind to the beads (Fig. 3.24). HRP activity was detected on 
phagosome beads after 15 min of mixing. The binding of HRP was also blocked by 
the addition of biocytin. Approximately 12.5 µl of phagosomes was the lowest 
volume where the fluorescence signal was sufficient such that if the total vesicle 
fusion was only 10 % of the maximum possible, a fluorescence signal could still be 
detected above the background noise. This experiment used 100 µl of beads, but 
it was not known how this related to the final amount of phagosomes purified (as 
beads were lost during washes, or were not released from the cells during 
homogenisation). 
3.3.4.4 Binding of biotin-HRP to beads was blocked by biocytin 
The fusion assay needed to distinguish between actual fusion of intact organelles, 
and the mixing of contents from damaged lysosomes and phagosomes. The assay 
was performed in the presence of saturating amounts of biocytin (biotinylated 
lysine), which would bind to streptavidin beads and prevent biotin-streptavidin 
interactions outside of an intact membrane This would reduce the overall possible 
signal that could be seen, but also reduce the background noise of the assay. 
Importantly, biocytin is not membrane permeable (due to the presence of a 
charged lysine group), and should only block the binding of biotin-HRP on 
phagosomes without an intact membrane. Biocytin was titrated to determine at 
 173 
what concentration it prevented the binding of biotin-HRP to streptavidin beads. 
The binding of biotin-HRP to beads was dose dependent, and was determined to 
be 500 ng/ml (Fig. 3.25). 
3.3.4.5 J774.2 cell lysate does not react with Amplex Red 
Phagosome beads were released from J774.2 cells from by ball-bearing 
homogenisation and isolated from the cell lysate on a magnet. Any endogenous 
material that was non-specifically bound to the beads may have oxidised Amplex 
Red to give a false fluorescence signal. When a J774.2 cell lysate was incubated 
with Amplex Red to test this, no fluorescence signal was observed (Fig. 3.26). 
These data along with the previous experiments suggested that any change in 
fluorescence was only due to the presence of biotin-HRP alone. 
3.3.4.6 Optimising the amount of lysosomes and phagosomes used in the fusion 
assay 
While it was clear that both markers could still bind after passing through cells, the 
amounts to use in the fusion assay needed to be optimised to ensure that neither 
was limiting. To help with this, an arbitrary volume of beads (20 µl) were used as a 
control to determine a set of conditions under which neither biotin-HRP lysosomes 
nor phagosome beads were limiting. The rationale behind this was as follows: 20 
µl of beads were incubated with biotin-HRP (not from lysosomes), until a point was 
reached where no more HRP could bind, and the availability of Amplex Red 
reagent was not limiting. This would then be a standard control for all further 
experiments, to show the maximum fluorescence signal from 20 µl of beads. Next, 
increasing volumes of biotin-HRP lysosomes were incubated with 20 µl of beads 
until the beads were saturated with HRP. This would give the conditions necessary 
to saturate beads with HRP from lysosomes. Next, increasing volumes of 
phagosomes would be incubated with biotin-HRP lysosomes, to determine the 
volume of phagosomes that corresponded to 20 µl of beads. This would then 
result in a set of conditions under which there was sufficient biotin-HRP and 
phagosomes capable of binding the majority of the HRP, to maximise the chance 
of seeing phagosome-lysosome fusion. 
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20 µl of beads were saturated with biotin-HRP when used at 500 ng/ml, and 150 µl 
of Amplex Red reagent was deemed sufficient to not be a limiting factor. When 
biotin-HRP lysosomes were used to try and saturate 20 µl of beads only 
approximately 35 % of the total possible fluorescence signal was obtained from 
beads (Fig. 3.29-3.31), indicating that a large proportion was unable to bind to the 
beads, possibly due to partial degradation of biotin-HRP.  It remains to be seen 
whether inhibiting lysosomal enzymes (through the use of inhibitors such as 
leupeptin) would protect biotin-HRP from degradation and result in higher binding 
to phagosomes. Overall, around 100-250 µl of purified biotin-HRP lysosomes 
(from a total of 1 ml) was deemed to be a reasonable balance between sufficient 
signal, and having enough sample for duplicates over a range of experimental 
conditions tested. 
Next, the volume of phagosomes needed was investigated. Approximately 100 µl 
of beads were used per 6 well plate of J774.2 cells (MOI:3) to purify phagosomes. 
While 100 µl of beads would be able to bind a significant amount of biotin-HRP, it 
was not known how the volume of phagosomes related to this. Unbound beads 
were lost when cells were washed and some cells likely remained intact. 
Furthermore, extracellular beads and damaged phagosomes were blocked with 
biocytin, meaning that amount of intact phagosomes recovered would not be the 
same as the starting volume of beads. However, the amount of viable 
phagosomes was extremely low, as the phagosomes purified from 100 µl of beads 
only bound 1.6 % of the total lysosomal biotin-HRP (Fig. 3.33). To improve upon 
this, beads were opsonised and the pulse and chase time increased to a total of 2 
h (1 h pulse, 1 h chase). Although this would alter the characteristic of the 
phagosome preparation, it was deemed more important to first establish a working 
assay. This increased the amount of biotin-HRP that the phagosomes could bind 
to 25 % of the total (Fig. 3.34). Thus, the biggest limiting factor appeared to be the 
phagosomes. In an attempt to get a working fusion assay, it was decided to 
proceed with the fusion assay based upon the results of these experiments. 
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3.3.4.7 Fusion of lysosomes and phagosomes in vitro 
The fusion assay was set up using conditions to demonstrate a requirement for 
physiological temperature and energy. An internal control was included, that had 
lysosomes, phagosomes, and either an energy regenerating system, or PBS 
without the addition of biocytin (table 3.1 conditions 5 & 6). This was incubated at 
either 4 ºC or 37 ºC. The lack of biocytin meant that upon the addition of RIPA 
buffer, biotin-HRP from lysosomes would have been free to bind to the beads. 
Therefore the highest fluorescent signal should have been seen with conditions 5 
& 6. Even in the absence of any fusion, HRP should have been detected in these 
samples, and the fluorescence should have been higher than all other samples. As 
no fluorescence was observed, it suggested that there was a fundamental problem 
with the assay that prevented any biotin-HRP binding to the phagosome beads, 
even in the absence of biocytin. This is confirmed by fact that the phagosomes 
were capable of binding biotin-HRP, and that the HRP-lysosomes yielded a 
fluorescence signal when assayed. Moreover, the binding capacity of the 
phagosomes was much greater than in previous experiments. If the phagosomes 
had a very low latency, or the phagosomes were not released from cells properly, 
then this could account for the lack of a signal although this is unlikely. Therefore, 
it is unclear why no fusion signal was seen. Fusion reactions were lysed with RIPA 
buffer at 4 ºC for 15 min. It is possible that this time was insufficient to see transfer 
of biotin-HRP to beads in control conditions. However, previous optimisation 
experiments have showed binding of biotin-HRP at 4 ºC within 30 min, suggesting 
that at least some biotin-HRP should bind. One change to the protocol was that it 
was performed in the presence of pig brain cytosol, as cytosol had previously been 
shown to be necessary for vesicle fusion in vitro (Mullock et al., 1989, Becken et 
al., 2010, Mullock et al., 1998, Ward et al., 1997). When the cytosol was assayed 
with Amplex Red, it gave a high fluorescent signal (data not shown). However, it 
was concluded that this should not have been a problem for the fusion assay, as it 
would be removed with multiple washes after the beads were recovered. 
Additionally, using cytosol to elute lysosomes from the cell column and resuspend 
phagosomes after washing, could have conceivably enhanced fusion, by allowing 
the formation of molecular complexes that are required for vesicle fusion  
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One possibility to determine whether or not vesicle fusion had occurred and not 
been reported, would be to examine the ultrastructure of the organelles before and 
after fusion had occurred. The interactions of endocytic organelles and 
phagosomes has been previous investigated by electron microscopy (Jahraus et 
al., 1998, Mayorga et al., 1991, Duclos et al., 2000). As FeDex would be 
particularly electron dense, it may have been possible to see the transfer of FeDex 
to phagosomes, which would be readily identifiable. This could be used to confirm 
whether fusion of phagosomes and lysosomes had occurred but the transfer of 
biotin-HRP to the beads had not.  
Phagosomes and lysosomes were mixed together to allow fusion to proceed for 90 
min to maximise the amount of fusion. Previous cell-free assays report fusion of 
phagosomes and endosomes/lysosomes as early as 10 min (Mayorga et al., 
1991), and late endosomes and lysosomes after 10 min (Mullock et al., 1998). 
Alternatively, fusion reactions were allowed to proceed for up to 80 min (Jahraus 
et al., 1998) but have also been reported to reach a plateau after 40 min (Becken 
et al., 2010). Had a reproducible fusion signal been detected, the length of time 
could have been varied to investigate the rate at which fusion occurred. The 
minimum time needed to see a fusion signal, and the time at which no further 
fusion occurred could also be studied. 
3.3.4.8 Pig brain cytosol may have interfered with vesicle fusion 
One source of error could be the possibility of endogenous biotin present in the 
brain cytosol. Biotin in rat brain may give false-positive results with streptavidin-
biotin assays (McKay et al., 2008) and it is not unreasonable to assume that the 
same may be true for pig brain cytosol. Biotin in pig brain cytosol would then 
compete with biotin-HRP for streptavidin binding sites in the control conditions. 
This could have been a significant problem if biotin crossed the phagosome 
membrane and bound to the streptavidin beads, but this is unlikely as biotin is 
actively transported into cells rather than freely diffusing across cellular 
membranes (Dyer and Said, 1997). Thus, while pig brain cytosol possible reduced 
the transfer of biotin-HRP to the beads in control conditions, this does not explain 
why no fusion was seen in the other conditions. 
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3.3.4.9 Troubleshooting of the fusion assay 
There are several ways that the fusion assay could be troubleshooted. Firstly, it 
was seen that biotin-HRP was slightly degraded after passing through cells. This 
could be prevented by using inhibitors of lysosomal hydrolases to increase the 
amount of intact biotin HRP and increase the total available biotin signal. This 
could also be achieved by using biotin-HRP at a high concentration in the cell 
culture media (although this would likely prove too costly). Alternatively, more cells 
could be used to purify biotin-HRP lysosomes, but again this would require the use 
of more biotin-HRP. 
It is likely that a limiting factor in the fusion assay was the amount of intact 
phagosomes that could fuse with lysosomes. To investigate this, more 
phagosomes could be purified from cells, or the phagosome protocol could be 
further optimised to i) remove more unbound beads, giving a better estimation of 
actual phagosomes purified (rather than extracellular beads), ii) increase 
phagosome latency further, or iii) investigate how phagosomes could be further 
separated from unbroken cells containing beads. This has previously been done 
using Ficoll-Paque centrifugation media and a 30 min centrifugation step (Shapiro 
et al., 2005). The ability of FeDex/biotin-HRP lysosomes and bead phagosomes to 
fuse with other endocytic organelles in vivo was not known. This could be 
investigated using fluorescent tracers (such as fluorescent dextrans) to examine 
the fusion of these organelles in living cells. This would confirm whether or not the 
these marker-loaded compartments are actually fusogenic. In an in vitro setting, a 
different approach could be used to investigate whether the purified lysosomes or 
phagosomes were receptive to vesicle fusion. Using previously established fusion 
assays it maybe possible to substitute in FeDeX purified lysosomes or streptavidin 
bead phagosomes. This may help to identify if either of these organelles can still 
participate in fusion. Finally, the first step that should be taken would be to identify 
conditions in which transfer of the biotin-HRP to beads in control conditions could 
be detected. This may include lysing the fusion reactions at room temperature, or 
allowing binding between biotin-HRP and beads to occur for a longer period of 
time. This should not affect other fusion conditions, as i) the vesicle membranes 
are lysed preventing further fusion from occurring, and ii) they contain biocytin that 
would block any further binding between free biotin-HRP and beads. 
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3.3.4.10 Conclusions 
Overall, the development of the fusion assay resulted in the optimisation of both 
lysosome and phagosome purification. While the fusion assay itself was 
unsuccessful, the experiments were invaluable for furthering lysosome purification. 
Firstly, SPION purified lysosomes were successfully purified with high latency (> 
75 %) and a reasonable recovery (~ 10 %). The purification of lysosomes by 
isopycnic centrifugation required the setting up of a gradient the day before 
purification, a 1 h centrifugation followed by fraction collecting (approximately 1 h). 
In contrast, magnetic isolation took approximately 1 h in total. Secondly, the 
lysosomes recovered were characterised by western blotting and shown to be 
enriched for lysosomal markers. The protocol can also easily be adapted to purify 
other endocytic compartments, by altering the pulse and chase of SPIONS. 
Alternatively, FeDex could be used to label pathogens such as Rhodococcus equi, 
(Sydor et al., 2013) and the resulting phagosomes could be purified and 
biochemically analysed. Such approaches have already been used to isolate 
Mycobacterium-containing phagosomes (Steinhauser et al., 2013, Pethe et al., 
2004, Sydor et al., 2013). Crucially, biotin-HRP still function when delivered to 
lysosomes. Although some was likely degraded, this could be improved using 
inhibitors of lysosomal proteases. This opens up the possibility of using other 
markers for different applications. For example, the protocol could easily be 
adapted to include fluorescent markers in both lysosomes and phagosomes that 
could be used to examine FRET between organelles, should a microscopy-based 
assay be required.  
Had vesicle fusion been successful, it could have been used to examine the 
molecular requirements for phagosome-lysosome fusion. Firstly, it is highly likely 
that there would be a requirement for energy, in the form of ATP. The fact that 
many different in vitro membrane fusion assays require ATP, demonstrates energy 
is absolutely required for fusion to proceed, or at the very least greatly reduces the 
overall amount of vesicle fusion when it is omitted (Balch and Rothman, 1985, 
Mullock et al., 1998, Jahraus et al., 1998, Becken et al., 2010, Mullock et al., 1989, 
Mayorga et al., 1991, Ward et al., 1997, Happe and Weidman, 1998). 
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Secondly, the assay could be used to determine the role of Rab proteins. Rab 
GTPases are key regulators of membrane trafficking and localise to distinct 
subcellular organelles, and their ability to promote selective tethering between 
membranes (Zerial and McBride, 2001). A key feature of Rab proteins, are their 
ability to function as molecular switches, which requires GTP. Rabs cycle between 
a functional “On” state where they bind GTP, and an inactive “off” state, where 
GTP is hydrolysed to GDP (Hutagalung and Novick, 2011). Inclusion of the poorly 
hydrolysable GTP analogue GTPγS in fusion assays, has been shown to enhance 
vesicle fusion (Jahraus et al., 1998, Mullock et al., 1998), suggesting a 
requirement for active Rab proteins in this process. Furthermore, Rab7 is found on 
late endosomal membranes, and is important in the regulation of late endocytic 
membrane traffic (Press et al., 1998, Vitelli et al., 1997, Bucci et al., 2000) The role 
of Rab7 in phagosome maturation is not as well characterised, but α-Rab7 
antibodies reduced the amount of fusion between lysosomes and E.coli containing 
phagosomes in vitro (Becken et al., 2010). The inclusion of mutant Rab7 proteins 
(such as the dominant-negative Rab7T22N or constitutively active Rab7Q67L or 
Rab7I41M (Vitelli et al., 1997), to fusion reactions could be used to investigate the 
requirement for Rab7 in phagosome-lysosome fusion. However, it is likely 
recombinant Rab7 protein would be unable to enhance fusion, as it requires lipid 
modification (geranlygeranylation) to associate with membranes (Seabra, 1996). 
Alternatively, siRNA depletion of cells could be used to generate cytosol depleted 
of Rab7 (Vanlandingham and Ceresa, 2009) or other fusion machineries such as 
components of the HOPS complex (Pols et al., 2013) to investigate their role in 
phagosome-lysosome fusion. Cytosol has been found to either increase, (Becken 
et al., 2010, Mayorga et al., 1991), or be essential for vesicle fusion (Mullock et al., 
1998). Altering the concentration of cytosol also influences the amount of fusion 
(Jahraus et al., 1998). Thus, the optimal level of cytosol needed for the assay 
could be determined. The source of the cytosol may also influence the amount of 
fusion seen. In general, cell-free fusion assays have demonstrated a requirement 
for NSF (Ward et al., 1997, Wattenberg et al., 1992, Balch and Rothman, 1985, 
Diaz et al., 1989), and fusion is inhibited by the addition of NEM to fusion reactions 
(Rodriguez et al., 1994, Robinson et al., 1997). SNARES are essential for 
membrane fusion, yet the specific SNARES involved in fusion at the phagosome 
membrane have not been extensively studied. Syntaxin 13 and 7 have been 
demonstrated to be important for phagosome maturation (Collins et al., 2002) but 
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the stage at which they are involved is unclear. In an in vitro phagosome-lysosome 
fusion assay, SNARE involvement in membrane fusion was tested by the addition 
of recombinant cytosolic domains of SNARE proteins into the reaction mixture 
(Becken et al., 2010). These solSNARES lack the transmembrane domains 
needed to drive vesicle fusion, and thus compete with wild type SNARES which 
has the effect of inhibiting vesicle fusion. However, results of such experiments 
need to be interpreted carefully, due to the promiscuous formation of some 
SNARE complexes (Wendler and Tooze, 2001). A working fusion assay could also 
be used to investigate the SNAREs involved in fusion between phagosomes and 
lysosomes.Inhibitors of lysosomal function may also reveal the mechanisms 
involved in lysosome-phagosome fusion. Bafilomycin A inhibits the action of the 
vATPase proton pump resulting in the dissipation of proton gradients (and thus 
pH) and nigericin (a potassium ionophore) which disrupts membrane potentials, 
both increase lysosomal pH. Bafilomycin was found not to inhibit membrane fusion 
(Mullock et al., 1998, Becken et al., 2010) and its absence in knockout mice does 
not affect phagosome-lysosome fusion (Kissing et al., 2015). Thus, acidification of 
the phagosome might be required for pathogen-killing, but not for fusion with the 
lysosome per se. Other chemical inhibitors have also been used to investigate the 
requirements of phagosome-lysosome fusion. The microtubule depolymerising 
agent nocodazole has been demonstrated to disrupt fusion with the lysosome in 
vivo (Funato et al., 1997, Matteoni and Kreis, 1987, Desjardins et al., 1994b) but 
microtubules may not be necessary for vesicle fusion in an in vitro setting (Becken 
et al., 2010). Finally, the fusion assay could be used to examine the disruption of 
phagosome-lysosome fusion by bacterial effector proteins. To date, there are no 
publications describing the inhibition of phagosome-lysosome membrane fusion by 
exogenously added bacterial effector proteins. However, cytosol from cells 
infected with Mycobacterium smegmatis or cytosol incubated with bacteria was 
able to inhibit phagosome-lysosome fusion in vitro (Peyron et al., 2001), indicating 
secreted bacterial factors are involved. In the case of R. equi, it may be possible to 
purify VapA-containing lysosomes and determine if they are still fusogenic. 
Alternatively, the cytosol of infected macrophages could be used in the assay as a 
potential source of bacterial effectors. 
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Chapter 4: Identifying R. equi effector proteins 
4.1 Introduction 
4.1.1 Yeast as a tool to investigate bacterial pathogenicity 
Model organisms are extensively used in almost all aspects of research into 
human biology and disease (reviewed extensively in Hedges, 2002, Aitman et al., 
2011 and Spradling, 2006). In particular, the budding yeast Saccharomyces 
cerevisiae (S. cerevisiae) is a widely used model (Botstein and Fink, 2011) as it 
has several advantages over other model organisms.  The use of yeast 
overcomes the ethical and financial restraints of using higher eukaryotes such as 
primates. Yeast can be used for high-throughput screens such as DNA 
microarrays (Eisen et al., 1998) yeast-two hybrid screens (Roberts et al., 2012) 
and plasmid overexpression (Fleming and Gitler, 2011). They have reasonable 
growth rates and temperature-sensitive mutants can be used to study the effects 
of mutations that would be lethal in other organisms (Li et al., 2011, Tan et al., 
2009). The genetics of yeast are heavily characterised and the genome has been 
sequenced (Goffeau et al., 1996) allowing it to be compared to the human genome 
(Adekoya et al., 2001). Due to the conservation of essential cellular processes 
between eukaryotic species, such as chromosome segregation (Kitagawa and 
Hieter, 2001), intracellular protein transport through the Golgi (Dunphy et al., 1986) 
and endocytic membrane trafficking (Conibear, 2010), yeast can be used to 
understand many aspects of mammalian cell biology. 
Intracellular pathogens must disrupt host cell defences if they are to survive 
intracellularly. This is achieved by the production of virulence factors, which 
interact with a vast array of different host lipids and proteins to disrupt host 
defences. For example, the lipid component of the M. tuberculosis cell wall 
(mannose-capped lipoarabinomannan) is thought to arrest phagosome maturation 
(Fratti et al., 2003), whereas Legionella penumophilia is predicted to have over 
300 effector proteins that prevent the Legionella containing-vacuole (LCV) from 
fusing with the lysosome (Hubber and Roy, 2010a). Some intracellular pathogens 
lack suitable animal models that accurately reflect the human disease or are not 
genetically tractable (Curak et al., 2009). Likewise, many effector proteins lack 
homology to proteins of known function meaning bioinformatics approaches are 
challenging. Those proteins that are identified by computational approaches often 
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have homology to known proteins, meaning many that do not, are overlooked (Zou 
et al., 2013). One way of understanding bacterial pathogenesis is to determine 
how bacterial effector proteins interfere with eukaryotic cell processes. This can be 
achieved by expressing single bacterial proteins in host cells and investigating any 
phenotype that arises. In yeast, disruption of intracellular trafficking produces 
easily identifiable phenotypes, such as aberrant protein secretion (Bankaitis et al., 
1986) or disrupted trafficking to the yeast vacuole (Bryant and Stevens, 1998). 
Alternatively, other phenotypes can be examined such as the inhibition of growth 
(Slagowski et al., 2008). Thus, bacterial genes can be expressed in yeast to 
determine whether they may be involved in pathogenicity and in particular 
disruption of membrane trafficking. 
4.1.2 Orthologous system to lysosomes 
The yeast vacuole is widely considered to be the equivalent of the mammalian 
lysosome (Matile and Wiemken, 1967) and is a useful tool to study lysosome 
biology. The biochemical and genetic tractability of the vacuole makes it an 
attractive model to study mammalian lysosome function. The yeast vacuole has a 
lipid composition that is distinct from other cellular membranes such as the plasma 
membrane (Zinser et al., 1991). In particular, the vacuole is rich in lipids essential 
for membrane fusion such as phosphatidylinositol 3,5-bisphosphate (PtdIns 
[3,5]P2) and yeast mutants that cannot produce this lipid have defective vacuoles 
that cannot undergo fission (Yamamoto et al., 1995). Similarly, in mammalian 
cells, disruption of PtdIns [3,5]P2  expression results in the formation of swollen 
endocytic compartments (Rutherford et al., 2006). However, the yeast vacuole 
also has additional functions, such as the storage of macromolecules and 
metabolites and is not just concerned with intracellular degradation (Klionsky et al., 
1990). The yeast vacuole is also large and easily seen under the light microscope. 
Any disruption in trafficking that results in aberrant vacuole morphology can easily 
be identified and quantified. Lipid-labelling dyes such as FM4-64 also allow 
visualisation of trafficking from the plasma membrane in live cells, allowing 
membrane trafficking to be studied in real-time (Vida and Emr, 1995).  
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4.1.3 Conserved steps in trafficking  
Many of the processes involved in trafficking to the lysosome in mammalian cells 
are conserved in yeast. These include proteins and protein complexes involved in 
vesicle priming, tethering, docking and fusion. For example, fusion of yeast 
vacuoles requires priming of vesicles by Sec18p (yeast NSF) and its cofactor 
sec17p (α-SNAP), to dissociate cis SNARE complexes to allow the formation of 
trans SNAREs (Collins and Wickner, 2007). This then allows vesicle docking 
through the association of the Vam2/6p complex (Price et al., 2000) and tethering 
through the concerted actions of Ypt7p (Mayer and Wickner, 1997) and the HOPS 
complex (Stroupe et al., 2006). This brings the membranes of acceptor and donor 
vesicles in close enough apposition for SNARE pairing and membrane fusion. 
There are many examples of orthology between mammals and yeast. For 
example, the human orthologue of Vam2p is VPS41 (Radisky et al., 1997) and 
VPS39 is the orthologue of Vam6p (Caplan et al., 2001a, Caplan et al., 2001b). 
Similarly, Rab7 is the human orthologue of yeast Ypt7p (Gallwitz et al., 1989, 
Haubruck et al., 1989, Wichmann et al., 1989). In mammalian cells, VPS41 and 
VPS39 are additional components of the HOPS complex, along with Vps11, 16, 18 
and 33 (Seals et al., 2000, Wurmser et al., 2000). Clearly, given the high degree of 
conservation between yeast and mammalian systems, S. cerevisiae is a powerful 
tool for studying membrane trafficking. 
4.1.4 Pathogen effector screening in yeast – PEPSY 
Pathogen effector screening in yeast, or PEPSY (Shohdy et al., 2005), takes 
advantage of the similarity between membrane trafficking in mammalian and yeast 
cells to identify bacterial genes that disrupt membrane trafficking. In yeast, 
membrane trafficking to the vacuole is controlled by vacuolar protein sorting (VPS) 
proteins. Many mammalian trafficking events are controlled by orthologues of 
yeast VPS proteins. For example, sorting nexin (SNX) 1 and SNX2 are 
orthologues of Vps5p, a core component of the yeast retromer complex (Haft et 
al., 2000); hVPS11 and hVPS18 are orthologues of yeast VPS11 and VPS18, 
components of the homotypic fusion and vacuolar protein sorting (HOPS) complex 
involved in late endosome/lysosome fusion (Kim et al., 2001). In mammalian cells, 
soluble proteins destined for the lysosome exit from the endoplasmic reticulum 
(ER) and are delivered to the Golgi. In the Golgi they may undergo extensive post-
translational modifications, including the addition of mannose-6-phosphate (M6P) 
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residues (Braulke and Bonifacino, 2009). M6P-tagged proteins are recognised by 
mannose-6-phosphate receptors (M6PR), of which there are two forms, a ~ 46kDa 
cation-dependent (cdM6PR) form and a ~ 250-300 kDa cation-independent 
(ciM6PR) form. The transport of M6PRs and their ligands (from the Golgi to late 
endosomes) is dependent on C-terminal signal sequences in the cytoplasmic tails 
of both variations of the receptor (Ghosh et al., 2003). The M6PR-cargo 
complexes exit the trans-Golgi network (TGN) and deliver their cargo to late 
endosomes, where the low pH causes dissociation between the receptor and its 
ligand (Fig. 4.0 A). The receptor is then retrieved and returned to the Golgi to pick 
up more cargo (Ni et al., 2006). A similar pathway exists in yeast. Newly 
synthesised proteases and other vacuolar enzymes contain signal sequences to 
target them to the endoplasmic reticulum (Valls et al., 1990) upon which they 
transit through the Golgi before they are delivered to the vacuole. In yeast, 
carboxypeptidase-Y (CPY) associates with a sorting receptor, vps10 (Marcusson 
et al., 1994) that cycles between the Golgi and a pre-vacuolar compartment to 
perform multiple rounds of CPY delivery (Cooper and Stevens, 1996). In yeast 
however, disruption of trafficking to the vacuole results in missorting of vacuolar 
enzymes into secretory vesicles (Fig. 4.0 B), giving rise to a VPS phenotype. 
Using previously established methodologies (Bankaitis et al., 1986, Robinson et 
al., 1988) VPS phenotypes can be identified by assaying for the secretion of a 
hybrid fusion protein. The yeast strain used for PEPSY screening expresses an 
Invertase (Inv) - Carboxypeptidase Y (CPY) fusion protein. The SUC2 gene 
encodes Inv (β-D – fructofuranoside fructohydrolase), which is normally secreted. 
The PRC1 gene encodes CPY. The first 50 amino acids of CPY contain a vacuolar 
sorting signal, which is fused to the last 433 amino acids of Inv. This results in an 
invertase protein that is sequestered within the vacuole and is not able to 
hydrolyse sucrose present at the cell surface. If normal trafficking is disrupted by 
the expression of exogenous genes (or lack of VPS proteins such as Vps10) target 
vesicles do not reach the vacuole and CPY-Inv is missorted into vesicles destined 
for the cell surface. This results in CPY-Inv being secreted and this secretion can 
be measured using a simple qualitative agar overlay assay on single colonies, or 
by a quantitative assay on liquid cultures (Darsow et al., 2000). PEPSY screening 
works by expressing a random library of bacterial genes in yeast. If the expressed 
protein disrupts membrane trafficking to the yeast vacuole then CPY-Inv is 
secreted. Therefore, entire bacterial genomes can be screened for effector 
proteins that may disrupt trafficking in mammalian cells.  
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Fig. 4.0. Schematic representation of PEPSY – Pathogen Effector Screening in 
Yeast. A. Mannose-6-phosphate tagged lysosomal hydrolases associate with mannose-6-
phosphate receptors (M6PR) in the Golgi. M6PRs and their cargo are then trafficked to 
the lysosome, (via late endosomes) where the low pH causes dissociation of the receptor 
and ligand. The receptor then recycles back to the Golgi to accept more cargo. B. In 
yeast, the vacuole is the equivalent of the mammalian lysosome. In yeast expressing a 
hybrid Carboxypeptidase-Y (CPY)-Invertase (Inv) fusion protein, CPY-Inv is trafficked to 
the vacuole by the CPY receptor, VPS10, in a mechanism analogous to M6PR trafficking 
in mammalian cells. If trafficking in CPY-Inv expressing yeast is disrupted, CPY-Inv 
becomes missorted into secretory vesicles and is secreted. The secreted invertase can be 
assayed. 
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4.1.5 Yeast as a tool to study the virulence of Rhodococcus equi 
The horse pathogen Rhodococcus equi causes granulomatous pneumonia in foal 
(Yager et al., 1987), which is fatal if left untreated. R. equi is also becoming 
increasingly isolated from human patients, particularly from immunocompromised 
hosts (Kedlaya et al., 2001, Topino et al., 2010). R. equi can also be mistaken as 
M. tuberculosis (Mistry et al., 2006) due to the similarities between these two 
pathogens. R. equi is an intracellular pathogen that resides inside alveolar 
macrophages (Hondalus, 1997), but how it circumvents host defences is not clear. 
As such, elucidating the mechanisms by which R. equi manipulates the host cell 
may give insights into bacterial pathogenesis, but also host cell function. 
To date, yeast have not been used to study R. equi virulence, nor have 
Rhodococcus genes been expressed in yeast. Yeast have however, been used to 
express Mycobacterium genes (Gurvitz et al., 2009). In this study, a Rhodococcus 
equi genomic and plasmid gene library was created for PEPSY screening to 
identify bacterial genes that resulted in a VPS phenotype. The optimisation of 
gene library generation and screening of the R. equi genome is discussed below. 
A schematic diagram depicting this methodology is show in figure 4.1. 
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Fig. 4.1. Schematic representation of R. equi library generation for the PEPSY 
screen. A. The yeast expression vector is linearised by BamHI and R. equi DNA digested 
with Sau3AI to produce random fragments. B. The gene fragments are ligated into 
pVT100-U C. Ligated plasmid are transformed into E.coli for plasmid propagation. D. 
Plasmids are extracted from E.coli by Midiprep and pooled to give a complete R. equi 
gene library. E. Plasmids are then transformed into yeast, which are assayed for a VPS 
phenotype using the CPY overlay assay previously described. 
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4.2 PEPSY screen-specific methods 
 4.2.1 Yeast strains 
The following table contains the genotype and source of Saccharomyces 
cerevisiae strains used in this study. 
 
Table 4.0 Yeast strains used in this study 
 
Strain Genotype Source/Reference 
SEY6210 MATα leu2-3,112 ura3-52 his3-∆200 trp1-∆901 lys2-
801 suc2-∆9 
(Horazdovsky et 
al., 1994) 
SEY6211 MATa leu2-3,112 ura3-52 his3-∆200 trp1-∆901 ade2-
101 suc2-∆9 
(Horazdovsky et 
al., 1994) 
BHY10 SEY6210 leu2-3,112::pBHY11 (CPY-Inv LEU2) (Horazdovsky et 
al., 1994) 
BHY11 SEY6211 leu2-3,112::pBHY11 (CPY-Inv LEU2) (Horazdovsky et 
al., 1994) 
BHY12 MATα/MATa leu2-3,112::pBHY11 (CPY-Inv LEU2)/ 
leu2-3,112::pBHY11 (CPY-Inv LEU2) ura3-52/ ura3-
52 his3-∆200/ his3-∆200 trp1-∆901/ trp1-∆901 suc2-
∆9/ suc2-∆9 ADE2/ ade2-101 lys2-801/LYS2 
(Horazdovsky et 
al., 1994) 
BHY10 
pVT100-U 
BHY10 [pVT100-U URA3] This study 
BHY10 
∆VPS10 
BHY10:: ∆VPS10:TRP [pVT100-U URA3] This study 
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4.2.2 Yeast transformation 
A single colony of BHY12 yeast were grown overnight in 10 ml YEP fructose at 
30oC with shaking. 0.5 ml aliquots of yeast were pelleted at 3,300 x g for 1 min in a 
microcentrifuge and the supernatant discarded. Cells were resuspended by 
vortexing with 20 µl single stranded carrier DNA (2 mg/ml salmon sperm DNA 
heated to 95oC for 5 min and rapidly cooled to 4oC) and 2.4 µg plasmid DNA and 
incubated at room temperature for 15 min. 250 µl of sterile filtered PLATE solution 
(10 mM Tris, pH 7.4, 1mM EDTA, 100 mM lithium acetate, 40 % (w/v) PEG4000) 
was added , mixed thoroughly and incubated at 30oC overnight. Cells were heat 
shocked for 15 min at 42 oC in a water bath. Cells were then gently resuspended 
in 400 µl YEP fructose and incubated at 30 oC for 1-2 h. Cells were then 
resuspended in 100 µl sterile ddH2O and 80 µl spread onto the appropriate 
selective agar. 
4.2.3 Preparation of yeast protein extracts. 
5-10 ml of selective media was inoculated with a single yeast colony and grown 
overnight at 30 ºC with shaking. The next day, 1.0 OD600 was pelleted at 3,300 x g 
for 1 min in a bench top centrifuge, washed once with ddH2O and cell pellets 
resuspended in 100 µl TWIRL buffer (50 mM Tris-HCl, pH. 6.8, 5 % (w/v) SDS, 8 
M urea, 10 % (v/v) glycerol, 0.2 % (w/v) bromophenol blue and 10 % (v/v) β – 
mercaptoethanol). Samples were heated at 65 ºC for 10 min, vortexed briefly and 
stored at -20 ºC until needed. For western blot analysis, 75 µl was loaded per lane 
of an SDS polyacrylamide minigel. Alternatively, 7.5 OD600 was washed once in 
ddH2O and cell pellets snap frozen in liquid nitrogen. The pellets were 
resuspended in 100 µl of TWIRL buffer (without β – mercaptoethanol), with 
approximately 80 µl of glass beads (acid washed, Sigma) and heated to 70 ºC for 
10 min. Cells were vortexed vigorously for 1 min and centrifuged at 16,000 x g for 
10 min. The supernatants were collected and placed on ice. β – mercaptoethanol 
was added to 10 % (v/v) and samples heated to 95 ºC for 5 min then frozen at -20 
ºC until further use. For western blot analysis, 75 µl was loaded per lane of an 
SDS polyacrylamide minigel. 
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4.2.4 Extraction of R. equi genomic and plasmid DNA 
50 ml of BHI medium was inoculated with a single R. equi colony and incubated 
overnight at 30 oC with shaking. The cell pellet was resuspended in 2 ml TE buffer 
(10 mM Tris, 1 mM EDTA pH 8.0) and split equally between 5 aliquots. 0.5g of 
acid washed glass beads were added and the suspension was vortexed for 5 
minutes. The supernatants were transferred to a fresh tubes and lysozyme added 
to a final concentration of 5 mg/ml. This was incubated at 55 oC for 2 h. 30 µl of 
10% (w/v) SDS and 3 µl proteinase K (20mg/ml) were added and incubated at 37 
oC for 1 h. 100 µl of 5 M NaCl was added and mixed thoroughly and 80 µl of CTAB 
(10 % w/v Cetyl trimethylammonium bromidide dissolved in 0.7M NaCl) 
warmed to 65oC was added. This was mixed gently and incubated at 65 oC for 
10 min. 750 µl of chloroform:isoamyl alcohol (24:1) was added, mixed well 
and the samples were centrifuged at 16,100 x g in a bench top centrifuge for 
10 min. The upper aqueous phase was transferred to a fresh tube and an 
equal volume of phenol:chloroform:isoamyl alcohol (25:24:1) was added 
and mixed gently. This was centrifuged at 16,100 x g for 10 min. The upper 
aqueous phase was transferred once more to a fresh tube and DNA 
(genomic and plasmid) was precipitated by the addition of 0.6 volumes of 
isopropanol. The tubes were gently inverted with a flicking motion to 
aggregate the DNA. The DNA pellet was removed from the tube using a 
sterile glass Pasteur pipette where the end had been melted to form a small 
hook. The DNA was dunked into 70 % (v/v) ethanol twice. The pellet was 
then dissolved in 100 µl TE by leaving the Pasteur pipette in TE at 37 ºC until the 
pellet was no longer visible. 
4.2.5. R. equi random gene library generation 
10 µg of Rhodococcus equi 103S genomic and plasmid DNA was digested with 
Sau3AI for 64 min at 37 oC. The restriction enzyme was heat inactivated at 70 oC 
for 20 min. 1.5 ml of buffer PB (Qiagen miniprep kit) was added and the DNA 
bound to a Qiagen gel extraction column, washed and eluted into 30 µl buffer EB. 
The digested DNA was run on a 0.8 % (w/v) agarose gel and fragments between 
1.5-5 Kb were excised with a sterile scalpel blade. The DNA was purified using a 
Qiagen gel extraction kit as per the manufacturers’ instructions. The DNA 
fragments were then ligated into the yeast expression vector pVT100-U, which had 
191 
been linearised with BamHI. E.coli were then transformed with plasmids as 
follows: XL1-blue electrocompetent cells (Agilent Technologies, UK) were 
defrosted on ice and mixed with 1 µl of the ligation reaction and then transferred to 
an ice cold electroporation cuvette with a 0.1 cm gap (Biorad). Cells were then 
electroporated using a  Biorad Micropulser with a field strength of 17  kV/cm. The 
cells were then rapidly transferred to 960 µl of prewarmed to 37oC SOC medium 
and incubated with shaking at 37oC for 1 hr. 500 µl of cells were spread (using 
glass plating beads) onto a 15 cm plates of LB agar + ampicillin and incubated at 
37oC overnight or until colonies were visible but not overgrown. Ampicillin resistant 
colonies from 116 plates (~ 427,000) were then scraped into LB and processed 
using 9 Midiprep columns (Qiagen) as per the manufacturer’s instructions. 
Approximately 5 ml of DNA was collected at 138.1 ng/µl and stored at -80oC.  
4.2.6 PEPSY screen  
20 ml of YEP supplemented with 2 % (v/v) fructose as the sole carbon source was 
inoculated with a single BHY12 yeast colony and grown overnight at 30 ºC with 
shaking. The next day, 0.5 ml aliquots of the yeast culture were centrifuged and 
resuspended in 0.5 ml of sterile ddH2O. The yeast were centrifuged again and the 
ddH2O removed. The cell pellets were resuspended by vortexing with 20 µl of 
sterile salmon sperm DNA (2 mg/ml heated to 95 ºC for 5 min and rapidly cooled 
to 4 ºC to generate single stranded DNA) and 2 µg of the R. equi library (per 
transformation). Yeast were then incubated at room temperature for 15 min. 250 µl 
of sterile PLATE solution (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 100 mM Lithium 
acetate, 40 % (v/v) PEG 4000) was then added to the yeast and the yeast were 
vortexed once more beforing incubating at 30 ºC overnight.  The next day, cells 
were heat shocked at 42 ºC for 15 min, pelleted at 3,300 x g for 1 min and 
resuspended in 400 µl YEP fructose. Cells were allowed to recovered at 30 ºC for 
1-2 h, pelleted and resuspended in 400 µl sterile ddH2O. Approximately 80 µl was 
spread onto selective agar plates (synthetic depleted -ura), which were incubated 
at 30 ºC until colonies appeared. Approximately 100 plates were screened, with 
750,000 colonies assayed for CPY secretion by the overlay assay. Colonies that 
showed a CPY secretion phenotype and turned brown were picked with a sterile 
toothpick and streaked onto a fresh agar plate for retesting. In order to determine if 
CPY secretion was plasmid dependent, colonies were streaked onto SD-ura 5-
FOA plates to cure yeast of their plasmids. Plasmids were extracted from yeast 
that lost secretion when grown on 5-FOA and were used to transform E.coli. 
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Plasmids were then used to re-transform BHY12 yeast and the CPY assay 
repeated. Plasmids that caused secretion were then sent off for DNA sequence 
analysis. 
4.2.7 Assays of CPY fusion protein secretion  
The assessment of a VPS phenotype was performed using previously described 
qualitative or quantitative methodologies (Darsow et al., 2000). A rapid qualitative 
overlay assay was performed to screen large numbers of yeast colonies for CPY 
secretion. Briefly, yeast were assayed by overlaying agar containing glucostat 
reagent directly onto yeast colonies. 100 ml of overlay solution was prepared as 
follows: 4.3 g of ultrapure sucrose (Fluka) was dissolved in 60 ml of ddH2O taking 
care not to introduce excess oxygen. Once the sucrose was dissolved, 10 ml of 1 
M sodium acetate, pH 5.5, 2 ml of 20 mM N-ethylmaleimide (NEM), 1 ml of 
Horseradish peroxidase (Type IV, 1 mg/ml), 0.8 ml of glucose oxidase (1000U/ml), 
6 ml of O-diansidine (10 mg/ml) and 20 ml of  3 % (w/v) Agar solution (heated to 
55oC) were added in that order. The solution was gently mixed and immediately 
poured onto yeast colonies, taking care not to wash yeast across the plate. Colour 
changes indicating invertase secretion were observed after approximately 30 min. 
Yeast positive for CPY secretion turned brown, whereas non-secreting yeast 
remained white.  
Alternatively, CPY secretion was quantitatively assayed by liquid CPY assay. 
Yeast expressing R. equi genes were grown in SD-ura selective media to 
stationary phase. 1 ml of yeast culture was taken and pelleted at 3,300 x g for 1 
min in a bench top centrifuge. Yeast were washed once with ddH2O and 
resuspended in 1 ml of ddH2O. 25 µl of yeast were then added to 775 µl (1 in 32 
dilution) of acetate buffer (0.1 M Sodium acetate, pH 4.9). 200 µl of this was taken 
(and kept on ice until required) to assay exogenous invertase activity (Secretion 
sample). 40 µl of the 1 in 32 dilution (or as a blank, 40 µl of acetate buffer) was 
added to 360 µl of acetate buffer and 10 µl of 20 % (v/v) Triton X-100 was added. 
Yeast were vortexed and freeze-thawed for 3 cycles by snap freezing in liquid 
nitrogen and thawing in a 30 ºC water bath. 200 µl of these yeast were taken to 
assay total invertase activity. At regular timed intervals, 50 µl of sucrose (0.5 M, 
sterile filtered) was added to the bottom of the tube containing the yeast samples 
using a positive displacement pipette. Tubes were placed in a 30 ºC shaking water 
bath for precisely 30 min to allow CPY-Inv to hydrolyse the sucrose. The reaction 
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was stopped by adding 0.3 ml of K2HPO4 (0.2 M, pH 10) and placing the tubes in a 
95 ºC water bath for 3 min. The tubes were placed on ice to cool and 2 ml of 
glucostat reagent (containing 39 ml 0.1 M K2HPO4, pH 7, 80 µl glucose oxidase 
(1000U/ml in PBS), 100 µl Horseradish peroxidase (Type VI 1 mg/ml in PBS), 200 
µl 20 mM NEM and 600 µl 10 mg/ml O-diansidine) was added at regular intervals 
to each tube. Tubes were then placed in a 30 ºC shaking water bath for precisely 
30 min. The reaction was stopped by the addition of 2 ml of 6 M HCl.  1 ml of the 
reaction was transferred to a cuvette and the absorbance was then read at 540 nm 
using a spectrophotometer. The percentage of CPY secretion was calculated as: 
[Extracellular OD540 /(Total OD540 X 10)] X 100 %. Yeast lacking the Vps10 
receptor (∆VPS10) were used as a positive control for CPY mislocalisation. 
BHY12 yeast harbouring an empty pVT100-U plasmid were used as a negative 
control. 
4.2.8 Extraction of plasmids from yeast 
Yeast were grown overnight in 10 ml of selective media at 30 ºC. The cells were 
pelleted and washed once with 500 µl of water. The cells were then resuspended 
in 200 µl of lysis buffer (2 % (v/v) Triton X-100, 1 % (v/v) SDS, 100 mM NaCl, 10 
mM Tris, pH 8, 1 mM EDTA). 200 µl of phenol-chloroform-isoamyl alcohol 
(25:24:1) and 0.3 g of acid washed glass beads, were added to each sample. 
Cells were vortexed vigorously for 4 min and then 200 µl of TE (10 mM Tris, pH 8, 
1 mM EDTA) was added. The sample was vortexed briefly and centrifuged at 
13,200 x g for 5 min. The upper aqueous phase was carefully transferred to a 
fresh microcentrifuge tube and 1 ml of 100 % ethanol (prechilled to  - 20 ºC) was 
added. The sample was mixed gently by inverting the tube and then incubated at -
20 ºC for 30 min. Precipitated DNA was then pelleted by centrifugation at 13,200 x 
g for 5 min at 4 ºC. The supernatant was discarded and the pellet washed with 200 
µl of 70 % (v/v) ethanol. The pellet was vortexed and centrifuged again. The 
ethanol wash was discarded and the pellet left to air dry. If transformation of E.coli 
was required, the pellet was resuspended in 40 µl of sterile water. For further 
purification, the DNA pellet was resuspended in 400 µl of TE and processed as 
follows. 30 µg of RNAse A, or 1 µg of RNAse 1 was added and incubated at 37 ºC 
for 10 min.10 µl of 4M Ammonium acetate and 1 ml of 100 % ethanol were added 
and mixed by inversion. The DNA was precipitated at -20 ºC for 10 min and 
pelleted by centrifugation at 13,200 x g for 5 min. The pellet was washed with 200 
µl of 70 % (v/v) ethanol and centrifuged once more for 2 min. The supernatant was 
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discarded and the DNA pellet dried at 37 ºC. The pellet was then resuspended in 
100 µl of TE and stored at – 20 ºC. 
4.2.7 Scoring of yeast vacuoles 
Yeast cultures were grown overnight in selective media and diluted so that the 
cultures had the same OD600. 1 µl of the diluted culture was placed onto a glass 
slide and covered with a glass coverslip. 3 separate images of each yeast strain, 
containing approximately 300 cells per image, were blindly scored for as having 
either single or multiple vacuoles, as judged by the expression of GFP-ALP  or 
GFP-ALP myc-VapA. Counts were repeated a minimum of 3 times.  
 
 
 
 
 
 
 
 
 
 
 
195 
4.3 Results 
4.3.1 Construction of the R. equi gene library 
In order to identify R. equi genes that induced a VPS phenotype when expressed 
in yeast a random R. equi gene library was required. When generating a library 
there are several considerations. Firstly, the DNA must be isolated and digested 
sufficiently to produce suitable fragment sizes and be representative of the entire 
genome. Secondly, it should not be skewed towards large or small fragments. 
Third, it must be relatively free of non-transformants to increase the likely hood of 
finding positive clones and finally it must cover the entire bacterial genome to 
increase the probability of each gene being represented. 
As the R. equi virulence factor VapA is the only known virulence factor that is 
essential for growth of R. equi inside macrophages (Jain et al., 2003, Giguere et 
al., 1999), yet it is not sufficient to enable plasmid-cured strains to survive 
intracellularly (Giguere et al., 1999), it was hypothesised that there must be 
additional virulence genes that may be present on the chromosome. Therefore, it 
was decided to try and purify chromosomal DNA rather than the plasmid, to 
identify these unknown factors. Secondly, to prevent the potential skewing of the 
library towards plasmid-encoded virulence factors, it was necessary to separate 
the plasmid and chromosomal DNA. To this end, different DNA extraction methods 
were used to purify genomic and plasmid DNA and then separate them using a 
caesium chloride gradient. The plasmid DNA could also be used to create a 
plasmid only library to screen for plasmid-encoded genes.  
To generate a random gene library it was necessary to purify Rhodoccocus DNA 
in sufficient quantity to perform the appropriate optimisation experiments. R. equi 
DNA (genomic and plasmid) has previously been purified using a variety of 
methods including alkaline lysis (Birnboim and Doly, 1979, Miranda-Casoluengo et 
al., 2005, Byrne et al., 2007, Makrai et al., 2002), phenol-chloroform/CTAB 
extraction (Rahman et al., 2003, Pei et al., 2007, Rodriguez-Lazaro et al., 2006) or 
caesium chloride density centrifugation (Tkachuk-Saad and Prescott, 1991, Takai 
et al., 1991). Figure 4.2 depicts the workflow used to optimise the purification of R. 
equi DNA. The purification of the 90 Kb plasmid DNA was attempted using a 
commercially available plasmid extraction kit (Qiagen Large construct kit). Despite 
several attempts, purification of R. equi DNA using this method proved 
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unsuccessful, possibly due to the copious amounts of mycolic acids produced by 
R. equi, which makes cell lysis difficult (Brennan and Nikaido, 1995). Next, a 
Qiagen Midiprep kit was used to try and purify R. equi DNA. Although some DNA 
was purified, it appeared to be a mixture of chromosomal and plasmid DNA and 
the yield was low (72ng/µl, data not shown). Next, a standard CTAB/phenol 
protocol was used to try and isolate DNA. This method also proved unsuccessful, 
until an extended 2 h digest with proteinase K at 37 ºC was included. This 
modified protocol yielded 31.4 µg of total chromosomal and plasmid DNA. Finally, 
the CTAB protocol was modified a final time. R. equi cell pellets were vortexed 
with glass beads for 5 min, to mechanically disrupt the cells before digestion with 
proteinase K. Additionally, bacteria were digested for 2 h at 55 ºC with lysozyme 
added to a final concentration of 5 mg/ml. These modifications were incorporated 
to produce a final method for the purification of total R. equi DNA, which is 
described in section 4.2.4. This method gave a total of 73 µg of DNA from 50 ml of 
R. equi culture. 
The genomic and plasmid R. equi DNA was applied to a caesium chloride 
gradient, to separate plasmid and genomic DNA. However, all attempts at this 
protocol were unsuccessful. The rationale for this step, was to separate out 
plasmid and genomic genes, to prevent skewing of the R. equi DNA library with 
plasmid virulence genes, which may have masked any chromosomally-encoded 
genes from appearing in the PEPSY screen. As an alternative approach, R. equi 
was sub-cultured continuously for over 20 passages at 37 ºC to cure the strain of 
the virulence plasmid (Takai et al., 1994). Colonies were periodically tested for the 
presence of the plasmid by PCR of the traA and VapA genes. Despite these 
efforts, bacteria were not cured of the virulence plasmid and a library was 
generated using total R. equi DNA. Due to the difficulty in separating out the DNA 
elements and inducing plasmid loss, it was decided to proceed with the creation of 
the library using both genomic and plasmid DNA. It was  hypothesised that as only 
~25 genes of the plasmid were part of the pathogenicity island (the rest being 
concerned with plasmid propagation and partitioning), that skewing of the library 
may not have been a concern. 
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Fig. 4.2. Work flow of R. equi DNA extraction. Schematic representation of 
different strategies used to purify Rhodococcus DNA. The final CTAB protocol 
used is described in section 4.2.4 
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To generate the library, the extent and time of digestion with Sau3AI was 
determined in order to produce fragments of 1.5 – 5 Kb. This fragment size was 
chosen to maximise the chance of including entire ORFs within each digested 
fragment, as the average size of a bacterial protein (300 amino acids, (Brocchieri 
and Karlin, 2005) which equates to approximately 1 Kb of DNA (Casjens, 1998). 
The optimal ratio of enzyme: DNA  and time of DNA digestion, were determined by 
small scale digests of R. equi DNA (Fig. 4.3 A&B). 0.9 µg of R. equi DNA was 
incubated with 1 to 3.9x10-3 units of the restriction enzyme Sau3AI for 1 h at 37 
ºC. The digested DNA was then electrophoresed. The optimal ratio of DNA: 
enzyme (that gave fragments between 0.5 and 5.0 Kbp) was determined to be 
3.125x10-2 units per 0.9 µg of DNA (Fig. 4.3 A). Next, the optimal time of digestion 
was determined. 10 µg of DNA was digested with 1.04 units of Sau3AI at 37 ºC. 
Every 8 min, 1/10th of the reaction was heat inactivated at 70 ºC for 20 min. 
Digested DNA was analysed by gel electrophoresis (Fig. 4.3 B). The optimal time 
of digestion was determined to be 64 min. These parameters were then used to 
scale up the digest of 10 µg of R. equi DNA (Fig. 4.4 A). R. equi DNA fragments 
ranging from 1.5 Kbp – 5.0 Kbp were then ligated into the BamHI site of the 
URA3+ 2µ yeast expression vector pVT100-U (Vernet et al., 1987) where 
expression of gene inserts is under control of the constitutive yeast ADH3 
promoter. 
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Fig. 4.3. Generation of a R. equi gene library. A. 0.9 µg of R. equi genomic and plasmid 
DNA was digested with the indicated units of Sau3AI for 1h at 37 º C. DNA was then 
electrophoresed on a 0.6 % (w/v) agarose gel B. 10 µg of R. equi DNA (27.4 µl) was 
added to 239.6 µl of 10 mM Tris, pH 8.0, containing 3 µl of BSA (10 mg/ml), 30 µl of 10X 
enzyme buffer and 1 µl (1.04 units). The reaction mixture was incubated at 37 ºC. 30 µl 
was taken at 8 minute intervals and heat inactivated at 70 ºC for 20 min. The digested 
DNA was then electrophoresed on a 0.6 % (w/v) agarose gel. 
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Fig. 4.4. Restriction digestion of R. equi DNA and yeast expression vector pVT100-
U. A. 10 µg of R. equi genomic and plasmid DNA was digested for 64 min at 37 ºC with 
1.04 units of Sau3AI. Digested DNA fragments between 0.5 and 5.0 Kbp were excised 
from the gel with a sterile scalpel and gel purified using a Qiagen gel purification kit as per 
the manufacturers’ instructions. B. 1 µg of the yeast expression vector pVT100-U was 
digested with BamHI overnight at 37 ºC. The linearised vector (arrowhead) was cut from 
the gel and purified as described in A. 
The manufacturer’s recommendations for the ligase suggested using an 
Insert:Vector ratio of 3:1 (3-30 fmol of vector ends and 9-90 fmol of insert ends), 
with a total DNA amount of 0.01-0.1 µg and 0.1 units of T4 ligase. For optimal 
transformation, it was also suggested to dilute the ligation reaction at least 5-fold 
before transforming it into competent cells. Therefore, small-scale ligations and 
transformations were performed to determine the optimal ligation conditions to 
produce the highest possible number of transformants. Ligation reactions were set 
up using different vector and insert ratios and the number of transformed colonies 
counted. A vector only control was included to estimate the number of background 
colonies transformed with non-linearised vector (Table 4.1. & 4.2). The optimal 
ratio of vector : insert was determined  to be 27 fmol of vector and 81 fmol of 
insert, as this gave the highest number of colonies. Next, the volume of the 
reaction used to transform a single aliquot of competent cells was investigated 
(Table 4.1) .The recommended protocol was to dilute the reaction at least 5-fold 
before transforming into competent cells. The reaction mixture was undiluted and 
1 µl used to transform cells. Alternatively, a tandem reaction was set up and 
diluted 5-fold to 100 µl and 10 µl was used to transform cells. The total number of 
201 
obtainable colonies from the total volume of ligation reaction these transformations 
was determined to be 1.406 x 105 (undiluted) and 6.72 x 104 (diluted). 
DNA (fmol) Ratio 
(I:V) 
Total 
DNA (µg) Number of colonies per ligation Vector (V) Insert (I) 
  
9 81 9 0.0789 1.1x105 
27 81 3 0.1392 1.94x105 
9 108 12 0.1254 6.2x104 
 
Table 4.0 Ratios of vector : insert used to optimise ligation reactions. The ligation of 
R. equi random gene fragments and pVT100-U yeast expression vector was optimised 
using the ratios of vector:insert shown. Each ligation reaction (20 µl) was made up to 100 
µl and 1 µl was used to transform one aliquot of competent cells. Cells were recovered in 
1 ml of S.O.C. medium and 100 µl of cells were plated out. Thus, the number of colonies 
obtained from the entire transformation reaction (100 µl) was calculated by multiplying the 
number of colonies from 100 µl of cells by 1000 
Volume of 
ligation  
Volume  used to 
transform 1 aliquot 
of cells 
No. of 
colonies from 
10 % of 
transformants 
No. of colonies 
obtainable from 
1 ligation 
reaction 
                
20 µl 
(undiluted) 1 µl 703 1.406x10
5 
100 µl  (5-fold 
dilution) 10 µl 672 6.72x10
4 
 
Table 4.1. Volume of ligation reactions used to transform competent cells. Ligation 
reactions were set up in tandem (27 fmol Vector : 81 fmol Insert) and 1 µl of the undiluted 
or 10 µl of the diluted reaction used to transform competent E.coli. 10 % of the ligation 
reaction was transformed into E.coli and the total number of transformants was 
determined. 
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One potential problem with generating a random gene library is that bacteria 
harbouring plasmids containing small plasmids would grow faster than those with 
larger plasmid, heavily skewing the library with a large proportion of partial or 
smaller reading frames. To analyse the size of inserts, plasmids from 10 individual 
colonies were extracted by DNA miniprep. A diagnostic digest was then performed 
using DraI to determine the average insert size (Fig. 4.5). When digested with 
DraI, the empty pVT100-U plasmid gives fragments of 3809 bp, 1381 bp, 955 bp 
and 692 bp (with an additional 2 x 18 bp fragments). By estimating the size of the 
shift of the 1381 bp fragment, it was possible to estimate the average insert size in 
the library. This was determined to be around 2.7 Kbp. This was also important to 
know, as the average size of the inserts determines how many times a genome 
must be covered in order to find one particular clone. As the average insert was a 
reasonable size, the ligation reactions were scaled up using the data obtained 
from the previous optimisations. Thus, 4 ligations reactions were performed, using 
27 fmol of vector and 81 fmol of insert DNA. Competent E.coli cells were 
electroporated with 1 µl of the undiluted ligation reaction and plated onto 116 15 
cm LB agar plates and incubated for 16 h. Approximately 426,000 colonies were 
obtained. The colonies were scraped from the plates, pooled and the DNA 
plasmids extracted by midiprep. Approximately 5 ml of DNA library was recovered, 
at a concentration of 138 ng/µl.  
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Fig. 4.5. Restriction digest analysis of a R. equi gene library. Plasmids from 10 E.coli 
colonies (1-10) containing R. equi random gene fragments were digested with DraI. 
Control – pVT100-U control plasmid containing no R. equi insert.   
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The Clarke-Carbon equation was used to determine the size of the E.coli library 
needed to cover 99 % of the R. equi genome (Clarke and Carbon, 1976). It was 
calculated that 8696 E.coli colonies were needed to find any one R. equi gene 
once. As 426,000 E.coli colonies were obtained, each R. equi gene should have 
been represented 48.9 times (Fig. 4.6).  
 
Fig. 4.6. Size of R. equi library needed for exhaustive screening of the genome. A. 
Carbon-Clark equation for determining number of colonies required to find any one 
particular gene. P – the desired probability of finding any one clone. f – fraction of insert to 
genome size. Average insert size 2700 bp, R. equi genome, 5.1x106 Mb. B. Library 
coverage of R. equi genome, where N is the number of colonies obtained and X is the 
number of colonies needed to be screened to find one particular gene. Calculations based 
upon the Clark-Carbon equation (Clarke and Carbon, 1976) 
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4.3.2 Screening of the R. equi genome 
The plasmid library was transformed into the URA3- diploid yeast strain BHY12, 
containing two copies of the intergrated CPY-Inv gene. Yeast transformants were 
plated onto selective plates containing fructose as the carbon source (SD-Ura F). 
Approximately 746,000 yeast colonies were obtained, giving ~ 87 X coverage of 
the R. equi genome. Yeast were screened for a VPS phenotype using the overlay 
assay, as previously described in section 4.2.7. Briefly, agar containing glucostat 
reagent is poured over yeast colonies. Exogenous CPY invertase is able to 
hydrolyse sucrose to glucose and fructose. Glucose oxidase then oxidises the 
glucose, producing H2O2, which is then in turn used by horseradish peroxidase 
(HRP) to oxidise O-diansidine, which results in a dark brown colour change (Fig. 
4.7) 
 
Fig. 4.7. Schematic representation of CPY-invertase assay. A. Exogenous CPY 
invertase hydrolyses sucrose to glucose and fructose. B. Glucose oxidase then oxidises 
the glucose, producing H2O2. C. Horseradish peroxidase (HRP) utilises H2O2 to oxidise O-
diansidine, which results in a dark brown colour change 
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Thus, yeast that turn brown when assayed potentially have a trafficking defect. 
These yeast colonies were picked, restreaked and retested. Those that remained 
positive for secretion were selected for validation, to ensure that the secretion of 
CPY was due to the expression of an R. equi effector protein and not a random 
mutation introduced through the transformation procedure. The screen was 
repeated 3 times in total. The first round of screening yielded 3 clones which 
displayed a VPS-like phenotype (Fig. 4.8 A&B). When restreaked and retested 
only one remained positive for CPY secretion (Fig. 4.8 C). To ensure the VPS 
phenotype was plasmid dependent, the clone was grown on media containing 5-
fluoroorotic acid (5-FOA). Yeast harbouring the URA3 gene (the selectable marker 
in pVT100-U) produces a toxic metabolite when grown on 5-FOA. In wild type 
yeast, 5-FOA is converted to 5-fluoro-orotidine monophosphate by conjugation to 
phosphoribosyl pyrophosphate (PRPP). PRPP is then decarboxylated to form 5-
fluoro-uridine monophosphate (FUMP). These steps are catalysed by the URA5 
and URA3 genes, respectively (Amberg et al., 2005, Boeke et al., 1984). 
Fluorodeoxyuridine is formed downstream and is a strong inhibitor of thymidylate 
synthetase (Sklower et al., 1986) preventing DNA replication. Therefore, yeast 
expressing with the URA3 gene are not viable and the plasmid is not maintained. 
Yeast grown on 5-FOA were then assayed along side secreting yeast. However, 
as 5-FOA-cured yeast can no longer grow on selective media they must be grown 
on non-selective media along side the secreting clone for a direct comparison (Fig. 
4.8 D). The positive clone lost secretion when grown on 5-FOA but secreted on 
selective media, indicating secretion was plasmid dependent.  
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Fig. 4.8. CPY overlay assay of yeast expressing a R. equi gene library. BHY12 yeast 
were transformed with an R. equi random gene library and assessed for a VPS phenotype 
by assaying for the activity of secreted CPY-invertase. A. Arrowhead shows a yeast 
colony positive for CPY secretion. B. Enlarged image of A. C.3 positive clones were 
picked, restreaked and re-assayed. Asterisk indicates a negative control which remains 
white. D. CPY secreting clone from C. was grown on non-selective (1) and 5-FOA (2) 
media and then streaked onto non-selective media and re-assayed. 
Plasmid DNA was then extracted from the yeast and used to transform into E.coli. 
Plasmids were then extracted from E.coli and sequenced. Unexpectedly, 
sequencing revealed the insert to be a 160 bp fragment of an E.coli phage protein 
and not a Rhodococcus gene. However, for completeness, this plasmid was 
retransformed back into yeast back into BHY12 yeast. The clone was retested for 
secretion but no VPS phenotype was observed. Due to the variable nature of the 
overlay assay, we hypothesised that secreting yeast may have harboured more 
than one plasmid. To try and prevent this, yeast were sub cultured for more than 
24 h to ensure proper plasmid segregation (Scanlon et al., 2009). Although 
unlikely, E.coli transformed with DNA extracted from yeast may have harboured 
more than one plasmid. However PCR analysis of yeast and E.coli DNA showed 
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that this was not the case. The PCR results showed that the plasmids had an 
insert of approximately 150 bp (+ 154 bp of the cloning site), consistent with the 
sequencing data (Fig. 4.9). Furthermore, PCR analysis showed that yeast grown 
on 5-FOA did indeed lose plasmids (Fig. 4.10). 
 
Fig. 4.9. PCR analysis of plasmid DNA extracted from yeast displaying a VPS 
phenotype. Yeast transformed with an R. equi gene library were screened for a VPS 
phenotype. Plasmids were extracted from positive clones for PCR analysis. A. PCR of 
pVT100-U plasmid extracted from a yeast clone (expressing an R. equi gene),identified as 
displaying a VPS phenotype. B. Colony PCR of E.coli transformed with plasmid DNA 
extracted from yeast in A. C. PCR on plasmids extracted from multiple colonies of E.coli 
transformed with DNA extracted from yeast in A. The pVT100-U empty vector control  
gives a product of 154 bp. Strong band of approximately 1500 bp in A. is a non-specific 
product produced when pVT100-U primers are used for yeast colony PCR.  
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Fig. 4.10. PCR analysis of yeast grown on media with or without 5-FOA. BHY12 and 
BHY10 ∆VPS10 yeast strains (auxotrophic for uracil) were both transformed with pVT100-
U (a yeast expression vector with the URA3 gene as a selectable marker). Yeast were 
grown on different media supplemented with or without 5-flouroorotic acid. The presence 
of the pVT100-U plasmid was determined by yeast colony PCR using primers for the 351 
bp multiple cloning site of pVT100-U. +, positive control (pVT100-U plasmid DNA). 
The screen was repeated for a second time and yielded a total of 269 colonies 
displaying varying levels of secretion. Due to the large number of clones, yeast 
were retested and validated in batches (Fig. 4.11). Positive clones were selected 
for retesting (Fig. 4.11 A). Those that still displayed a secretion phenotype were 
grown on 5-FOA to cure them of plasmids and they were retested. Yeast grown on 
selective media were then streaked out side by side (onto non selective media), 
next to yeast that were cured of their plasmids by 5-FOA selection, to compare 
secretion between them. If a yeast colony did not secrete after growth on 5-FOA, 
the secretion phenotype was deemed to be plasmid dependent (Fig. 4.11 B). 
Additionally, yeast were subjectively grouped according to the level of secretion 
(Fig. 4.11 B, coloured boxes). 13 clones were identified that appeared to displayed 
plasmid-dependent secretion. The plasmids from two of these clones were 
sequenced were in order to confirm that the plasmids contained R. equi genes and 
found to contain R. equi genes. Indeed, these two clones were found to have R. 
equi inserts of 3.8 Kbp and at least 1.7 Kbp (additional sequencing was required to 
determine the full size of this insert, which was not performed). However, when the 
plasmids from these 13 clones were retransformed back into BHY12 yeast, no 
secretion was observed (Fig. 4.12). 
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Fig. 4.11. Validation of yeast clones displaying a vacuolar trafficking defect when 
expressing R. equi genes. Yeast transformed with an R. equi random gene library were 
tested for a trafficking defect by overlay assay (yeast with a VPS phenotype turn brown). 
A. Retesting of positive clones 1-42 (top) and 43-107 (bottom). B. Positive clones from A. 
were grown on selective media and media containing 5-FOA, before being assayed side 
by side on non-selective media (left and right patches respectively). Clones were classed 
as displaying strong secretion (red boxes), moderate secretion (yellow box), weak 
secretion (blue box), very weak secretion (orange box), or no secretion/plasmid 
independent secretion (white boxes). 
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Fig. 4.12. Validation of yeast screen hits. Yeast displaying a trafficking defect when 
expressing R. equi genes were retested to ensure a plasmid dependent effect. Plasmids 
were extracted from positive clones and used to re-transform yeast.  Yeast were once 
more retested for a secretion phenotype using an agar overlay assay (yeast with a 
trafficking defect secrete CPY-Inv and turn brown when overlaid with Glucostat reagent, 
whereas WT yeast remain white). ∆VPS10, SpvC (yeast expressing Salmonella effector 
protein SpvC), positive controls. –tve , BHY12 yeast negative control. Yeast clones 
43,60,262 and 264 were tested. 
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As the invertase overlay assay was qualitative and not quantitative, it was 
inconsistent in the results that it would give and it was not always clear if a yeast 
colony was secreting CPY. There are several possibilities for this. Firstly, there 
may have been incomplete plasmid segregation in transformed yeast, which could 
have resulted in yeast that stopped secreting when the trafficking defect causing 
plasmid was lost. Secondly, the transformed yeast (and negative control yeast) all 
secrete a basal level of CPY (Valls et al., 1987). As the assay is qualitative, it was 
not always easy to distinguish between secreting and negative control yeast if the 
assay had a high level of background. Additionally, the age of the yeast and the 
amount of yeast also likely affected the results of the overlay assay. In hindsight, it 
may have been better to allow yeast to grow for a set period of time to more easily 
compare yeast of the same age. This may have avoided any potential cell death 
and cell lysis, which would have released vacuolar CPY and given the impression 
that a yeast colony was secreting. Similarly, it may have been better to inoculate 
agar plates so that they had approximately the same amount of yeast each time. 
Inoculating with too much yeast would result in large colonies that would turn 
brown due to the shear amount of CPY present. Thirdly, as CPY-Inv was secreted 
into the agar, it was possible that the movement of the overlay-agar solution 
across the plate had the effect of washing CPY-Inv over yeast colonies that were 
not secreting, resulting in what appeared to be a high level of background 
secretion. To try and prevent this, overlay solution was poured onto a region of the 
plate absent of yeast and the agar solution was allowed to slowly settle across the 
plate, rather than rocking the plate to cover all of the yeast. Finally, there were 
some inconsistencies with the overlay assay solution. On occasion, the glucostat 
reagent would immediately develop with the addition of o-diansidine, possibly 
indicating the presence of a contaminating oxidising agent in the glassware. To try 
and prevent this, the glucostat reagent was made up using disposable plastics.  
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However, in order to be thorough, the screen for a third and final time, taking into 
account some of these considerations. After the first round of screening, 23 clones 
were picked that displayed a VPS phenotype (Fig. 4.13). 
 
Fig. 4.13. Qualitative CPY overlay assay of yeast expressing R. equi genes. Yeast 
expressing Rhodococcus genes were assayed for secretion of CPY-Invertase using an 
agar overlay assay (yeast displaying a VPS phenotype turn brown, those that do not 
remain white). –tve, negative control +tve , ∆VPS10 positive control. A. shows examples 
of two negative clones, while B. shows two examples of secreting clones. 
These clones were restreaked onto selective media and retested once more using 
the overlay assay. 15 of the 23 colonies remained positive for CPY secretion and 
were then validated by plasmid curing on 5-FOA media as previously described 
(data not shown). Due to the inconsistency seen with this assay previously, the 5-
FOA plasmid curing was repeated a second time to ensure the result was reliable 
(Fig. 4.14). When retested a second time, only clones 2, 5 and 8 appeared to stop 
secreting, indicating that only these clones had plasmid-dependent CPY secretion.  
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Fig. 4.14. Validation of yeast clones displaying a vacuolar trafficking defect using 5-
FOA plasmid curing. Yeast transformed with plasmids containing R. equi genes were 
assayed for the secretion of CPY invertase as an indication of a trafficking defect. Yeast 
were then grown on media containing 5-fluoroorotic acid to cure them of the plasmids and 
assayed again for CPY secretion. Secretion was deemed to be plasmid dependent if 
yeast clones did not secrete CPY when assayed after growth on 5-FOA. –tve, negative 
control +tve , ∆VPS10 positive control. 
Despite thoroughly investigating the cause of inconsistency the overlay assay was 
still not reproducible. Therefore performed a quantitative assay of CPY secretion 
on liquid cultures of clones picked from all three screens. Unfortunately, none of 
the clones displayed any significant secretion of CPY-Inv (Fig. 4.15).  
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Fig. 4.15. Quantitative assessment of CPY secretion by yeast expressing R. equi 
genes. Yeast were transformed with a random R. equi gene library. R. equi genes that 
interfere with trafficking to the yeast vacuole cause yeast to secrete CPY-Inv. Yeast 
clones from three rounds of screening were assessed for CPY secretion using a 
quantitative assay of liquid cultures as described in section 2.3.7. A. Clones from screens 
1 & 2 (SS-strong secretor, screen one, all other clones, screen two) B. Clones 1-23 from 
third round of screening. +/+tve – positive control (∆VPS10, constitutive CPY secretor),       
-/-tve – negative control. Data are means ± the range (n=2). 
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4.3.3 Expression of VapA in Yeast 
Despite the extensive screening of the R. equi genome, no genes were found that 
could perturb yeast membrane trafficking. Three caveats to this approach were 
that i) it was not clear if yeast could express R. equi proteins correctly, ii) the 
screen relied on R. equi proteins having their targets in the cytoplasm of the host 
cell and iii) that there was sufficient homology between the mammalian target of 
VapA and its yeast counterpart. To address the first caveat, the R. equi virulence 
factor VapA was cloned into the yeast expression vector pVT100-U, with a myc 
epitope on the N-terminus (myc-VapA). Western blotting of yeast lysates with anti-
myc antibodies revealed the presence of a 25 kDa protein. This was slightly larger 
than the predicted molecular weight of myc-VapA (20 kDa), but was consistent 
with the expression of myc-tagged VapA as it was not present in the 
untransformed control yeast (Fig. 4.16 A). Secondly, as VapA was an essential R. 
equi virulence factor, it was asked whether myc-VapA could disrupt membrane 
trafficking in yeast. Liquid cultures of VapA-expressing yeast were quantitatively 
assayed for secretion of CPY-Inv, as a measure of disrupted trafficking. Yeast 
clones expressing myc-VapA did not display significant levels of CPY secretion 
above that of the untransformed negative control (Fig. 4.16 B, p=0.993). 
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Fig. 4.16. Expression of myc-VapA in yeast. A. BHY12 yeast (BHY12) or BHY12 yeast 
expressing myc-VapA (myc-VapA) were western blotted for myc. Equal OD600 units were 
loaded per lane. Western blots are representative of at least two separate experiments. B. 
Three separate yeast clones expressing myc-VapA (1-3) were subjected to a quantitive 
assay of CPY-Inv secretion. Positive control (+tve, BHY12 ∆VPS10 yeast), negative 
control (-tve, BHY12 yeast). Data are means ± SEM. Statistical analysis was performed 
using one-way ANOVA between the negative control and clones 1-3 (n=2). 
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As VapA did not cause a trafficking defect when expressed in the yeast cytoplasm 
(but is the only described essential virulence factor) it was hypothesised that this 
may be because VapA has its cellular target inside the host vacuole. This 
hypothesis was further supported by the fact that R. equi has no known secretion 
system that can span host cellular membranes. Therefore an alternative 
methodology was used to target VapA to the yeast vacuole. Alkaline phosphatase 
(ALP) is a yeast vacuolar enzyme synthesised in an immature form that is 
proteolytically processed in the vacuole by cleavage of a small portion of its C-
terminus (Klionsky and Emr, 1989). Fluorescently tagged ALP has been used in 
numerous studies to visualise the yeast vacuole (Cowles et al., 1997, Berger et al., 
2007, Coonrod et al., 2013). Myc-tagged VapA was cloned onto the C-terminal 
end of GFP-ALP in order to target it to the vacuole (Fig. 4.17) The vacuole 
morphology of yeast expressing GFP-ALP or GFP-ALP myc-VapA (GAMV) was 
then assessed by confocal microscopy (Fig. 4.18). No clear differences in yeast 
vacuole morphology were observed in yeast expressing GAMV compared to the 
GFP-ALP control. The numbers of vacuoles in these yeast strains was also 
counted. GA or GAMV expressing yeast were scored as having single or multiple 
vacuoles. There were no significant differences between the different yeast strains 
(p = 0.211, Fig. 4.18 B). It was noted that expression of GFP-ALP and GAMV was 
inconsistent and highly variable. This was most likely due to the fact that the 
expression vector was a 2-micron (2 µm) plasmid. 2 µm plasmids are stably 
maintained at a high copy number (60-100), but it is probable that individual yeast 
had varying copies of the plasmid, resulting in uneven protein expression (Caunt 
et al., 1988). 
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Fig. 4.17. Targeting VapA to the yeast vacuole. Schematic representation of the 
strategy used to target VapA to the yeast vacuole. GFP was fused to the yeast vacuolar 
enzyme, alkaline phosphatase (ALP) The GFP remains cytoplasmic and marks the 
vacuole membrane, while cleavage of a small C-terminal portion of ALP, (by endogenous 
vacuolar proteases) produces a mature enzyme. Myc-tagged VapA was added to the C-
terminus of GFP-ALP (GAMV). Thus, upon cleavage of ALP, myc-VapA is liberated.  
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Fig. 4.18. Confocal analysis of yeast vacuole morphology and number. A. Differential 
interface contrast (DIC) and confocal images of yeast expressing either GFP-ALP (GA) or 
GFP-ALP myc-VapA (GAMV). Scale bars 10 µm. B. Quantification of yeast vacuole size 
in A. Yeast expressing GA or GAMV were scored as having single or multiple vacuoles.  
Yeast from at least 9 individual fields of view were counted (approximately 1000 individual 
cells scored per construct per experiment). Data are means ± SEM. The % of yeast cells 
with multiple vacuoles was statistically analysed by t-test (n=2). 
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As no change in vacuole morphology could be seen between yeast expressing 
GFP-ALP or GFP-ALP myc-VapA, it was reasoned that this could be due to low 
levels of exogenous protein expression. Yeast expressing either construct were 
western blotted with α- ALP antibodies to analyse protein expression (Fig. 4.19 A). 
Endogenous ALP is found as immature pro-ALP (pALP ~72 kDa) and mature ALP 
(mALP ~66-68 kDa). Two proteins bands were seen in the BHY12 control between 
50 kDa and 75 kDa and were found in all lysates. These bands ran slightly 
differently to the predicted sizes of pALP and mALP but were consistent with the 
processing of ALP. A further band of ~100 kDa was found in yeast expressing 
GFP-ALP (closed arrowhead) and GAMV, indicating expression of GFP-ALP 
(predicted size 91 kDa) and probable processing of GAMV to form GFP-ALP.  An 
additional band at a higher molecular weight (~110-120 kDa, open arrowhead) 
was found only in GAMV lysates (GAMV predicted size 110 kDa). This band was 
most likely full length GAMV. The same yeast lysates were then probed with α-
myc antibodies (Fig. 4.19 B) which revealed the expression of a protein of ~120 
kDa, specific to yeast expressing GAMV but not GFP-ALP (closed arrowhead). A 
stronger band of 100 kDa detected by the myc antibody could be due to the 
degradation of VapA from the C-terminal end of the fusion protein. However, 
cleaved myc-VapA could not be detected. Next, myc-VapA, GA and GAMV yeast 
lysates were probed with α-VapA antibodies (Fig. 4.19 C). A band of ~25 kDa was 
detected in myc-VapA expressing yeast (closed arrowhead), along with bands at 
~20 kDa and 15 kDa indicating possible degradation of myc-VapA. In GAMV 
yeast, a doublet band was detected at ~120 kDa (open arrowhead), along with a 
single band at ~15 kDa (Fig. 4.19 *). This is consistent with expression of GAMV 
and cleavage of the C-terminal signal sequence to yield myc-VapA. No protein 
bands were seen in GFP-ALP yeast demonstrating that the bands seen were 
specific to yeast expressing myc-VapA and GAMV. In all these cases, the 
detected bands ran slightly higher than the predicted molecular weights of the 
proteins. The laddering pattern seen in both GFP-ALP and GAMV lysates (Fig. 
4.19 A & B) was probably due to degradation of the expressed fusion proteins. 
Taken together these data are consistent with the expression of GFP-ALP and 
GAMV. Next, GFP-ALP and GAMV expressing yeast were assessed for secretion 
of CPY (Fig. 4.19 D). Yeast expressing GFP-ALP or GAMV secreted levels of 
CPY-Inv above that of the negative control (2.35 % & 1.65 % compared to 0.86 %, 
respectively) but this was not significant (p = 0.367). The degradation of VapA may 
have masked any potential effects of VapA on CPY secretion. 
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Fig. 4.19. Expression of VapA in the yeast vacuole. A. BHY12 yeast (BHY12) or 
BHY12 yeast expressing GFP-ALP or GFP-ALP myc-VapA (GAMV) were subjected to 
western blotting (W.B.) using α-ALP antibodies. Endogenous ALP appears as a doublet in 
pro (pALP) and mature (mALP) forms. B. Yeast lysates in A were probed with α-myc 
antibodies C. BHY12 yeast expressing myc-VapA, GFP-ALP, or GAMV were subjected to 
western blotting with α-VapA antibodies. Equal OD600 units of yeast were loaded per lane 
for all western blots. D. Quantitative assay of CPY-Inv secretion by yeast expressing GFP-
ALP (GA) or GAMV. Positive control (+tve, BHY12 ∆VPS10 yeast), negative control (-tve, 
BHY12 yeast). Data are means ± SEM and were analysed by one-way ANOVA and 
significance compare to the –tve control determined (n=2). Western blots are 
representative of at least two separate experiments except for C (n=1).  
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4.3.4 Expression of VapA in mammalian cells 
Since no effect on vacuolar trafficking was observed when VapA was expressed in 
yeast, it was hypothesised that the yeast orthologue of the mammalian target of 
VapA may not have sufficient homology for VapA to interact. As mammals are a 
natural host of R. equi, expressing Rhodococcus proteins in mammalian cells may 
be more representative of an in vivo infection. An inducible HeLa cell line stably 
expressing myc-tagged VapA was generated (Fig. 4.20). Expression of myc-VapA 
was induced with 1 µg/ml doxycycline for 24 h (Fig. 4.20 A) and the cellular 
localisation of VapA was examined by immunofluorescence. VapA appeared to be 
evenly distributed throughout the cell cytoplasm and not associated with any 
specific organelles. HeLa cell morphology also appeared normal, as did lysosome 
distribution and morphology. As it was hypothesised that R. equi prevents delivery 
to the lysosome by interfering with membrane trafficking, the colocalisation of myc-
VapA with early endosomes, late endosomes and lysosomes, was examined.  
Expression was induced for 24 h and cells were treated with cytosol extraction 
buffer (CEB) before fixation, in order to remove any myc-VapA that was not 
associated with cellular organelles. Myc-VapA did not co-localise with EAA1 (early 
endosomes), ciM6PR (late endosomes) or LAMP1 (lysosomes, Fig. 4.21).  As 
previously discussed, VapA may need to be on the lumenal side of an endocytic 
organelle in order to have a functional effect. Therefore, it was decided to produce 
recombinant proteins in order to feed to cells and test this hypothesis. 
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Fig. 4.20. Expression of myc-VapA in HeLa cells. A. myc-VapA expression was 
induced with doxycycline for 24 h. Protein lysates were probed by western blotting with α-
myc antibodies. 20 µg of protein per lane. B. VapA expressing HeLa cells were double 
labelled with α-myc and α-LAMP1 antibodies followed by fluorescently labelled secondary-
antibodies (Alexa fluor 555; red and Alexa fluor 488; green, respectively). All images are 
confocal maximum-intensity z-projections. Scale bars 20 µm. 
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Fig. 4.21. myc-tagged VapA does not co-localise with endocytic markers when 
expressed in the cell cytoplasm. Doxycycline was added to HeLa cells to induce the 
expression of myc-VapA for 24 h. Cells were then fixed and double labelled with α-myc 
and α-EEA1 (early endosomes), α-ciM6PR (late endosomes), or α-LAMP1 (lysosomes) 
followed by fluorescently labelled secondary-antibodies. Myc labelling is shown in red, 
organelle labelling is shown in green and nuclei were stained with DAPI (blue). All images 
are confocal maximum-intensity z-projections. Scale bar 20 µm. 
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4.3.5 Production of recombinant VapA 
In order to target VapA to the lumen of the mammalian lysosome, recombinant 
VapA was produced to feed to cells. VapA was cloned into the E.coli expression 
vector pGEX 3-PLX, with a myc tag on either the N or C terminus of VapA (Fig. 
4.22). A small scale test expression was performed to assess the solubility of each 
fusion protein. Two individual clones were chosen for each construct. For both 
fusion proteins, a large band of approximately 46 kDa was observed upon the 
addition of IPTG, but not in the pre-induction sample. A band at the same 
molecular weight was also observed in the soluble and insoluble fractions, 
consistent with the expression of myc-tagged (N or C) GST-VapA. The addition of 
the myc tag to the C-terminus of VapA appeared to decrease its solubility. 
Therefore, GST-myc-VapA was chosen for large-scale purification (Fig. 4.22 B). 
Recombinant VapA was purified from a 1 L culture using affinity chromatography 
and 1 ml fractions of the eluate were analysed by SDS PAGE. A single band at 46 
kDa was found in the eluates, along with a strong band at 26 kDa, likely to be free 
GST. Fractions 1-5 were then pooled and dialysed into PBS for further use. 
Approximately 1 mg of fusion protein was recovered from a 1 L culture. In addition 
to the production of GST-myc-VapA, myc-VapA with a C-terminal His tag was also 
produced, as the yield of GST fusion protein was relatively low compared to the 
higher yield of the His-tagged protein. Moreover, a large proportion of the purified 
protein was likely to be free GST, which would further reduce the actual amount of 
active VapA protein. Recombinant VapA-His6 was produced by cloning VapA into 
the expression vector pMW172. Small scale test expressions were carried out as 
previously described (Fig. 4.23 A). Two clones were tested for the expression of 
the fusion protein by western blotting using α-myc antibodies, which revealed the 
expression of a protein between 20 kDa and 25 kDa present in the induced, 
soluble and insoluble samples, but to a much lesser extent in the pre-induction 
sample. This clone was then selected for large scale production of myc-VapA-His. 
The supernatant from a 1 L culture was incubated with nickel sepharose for 2 h at 
4 ºC. The sepharose was washed extensively and the fusion protein eluted from 
the column using an elution buffer containing 250 mM imidazole. 1 ml fractions 
were collected an analysed by SDS PAGE (Fig. 4.23 B). Fractions 1-5 were 
pooled and extensively dialysed into PBS. The yield was approximately 1 mg from 
a 1 L culture.  
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Fig. 4.22. Purification of recombinant VapA. A. GST-tagged VapA was expressed in 
E.coli with a myc epitope on the N or C terminus of VapA. Expression of VapA was 
induced with 0.2 mM IPTG. Pre-induction (-), post-induction (+), soluble (sol.) and 
insoluble (insol.) fractions were analysed for expression of GST-VapA. Closed 
arrowheads indicate GST-VapA-myc/GST-myc-VapA at approximately 46 kDa. B. E.coli 
expressing GST-myc-VapA were grown to an OD600 of 1.0-2.0. Protein expression was 
induced with the addition of IPTG to 0.2 mM for 4 hours. The cell pellet was lysed and the 
soluble fraction applied to a GST-sepharose column. Samples of the lysate were collected 
before and after the column for analysis. The column was washed extensively and 1 ml 
fractions were eluted from the column and analysed by SDS PAGE. Closed arrowhead 
indicates GST-myc-VapA, open arrowhead indicates soluble GST/degradation products.  
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Fig. 4.23. Production of myc-VapA-His. A. Small scale test expression of Myc-VapA-
his. Two E.coli clones were grown to an OD600 of 1.0-2.0 and protein expression was 
induced for 4 h by the addition of IPTG to 0.2 mM. Cell pellets were lysed and soluble and 
insoluble fractions analysed by western blot using anti-myc antibodies. Closed arrowhead 
indicates induction of VapA expression in clone 2. B. Large scale expression of myc-
VapA-his. The cell pellet from a 1 l culture was lysed and the soluble fraction applied to a 
Ni-affinity sepharose column. Samples of the lysate were collected before and after the 
column for analysis. The column was washed extensively and 1 ml fractions of 
recombinant protein were eluted from the column and analysed by SDS PAGE. The 
closed arrowhead indicates myc-VapA-His, the open arrowhead indicates degradation 
products. The predicted molecular weight of myc-VapA-His is 21 kDa. 
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4.3.6 Recombinant VapA causes swelling of lysosomes in 
mammalian cells. 
As VapA did not cause a phenotype when expressed in the mammalian cell 
cytoplasm, it was targeted to the lysosome lumen. By culturing cells in the 
presence of recombinant protein, VapA would be internalised through fluid-phase 
endocytosis and trafficked to the lysosome for degradation. Thus, if the target of 
VapA is on the lumenal side of the lysosomal membrane then this methodology 
should reveal if VapA is able to disrupt lysosome function. To investigate whether 
VapA had any effect on mammalian intracellular trafficking, J774.2 mouse 
macrophages were incubated with either GST or GST-myc-VapA at 100 µg/ml for 
24 h and the effect on lysosomes examined by confocal microscopy (Fig. 4.24).  A 
potential caveat to this method is that any effect on the cells could be due to 
contaminating proteins or endotoxin from the bacterial expression strain. To 
control for this cells were also incubated with GST alone at the same 
concentration. 
Lysosome size and distribution in J774.2 cells incubated with GST did not appear 
be different from control cells. However, cells incubated with GST-myc-VapA 
appeared to have larger and swollen lysosomes compared to control cells and 
cells incubated with GST alone. Therefore, it was decided to further characterise 
the effect of VapA on lysosomes and identify the underlying mechanisms behind 
this.  Although macrophages are the normal host cell for R. equi, the available cell 
line (J774.2) was not ideal for confocal analysis of lysosome morphology. This was 
because J774.2 cells have a small cytoplasmic volume and their lysosomes do not 
form discrete puncta (see control cells). Moreover, there is not a clear perinuclear 
distribution of lysosomes and larger puncta can sometimes be observed in control 
cells. The magnification needed to view these cells also makes it difficult to resolve 
the morphology of the lysosomes. An alternative cell line, Normal Rat Kidney 
(NRK) cells, were available to confirm the observation that recombinant VapA 
induces lysosome swelling. In NRK cells, the lysosomes are primarily distributed 
around the perinuclear region and take the form of discrete puncta (Fig. 4. 26). To 
see if NRK cells could be used as an alternative cell line for these experiments, 
cells were incubated with GST or GST-Myc-VapA at 10 µg/ml or 100 µg/ml for 24 
h. Cells were then imaged using confocal microscopy to assess the lysosome 
phenotype. When incubated with GST at either 10 µg/ml or 100 µg/ml, the 
lysosomes remained perinuclear and punctate (Fig. 4.25). When the cells were 
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incubated with GST-myc-VapA at 10 µg/ml and 100 µg/ml, lysosomes in both the 
perinuclear region and cell periphery showed a swollen morphology. Moreover, to 
demonstrate that this was an effect of the VapA protein and not contaminating 
endotoxin, cells were incubated with VapA that had been heated to 95 ºC for 15 
min (Fig. 4.26). This would denature the secondary protein structure of VapA, 
abolishing its activity, but would not destroy LPS. Thus, any effects seen after the 
protein was heated would not be attributable to VapA. Lysosomes in cells 
incubated with heated VapA were indistinguishable from control cells. These data 
confirmed the previous observations in J774.2 macrophages. Therefore, NRK cells 
were used for further experiments to more easily examine the effect of VapA and 
the other Vap proteins on lysosome morphology, since the effects of VapA were 
more readily visualised in this cell line. Lysosomal swelling in cells treated with 
VapA-His appeared to be exaggerated compared to cells incubated with GST-
myc-VapA. This may have been due to a higher purity his-tagged protein 
compared to the GST fusion protein, which also contained soluble GST. 
Therefore, his-tagged VapA was used for further experiments. 
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Fig. 4.24. The effect of recombinant GST-VapA on lysosome morphology. J774.2 mouse macrophages were incubated with no protein (control), GST 
or GST-myc-VapA at 100 µg/ml for 24 h. Cells were washed in PBS and then fixed by incubation in methanol at   – 20 ºC for 5 min.  Cells were then 
labelled with α-LAMP1 antibodies followed by a fluorescently secondary antibody (Alexa fluor 555; red) and nuclei stained with DAPI (blue). Scale bar 10 
µm. Confocal images are maximum-intensity z-projections. Images are representative of two independent experiments. 
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Fig. 4.25. The effect of recombinant VapA on lysosome morphology. Normal Rat 
Kidney (NRK) cells were incubated with GST or GST-myc-VapA or at 10 µg/ml or 100 
µg/ml for 24 h. Cells were washed three times with PBS and fixed in 4 % formaldehyde in 
PBS. Cells were then permeabilised and labelled with α-Lysosomal glycoprotein 110  
(Lgp110) antibodies followed by fluorescent secondary antibodies (Alex Fluor 488; green). 
Nuclei were stained with DAPI (blue). Scale bar 20 µm. Confocal images are maximum-
intensity z-projections and images are representative of two independent experiments. 
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Fig. 4.26. Heat denatured recombinant VapA does not induce lysosomal swelling. 
NRK cells were incubated with recombinant VapA-His6 (for 8h or 24 h), where the protein 
had either been heated or not to 95 ºC for 15 min,. Cells were rinsed with PBS and fixed 
with 4 % formaldehyde in PBS. Cells were permeabilised and labelled with α-Lgp110 
antibodies followed by fluorescent secondary antibodies (Alex Fluor 488; green). Nuclei 
were stained with DAPI (blue). Scale bar 20 µm. Confocal images are maximum-intensity 
z-projections (n=1). 
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4.4 Discussion 
4.4.1 Generation of an R. equi gene library 
The purification of sufficient quantities of R. equi DNA was challenging. At the time 
of this work, there were no published instance of the creation of a R. equi gene 
library. Previously described methods were inefficient and did not yield enough 
DNA. This is most likely due to difficulty in releasing DNA from the cells. In another 
mycobacterial species, Mycobacterium tubercuolosis, DNA purification using 
commercial kits is difficult unless additional digestion/chemical lysis steps are 
added to weaken the bacterial cell wall (Thakur et al., 2011), which is particularly 
resistant to degradation due to its thickness and large amount of polysaccharides 
(Brennan and Nikaido, 1995). Despite this, a modified CTAB/Phenol:chloroform 
method was successful at purifying large amounts of R. equi for generating the 
library. The separation of plasmid and chromosomal DNA using caesium chloride 
centrifugation was unfortunately unsuccessful. This may have been because more 
DNA was needed to clearly see the separation of DNA at different parts of the 
gradient, since the virulence plasmid is at a low copy number. However, the 
inclusion of the plasmid DNA in the library was deemed to be acceptable due to 
the low number of putative virulence genes (~ 25). Thus, a library was made that 
covered the R. equi genome sufficiently and required the screening of 8,700 
colonies to cover each gene once. 
4.4.2 Screening of the R. equi genome 
As ~8,700 colonies were needed to find one particular clone and 746,000 yeast 
colonies were screened, this gave an average of 87 yeast colonies for any one R. 
equi gene. As the screen was repeated 3 times this represents a substantial 
screening of the R. equi genome. The fact that the PEPSY screen did not yield 
any positive clones, despite the significant coverage of the R. equi genome and 
high number of clones may indicate that this particular methodology was not 
suitable for Rhodococcus. The PEPSY screen is a proven methodology that has 
been used successfully for, Legionella (Shohdy et al., 2005), Salmonella and 
Yersinia (Tabuchi et al., 2009). These pathogens are all gram negative and 
posses type three secretion systems (T3SS), or in the case of Legionella, type four 
secretion systems (T4SS). These are multi-subunit protein translocation 
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apparatus, related to the flagellum (Gophna et al., 2003), that are used by bacteria 
to deliver effector proteins across host cell membranes (Cornelis, 2006). For 
intracellular pathogens, a T3SS/T4SS may be used to deliver factors across the 
phagosome membrane into the host cell cytosol. In the case of Salmonella and 
Legionella, these virulence proteins may act to prevent the fusion of the pathogen 
containing phagosome with the lysosome (Ramos-Morales, 2012, Hubber and 
Roy, 2010b). The host cell targets of these proteins are therefore cytoplasmic. 
This is in stark contrast to R. equi which does not have a T3SS. R. equi has a type 
seven secretion system (T7SS) which is unable to span host cellular membranes 
(Letek et al., 2010). It must be assumed that R. equi can only secrete factors into 
its immediate surroundings and cannot actively translocate proteins into the host 
cell cytoplasm. As such, the host cell targets of any R. equi virulence factors that 
prevent its delivery to the lysosome are likely to be on the lumenal side of the 
phagosome membrane. Expressing these proteins in the yeast cytoplasm may not 
result in a VPS phenotype, as their targets are inaccessible. Similarly, M. 
tuberculosis does not have a T3SS but does have multiple T7SSs (Abdallah et al., 
2007). Interestingly, M. tuberculosis has several virulence factors which act upon 
cytoplasmic host cell proteins (Chopra et al., 2004, Sun et al., 2013, Wong et al., 
2011) including a type seven secretion substrate (Mehra et al., 2013). Despite the 
current ambiguity as surrounding the mechanisms by which M. tuberculosis factors 
enter the cytoplasm, clearly there are some proteins that do indeed escape the 
phagosome and exert their effects cytoplasmically. Furthermore, PEPSY 
screening has also been used to identify a novel M. tuberculosis effector that 
disrupts phagosome maturation (Thi et al., 2013). Given this fact and the 
similarities between R. equi and M. tuberculosis, it was not unreasonable to 
assume that this methodology may have been suitable for Rhodococcus. 
Yeast has been used extensively to study the effects of over expressing bacterial 
proteins on yeast cellular functions. Aleman et al., (2009), screened two separate 
Salmonella gene libraries and identified 68 ORFs that induced a growth inhibition 
phenotype when over expressed in yeast, including two previously unidentified 
effector proteins, SteC and SseF. A similar methodology was employed by 
Slagowski et al., (2008), who developed a high throughput screen which analysed 
the growth kinetics of yeast expressing Shigella or Francisella proteins. The 
authors demonstrated that growth inhibition phenotypes in yeast expressing 
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pathogen effector proteins, is specific and sensitive. The expression of 19 T3SS 
substrates resulted in half of them causing growth inhibition, whereas expression 
of 20 non-translocated proteins did not. The expression of >1000 Francisella 
genes resulted in only three that induced minimal growth inhibition. Many of these 
genes had previously been assigned a putative housekeeping function, indicating 
that the over expression of proteins that do not have eukaryotic targets rarely 
causes a negative phenotype. Francisella prevents phagosome acidification and 
ultimately escapes into the host cell cytoplasm (Steiner et al., 2014). Interestingly it 
does not have a known (identified) secretion system that is capable of 
translocating proteins into the host cell cytoplasm (Forsberg and Guina, 2007). 
Similarly, Rhodococcus effector proteins may be secreted within the phagosome 
lumen and have no effect when expressed in the yeast cytoplasm. Yeast have 
been used to express a variety of different bacterial effector proteins from both 
gram negative and gram positive bacteria, including Salmonella (Vinh et al., 2010) 
Legionella (Shohdy et al., 2005) and Mycobacterium (Thi et al., 2013). Lesser and 
Miller (2001), found that both Salmonella and Yersinia effector proteins localised to 
the same subcellular locations in yeast as in mammalian cells. This shows firstly, 
that yeast can be used as a system to study bacterial virulence factors, providing 
that the targets of those effector proteins are evolutionarily conserved between 
higher and lower eukaryotes. Secondly, it demonstrates that the mode of delivery 
is not important when studying these proteins in yeast, (i.e. delivery through a 
bacterial secretion system, or de novo synthesis). The relative easy at genetically 
manipulating yeast also makes them a good system for studying bacterial 
pathogenesis. 
 4.4.3 Expression of VapA in yeast 
As the PEPSY screen failed to identify any R. equi genes able to disrupt 
intracellular trafficking, it was decided to take a more targeted approach to 
unravelling the intracellular survival of R. equi. The genome analysis of R. equi 
revealed several potential genes that shared homology to known or putative 
virulence factors in other pathogenic species of bacteria (Letek et al., 2010). Given 
that R. equi strains lacking the virulence plasmid are non-pathogenic it was 
possible that genes present on the virulence plasmid were most likely responsible 
in part for its virulence. As such, genes from the plasmid pathogenicity island, 
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(specifically the Vap genes) were good candidates to express in yeast and 
mammalian cells to determine if they had any functional effects. One of the Vap 
genes, VapA, was an obvious target, having been shown to be the only known 
essential gene for R. equi virulence (Giguere et al., 1999, Jain et al., 2003). 
The PEPSY screen relied upon yeast being able to effectively express R. equi 
proteins with correct protein folding. The expression of proteins could not be tested 
on yeast clones transformed with the gene library, as the pVT100-U expression 
vector did not include an epitope tag. Myc-tagged VapA was expressed using the 
same expression plasmid as the PEPSY screen, to determine i) if R. equi genes 
could be expressed properly in yeast and ii), if VapA had a functional effect. 
Western blotting of yeast lysates using α-myc antibodies revealed the presence of 
a 20-25 kDa band in myc-VapA expressing yeast, but not in control yeast, 
indicating that VapA could be expressed. To date, this is the first instance of R. 
equi genes being expressed in yeast. Western blotting using α-VapA antibodies 
showed a similar band of 25 kDa was detected, along with two smaller bands < 20 
kDa, indicating possible degradation of the over-expressed protein. To determine 
whether myc-VapA disrupted trafficking in yeast, clones over-expressing the 
protein were assessed for secretion of CPY-invertase, using a qualitative assay. 
None of the clones exhibited a VPS phenotype. The variable expression of myc-
VapA may have masked any phenotype, or yeast expressing enough myc-VapA to 
cause a trafficking defect may not have been viable. 
While expression of VapA could be detected, no phenotype was observed when 
analysing endocytic trafficking (by CPY assay). Given that R. equi has no known 
means of translocating proteins from the Rhodococcus-containing vacuole into the 
cytoplasm, VapA would never see the cell cytoplasm in an infection in vivo. If 
VapA plays a role in pathogenesis from within the vacuole, it may be unsurprising 
that no phenotype is observed when VapA is expressed in the cell cytoplasm. To 
address this issue, VapA was targetted to the yeast vacuole by expressing it as a 
GFP-ALP fusion protein. When analysed by western blotting, a ~100 kDa band 
was found in strains expressing GFP-ALP, but not in the control parental strain. 
GAMV strains were found to express a band of the same molecular weight, but 
also one of ~120 kDa. This most likely corresponded to the expression of full 
length GAMV, but also with the expression of the cleaved protein. However, 
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cleaved VapA could not be detected using α-myc antibodies. Protein bands of 120 
kDa and 15 kDa were detected when GAMV yeast were blotted using α-VapA 
antibodies. This was consistent with the cleavage of VapA from GFP-ALP, but the 
result of this single experiment should be viewed with caution. These data may 
explain the lack of CPY secretion, as rapid degradation of cleaved VapA by 
resident vacuole proteases would prevent VapA from disrupting vacuolar 
trafficking. Secondly, the epitope tag used to detect expression by western blotting 
may have hindered the ability of VapA to disrupt trafficking. To determine if this 
was the case, these experiments were repeated with the myc tag added to the C-
terminus of VapA. However, this did not result in a change in CPY secretion, 
suggesting that the epitope tag had no effect (data not shown). The most likely 
explanation for the lack of a phenotype in yeast expressing VapA, is that the 
mammalian target of VapA may not have an orthologue in yeast, or the yeast 
equivalent may not have a high enough degree of homology to interact with VapA. 
As with myc-VapA, the heterogeneous expression of exogenous proteins driven 
off of 2 µm plasmids may have also masked any potential effects of GAMV. 
Alternatively, yeast expressing enough GAMV to cause a trafficking defect may 
not have been viable.  
4.4.4 Expression of VapA in mammalian cells 
As the natural host of R. equi is equine alveolar macrophages, expressing VapA in 
mammalian cells would be more representative of Rhodococcus infection. Myc-
VapA was expressed in HeLa cells to examine the effects of VapA. Myc-VapA was 
detectable in HeLa cell lysates, but immunofluorescence microscopy revealed that 
only 10-20 % of cells expressed VapA strongly. To determine if VapA had an 
effect on endocytic trafficking, it was asked whether VapA co-localised with 
markers of the endocytic pathway. Expression of VapA was induced for 16 h and 
cells were labelled with antibodies for early endosomes (EEA1), late endosomes 
(ciM6PR) and lysosomes (LAMP1). Surprisingly, VapA did not co-localise with any 
of these markers and the appearance of these organelles was indistinguishable 
from control cells. 
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As with the yeast, it was hypothesised that VapA had to be on the lumenal side of 
the lysosome in order to exert any effect. To target VapA to the mammalian 
lysosome, recombinant fusion proteins were made. A myc tag was added to the N 
or C terminus of VapA, as it was not clear whether the epitope tag would interfere 
with VapA function when added to either end of the protein. This was so VapA 
could be visualised by immunofluorescence using α-myc antibodies should the 
GST affinity tag be removed. The GST-VapA-myc proved less soluble than GST-
myc-VapA, which was then taken forward for large scale production. The yield of 
protein was low (1 mg from a 1 L culture), but sufficient for feeding experiments. 
As the GST-tag may have inhibited VapA function, His6-tagged VapA was also 
produced, as the smaller his tag (1 kDa c.f. 26 kDa) would be much less likely to 
disrupt VapA function. The presence of GST did not prevent VapA from 
functioning, as indicated by the feeding experiments. However, the presence of 
soluble GST/GST-VapA degradation products in the purified protein reduced the 
actual amount of full-length VapA present in the sample. Therefore, VapA-His was 
used for further experiments. 
Recombinant VapA was able to induce swelling of lysosomes when taken up 
J774.2 cells. These cells were used initially as macrophages are the natural host 
of R. equi. However, their small size and general lack of small/discrete lysosomal 
puncta made it hard to perform any quantification on lysosomal size, as multiple 
coalescing lysosomes would be scored as a single lysosome when using image 
analysis software. NRK cells are much larger and have an easily identifiable 
perinuclear distribution of small lysosomes. When VapA was fed to NRK cells, the 
effect of VapA was more readily observable. Heating of VapA before adding to 
cells abolished the lysosomal swelling phenotype. This indicated the effect was 
protein-dependent and not due any contaminants or co-purified endotoxins. These 
results may indicate that VapA may affect mammalian cells regardless of cell type. 
The functional effects of VapA seen when in the mammalian cell lysosome but not 
in the yeast vacuole, indicates that yeast may not be a suitable system to study R. 
equi pathogenicity. These data also suggest that VapA is not active in the host cell 
cytoplasm, as recombinant VapA only caused lysosomal swelling when introduced 
to the lysosome lumen by fluid phase endocytosis. Thus, this effect of VapA was 
further characterised to determine how it may facilitate the intracellular survival of 
R. equi. 
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Chapter 5: The role of VapA in the intracellular survival of 
R. equi 
5.1 Introduction 
5.1.1 Rhodococcus equi 
Rhodococcus equi (R. equi), is a Gram-positive facultative intracellular pathogen 
with similarities to Mycobacterium tuberculosis (Vazquez-Boland et al., 2013). It 
infects a wide variety of animals, but has increasingly been isolated from patients 
with a significant mortality rate (Khan et al., 2013, Nath et al., 2013, Topino et al., 
2010, Hayes et al., 2011). R. equi survives and replicates in a vacuolar 
compartment within the host cell (Hondalus and Mosser, 1994), but it is unclear 
whether R. equi prevents its delivery to the lysosome (Fernandez-Mora et al., 
2005) or alters the degradative capacity of the lysosome itself (Toyooka et al., 
2005). 
5.1.2 R. equi virulence plasmid 
The 90 Kb virulence plasmid of R. equi plays a crucial role in intracellular survival. 
Loss of the virulence plasmid renders the bacteria unable to replicate inside 
macrophages in vitro (Hondalus and Mosser, 1994, Giguere et al., 1999). Avirulent 
strains are cleared significantly faster in a mouse lung infection model than those 
strains harbouring the extrachromosomal element (Gonzalez-Iglesias et al., 2014). 
The virulence plasmid has 73 coding sequences including 8 pseudogenes (Letek 
et al., 2010). Within the virulence plasmid is an approximately 27 Kb pathogenicity 
island (PI) characterised by the presence of insertion elements (ORF61 and 
ORF22) at either end of a block of genes (Takai et al., 2000). A striking feature of 
the PI is the presence of seven virulence-associated protein (Vap) genes (VapC-
H), which were found due to their similarity to VapA (Takai et al., 2000). VapA, C 
and D are located in close proximity to each other. VapE and VapF are adjacent 
genes. VapG and VapH are present as separate genes, with VapH as the only 
Vap gene found on the negative strand. Vaps A,C,D,E,G,H are found as full length 
genes, whereas VapF, I and X are found as pseudogenes (Letek et al., 2008, 
Polidori and Haas, 2006, Takai et al., 2000). Figure 5.0 shows a schematic 
representation of the plasmid pathogenicity island and protein alignment of the 
different Vaps. 
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Non-equine isolates of R. equi also possess a virulence plasmid, but these strains 
produce VapB instead of VapA. VapB is a slightly larger surface protein that 
shares a high degree of sequence similarity to VapA (81% nucleotide sequence 
identity). Consistent with a role in virulence, plasmids containing the VapB gene 
harbour 5 genes with similarity to the Vap containing region of VapA plasmids. 
VapA and VapB are allelic variants of a single ancestral gene (Letek et al., 2008). 
Both VapG and VapL are on the negative strand and are likely to be derived from 
a common gene. Similarly, VapK is the counterpart to VapD and VapM to that of 
VapX. VapB plasmids also contain two additional genes, VapK1 and VapK2, which 
likely arose from a duplication event of the ancestral AB gene (Fig. 5.1, Letek et 
al., 2008). The conservation of Vap genes between strains isolated from different 
hosts may indicate their role in virulence. Isolates obtained from foals are 
exclusively VapA+ strains with isolates obtained from non-equine sources 
(including humans) harbouring plasmids with VapA, VapB or no plasmid at all 
(Makrai et al., 2002). Interestingly, VapB+ strains only display intermediate 
virulence in a mouse infection model (Takai et al., 1995). These differences in 
plasmid architecture and Vap genes may indicate that they play a key role in host 
tropism.  
 
 
 
 
Fig. 5.0. Organisation of VapA-plasmid pathogenicity island and Vap protein 
alignment. A. Schematic representation demonstrating the gene order and orientation of 
the R. equi VapA-type virulence plasmid pVAPA1037 (Genbank accession no. 
AM947677.1). Vap genes are shown in white. B. Multiple amino acid alignment of the 
family of Vap genes (including signal peptides) encoded by the plasmids pVAPA1037 
(Takai et al., 2000) and pVAPB1593 (Letek et al., 2008). Protein alignment was performed 
using ESPript (http://espript.ibcp.fr (Robert and Gouet, 2014). The secondary structure of 
VapD is shown above the alignment. Identical residues are shown in red. 
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Fig. 5.1. Phylogenetic tree of the Vap genes of R. equi. Neighbour-joining unrooted 
phylogenetic tree of the Vap multigene family constructed from a ClustalW alignment of 
the mature Vap proteins encoded by pVAPB1593 and pVAPA1037. For the analyses, a 
full-length VapF protein was reconstructed by correcting the two frameshift mutations in 
the 3′ region of the gene. Bootstrap values (10,000 replicates) are indicated at the nodes. 
Outgroup, putative DnaB protein from pVAPB1593 (pVAPB_0390). The bar indicates 
genetic distance. Figure and figure legend reproduced, with permission, from Letek et al., 
2008. 
5.1.3 VapA is essential but not sufficient for virulence 
The presence of the plasmid is widely accepted as a prerequisite for intracellular 
survival and replication inside eukaryotic cells, although plasmid free strains may 
also persist inside non-phagocytic cell types (Ramos-Vivas et al., 2011). The 
expression of VapA in particular has been associated with virulence in vivo in both 
mice and foals (Takai et al., 1991, Giguere et al., 1999). VapA has also been 
shown to be necessary but not sufficient for virulence, since VapA alone can 
restore virulence to a VapC-F mutant, (Jain et al., 2003) but cannot restore 
virulence to plasmid-cured R. equi strains (Giguere et al., 1999).  
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Recently, it has been shown that the expression of VapA along with two other 
genes VirR and VirS are the minimum genes required for intracellular growth of R. 
equi (Coulson et al., 2015). VirR is a LysR-type transcriptional regulator (Russell et 
al., 2004) and VirS is an OmpR/PhoB response regulator (Kakuda et al., 2014), 
both of which required for proper VapA gene expression (Ren and Prescott, 2004). 
When VirR, VirS and VapA were added back to plasmid cured R. equi (under 
control of their native promoters), virulence was restored to near wild-type levels 
(Coulson et al., 2015). This may explain why VapA alone cannot restore virulence. 
Additionally, the presence of VirR and VirS was shown to induce changes in gene 
transcription in 18 % of the R. equi genome (Coulson et al., 2015). This suggests 
that the presence of the plasmid is needed to regulate chromosomal genes that 
may be required for intracellular growth. It is also interesting to note that another 
gene Icga, actually lowers the intracellular replication of R. equi resulting in 
prolonged infection of macrophages (Wang et al., 2014). 
5.1.4 Induction of Vap gene expression 
The expression of the Vap proteins has been shown to be regulated by several 
different factors. Growth at 37 ºC but not 30 ºC results in production of the Vap 
proteins (Byrne et al., 2001). Similarly, growth at 38 ºC induces VapA expression, 
but not unless the pH is below 8 (Takai et al., 1996). Exposure of R. equi to low pH 
(5.0) has also been shown to increase the expression of VapA (Benoit et al., 2001) 
and expression of plasmid genes in low concentrations of iron, calcium and 
magnesium, mimics that of protein expression in vivo (Ren and Prescott, 2003). 
These are conditions encountered inside the macrophage phagosome and these 
data are consistent with the Vap proteins having a role in pathogenicity (Byrne et 
al., 2001). Interestingly, VapA appears to be the only Vap that is not secreted and 
that is anchored to the bacterial surface (Tan et al., 1995). 
5.1.5 The structure of VapA 
The structures of VapB, (Geerds et al., 2014) VapD, (Whittingham et al., 2014) 
and VapG (Okoko et al., 2015) have been solved. While the N-terminus of the 
Vaps varies and is presumed to be disordered, the C-terminal core is remarkable 
conserved between the different Vaps (Fig. 5.0 & 5.2). While there are some 
differences the core of the Vap proteins is very similar. The core of VapD consists 
of a compact, closed β-barrel (Whittingham et al., 2014). One end of the barrel has 
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a smooth apolar surface, whilst the more complex end of the barrel is made of 
polar and charged residues. However, the structure of the Vap proteins lacks an 
obvious ligand-binding site or an enzyme active site and gives no clues as to its 
function (Whittingham et al., 2014). 
 
Fig 5.2. The crystal structures of VapB, VapG and VapD. A&B. The structures of VapG 
(blue), VapD (red) and VapB (green) polypeptide backbones displayed as worm tracings. 
The superposed protein chains are viewed from the side illustrating the whole molecules 
(A) and from above parallel to the long axis of the barrel with the molecule clipped for 
clarity (B). C. Electrostatic surface renderings of VapB, VapD and VapG with positive 
electrostatic potential in blue and negative electrostatic potential in red. The three 
molecules are viewed in two orientations which are illustrated by the ribbon tracing for 
VapG at the left. The extended apolar surface previously noted for VapD and VapB is 
evident. Figure and figure legend reproduced with permission from Okoko et al., (2015). 
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5.2 Materials and methods 
5.2.1 Recombinant VapA feeding 
J774.2 mouse macrophages were seeded in 6 well-plates containing glass 
coverslips at a density of 1x105 cells per well and cultured in DMEM for 24 h. 
Alternatively, Normal Rat Kidney (NRK) cells were plated onto glass coverslips at 
a density of 1x104 cells per well of a 24 well plate and cultured in DMEM for 24 h. 
The media was then replaced with 1 ml of DMEM containing recombinantly 
produced GST (100 µg/ml) or DMEM containing recombinant GST-myc-VapA or 
VapA-His6 (100 µg/ml) and cells cultured for the different lengths of time. Where 
protease inhibitors were used, leupeptin was added to all cells at the beginning of 
the time course to a final concentration of 21 µM. Coverslips were rinsed three 
times with Dulbecco’s modified phosphate buffered saline (Sigma) and fixed using 
methanol, or alternatively, 4 % formaldehyde in PBS, followed by immunolabelling 
using appropriate antibodies, as previously described in section 2.16.  
5.2.2 Infection assays 
J774.2 cells were seeded at 5 x 105 cells per well of a 6-well plate and cultured 
overnight in antibiotic-free DMEM supplemented with 10 % (v/v) FBS (heat 
inactivated to 56 ºC for 30 min) and 2 mM glutamine. R. equi was cultured 
overnight in BHI media with shaking at 30 ºC followed by a 1 h incubation at 37 ºC 
to induce the production of Vaps (virulence associated proteins) and other 
virulence factors. Bacteria were pelleted at 3000 x g for 10 min in a 
microcentrifuge and washed twice in PBS. Cell number was determined by 
measuring the OD600 and comparing the value to a standard curve of bacterial 
OD600 vs colony forming units (cfu). An OD600 of 1.0 was approximately 1x108 
bacteria per ml. Bacteria were resuspended in PBS and an appropriate number of 
cells taken to infect mammalian cells at an MOI (multiplicity of infection) of 10. 
Bacteria were centrifuged onto cells at 80 x g for 5 min and incubated for 1 h at 37 
ºC to allow phagocytosis of bacteria. Monolayers were rinsed 3 times with DMEM 
to remove unbound bacteria and the media replaced with DMEM containing 150 
µg/ml gentamycin to kill extracellular bacteria. The cells were cultured for a further 
hour and washed again with PBS. The media was then replaced with DMEM 
containing 10 µg/ml gentamycin and cells cultured for different lengths of time, 
upon which the cells were fixed with 4 % formaldehyde in PBS for 20 min at room 
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temperature, or by incubation at -20 ºC in 1 ml of methanol that had been cooled 
to -20ºC, for 5 min. Cells were then labelled using the appropriate primary and 
fluorescently labelled secondary antibodies, as described in section 2.16. Colony 
PCR of R. equi for VapA and traA (both plasmid encoded genes) were performed 
to check for plasmid loss, as previously described in section 2.9.4. 
5.2.3 Affinity capture of biotinylated proteins in the cytoplasm 
Flp In HeLa cells transfected with either myc-BirA* or VapA-myc-BirA* were grown 
to confluency (4 x 75 cm2 flasks per condition) and expression of myc-BirA* or 
myc-BirA*-VapA was induced with 1 µg/ml doxycycline, in DMEM supplemented 
with biotin (to a final concentration of 50 µM) for 24 h. The cells were then rinsed 
three times with PBS and detergent soluble lysates generated as follows: cells 
were lysed at room temperature (approximately 25 ºC) with 1 ml of lysis buffer (50 
mM Tris, pH 7.4, 500 mM NaCl, 0.4 % (w/v) SDS, 5 mM EDTA, 1 mM DTT with 
protease inhibitors) per flask. Lysates were sonicated in 15 ml tubes for 10 s on 
ice. Triton X-100 was added to a final concentration of 2 % (v/v) and lysates were 
sonicated once more for 10 s. An equal volume of 4 ºC 50 mM Tris, (pH 7.4) was 
added before a final sonication was performed. Lysates were then centrifuged at 
16,000 x g for 15 min at 4 ºC. Detergent soluble supernatants were collected and 
their protein concentration determined by BCA assay. Lysates were normalised to 
protein concentration and were then incubated with 600 µl of Dynabeads (MyOne 
Streptavidin C1, Invitrogen) overnight at 4 ºC with gentle rotation to capture 
biotinylated proteins (20 µg of each lysate was taken before and after incubation 
with the beads to determine the efficiency of the experiment by western blotting 
with a streptavidin-HRP conjugate). The beads were collected on a magnet and 
resuspended in 1 ml of 2 % (w/v) SDS in ddH2O for 8 min. The beads were 
collected on the magnet and the supernatant was discarded. The beads were 
washed once more in 2 % SDS for 8 min. This was repeated once with the second 
wash buffer (0.1 % (w/v) sodium deoxycholate, 1 % (v/v) Triton X-100, 500 mM 
NaCl, 1 mM EDTA, 50 mM HEPES, pH 7.5), once with the third wash buffer (250 
mM LiCl, 0.5 % (v/v) NP-40, 0.5 % (w/v) sodium deoxycholate, 1 mM EDTA, 10 
mM Tris, pH 8.1) and twice with the fourth wash buffer (50 mM Tris, pH 7.4, 50 
mM NaCl). The beads were resuspended in 600 µl of the final wash buffer and 10 
% (60 µl) taken for western blot analysis. The remainder of the beads to be 
analysed by (mass spectrometry) were washed twice (1 ml each wash for 8 min) 
with 50 mM NH4HCO3. 
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5.2.4 Affinity capture of biotinylated proteins in the lysosome 
For capture of biotinylated proteins from the lysosome lumen, Flp In HeLa cells 
were grown to confluency in T75 flasks (2 flasks for myc-BirA* control, 2 flasks for 
myc-VapA-BirA*). The cells were then incubated with DMEM containing 100 µg/ml 
myc-BirA*-His or VapA-myc-BirA*-His for 16 hours. The media was then replaced 
with fresh DMEM and the cells cultured for a further 4 h. The media was then 
supplemented with 0.55 ml of PBS saturated with biotin (900 µM) to give a final 
biotin concentration of 50 µM. Cells were then cultured for a further 24 h. Cells 
were rinsed 3 times with PBS and the generation of lysates and capture of 
biotinylated proteins performed as described in section 5.2.3. 20 µg of each lysate 
before and after incubation with the beads and 10 % of eluted proteins were kept 
to determine the efficiency of the experiment by western blotting with a 
streptavidin-HRP conjugate. 
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5.3 Results 
Previously, a yeast-based screen was carried out to identify R. equi genes that 
caused a VPS- phenotype. The screen did not identify any R. equi genes and a 
target approach was taken to study R. equi virulence. The only known essential 
virulence factor, VapA, was expressed in the yeast cytoplasm and vacuole, but no 
phenotype was observed. When VapA was expressed in the mammalian cell 
cytoplasm, no effect on endocytic trafficking was observed. In stark contrast to 
these results, when VapA was target to the mammalian lysosome lumen (by way 
of feeding cells recombinant VapA protein), the lysosomes swelled up. This 
swelling phenotype was further characterised and attempts made to dissect the 
mechanism behind it. 
5.3.1 Lysosomal swelling increases over time 
The lysosomes of NRK cells were previously shown to swell up when incubated 
with recombinant VapA for 8 h or 24 h. Next, NRK cells were incubated with GST 
or GST-VapA at 100 µg/ml for 2 h, 4 h, 8 h, 16 h, or 24 h (Fig. 5.3) Cells incubated 
with GST showed lysosomes of normal size and distribution at all time points.  The 
effect of VapA on lysosomes was observable as soon as 2 h, with large lysosomal 
puncta observable in the perinuclear and peripheral regions of the cell. The 
number of larger puncta increased over time. At later time points (16 h and 24 h) 
the vast majority of lysosomes were affected. The overall area of lysosomal 
staining within the cell appeared to have increased. However, it was not clear 
whether this was due to increased numbers of lysosomes or an increase in the 
size of the lysosomes.  
 
 
 
 
. 
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Fig. 5.3. VapA induced lysosomal swelling increases over time. NRK cells were incubated with GST or GST-myc-VapA at 100 µg/ml for the times 
indicated. Cells were rinsed three times with PBS and fixed with 4 % formaldehyde in PBS before processing for immunofluorescence microscopy. Cells 
were labelled with α-Lgp110 antibodies followed by fluorescently labelled secondary antibodies (Alexa Fluor 488; green). Nuclei were stained with DAPI 
(blue). Scale bar 20 µm. Images are maximum-intensity z-projections (n=1). 
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5.3.2 VapA affects late endocytic compartments 
Although the effect of VapA on lysosomal compartments in NRK cells was clear, it 
was not known if this was specific to lysosomes, or whether early and late 
endocytic compartments were also affected. To test this, NRK cells were 
incubated with VapA-His at 100 µg/ml for 8 h, 24 h, or 48 h and processed for 
immunofluorescence using α-EEA1 and α-Lgp120 antibodies, followed by 
fluorescent secondary antibodies to visualise early endosomes and late 
endosomes/lysosomes respectively (Fig. 5.4). In control cells, EEA1 is both 
cytoplasmic and membrane associated, giving a weak cytoplasmic staining 
pattern, with some small puncta. After 8 h incubation with VapA, the majority of 
cells were indistinguishable from control cells. In ~ 1 % of cells however, the 
distribution of EEA1 altered slightly, with some staining concentrating around the 
perinuclear region. Some larger EEA1 positive puncta were also observable in 
these cells. This was also seen at 24 and 48 h. These vesicles were often in close 
proximity to lysosomes, but there was little colocalisation between the two and the 
compartments remained distinct. As expected, Lgp120 staining showed that the 
lysosomes continued to swell and coalesce from 8 h to 48 h. 
As there was not a pronounced effect on early endosomes, the effect of VapA on 
late endosomes/ciM6PR positive vesicles was investigated. NRK cells were 
incubated with 100 µg/ml VapA for 24 h and the morphology of late endosomes 
and lysosomes was examined (Fig. 5.5) In contrast to early endosomes, ciM6PR 
compartments formed large swollen puncta after 24 h of incubation with VapA. Co-
staining for ciM6PR and LAMP proteins was performed to distinguish between late 
endosomes (ciM6PR +, Lgp120 -), lysosomes (ciM6PR -, Lgp120 +) and 
endolysosomes (ciM6PR +, Lgp120 +).  All three of these compartments displayed 
a swollen morphology after incubation with VapA. Interestingly, some of the 
ciM6PR staining appeared to be surrounded by Lgp120 staining, but these 
structures were difficult to resolve. These data indicate that VapA selectively 
effects late endocytic compartments and does not appear to directly affect early 
endosomes. 
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Fig. 5.4. VapA does not affect EEA1+ endocytic compartments. NRK cells were 
incubated with recombinant VapA-His6 at 100 µg/ml for the times indicated. Cells were 
rinsed three times with PBS and fixed with 4 % formaldehyde in PBS before processing 
for immunofluorescence microscopy. Cells were double labelled with α-EEA1 antibodies 
and α-Lgp120 antibodies, followed by fluorescently secondary antibodies (Alexa fluor 488; 
green and Alexa fluor 555; red, respectively). Scale bars 20 µm. Images are maximum-
intensity  z-projections. Images shown are representative of three separate experiments. 
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Fig. 5.5. VapA causes swelling of ciM6PR+ compartments. NRK cells were incubated 
with recombinant VapA-His6 at 100 µg/ml for 24 h. Cells were rinsed three times with PBS 
and fixed with 4 % formaldehyde in PBS before processing for immunofluorescence 
microscopy. Cells were double labelled with α-ciM6PR antibodies and α-Lgp120 
antibodies, followed by fluorescently secondary antibodies (Alexa fluor 488; green and 
Alexa fluor 555; red, respectively). Scales bar 20 µm. Images are maximum-intensity z-
projections. Images shown are representative of three separate experiments. 
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The size of VapA affected lysosomes was quantified over a longer time course. 
NRK cells were incubated with VapA for 24 h, 48 h and 72 h. Cells were labelled 
with α-Lgp120 antibodies followed by fluorescently labelled secondary antibodies 
and lysosome size analysed (Fig. 5.6). The swollen lysosome phenotype was 
observed when cells were incubated with VapA for 24 h (Fig. 5.6 A). By 48 h, the 
size of lysosomal aggregates had increased greatly, with large, singular structures 
clearly observable. However, by 72 h the larger lysosomes appeared to have 
collapsed, with many smaller puncta filling the majority of the cell. The size of 
these lysosomes was analysed using ImageJ analysis software (Fig. 5.6 B). The 
average area of individual control cell lysosomes was 0.25 µm2, which is 
consistent with the area of a lysosome with a diameter of 500 nm (0.20 µm2). This 
increased to 0.51 µm2 after 24 h of incubation with VapA. Lysosome area dropped 
to 0.33 µm2 and 0.31 µm2 after 48 h and 72 h respectively, but remained higher 
larger than that of control cells. Larger puncta and regions where lysosomes in 
close apposition were counted as one large particle, were omitted from the 
analysis by disregarding any particle with an area greater than 50 µm2. This was 
performed to prevent large regions of unresolvable puncta from being scored as a 
single large puncta. While this may have underestimated the size of the lysosomes 
at 48 h and 72 h, the lysosomes at all time points were significantly larger than 
those of control cells (p = < 0.001). 
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Fig. 5.6. Quantification of lysosome size in cells incubated with VapA. A. NRK cells 
were fed recombinant VapA-His6 at 100 µg/ml for the times indicated. Cells were then 
rinsed three times with PBS and fixed with 4 % formaldehyde in PBS. Cells were labelled 
with α-Lgp120 antibodies, followed by fluorescently secondary antibodies (Alexa fluor 555; 
red). Scale bars 10 µm. Images are maximum-intensity z-projections (n=1). B. 
Quantification of lysosome size from images in A. Lysosome size was quantified using 
ImageJ software. Images were converted to binary images and puncta area was 
measured. To prevent the perinuclear and other unresolvable regions of each cell being 
counted as single lysosome, particles with an area greater than 50 µm2 were excluded 
from the analysis. A minimum of 5 separate images were counted for each time point, with 
approximately 5 separate cells per image and 1000 individual particles counted per 
image. Data are means ± SEM and were analysed using One-way ANOVA (n=1).  
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5.3.3 VapA alone causes lysosomal swelling 
VapA has previously been shown to be the only Rhodococcus Vap protein 
necessary for virulence. A R. equi mutant lacking Vap proteins A,C,D,E & F was 
found to be attenuated for virulence in mice, a phenotype that could be rescued by 
complementation with VapA, but not VapD (Jain et al., 2003). Expression of VapG 
is highly upregulated in macrophages, yet VapG mutants remain fully virulent 
(Coulson et al., 2010). To determine whether these other Vap proteins were able 
to cause swelling of lysosomes, cells were incubated with recombinant VapD or 
VapG for 8 h and 24 h at 100 µg/ml (Fig. 5.7).  Neither VapD nor VapG induced 
any changes in lysosome morphology or distribution at any of the time points 
analysed. 
 
Fig. 5.7. Recombinant VapD and VapG do not effect lysosome morphology or 
distribution. NRK cells were incubated with 100 µg/ml of recombinant VapD or VapG for 
the times indicated. Cells were then rinsed three times with PBS and fixed with 4 % 
formaldehyde in PBS. Cells were labelled with α-Lgp120 antibodies, followed by 
fluorescently secondary antibodies (Alexa fluor 488; green). Cell nuclei were stained with 
DAPI (blue). Scale bar 20 µm. All images are maximum-intensity z-projections (n=2). 
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The Vap proteins have a conserved core structure, with a variable N-terminus 
(Okoko et al., 2015). As VapA appeared to be the only Vap capable of inducing 
lysosomal dysfunction, it was asked whether the N-terminus was responsible 
and/or necessary for this activity, given the similarity between the core of the other 
Vaps yet their inability to disrupt lysosomes. To test this, NRK cells were incubated 
with either a VapA N-terminus - VapD-core chimeric protein (VapA/D), or VapA 
core lacking the N-terminus (residues 22-136) for 8 h and 24 h. The Vap D/A 
chimeric protein did not induce an observable change in lysosomal morphology or 
distribution in the cells at either 8 h or 24 h (Fig. 5.8) Unexpectedly, at both 8 h 
and 24 h the VapA-core induced lysosomal swelling. Thus, taken together, these 
data indicate that the ability of VapA to cause lysosomal disruption is conferred by 
the core barrel of the protein and the N-terminus is not responsible for the 
observed phenotype. This hypothesis is further supported by the fact that neither 
VapD and VapG, which have different N-termini, have the same effect on 
lysosomes as VapA.  
As lysosomal swelling was induced by the core of VapA, but not VapD or VapG, it 
was hypothesised that the N-terminus of the other Vap proteins could potentially 
be inhibitory to any function that the core region of the protein may posses. This 
was tested by incubating cells with a VapD/A chimeric protein. Residues 1-20 of 
the mature VapD protein, were fused to the C-terminal core of VapA (starting at 
residue 22 of the mature VapA protein). NRK cells were then incubated with 
recombinant protein at 100 µg/ml for 8 h, 24 h and 48 h and the morphology of 
early endosomes and lysosomes was examined (Fig. 5.9). At all time points, the 
majority of EEA1 positive puncta appeared normal. Interestingly, at 24 h and 48 h, 
there were examples of larger EEA1 puncta, although this was only seen in 
around 1 % of cells, suggesting that they were not directly affected as seen 
previously (Fig. 5.4). At 48 h, some early endosomes appeared to be in close 
apposition to lysosomes and displayed a more perinuclear distribution compared 
to earlier time points (8 h). After 8 h of incubation with VapD/A, large, swollen 
Lgp120 positive puncta were observable in cells incubated with VapD-A. The 
lysosomes continued to coalesce and/or enlarge at both 24 h and 48 h. At 48 h 
several large vacuoles were observable in the cells. This data indicates that the N-
terminus of VapD is not inhibitory, suggesting that the core of VapA alone induces 
lysosomal swelling and early endosomes remain largely unaffected. 
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Fig. 5.8. The C-terminal core of VapA is sufficient to cause lysosomal dysfunction. 
NRK cells were incubated with a VapA N terminus/VapD core chimeric protein, or VapA 
core, (residues 22-136 as per the numbering of (Whittingham et al., 2014)). Cells were 
rinsed three times with PBS and fixed with 4 % formaldehyde in PBS before cells were 
labelled with α-Lgp110 antibodies followed by fluorescently secondary antibodies (Alexa 
fluor 488; green). Nuclei were stained with DAPI (blue). Scale bars 20 µm. Images are 
maximum-intensity z-projections (n =1). 
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Fig. 5.9. VapD-A chimera induces lysosomal swelling. NRK cells were incubated with 
recombinant VapD-A chimeric protein at 100 µg/ml for the times indicated. Cells were 
fixed in 4 % formaldehyde in PBS. The cells were then double labelled with α-EEA1 
antibodies and α-Lgp120 antibodies followed by fluorescently labelled secondary 
antibodies (Alexa fluor 488; green and Alexa fluor 555; red, respectively). Scale bars 20 
µm. Images are maximum-intensity z-projections (n=1). 
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5.3.4 VapA fed cells still contain acidic endocytic compartments 
As VapA induced swelling of lysosomes and late endocytic compartments was 
reminiscent of the phenotype of some lysosomal storage disorders, it was 
hypothesised that like LSDs, these aberrant organelles may no longer be 
functional. To test this, VapA-fed cells were incubated with Magic Red (MR) 
cathepsin B substrate. MR is a non-cytotoxic, membrane permeable, cresyl violet 
flurophore, with two cathepsin cleavage sites added to it, rendering it non-
fluorescent. Upon cleavage by cathepsin B, the MR becomes fluorescent. 
Therefore, fluorescent MR accumulates in compartments containing active 
proteases. MR was added to NRK cells and imaged using spinning disk confocal 
microscopy (Fig. 5.10). In control cells, the MR flurophore was observed in small 
puncta in the perinuclear region and in the periphery of the cell. Unexpectedly, 
VapA-fed cells also contained fluorescently labelled, large, swollen puncta, 
consistent with the lysosome/late endocytic staining obtained in previous 
experiments. This indicated that VapA-fed cells still possessed proteolytically 
active vesicles. However, it was not possible to determine the identity of these 
compartments in this experiment. 
 
Fig. 5.10. Cathepsin B is still active in VapA-fed NRK cells. NRK cells were cultured 
for 48 h on glass bottomed dishes and then incubated with or without VapA at 100 µg/ml 
for 24 h. Cells were then incubated with Magic Red (MR) cathepsin B substrate for 5 
minutes before live-cell images were acquired. Scale bars 20 µm (n=2). 
 
261 
The experiment was then repeated using NRK cells transiently transfected with 
LAMP1-GFP, in order to specifically label the lysosomes (Fig. 5.11). In control 
cells, LAMP1-GFP was found to label discrete puncta in the perinuclear region and 
throughout the cell. Some of these puncta colocalised with MR positive vesicles, 
but MR puncta that did not co-localise with LAMP1-GFP were also seen. In cells 
incubated with VapA for 24 h, larger, swollen vacuoles were visible, which 
colocalised with LAMP1-GFP positive vesicles confirming these vesicles were late 
endocytic/lysosomal in origin. However, there were many puncta that did not co-
localise with MR. As cathepsin B has a long half-life (14 h, Katunuma, 2010) any 
disruption of trafficking to the lysosome (preventing delivery of newly synthesised 
lysosomal proteins) would not been seen within the time frame of the experiment. 
Despite this, it can be concluded that VapA-affected compartments retain their low 
pH. 
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Fig. 5.11. Lysosomes retain protease activity in VapA-fed NRK cells. A. NRK cells 
were transiently transfected with LAMP1 GFP for 24 h to visualise lysosomes. Cells were 
then incubated in DMEM or DMEM containing 100 µg/ml VapA, for 24 h. Magic Red (MR) 
cathepsin B substrate was added to the cells for 5 minutes before live cell images were 
acquired. Scale bars 20 µm (n=2). 
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5.3.5 Both virulent and plasmid-cured R. equi reside in LAMP1 
positive compartments. 
R. equi has previously been reported to arrest phagosome maturation after the 
early endosomal/phagosomal stage (Fernandez-Mora et al., 2005). Rhodococcus 
containing vacuoles (RCVs), do not fuse with pre-labelled lysosomes and are 
devoid of classical markers of late endocytic vesicles, such as the vATPase and 
cathepsin D. After 48 h of intracellular growth inside bone marrow-derived 
macrophages (BMDMs), virulence plasmid associated strains maintain a non-
acidified compartment (Fernandez-Mora et al., 2005). Secondly, a caveat to the 
VapA feeding experiments was that it was unknown at what level, if at all, VapA is 
secreted during infection of cells with R. equi. 100 µg/ml of recombinant protein 
was chosen as an arbitrary level, as this was sufficient to elucidate whether a Vap 
or chimeric protein was able to disrupt lysosome function. During an infection, the 
physiological amount of VapA produced by R. equi is unknown. To confirm some 
of this data, J774.2 cells were infected with virulent (103s+) and avirulent (103s-) 
strains of R. equi at an MOI of 10 and the intracellular location of the bacteria after 
16 h was determined (Fig. 5.12). 
Small numbers of R. equi lacking the virulence plasmid (103s-) were found 
surrounded by LAMP1 positive membrane after 16 h (Fig. 5.11 A). Consistent with 
the lack of Vap proteins in avirulent strains, 103s- R. equi did not stain with α-VapA 
antibodies and only weak levels of background staining were detected with this 
antibody. In contrast, J774.2 cells were found to be heavily infected with 103+ R. 
equi 16 h post-infection, indicating intracellular replication of bacteria (Fig. 5.12 B). 
The majority of these bacteria were also found to be surrounded by a LAMP1 
positive membrane, although some intracellular bacteria were not associated with 
LAMP1 staining. Interestingly, VapA appeared to colocalise to a high degree with 
LAMP1 positive membranes, as well a large proportion of bacteria. Those bacteria 
that colocalised with VapA, were either in LAMP1 compartments (large 
arrowheads), or not associated with LAMP1 staining (small arrowheads). Some 
bacteria were found to be devoid of LAMP1 and VapA staining. 
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Fig. 5.12. Infection of J774.2 macrophages with Rhodococcus equi. J774.2 cells were 
infected with avirulent (103s-, A) or virulent (103+, B) R. equi, at an MOI of 10. At 16 h 
post infection, cells were rinsed 5 times with PBS and fixed in 4 % formaldehyde in PBS. 
Cells were then double labelled with α-Lgp120 antibodies and α-VapA antibodies, 
followed by fluorescently labelled secondary antibodies (Alexa fluor 555; red and Alexa 
fluor 488; green, respectively). Large arrowheads show bacteria surrounded by a LAMP1+ 
membrane, small arrowheads shown bacteria with no LAMP1 staining. Bacteria and cell 
nuclei were stained with DAPI (blue). Scale bar 10 µm. Images are maximum-intensity z-
projections (n=2). 
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5.3.6 Incubation with VapA causes changes in levels of LAMP1 
Lysosome biogenesis is upregulated in response to lysosome dysfunction 
(Sardiello et al., 2009). At later time points in previous experiments (48 h-72 h), the 
number of lysosome puncta observed in Vap-fed cells appeared to increase. 
However, it was not clear if this was due to collapse of swollen vacuoles, 
lysosomes aggregating, or a genuine upregulation of lysosome biogenesis. To try 
and answer this, the levels of LAMP1 in control and Vap fed cells were analysed 
by western blotting (Fig. 5.13 A&B). J774.2 or NRK cells were incubated with 
recombinant VapA, VapD, or VapG at 100 µg/ml for 8 h, 24 h, 48 h, or 72 h. Cell 
lysates probed with α-LAMP1 (J774.2 cells), or α-Lgp120 and cation-independent 
mannose-6-phosphate receptor (ciM6PR) antibodies (NRK cells). In J774.2 cells 
incubated with VapA, levels of LAMP1 increased from 24 h to 72 h, with the 
highest levels seen at 48 h. In contrast, cells incubated with VapD or VapG did not 
show an increase in LAMP1 levels. Similarly, in NRK cells, the levels of Lgp120 
(LAMP1) increased after cells were incubated with VapA, but not with VapD or 
VapG. Levels of Lgp120 increased from 8 h and were at their highest at 72 h. The 
levels of ciM6PR in NRK cells were also probed. Between 8 and 72 h there was no 
significant change in the levels of ciM6PR in NRK lysates of cells incubated with 
any of the Vap proteins tested. It was observed that J774.2 macrophages began to 
die after 24 h of incubation with VapA, whereas NRK cells could be cultured for up 
to 72 h (data not shown). In most cases, the amount of α-tubulin loading control 
was roughly equivalent, with levels of α-tubulin decreasing at 72 h in VapA fed 
J774.2 cell lysates. The activity of the lysosomal enzyme β-hexosaminidase in 
cells incubated with the different Vap proteins was also measured. In both J774.2 
(Fig. 5.13 C) and NRK (Fig. 5.13 D) cells, the activity of β-hexosaminidase (as a 
fold change of the control cells at 72 h) did not significantly alter when cells were 
incubated with any of the Vaps tested (p = 0.510 J774.2 cells, p = 0.258 NRK 
cells).  
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Fig. 5.13. Upregulation of lysosome biogenesis in cells incubated with VapA. J774.2 
macrophages (A) or NRK cells (B) were incubated with recombinant VapA, VapD or VapG 
at 100 µg/ml for the times indicated. Cell lysates were then probed using α-Lgp120/α-
LAMP1, α-α tubulin and α-ciM6PR antibodies. The levels of the lysosomal enzyme β-
hexosaminidase were also measured at the indicated time points in VapA-fed J774.2 and 
NRK lysates (C&D). Data are represented as arbitrary units of β-hexosaminidase enzyme 
activity per µg of protein, as a fold change of the control sample. Western blots are 
representative of at least two independent experiments. Graphs show mean + the range 
and data were analysed by two-way ANOVA (n=2). 
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5.3.7 Identifying the binding partner of VapA 
The data accumulated thus far demonstrates that VapA, (but not VapD or VapG), 
is able to induce a swollen lysosomal phenotype. While these observations are 
important to understand how VapA promotes intracellular survival, they do not 
provide any evidence of a mechanism by which VapA acts. To try dissect the 
molecular mechanism by which VapA allows Rhodoccocus survive inside 
macrophages, immunoprecipitation experiments were performed to identify what 
host protein(s) VapA interacts with. Immunoprecipitation experiments were 
performed on lysates generated from myc-VapA expressing HeLa cells (Fig. 5.14 
A). Initially, the IP protocol was optimised to maximise the chance of finding an 
interacting partner. 10 µg of α-myc antibody was covalently coupled to sepharose 
and incubated with 0.75 mg, 1.0 mg, 1.5 mg, or 2.0 mg of lysate for 2 h. The 
sepharose was washed and proteins eluted from the sepharose using a low pH 
elution buffer. Equal volumes of all samples were subjected to western blotting 
using α-myc antibodies. There was less myc-VapA detected in 0.75 mg and 1.0 
mg samples compared to the 1.5 mg and 2.0 mg samples. However, 1.5 mg of 
lysate appeared to reach the binding capacity of 10 µg antibody, as no more was 
pulled out when the sepharose was incubated with 2.0 mg of lysate. Therefore, 1.5 
mg and 10 µg of antibody was chosen as the optimal ratio for further experiments.  
In all cases, there was a significant amount of myc-VapA remaining after 
incubation with α-myc sepharose. To improve the efficiency of the IP, 1.5 mg of 
lysate was incubated with α-myc sepharose for 1 h or overnight at 4 ºC (Fig. 5.14 
B). Western blotting of the eluted proteins showed that the efficiency of the IP was 
increased when incubating the lysates overnight. Therefore, this was continued for 
further experiments. As the lysates still had significant amounts of myc-VapA after 
incubation with the sepharose, the amount of sepharose was increased to try and 
leave no more than 10 % of myc-VapA in the lysate after incubation with the α-
myc sepharose (Fig. 5.14 C). 1.5 mg of lysate was incubated with 10, 20, 30, or 40 
µg of coupled antibody overnight. Protein eluates were then subjected to western 
blotting. 40 µg of antibody was sufficient to pull out the majority of myc-VapA from 
1.5 mg of HeLa cell lysate. Therefore, further experiments were performed 
overnight using a ratio of 1.5 mg of lysate to 40 µg of covalently coupled antibody. 
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Fig. 5.14. Optimisation of myc-tagged VapA Immunoprecipitation. A. 10 µg of α-myc 
antibody was covalently coupled to sepharose and incubated with the indicated amounts 
of lysates of myc-VapA expressing HeLa cells. After 2 h, the sepharose was washed and 
bound proteins eluted. Equal volumes of the input and lysate after the IP were loaded. 
Lysates and eluted proteins were then probed by western blotting (W.B.) with α-myc 
antibodies. B. 1.5 mg of myc-VapA expressing HeLa cell lysate was incubated with α-myc 
sepharose for 1 h or overnight at 4 ºC. The input, lysate after IP and eluates were probed 
with α-myc antibodies C. 1.5 mg of myc-VapA expressing HeLa cell lysate was incubated 
with the indicated amounts of α-myc antibody covalently coupled to sepharose, for 2 h at 
4 ºC. The input, lysate after IP and eluate were probed with α-myc antibodies. 
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Next, the IP was scaled up using the determined ratio of antibody and lysate until 
immunoprecipitated proteins were visible by silver staining on an SDS PAGE gel 
(Fig. 5.15 A & B). 1.5 mg, 3 mg, 6 mg and 12 mg of myc-VapA or control lysate 
was incubated with α-myc sepharose overnight at 4 ºC. Eluates were resolved on 
a 8-15 % SDS PAGE gel and visualised by coomassie stain. As protein bands 
were only just visible by coomassie stain, the gel was then silver stained. No clear 
band of the approximate molecular weight corresponding to over-expressed myc-
VapA (~ 25 kDa) was visible by silver staining.  
While immunoprecipitated myc-VapA was detectable by western blotting (Fig. 
5.14), it was not visible on larger scale IPs. As it was possible that the myc-VapA 
was not being efficiently eluted from the sepharose, different elution conditions 
were compared to improve the efficiency of the IP (Fig. 5.15 C). 5 different elution 
buffers were used to elute immunoprecipitated proteins from 20 µl of sepharose. 
The sepharose was then resuspended in 50 µl of SDS PAGE sample buffer and 
remaining proteins eluted by boiling at 95 ºC for 5 min. Samples were then 
resolved by SDS PAGE and subjected to western blotting using α-myc antibodies. 
In all cases, elution of protein from the sepharose was inefficient, with the majority 
remaining bound to the beads (eluates c.f. beads, Fig. 5.15 C). Heavy and light 
immunoglobulin chains were also eluted with immunoprecipitated proteins with all 
elution buffers. However, this was much less for the low pH IgG and glycine 
elution buffer compared to the others. 1 % SDS and 100 mM triethylamine were 
the most efficient at eluting immunoprecipitated proteins, but also had the highest 
amounts of heavy and light Ig chains. 3.5 M MgCl2 did not elute any protein from 
the sepharose. As none of the elution buffers were significantly better at eluting 
the protein from the sepharose, low pH IgG buffer continued to be used. In all 
cases, the amount of myc-VapA that was immunoprecipitated was very low 
(arrowheads) and myc-VapA was not detected in the input sample by western 
blotting. Therefore the expression of myc-VapA was optimised to improve the 
efficiency of the IP. 
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Fig. 5.15. Scaling up of myc-VapA IP. A. Increasing concentrations of HeLa (Con) or 
myc-VapA expressing HeLa (VapA) cell lysates were incubated with α-myc Sepharose 
(40 µg of α-myc antibody per 1.5 mg of lysate) overnight at 4ºC. Sepharose was 
extensively washed and bound proteins eluted with 300 µl of low pH IgG elution buffer. 
Eluates were neutralised with 1 M Tris (pH 8.0) and were resolved on an 8-15 % SDS 
PAGE gel. Proteins were visualised by silver staining. B. As in A, but with 12 mg of lysate. 
C. Comparison of efficiencies of different elution buffers. 20 µg of α-myc antibody 
covalently coupled to sepharose was incubated with 0.75 mg of myc-VapA HeLa lysate 
overnight at 4 ºC. Immunoprecipitated proteins were eluted from the sepharose by the 
addition of a pre elution buffer (10 mM phosphate, pH 8.0), followed by 50 µl of elution 
buffer (1- low pH IgG elution buffer, 2 – Glycine, pH 2.5, 3 - 100 mM Triethylamine, pH 
11.5, 4 - 1 % (w/v) SDS, 5 - 3.5 M MgCl2, pH 7.0). The sepharose beads were then boiled 
in 50 µl of Laemmli sample buffer at 95 ºC for 5 min. The equal volumes of before and 
after samples, eluates and proteins liberated from the beads were western blotting for 
myc. Arrowheads indicate immunoprecipitated myc-VapA. W.B.-western blot. 
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To improve IP efficiency, low passage (P2) and high passage (P10) myc-VapA 
expressing HeLa cells were compared for over-expression of myc-VapA. (Fig. 5.16 
A). Cells were induced to express myc-VapA with 1 µg of doxycycline for 16 h and 
protein lysates subjected to western blotting for myc. Lower passage cells 
expressed more myc-VapA than higher passage cells, indicating that protein 
expression was being lost as the passage number of the cells increased. This was 
puzzling, as the Flp In system should result in the selection of an isogenic cell line 
and protein expression should be consistent. It is possible that expression of myc-
VapA was detrimental to the cells, or reduced their growth rate, resulting in 
selection of cells which expressed lower amounts of myc-VapA. This was unlikely, 
as expression of myc-VapA did not appear to result in a phenotype and ii) 
exogenous protein express was inducible and not constitutive. One possibility is 
that trace amounts of tetracycline (a doxycycline analogue) found in fetal calf 
serum could induce low levels of protein expression, that may have resulted in the 
selection of low-expressing clones. Nethertheless, lower passage clones were 
used for further experiments. Previous IP experiments had shown that elution of 
proteins from α-myc sepharose was inefficient. As such, the number of elutions 
was increased to determine if this resulted in improved protein elution (Fig. 5.16 
B). A small-scale IP experiment was performed using 1 mg of lysate. After the first 
elution, 5 further elutions (of equal volume) were performed. Western blotting of 
these eluates revealed that not all of the myc-VapA had been eluted from the 
sepharose. Therefore, the volume of elution buffer used in further IPs was 
increased from 5 x the sepharose volume to approximately 10 x. The amount of 
doxycycline used to induce the cells and the length of induction, was also 
investigated (Fig. 5.16 C). Cells were induced for 16 h, 24 h and 48 h, with 0.1 
µg/ml, 1.0 µg/ml, or 10 µg/ml doxycycline. Expression of myc-VapA was strongest 
at 16 h when cells were induced with 1.0 µg/ml doxycycline, whereas expression 
of myc-VapA was poorest when cells were induced with 10 µg/ml. The levels of 
myc-VapA also appeared to slightly decrease from 16 h to 48 h. For further 
experiments, protein over-expression was performed for no longer than 16 h. 
These optimisations were incorporated into the IP protocol and a large scale IP 
was performed with 40 mg of protein lysate (Fig. 5.16 D). Despite the 
improvements in protocol efficiency, no obvious band corresponding to 
immunoprecipitated myc-VapA was identifiable. The IP was then repeated a final 
time, using lysate that had been precleared with control resin before the IP (Fig. 
5.16 E). 
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Fig. 5.16. Large scale myc-VapA co-IP.A. Expression levels of low and high passage 
myc-VapA expressing HeLa cells.20 µg of protein per lane B. Small scale myc-VapA co-
IP. Immunoprecipitated proteins were eluted with 50 µl of low pH IgG elution buffer. 5 
further elutions (50 µl each) were collected and eluates subjected to western blotting 
using α-myc antibodies.  C. HeLa cells were induced to over express myc-VapA with 0.1, 
1.0 or 10 µg/ml doxycycline for 16 h, 24 h, or 48 h. 20 µg of protein per lane D & E. Large 
scale myc-VapA co-IP. 40 mg of HeLa or myc-VapA HeLa lysate was incubated with α-
myc sepharose overnight at 4 ºC. Immunoprecipitated proteins were concentrated using 
Slide-A-Lyzer cassettes (3.5 kDa cut-off) and then resolved on a 8-15 % SDS PAGE gel 
and visualised by silver staining. Arrowhead indicates immunoprecipitated myc-VapA.  
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Despite preclearing the lysate by incubating it with control resin for 2 h, the 
background was particularly high. A band of approximately 22 kDa was present in 
the myc-VapA sample, which may have been immunoprecipitated VapA 
(arrowhead). However, the efficiency of the IP was still particularly poor. Moreover, 
there were no obvious bands present in the myc-VapA sample compared to the 
control. The background was also particularly high, with many protein bands 
stained in both samples. Therefore, an alternative methodology was used to try 
and identify the interacting partner of VapA. 
5.3.8 BirA*-VapA biotin-ligase pull down 
Due to the problems encounter with the IP, an alternate methodology to identify 
the mammalian target(s) of VapA was used. A recent publication by Roux et al. 
(Roux et al., 2012), described proximity-dependent biotin-labelling of proteins 
(BioID). This system utilises a promiscuous prokaryotic biotin ligase (BirA*) that is 
fused to a protein of interest. The chimera is then expressed in mammalian cells 
where the BirA* biotinylates proteins in its immediate vicinity when the tissue 
culture media is supplemented with biotin. Biotinylated proteins can then be 
isolated from a cell lysate using streptavidin beads and proteins identified by mass 
spectrometry. A BirA*-VapA expressing HeLa cell line was generated to identify 
VapA interactors using this approach (Fig. 5.17 A). Firstly, protein expression was 
induced in HeLa cells expressing myc-BirA*-VapA for 16 h and the subcellular 
localisation of the protein examined (Fig. 5.17 B). Myc staining revealed that myc-
BirA*-VapA was expressed throughout the cell cytoplasm and was not associated 
with any one organelle. No staining was visible in uninduced control cells. Next, a 
pulldown experiment was performed. Protein expression was induced in myc-
BirA*-VapA cells with doxycycline for 24 h, in tissue culture media supplemented 
with 50 µM biotin. A control BirA* expressing parental HeLa cell line was used as a 
control Cells were subsequently lysed and the lysate incubated overnight with 600 
µl of magnetic streptavidin beads (Dynabeads MyOne Streptavidin C1, Thermo, 
catalogue # 65001). The beads were subjected to several washes and biotinylated 
proteins eluted by boiling the beads at 95 ºC for 5 min in SDS PAGE sample buffer 
saturated with biotin. 10 % of the eluted proteins were then analysed by western 
blotting, using a streptavidin-HRP conjugate (Fig. 5.17 C). Western blotting 
revealed single obvious band at ~40 kDa, which was most likely self-biotinylated 
myc-BirA*. Correspondingly, a larger band running at >50 kDa was seen in the 
BirA*-VapA sample. Additional biotinylated proteins were seen in the BirA*-VapA 
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sample, but not in the BirA* control, suggesting that BirA* does not biotinylate non-
specific proteins. 
 
Fig. 5.17. Proximity-dependent promiscuous biotinylation by BirA*-VapA. A. 
Schematic of representation of proximity dependent biotinylation.1. BirA*-VapA fusion 
protein is expressed inducibly in HeLa cells. 2. Expression of BirA* VapA is induced for 24 
h. Tissue culture media is supplemented with biotin and VapA interacting and proximal 
proteins become biotinylated. Non-proximal proteins that do not interact with VapA do not 
become biotinylated. 3. After cell lysis and protein denaturation, biotinylated proteins are 
captured on streptavidin beads. Biotinylated proteins are then eluted from the beads and 
identified by mass spectrometry. B. Confocal analysis of myc-BirA-VapA expression. 
Protein over-expression was induced in HeLa cells expressing BirA*-VapA for 16 h. Cells 
were then fixed with 4 % formaldehyde in PBS and cells labelled with α-myc antibodies 
followed by fluorescently labelled secondary antibodies (Alexa fluor 555; red). Cell nuclei 
were stained with DAPI (blue). Scale bar 20 µm. Image is a maximum-intensity z-
projection C. Protein over-expression was induced in HeLa cells expressing BirA*-VapA or 
BirA* (control) for 24 h in the presence of excess biotin. Cells were lysed and biotinylated 
proteins recovered on streptavidin beads. The beads were boiled in SDS PAGE sample 
buffer saturated with biotin for 5 min at 95 ºC. 5 % of the total eluate was analysed by 
western blotting using a streptavidin-HRP conjugate (1:40,000).  
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 Biotinylated proteins were analysed by 1D LC-MS. Proteins unique to the BirA*-
VapA pull-down were classed as possible VapA-interactors (Table 5.0, full list 
appendix 1.1).  The mass spectrometry data did reveal many proteins unique to 
the VapA sample. Three of these proteins were highlighted due to their roles in 
membrane trafficking and lysosome function. These included Annexin A1, found 
on endosomal membranes (Seemann et al., 1996), Exocyst component 6B, 
involved in vesicle exocytosis (Heider and Munson, 2012) and Cathepsin D, a 
lysosomal protease (Benes et al., 2008). 
  
 
Table 5.0. BirA*-VapA interacting proteins. A proximity-dependent biotin ligation 
experiment was performed in HeLa cells expressing myc-BirA*-VapA to identify proteins 
that interacted with VapA, as described in section 5.2.3. Biotinylated proteins were 
analysed by 1D LC-MS. Hits unique to myc-BirA*-VapA were classed as potential VapA-
interacting proteins. 
 
 
 
 
 
 
Protein Identity Mascot Score 
Spectra 
matches 
Maximum 
Peptide 
Sequences 
Molar 
% 
 Annexin A 1 51 3 3 0.38 
Exocyst complex component 6B  17 1 1 0.04 
Cathepsin D  15 1 1 0.10 
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5.3.9 Production of recombinant BirA*-His6 and VapA- BirA*-His6 
While the BirA*-VapA pulldown identified some possible VapA-interacting proteins, 
a caveat to this experiment was that VapA exerts its effects upon late endocytic 
and lysosomal compartments from within those vesicles. As such, VapA would 
most likely interact with proteins on the lumenal side of these compartments. 
BirA*-VapA was expressed in the cell cytoplasm and so would not have access to 
any potential interacting proteins on the lumenal side of the lysosome membrane. 
Therefore, similar to the VapA feeding experiments, a BirA*-VapA fusion protein 
would need to be introduced to the lysosome lumen by fluid phase endocytosis. To 
this end, C-terminal His6-tagged BirA* and BirA*-VapA recombinant proteins were 
produced to feed to cells.  
BirA*-His was purified to use as a control for BioID experiments. Small scale test 
expression of BirA*-His was assessed by western blotting (Fig. 5.18 A). There was 
a clear induction of the expression of a < 37 kDa protein  upon addition of IPTG 
(predicted molecular weight of BirA*-His 36 kDa). Similar to VapA-BirA* 
expression, his-tagged protein was detected in the insoluble fraction, as well as in 
soluble eluates (1-3). The western blot also revealed that not all of the his-tagged 
protein was removed after incubation with the affinity resin. The yield of BirA*-his 
was also very low, with around 60 µg obtained from a 1 L culture. When the 
purification was repeated and the volume of nickel affinity resin used was 
increased to 1 ml, the yield was greatly improved (Fig. 5.18 B). Analysis of 
samples before and after incubation with the resin indicated that there was a large 
amount of protein that was not pulled out of the lysate. Despite this, a < 37 kDa 
band was detected in eluted fractions (arrowhead). However, some degradation 
was also visible. Fractions 1-4 were pooled and dialysed into PBS. The protein 
concentration was 1.68 mg/ml. 
Expression of VapA-BirA*-His was analysed by small scale test expression of two 
bacterial clones (Fig. 5.18 C). A small level of basal level of expression was 
detected. However, there was a large induction of protein expression upon 
addition of IPTG. His-tagged protein was detected in both the insoluble and 
soluble fractions. Degradation products were also detected in the soluble fraction. 
BirA*-VapA was then purified from a 1 L culture (arrowhead, Fig. 5.18 D). A 
bacterial supernatant was generated and incubated with nickel affinity resin 
overnight at 4 ºC. Equal volumes of the supernatant were taken before and after 
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for SDS PAGE analysis, as were 4 µl samples of each eluted fraction. A ~50 kDa 
protein was detected in almost all of the 12 eluted fractions analysed (estimated 
molecular weight of VapA-BirA*-His, 53 kDa). Fractions 1-5 were pooled and 
dialysed into PBS. The protein concentration of the purified VapA-BirA* was 
determined to be 1.3 mg/ml. 
To ensure VapA remained functional with the addition of BirA* to its C-terminus, 
NRK cells were incubated with BirA*-VapA at 100 µg/ml for 24 h and then fixed 
with 4% formaldehyde in PBS. Lysosome morphology was then assessed by 
confocal microscopy (Fig. 5.18 E). Lysosomes were found to be swollen in NRK 
cells incubated with BirA*-VapA, indicating that the BirA* protein did not interfere 
with the ability of VapA to disrupt lysosomal morphology.  
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Fig. 5.18. Purification of BirA*-His6 and VapA-BirA*-His6. A. Small scale test 
expression of BirA*-His. Uninduced (-IPTG), induced (+ITPG), insoluble (In.) soluble (sol.) 
and 3 eluted fractions were probed with α-His antibodies. B. Large scale purification of 
BirA*-His. A Bacterial supernatant from a 1l culture was incubated with Ni affinity resin 
overnight at 4 ºC. The resin was washed thoroughly and 1 ml fractions eluted. 20 µl 
samples were taken before and after incubation with the resin. 4 µl of each eluted fraction 
was analysed by SDS PAGE. Arrowhead indicates ~35 kDa BirA*-His C. Western blot 
analysis of VapA-BirA*-his expression. Two clones expressing VapA-BirA* were analysed 
for protein expression. Fractions were probed with α-His antibodies. D. Large scale 
expression of VapA-BirA*-His. The bacterial supernatant from a 1l culture was incubated 
with Ni affinity resin overnight at 4 ºC. The resin was washed thoroughly and 1 ml 
fractions eluted. 20 µl samples were taken before and after incubation with the resin. 4 µl 
of each eluted fraction was analysed by SDS PAGE. Arrowhead indicates ~ 50 kDa VapA-
BirA*-His E. NRK cells were incubated with recombinant BirA*-VapA at 100 µg/ml for 24 h 
and then fixed in 4 % formaldehyde in PBS. Cells were labelled with α-Lgp110 antibodies 
followed by fluorescently labelled secondary antibodies (Alexa fluor 488; green). Cell 
nuclei were stained with DAPI (blue). Image is a maximum-intensity z-projection. Scale 
bar 20 µm. 
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5.3.10 Affinity capture of biotinylated proteins using recombinant 
VapA-BirA*-His6  
As expression of BirA*-VapA in HeLa cells was on the cytoplasmic side of the 
lysosome membrane and VapA was hypothesised to function when in the lumen of 
the lysosome, BirA*-His and VapA-BirA*-His were made recombinantly to feed to 
NRK cells. Cells were pulsed with these proteins at 100 µg/m for a 16 h chase, 
followed by a 4 hour protein-free incubation to chase BirA* and VapA-BirA*-His to 
the lysosome. The cells were then cultured in the presence of biotin, to allow 
biotinylation of VapA-interacting proteins. Detergent-soluble lysates were then 
made and incubated with streptavidin beads to capture biotylated proteins. After a 
stringent washing protocol, biotinylated proteins were eluted from the beads by 
boiling at 95 ºC with Laemmli sample buffer saturated with biotin. 90 % of the 
sample was analysed by 1D liquid chromatography – mass spectrometry (LC-MS) 
and 10 % was subjected to western blotting using a streptavidin-HRP conjugate 
(Fig. 5.19). Equal volumes of the input lysates before and after incubation with the 
beads were also blotted to analyse the efficiency of the pulldown. No biotinylated 
proteins could be detected in either of these samples for both BirA* and BirA*-
VapA. A strong band was detected at ~ 37 kDA in BirA*-His eluate and similarly, a 
~ 50 kDA in VapA-BirA*-His eluate. These were probably biotinylated BirA* and 
BirA*-VapA, which become-self biotinylated. In both samples, a few protein bands 
were detected just under each of these strong bands. Proteins of  < 25 kDa and  > 
25 kDa were also seen in BirA* and VapA-BirA* eluates respectively, which may 
be degradation products of the recombinant proteins. However, there were no 
obvious differences between samples detected by western blotting. 
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Fig. 5.19. Western blot analysis of VapA-BirA biotin ligase-pulldown. NRK 
cells were pulsed with recombinant BirA*-His or VapA-BirA*-His at 100 µg/ml for 
16 h. The cells were rinsed once with PBS and the media replaced with DMEM for 
a further 4 h chase period. The cells were then cultured for a further 24 h in DMEM 
supplemented with biotin to a final concentration of 50 µM. The cells were rinsed 
with PBS and detergent-soluble lysates generated. Lysates were normalised to 
protein and incubated overnight at 4 ºC with 600 µl of streptavidin beads to 
capture biotinylated proteins. The beads were washed thoroughly and biotinylated 
proteins eluted by boiling in Laemmli sample buffer saturated in biotin. 10 % of the 
sample was retained for western blotting (W.B.) with a streptavidin-HRP 
conjugate. Equal volumes of the lysates before and after incubation with the beads 
were loaded. Arrowheads indicate 37 kDa BirA*-His and 50 kDa VapA-BirA*-His. 
Biotinylated proteins were identified by 1D LC-MS. Proteins unique to the VapA-
BirA* pulldown were deemed to be possible-VapA interactors. The pulldown 
experiment yielded more possible VapA interacting proteins than the previous 
methodology, but as before, the confidence in these hits was not high due to the 
low number of matched peptides. Regardless, several of these hits were 
associated with membrane trafficking and endocytosis. These included positively 
charged multivesicluar body protein 4B-like protein 1 (CHMP4BP1), AP-5, AP-4, 
Rab10, Rab21 and VPS35 (Table 5.1). The full list of identified proteins is shown 
in appendix 1.2. 
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Table 5.1. VapA-BirA* interacting proteins A proximity-dependent biotin ligation 
experiment was performed in HeLa cells fed recombinant VapA-BirA*-His to identify 
proteins that interacted with VapA, as described in section 5.2.4. Biotinylated proteins 
were analysed by 1D LC-MS. Hits unique to VapA-BirA*-His were classed as potential 
VapA-interacting proteins. 
 
 
 
 
 
 
 
 
 
Protein Identity Mascot Score 
Spectra 
matches 
Maximum 
Peptide 
Sequences 
Molar 
% 
  
Charged multivesicular body protein 
4B-like protein CHMP4BP1 56 1 1 0.09 
AP-5 complex subunit zeta-1  53 3 1 0.04 
Ras-related protein Rab-10  32 1 1 0.08 
Ras-related protein Rab-21  28 1 1 0.07 
AP-4 complex subunit epsilon-1 17 1 1 0.01 
Vacuolar protein sorting-associated 
protein 35 16 1 1 0.02 
Rho guanine nucleotide exchange 
factor 12  14 1 1 0.01 
Dynein heavy chain 17 14 1 1 0.01 
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5.4 Discussion 
5.4.1 Characterisation of VapA-induced lysosomal swelling 
The effect of VapA on lysosomes could be observed as early as 2 h and the 
number of larger lysosomal puncta steadily increased over a 24 h period. At 24 h, 
the majority of the lysosomes seen in NRK cells were enlarged. It was not clear if 
this phenotype was unique to lysosomes, or whether other endocytic organelles 
were affected. It was found that early endosomes were not effected by VapA, but a 
small proportion of cells had an altered EEA1 distribution, with staining 
concentrating around the perinuclear region. Occasionally, larger EEA1 puncta 
were seen, but not to the extent or size of affected lysosomes. This may indicate 
an indirect effect on early endosomal trafficking events, as a result of disrupted 
lysosome function. In some lysosomal storage disorders, the accumulation of 
macromolecules can result in off-target inhibition of other lysosomal enzymes 
(Walkley and Vanier, 2009). This can result in a disruption of not just lysosome, 
but the endolysosomal system as a whole. Similarly, if VapA disrupts lysosomal 
function, then other components of the endocytic system may be affected. 
ciM6PR+ late endosomes also swelled up when cells were incubated with VapA. 
To ascertain whether endolysosomes were also effected, cells were co-stained for 
ciM6PR and LAMP1. It was found that lysosomal, late endocytic and 
ciM6PR+/LAMP1+ endolysosomes also swelled up. This suggested that VapA 
effects late endocytic compartments. One explanation for this result is that VapA 
may not accumulate in early endosomes to the same extent as in late 
endosome/lysosomes. This may be difficult to test, as delaying the maturation of 
early endosomes (EEs) to examine whether VapA disrupts EE morphology, is 
itself likely to result in the swelling of EEs. One key difference between early 
endosomes and late endosomes/lysosomes, is the decrease in pH between these 
compartments. As VapA only appeared to affect late endocytic organelles, it is 
possible that VapA is only active at a pH lower than that of early endosomes. 
Given that VapA has no obvious ligand binding sites and its barrel does not seem 
to form a pore, it is not inconceivable that a pH-induced conformational change is 
needed for VapA activity. This could be tested using inhibitors such as Bafilomycin 
A1 or chloroquine, which increase lysosomal pH and might abolish the activity of 
VapA. Alternatively, VapA may be interacting with protein(s) such as LAMPs, that 
present in both late endosomes and lysosomes, but not present in early 
endosomes.  
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From 0 h – 48 h, lysosomes continued to aggregate and swell, forming very large 
structures. Interestingly, at 72 h, these appeared to collapse and the cell 
cytoplasm was filled with many smaller puncta, similar to 8 h time points seen 
previously. This may be due to collapse of the large lysosomes into multiple 
smaller vesicles. This could also be due to upregulation of lysosomal biogenesis 
as a result in the dysfunction of the lysosomes. Western blotting of LAMP1 levels 
of VapA fed cells supported this idea, as LAMP1 was shown to increase over time 
in both NRK and J774.2 cells. Cells incubated with VapD or VapG showed no 
increase in LAMP levels. The localisation of the transcription factor TFEB, could 
be monitored by confocal microscopy to investigate whether VapA-induced 
lysosome swelling causes translocation of TFEB from the cytosol to the nucleus. It 
was observed that J774.2 cells were particularly susceptible to VapA, which killed 
cells some when between 24 h and 48 h. NRK cells may be more resilient, or 
VapA may affect macrophages more strongly than other cell types. 
The swelling of lysosomes induced by VapA may be indicative of lysosomal 
dysfunction. In some lysosomal storage disorders, (such as Fabry disease 
(Masson et al., 2004) non-functional enzymes fail to metabolise substrate 
macromolecules, resulting in their accumulation within the lysosome. Alternatively, 
lysosomes may become swollen due to decrease in lysosomal fission/reformation, 
such as in Chediak- Higashi syndrome (Durchfort et al., 2012) or Niemann-Pick 
disease (Platt et al., 2012). It is not clear however, if the lysosomal swelling seen 
in VapA treated cells is due to an accumulation of non-degraded macro molecules, 
or is due to an actual disruption to lysosomal fission/fusion. The Magic Red data 
indicates that lysosomal pH is unaffected by VapA. Some intracellular pathogens 
also disrupt membrane trafficking, giving rise to a phenotype reminiscent of an 
LSD.  Coxiella burnetii, the causative agent of Q fever, resides in a large, 
cholesterol-rich swollen vacuole (Howe and Heinzen, 2006). Similarly, 
Mycobacterium tuberculosis promotes a “foamy macrophage” phenotype, in which 
Infected macrophages accumulate lipid droplets that the bacterium uses as 
nutrient source (Singh et al., 2012). 
5.4.2 VapA is the only Vap capable of inducing lysosomal swelling 
The large degree of homology in the Vaps in both sequence and structure, 
suggested that other Vap proteins may be able to induce the same effects as 
VapA. When both VapD and VapG were incubated with NRK cells, no changes to 
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lysosome morphology were seen and lysosomal staining was indistinguishable 
from that of control cells. It may have been possible that the other Vap proteins act 
synergistically, or some how modified or regulated the activity of VapA. However, 
when incubated in combination, VapD and VapG had no effect on lysosomes. 
Additionally, lysosomal swelling was still observed when VapD or VapG were 
incubated along with VapA, indicating that they do not inhibit the activity of VapA 
(data not shown). It is therefore unclear what the function of these additional Vaps 
is, considering that the expression of these proteins is induced during intracellular 
growth (Ren and Prescott, 2003), or conditions encountered in the macrophage 
phagosome, such as low pH (Benoit et al., 2001) or an increase in temperature 
(Byrne et al., 2001).  
5.4.3 The activity of VapA is confined to its C-terminal core 
While it was clear that VapA exerted an effect on lysosomes, it was not known 
what regions of VapA were responsible for this activity. The Vap proteins share 
significant homology in their C-terminal core structure, with variability in the N-
terminal regions. Given that VapA had previously been identified as the only Vap 
essential for virulence, it was hypothesised that the activity of VapA may lie in this 
N-terminal peptide. Surprisingly, it was found that the core of VapA alone was 
sufficient to induce lysosomal swelling.  This was confirmed by the fact that a 
VapA N-terminus/ VapD core chimeric protein had no effect on lysosome 
morphology. These data strongly suggest that the activity of VapA can be 
attributed to the core barrel structure.  
It is striking that only the core of VapA is able to cause swelling of lysosomes, 
given the large degree of homology between the Vap proteins.  However, this may 
not be so surprising, given that the N-terminal region of the Vap proteins is 
predicted to be natively unstructured and as such may have no function in 
virulence (Whittingham et al., 2014). The novel structure of the core of VapD has 
similarities to other β-barrel proteins, including OmpX from E.coli (Vogt and 
Schulz, 1999) and PliC from S. typhimurium (Leysen et al., 2011). OmpX is an 
outer membrane-spanning barrel, that has a high unusual protruding “flag waving” 
β-sheet formed by loops 2 and 3 of the barrel. This may be important in virulence 
by facilitating attachment and invasion of host cells and by acting as a binding 
partner for host complement proteins. The Vap structure does not have this 
feature, nor does it have any obvious ligand binding sites or grooves. The barrel of 
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OmpX is highly unlikely to form a pore. Similarly, the core Vap structure is a closed 
barrel, which has no obvious passage for small molecules. Unlike OmpX,  some of 
the Vap proteins are secreted (namely VapG and VapD). VapA is thought to be be 
cell surface anchored (Takai et al., 2000) but it remains to be seen whether VapA 
interacts with the lysosome while it is bound to the bacterial surface, but the 
immunofluorescence data suggested that this is the case. The interaction of VapD 
with octyl-β-d-glucoside (used in its crystallisation solution) suggests it may 
transiently interact with the cell wall mycolic acids (Whittingham et al., 2014). This 
may also be true for VapA. It is particularly interesting that in infected 
macrophages, VapA was found to colocalise not only with lysosomes but also 
bacteria. However, this does not rule out the possibility that VapA may be released 
from the bacterial cell surface. 
Given that the N-terminus of the Vap proteins is not required to swell lysosomes 
and its activity lies within the core barrel structure, any differences in the core 
between VapA and the other Vaps may hint at which regions are important. One 
such region lies between the 2nd and 3rd β-sheet (see Fig. 5.0 & 5.2). The 
generation of chimeric Vap-fusion proteins would be a useful tool in understanding 
which regions of the protein are essential for virulence. For example, this region of 
VapA could be used to replace the same region in VapD and vice versa. This 
might reveal whether the key activity is conferred by a particular part of the protein. 
Alternatively, individual residues could be mutated to unravel those that are 
necessary for the function of the protein. However, it should be noted that given 
the structural similarity between the Vaps and the striking difference in their 
function, it cannot be concluded that the remaining untested Vaps do no not have 
any role in virulence. 
5.4.4 VapA-affected compartments are still acidic 
Upon discovering VapA was able to induce the swelling of lysosomes, it was 
hypothesised that (like in an LSD) the lysosomes were non-functional. It was 
possible that the Vaps may render host endosome/lysosome-associated enzymes 
inactive. To test this, VapA-fed cells were incubated with the fluorescent cathepsin 
B substrate, Magic Red (MR). Unexpectedly, VapA-fed cells had large, swollen, 
MR positive vesicles. The half-life of cathepsin B is particularly long, meaning any 
VapA effects would take some time to manifest. However, NRK cells still had 
Magic Red puncta after 72 h of incubation with VapA (data not shown), suggesting 
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this was unlikely. Two things can be inferred from this result. Firstly, VapA does 
not inhibit the activity of cathepsins and secondly, the swelling phenotype does not 
(at 24h) affect the pH of these compartments. Moreover, it was observed that in 
control cells, MR and LAMP1-GFP did not completely colocalise, demonstrating a 
distinction between MR positive endolysosomes and lysosomes (MR negative). 
Interestingly, in VapA-fed cells, few MR puncta were found that did not colocalise 
with LAMP1-GFP. It is tempting to speculate that the reformation of lysosomes 
from MR positive endolysosomes had been perturbed, although this remains to be 
tested or quantified. An alternate hypothesis may be that these VapA affected 
lysosomes are non-fusogenic and therefore unable to deliver their bactericidal 
enzymes to the R. equi containing vacuole. The question then remains, how VapA 
is able to spread from affected organelles to other lysosomes, to prevent them 
from fusing with the RCV? 
5.4.5 Infection of cells with R. equi  
R. equi has previously been reported to arrest phagosome maturation at an early 
phagosome/endosome stage RCVs of both virulent and avirulent strains were 
found to acquire LAMP1. Phagosomes of virulent strains did not acquire the 
vATPase, nor did they acidify to the same extent as plasmid-cured bacteria 
(Fernandez-Mora et al., 2005). The acidification of RCVs in this study was not 
investigated. In agreement with this data, both plasmid-cured and virulent R. equi 
were surrounded by LAMP1 staining. Some plasmid-positive bacteria were not 
associated with LAMP1. VapA colocalised with both bacteria and LAMP1 staining, 
which is not unexpected given that it may remain associated with the cell surface 
and disrupts lysosome morphology. Purified RCVs (virulent and avirulent) were 
found to be devoid of Cathepsin B and had low levels β-galactosidase activity, 
suggesting that RCVs do not acquire these enzymes (Fernandez-Mora et al., 
2005). Although compartments affected by VapA retain their acidity and have 
active cathepsin B, it is not known if this is the case in an in vivo infection. Thus 
data presented here, in part, supports previous observations. 
5.4.6 Induction of lysosome biogenesis in cells treated with VapA 
The biogenesis of lysosomes is highly regulated and under the control of the TFEB 
transcription factor (Sardiello et al., 2009). Expression levels of lysosomal genes 
are upregulated in a response to accumulation of substrates in lysosomes in both 
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sucrose-induced vacuolation models (Karageorgos et al., 1997, Helip-Wooley and 
Thoene, 2004) and fibroblasts derived from LSD patients (Song et al., 2013). To 
determine whether VapA-induced swelling of lysosomes resulted in their 
dysfunction, levels of a common lysosomal protein, LAMP1, were analysed by 
western blotting. In both NRK and J774.2 cells, it was found that LAMP1 levels 
increased over the course of the experiment. Moreover, when the levels of the 
lysosomal enzyme β-hexosaminidase in NRK cell lysates were measured, it was 
found that the level of enzyme activity increased over the time course, although 
not significantly. In J774.2 cells, the levels remained constant, which is most likely 
explained by the fact that the cells begin to die after 24h incubation with VapA. In 
addition, where cells were not adhered to the tissue culture dishes, the cells were 
pelleted and resuspended in cell lysis buffer. The loss of lysosomal and plasma 
membrane integrity in J774.2 cells would result in the leaking of lysosomal 
enzymes into the cell culture media, which was discarded when the cells were 
pelleted, thus underestimating the amount of β-hexosaminidase at later time 
points. 
Levels of LAMP1 and other lysosomal enzymes have also been observed to 
increase during intracellular infection of macrophages with Salmonella. In infected 
cells, levels of LAMP1 and acid phosphatase were elevated compared to 
uninfected cells. This increase could have been a cellular response to target more 
lysosomes to Salmonella-containing vacuoles (Eswarappa et al., 2010). 
Interestingly, LAMP1 is also the target of bacterial enzymes. The type 2 IgA1 
protease produced by species of Neisseria actively cleaves LAMP1 to promote 
intracellular survival (Lin et al., 1997). It is unclear if lysosome biogenesis is 
upregulated in response to a loss of lysosomal integrity in these studies. Other 
components of the endocytic pathway have also shown to be upregulated in 
response to pathogen manipulation of intracellular compartments. The LYST 
(Lysosomal trafficking regulator protein) gene is and is upregulated during 
infection of bone marrow derived macrophages by Leishmania amazonensis to 
limit the expansion of the parasitophorous vacuole (Wilson et al., 2008). LYST is 
mutated in Chediak-Higashi syndrome (CHS) (Barbosa et al., 1996). One hallmark 
of this disease is enlarged lysosomes and lysosome-related organelles. LYST has 
has previously been shown to regulate lysosome size (Holland et al., 2014), but 
although lysosomes are enlarged in CHS cells, they remain acidic and trafficking, 
autophagy and endocytosis is not affected in these cells. Parallels can be drawn to 
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lysosomes of cells treated with VapA, which also remain acidic despite being 
swollen. It could be speculated therefore, that similar to many LSDs, lysosomes of 
VapA treated cells have disrupted fission/fusion.  
Taken together, these data indicate that VapA –induced swelling of lysosomes 
may lead to increased lysosome biogenesis as a response to lysosomal 
dysfunction. However, the Magic Red experiments showed that VapA-swollen 
lysosomes were still acidic and contained active proteases. Therefore, this 
dysfunction may be separate to the degradative function of the lysosome. This is 
further supported by the observation that LAMP1 and Magic Red signals 
overlapped in VapA treated cells, but remained largely separate in control cells. 
This hints at the possibility that VapA swollen lysosomes may be endolysosomal 
compartments from which lysosomes are unable to reform. In this manner, R. equi 
may be able to deplete the available pool of lysosomes that can fuse with the 
RCV.  
5.4.7 Identifying the mammalian target of VapA 
Identification of the target of VapA is critical in understanding how it effects 
eukaryotic cells and contributes to the intracellular survival of R. equi. There are 
two main approaches that could have been used. Firstly, yeast two-hybrid (Y2H) 
systems use transcription factor domains to drive reporter gene expression as a 
measure of protein interactions. The second approach is utilisation of pull-downs 
or co-immunoprecipitation, whereby a protein of interest is expressed with an 
epitope tag and interacting proteins are identified by mass spectrometry. Each of 
these techniques has its own particular advantages and drawbacks. Y2H systems 
rely upon the correct folding of both “bait” and “prey” proteins when they are 
expressed as a fusion protein with a transcription factor domain. This assumes 
that the proteins are still able to interact when expressed as a hybrid protein, 
without their usual chaperones and post-translational modifications and often 
outside of their normal cellular localisation. This may result in false-positive 
interactions between proteins that would never normally be expressed in the same 
location, e.g DNA binding proteins being expressed in the cytoplasm. This is 
particular problematic for integral membrane proteins (although split-ubiquitin Y2H 
systems can be used in this case). An advantage of the Y2H approach is that as it 
is based on a cDNA library screen, it can identify interactions between proteins 
that are of particularly low abundance, or that have a weak or transient interaction. 
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The immunoprecipitation approach has been used extensively to identify protein-
protein interactions. One limitation to this approach is the availability of a protein of 
interest. In some instances, it may not be practical to express or purify enough 
starting material to be able to detect an interacting protein. This becomes 
extremely difficult if the interactions are weak or transient. Secondly, this approach 
is only viable if the protein of interest remains soluble under the conditions used to 
generate a cell lysate. Moreover, it depends upon protein-protein interactions still 
taking place under these conditions. 
5.4.8 VapA immunoprecipitation 
To understand how VapA disrupts lysosomes, immunoprecipitation experiments 
were performed to try and identify the mammalian target of VapA. The IP protocol 
was heavily optimised to increase the chance of finding any low abundance 
proteins, or weak interactions. Firstly, the optimal ratio of α-myc antibody and 
protein lysate needed to immunoprecipitate detectable amounts of myc-VapA was 
determined. It was found that 10 µg of antibody was saturated when incubated 
with 1.5 mg of myc-VapA lysate. However, the IP was still inefficient, as the 
majority of the myc-VapA remained in the lysate. This was improved when lysates 
were incubated with the antibody overnight compared to 1 h. The amount of 
antibody necessary to remove > 90 % of myc-VapA from 1.5 mg of lysate was 
found to be 40 µg. With these optimisations, the IP was scaled up using 1.5, 3, 6 
and 12 mg of lysate. These amounts were visible on SDS PAGE gels by 
coomassie staining. However, no band corresponding to immunoprecipitated myc-
VapA was visible. Gels were then silver stained, but no protein of the expected 
molecular weight was identified. This may have been due to inefficient elution of 
proteins from the α-myc sepharose. To address this, a small scale IP was carried 
out with several elution conditions. 1 % SDS and 100 mM Triethylamine were 
found to be the most effective at eluting proteins from the sepharose. However, 
these buffers were also the two that resulted in the elution of large amounts of 
heavy and light IgG chains from the sepharose. Eluates using low pH IgG and 
glycine elutions buffers were relatively free of IgG chains. 3.5 M MgCl2 salt elution 
buffer did not elute any proteins or IgG chains. In all cases, a large amount of 
protein remained bound to the sepharose. The inefficiency of elution of proteins 
from the sepharose was confirmed when additional elutions were found to still 
contain myc-VapA. Therefore, the volume of elution buffer used was doubled for 
remaining experiments. The amount of myc-VapA that was immunoprecipitated 
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was low in these optimisation experiments. The loss of protein expression most 
likely contributed to this problem, but it was not clear why this happened as the 
expressing of myc-VapA was inducible and not constitutive. Low passage cells 
were subsequently used for the large scale IPs to try and increase the amount of 
expressed protein. Protein expression was also optimised by changing the levels 
of doxycycline and time of expression. Despite these changes, two IPs using 40 
mg of lysate did not immunoprecipitate sufficient amounts of myc-VapA to detect 
any interacting proteins. 
There are several possible reasons why the immunoprecipitation experiments did 
not work effectively. Firstly, it was clear that some myc-VapA could be 
immunoprecipitated, but the IP was inefficient. While it was detectable by western 
blot, insufficient protein may have been immunoprecipitated for detection by silver 
staining. This would have been further complicated by the inconsistent expression 
of exogenous protein seen in the myc-VapA cell line. Secondly, the myc-tag was 
on the N-terminus of VapA. Any cleavage of the N-terminus from the main core of 
the VapA protein would have resulted in immunoprecipitation of the non-functional 
N-terminus, leaving behind the C-terminal core. It is possible that 
immunoprecipitated myc-VapA remained bound to the α-myc sepharose and was 
not efficiently eluted. Thirdly, the myc-VapA was expressed in the cytoplasm of 
HeLa cells, but it was demonstrated that VapA needed to be on the lumenal side 
vesicle membranes to have any function. This suggested its target is in the 
lysosome lumen, which would not have been accessible until a cell lysate was 
generated. This also relied upon the interaction between VapA and its partner 
being stable in the lysis conditions. Finally, it is possible that VapA interacts with a 
lipid specific to late endosomes/lysosomes (such as lysobisphosphatidic acid, 
LBPA). If this is the case, other approaches are needed to identify what VapA 
interacts with. These could include vesicle cosedimentation/cofloatation assays, to 
asses the affinity and specificity of lipid binding, diphenylhexatriene (DPH) 
anisotropy, to measure membrane fluidics up protein binding and fluorometric 
based assays, using fluorescent probes such as boron-dipyrromethene (BODIPY), 
to measure fluorescence quenching when proteins bind to lipid layers (Zhao and 
Lappalainen, 2012).   
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5.4.9 Proximity-dependent biotin identification - BioID 
Due to the technical difficulty of identifying the binding partner of VapA through a 
traditional immunoprecipitation approach, an alternative method was used that 
circumvented these issues. BioID utilises a prokaryotic biotin-ligase, BirA, to attach 
biotin molecules to primary amines, in a proximity dependent manner. This 
approach has been used to successfully identify proteins that are interacting 
partners, or in close proximity to Lamin-A, an intermediate filament of the nuclear 
lamina (Roux et al., 2012).  
The immunoprecipitation of VapA most likely proved difficult due to low expression 
of myc-tagged VapA, but may have also been due to the disruption of protein-
protein interactions under the denaturing conditions used to generate a cell lysate. 
A key advantage of BioID in this respect, is that biotinylation of interacting proteins 
occurs before the generation of a cell lysate. Therefore, weak or transient 
interactions can be detected and protein-protein interactions do to not need to 
remain intact for biotinylated proteins to be immunoprecipitated and identified. The 
abundance of biotinylated material does not indicate the strength of an interaction, 
more the abundance of primary amines within an identified protein. Therefore, this 
approach should be used a screen to identify candidate proteins, which should be 
validated using other biochemical analyses.  
This method was dependent upon the ability of VapA to function properly when 
expressed as a chimera with BirA*. The addition of BirA* did not effect the 
localisation of VapA in HeLa cells. However, as discussed previously, the 
expression of BirA*-VapA in the cytoplasm was most likely not optimal given that 
VapA has no effect unless on the lumenal side of endocytic membranes. This was 
confirmed when VapA-BirA* was expressed as a his-tagged protein and fed to 
cells, as these cells showed the same swelling phenotype as cells incubated with 
VapA-his. Furthermore, producing VapA-BirA* in E.coli, rather than expressing it  
in vivo meant that low expression of VapA was not an issue and ensured that 
VapA reached the lumen of the lysosome/late endosome, where it carries out its 
function. 
Despite the limitations of expressing BirA-VapA* in the cytoplasm, some proteins 
unique to BirA*-VapA included Annexin 1a, Exocyst complex component 6b 
(Sec15/EXOC6) and cathepsin D (Table 5.0). Annexin 1a is a calcium-dependent 
292 
phospholipid binding protein that is found on the plasma membrane and early 
endosomes (Rescher et al., 2000) and has also been found on phagosomal 
membranes (Diakonova et al., 1997). It is also thought to be important in M. 
tuberculosis infections, as mice deficient in Annexin 1 were more susceptible to 
infections and were less able to mount a T-Cell response to the bacteria (Tzelepis 
et al., 2015). Overall, relatively little is known about the precise functions of 
annexins in the endocytic pathway. 
The exocyst is a multisubunit tethering complex made up of 8 subunits (Sec3, 
Sec5, Sec6, Sec8, Sec10, Sec15, Exo70 and Exo84), that is involved in 
exocytosis of secretory vesicles at the plasma membrane (Yu et al., 2011). As 
such, it is localised to the inner leaflet of the plasma membrane. The exocyst 
complex also mediates many of the membrane trafficking functions of the GTPase 
Rab11, such as the trafficking of the Toll-Like receptor TLR4 to phagosomes and 
the exocytosis of pore-forming toxins from the cell surface (Guichard et al., 2014). 
Sec15 interacts with Rab11 and may be important for endosomal recycling (Zhang 
et al., 2004). Some pathogens hijack Rab11/exocyst function to promote 
intracellular survival. A component of the Salmonella type three secretion system, 
SipC, interacts with the exocyst subunit Exo70, to recruit the exocyst complex to 
the plasma membrane and promote invasion of the host cell (Nichols and 
Casanova, 2010).  
Cathepsin D is a aspartic endopeptidase that is synthesised as a preprocathepsin 
D (Benes et al., 2008). After the removal of a signal peptide, procathepsin D is 
then targeted to lysosomes (Hasilik and Neufeld, 1980). Cathepsin D is a 
glycoprotein, that is glycosylated by the addition of mannose-6-phosphate 
residues at asparagine 70 and 199, which is essential for its correct targeting to 
the lysosome (Fortenberry et al., 1995). Genetic deficiency of cathepsin D in mice 
is not lethal, but results in abnormalities in later life (Saftig et al., 1995, Koike et al., 
2000). In humans, cathepsin D deficiency is associated with lysosomal 
accumulation of lipofusin, resulting in neuronal ceriod lipofusinosis (Siintola et al., 
2006, Steinfeld et al., 2006). Cathepsin D is also important for macrophage 
apoptosis in the mouse lung, to help clear Streptococcus pneumoniae infections 
(Bewley et al., 2011). Cathepsins L and B are inhibited by a cysteine-protease 
inhibitor expressed on the surface of Plesiomonas shigellodies, a possible 
mechanism of bacterial protection against host defences (Pavlova et al., 2006).  
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Whether VapA interacts with these proteins has yet to be validated. It is interesting 
that these proteins are involved in different aspects of the endocytic pathway and 
are found on endosomes and in the case of cathepsin D, in the lumen of the 
lysosome. However, from the immunofluorescence data it appears that expressed 
myc-VapA does not colocalise with the plasma membrane in HeLa cells. Thus, its 
possible association with Annexin 1a and Exo6B is not supported by this. 
Secondly, it is hard to see how myc-VapA would associate with cathepsin D when 
expressed in the cell cytoplasm, suggesting this is not likely to be a real 
interaction. This is idea is also supported by the fact that VapA-BirA* was not 
found to interact with cathepsin D.  
The experiment was repeated with recombinant VapA-BirA* to target VapA to the 
lysosome lumen. This identified several biotinylated proteins unique to the VapA 
sample, some of which are involved in membrane trafficking. Charged 
multivesicluar body protein pseudogene 1 (CHMP4BP1), was classed as a 
possible VapA interactor. CHMP4BP1 has > 95 % sequence similarity to 
CHMP4B. CHMP4B is part of the endosomal sorting complexes required for 
protein transport (ESCRT) machinery. In particular, CHMP4B (Snf7) forms the 
core of the ESCRT III complex, along with CHMP6 (Vps20), CHMP2 (Vps2) and 
CHMP3 (Vps24). These four subunits are joined by three accessory proteins, 
CHMP1 (Did2), CHMP5 (Vps60) and Ist1 (Schmidt and Teis, 2012). Unlike the 
other ESCRT complexes (0, I and II), which form stable cytoplasmic complexes, 
ESCRT III polymerises from cytoplasmic monomers and transiently associates 
with endosomes (Henne et al., 2011), where it is required for the sorting of cell 
surface receptors into intraluminal vesicles for degradation (Babst et al., 2002). 
CHMP4B is the most important component of the ESCRT III machinery (Wollert et 
al., 2009). It is present in the highest concentrations in the cytoplasm and the other 
subunits of the complex act to polymerise CHMP4 (Teis et al., 2008). However, 
little is known about CHMP4BP1, with regards to its localisation, expression, or its 
function.  
Adapter proteins (AP) are heterotetramic protein complexes that facilitate the 
sorting of membrane proteins in the endocytic and exocytic pathways (Nakatsu 
and Ohno, 2003). APs are essential for clathrin-coated vesicle formation, as they 
act as a bridge between clathrin coats and lipid membranes (Young, 2007). 
Currently, 5 different adaptor protein complexes are known to exist. While the 
roles of AP-1, AP-2 and AP-3 are known, the role of AP-4 and AP-5 in protein 
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sorting are poorly understood (Hirst et al., 2013). AP-1 and AP-2 knockouts are 
lethal, (Zizioli et al., 1999, Mitsunari et al., 2005), whereas mutations in AP-3 
causes Hermansky-Pudlack syndrome (Dell'Angelica et al., 1999). Mutations in 
AP-4 and AP-5 cause human neurological disorders (Abou Jamra et al., 2011, 
Slabicki et al., 2010). Unlike the other adaptor complexes, AP-4 and AP-5 do not 
appear to interact with clathrin. AP-4 may function as an exporter of specific 
proteins from the Trans Golgi network (TGN), but the function of AP-5 is not 
known (Hirst et al., 2013). 
Rab10 has a role in protein trafficking to the plasma membrane and associates 
with the exocyst complex (Babbey et al., 2010). Rab10 also regulates the 
translocation of GLUT4 storage vesicles to the adipocyte plasma membrane (Sano 
et al., 2007) and is involved in the regulation of ER dynamics (English and Voeltz, 
2013). Rab10 has also been found in phagosome proteomic studies (Rogers and 
Foster, 2007, Garin et al., 2001). Rab10 has been shown to be required for 
recycling of proteins from the phagosome back to the plasma membrane and over 
expression of Rab10 accelerates the maturation of M. tuberculosis containing 
phagosomes (Cardoso et al., 2010). 
Rab21 regulates endosomal traffic (Pellinen et al., 2006, Simpson et al., 2004) as 
well as the formation of macropinosomes (Egami and Araki, 2009). In 
Dictyostelium, Rab21 regulates phagocytosis, along with two novel LIM domain 
proteins, LimF and ChLim (Khurana et al., 2005). Rab21 has been found in 
proteomic studies of M.bovis Bacille Calmette-Guérin (BCG) phagosomes (Lee et 
al., 2010). The Legionella effector protein Lpg0393 has recently been shown to be 
a guanine-nucleotide exchange factor (GEF) for Rabs 5, 21 and 22, raising the 
possibility that modulating the activity of these GTPases promotes bacterial 
intracellular survival (Sohn et al., 2015). 
VPS35 (vacuolar protein sorting associated-protein 35), is a key component of 
retromer, a complex of proteins required retrograde transport of hydrolase 
receptors from endosomes to the Golgi (Seaman, 2012). Retromer is a pentameric 
subunit complex, consisting of a sorting nexin (SNX) dimer, which binds to 
phosphatidylinositol 3-phosphate (PI(3)P) and a cargo recognition complex 
heterotrimer, consisting of Vps26, Vps35 and Vps29 (Bonifacino and Hurley, 
2008). Cells lacking Vps26 fail to retrieve ciM6PR from late endosomes, resulting 
in its degradation or mislocalisation to the plasma membrane (Seaman, 2004) and 
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a mutation in VPS35 causes a rare form of Parkinson’s disease (Zavodszky et al., 
2014) with a similar phenotype seen in a VPS35 knockdown in Drosophila (Miura 
et al., 2014). Thus, retromer function is crucial to normal cell function. Proper 
retromer function is also important in bacterial pathogenesis, as siRNA knockdown 
of the Vps26-Vps35-Vps29 complex prevented intracellular replication of Coxiella 
(McDonough et al., 2013), suggesting this pathway is important for bacterial 
replication. 
In contrast to cytoplasmic expression of BirA*-VapA, VapA-BirA*-His was on the 
correct side of the lysosome lumen. It is therefore unclear how VapA could interact 
with these proteins considering they function in the cytoplasm. One possibility is 
that VapA may have caused lysosome lysis, upon which VapA would then have 
access to the cytoplasm. The hazy LAMP1 staining sometimes seen in 
immunofluorescence of VapA-fed cells may support this idea. These data should 
also be viewed with caution considering that for many of them, only single 
peptides were found. Nethertheless, it is interesting that components of membrane 
trafficking complexes were identified using this approach. 
A potential caveat to the feeding of VapA-BirA* to cells, is that it is not known 
whether VapA-affected compartments remain fusogenic. If they do, the biotin 
taken up by fluid phase endocytosis should reach lysosomes that contain VapA-
BirA*-His and biotinylation should occur. If these lysosomes are not fusogenic, 
then it is not clear how biotin would gain access to the lysosome lumen, as there 
was a 4 h chase period before biotin was added to the tissue culture media. Future 
experiments should aim to determine if these swollen lysosomes can still accept 
material from the endocytic pathway, which would also confirm the practicality of 
this methodology. Should they be repeated, producing BirA*-His and VapA-BirA*-
His to a higher quality would be advantageous. This would also allow the 
optimisation of the protocol. For example, both proteins were used at 100 µg/ml, 
but it was not known how much of this was actually taken up by cells and whether 
it was sufficient to biotinylate enough target protein for detection by LC-MS. BirA*  
combines biotin with ATP to form biotinoyl-5’ AMP (bioAMP), which reacts with 
primary amines of interacting proteins, resulting in their biotinylation. The bioAMP 
molecule is thought to only diffuse 20-30 nm from the BirA* enzyme before 
reacting with a protein (Roux et al., 2012). Thus, the active radius of VapA-BirA* is 
unknown and is likely to limit the volume of the lysosome that could potentially be 
biotinylated. If VapA-BirA* inserts into lysosomal membranes, (which may be a 
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possibility given that the immunofluorescence data showed VapA colocalising with 
LAMP1), then BirA* can only biotinylate proteins within 20-30 nm of the limiting 
membrane. However, this may not be a problem given that VapA-BirA* can still 
cause swelling of lysosomes, indicating that if it is interacting with a protein, it is 
able to do so while fused to BirA*. Thus, the limitation of this approach is likely to 
be the volume of material required to identify proteins, which can easily be 
optimised and scaled up accordingly. 
5.4.10 Conclusions 
The data presented here demonstrates that recombinant VapA induces swelling of 
late endosomes and lysosomes, but not early endosomes. This activity is 
dependent upon delivery of VapA to the lysosome lumen and is not seen when 
VapA is expressed in the cell cytoplasm. The ability of VapA to induce swelling is 
conferred wholly by the C-terminal core of the VapA protein and the N-terminus of 
VapA is dispensable for this activity. Other Vap proteins (VapD and VapG), that 
have a similar structure, are not able to induce lysosomal disruption. Lysosome 
biogenesis may have been upregulated in response to lysosomal disruption by 
VapA, as levels of LAMP1 increased in VapA-fed J774.2 and NRK cells. The 
swollen-lysosome phenotype was also seen in J774.2 cells infected with virulent 
R. equi, but not avirulent strains that do not posses VapA. Both virulent and non-
virulent R. equi were shown to reside within a LAMP1 positive compartment, 
although avirulent plasmid-cured strains did not replicate. Moreover, VapA was 
found to colocalise with both bacteria and lysosomes. Thus, VapA induced 
lysosome disruption may be a mechanism used by R. equi to survive inside cells. 
Two biochemical approaches were taken to identify the binding partner of VapA, 
but these were inconclusive.   
These data give rise to some key research questions that should be addressed in 
the future. Firstly, what are the protein domains or residues responsible for the 
activity of VapA? Secondly, given the similarity in their structure and the fact that 
they are upregulated in macrophages, what are the functions of the other Vap 
proteins? Finally, what is the target of VapA and how does VapA interfere with its 
function to induce lysosomal disruption and promote bacterial survival?  
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Chapter 6: General Discussion 
The purification of subcellular organelles has been instrumental in studying their 
function and composition. Decades of research has led to the development of a 
variety of different methods to achieve this aim. These methods are not without 
their caveats, but in general relatively pure fractions of most organelles can be 
isolated. The purification of lysosomes can be tricky. Isolating them on 
centrifugation gradients is not trivial and lysosomal fractions will be contaminated 
with organelles of the same density unless specific centrifugation media is used or 
the density of the lysosome is altered. Endocytic vesicles present themselves 
nicely for purification using endocytosed substrates which only label vesicles that 
have taken up the substrate used to aid in their purification. Such techniques have 
been developed extensively and are becoming the method of choice for purifying 
endocytic vesicles (Walker and Lloyd-Evans, 2015). The purification of 
phagosomes presents similar challenges but is often simpler. Most phagosome 
purification protocols involve the use of latex beads or other synthetic particles that 
are chosen as their properties allow easier purification. For example, latex beads 
will float to the top of a sucrose gradient and magnetic bead phagosomes can 
easily be removed from a cell lysate using a strong magnet. The isolation of 
phagosomes has been used extensively in proteomic analysis of phagosome 
maturation (Desjardins and Griffiths, 2003, Garin et al., 2001, Buschow et al., 
2012, Guo et al., 2015).  
The development of in vitro assays to study vesicle fusion have been influential in 
unravelling the molecular basis behind the fusion of membranes. Such techniques 
require the development of protocols to purify both acceptor and donor 
compartments and have a method of reporting membrane fusion. They must also 
include appropriate controls to ensure that the results seen are due to bona fide 
membrane fusion and not the mixing of membrane fragments or damaged 
organelles. The endocytic pathway is a key part of our innate immunity and is 
critical for the destruction of phagocytosed microbes. Given that phagosome-
lysosome fusion is so important, it is surprising that only one current in vitro assay 
of phagosome-lysosome fusion has been published (Becken et al., 2010). 
 298 
Intracellular pathogens manipulate membrane trafficking events in the endocytic 
pathway to prevent their delivery to the lysosome. One such pathogen, 
Rhodococcus equi, arrests phagosome maturation at an early endosomal-like 
stage. The mechanisms behind this are unclear, but are likely to involve the key 
virulence associated proteins (Vaps) produced by R. equi. This thesis describes 
the optimisation of techniques for the purification of lysosomes and phagosomes 
for use in an in vitro phagosome-lysosome fusion assay. Secondly, it details the 
characterisation of Vap-induced lysosome dysfunction and builds upon our 
understanding of the survival mechanisms of Rhodococcus.   
6.1 Purification of lysosomes 
The purification of lysosomes from J774.2 mouse macrophages using 
superparamagnetic iron oxide nanoparticles (SPIONS) was an established method 
in the laboratory and was based upon a previously established method 
(Rodriguez-Paris et al., 1993). This method was chosen as it was quicker and 
simpler than purifying lysosomes by isopycnic centrifugation and could be 
performed on smaller numbers of cells. However, this method had not been 
optimised to purify lysosomes for use in a phagosome-lysosome in vitro fusion 
assay. To purify lysosomes for such a use, a protocol was needed that had two 
main requirements; i) that purified lysosomes were intact and largely free from 
contamination of other organelles and ii) that the lysosomes contained a marker 
that could be used to detect the fusion of lysosomes and phagosomes. Therefore, 
optimisations were performed to achieve these aims. 
Initial experiments began with the comparison of two methods to break open cells 
and release lysosomes. These were ball-bearing homogenisation and nitrogen 
cavitation. It was found that these methods yielded similar results with regards to 
the latency and recovery of lysosomes. Both of these methods have previously 
been used to release lysosomes from cells (Graves et al., 2008, Ward et al., 
1997). It was decided to continue using nitrogen cavitation as the method of 
choice as it could more easily accommodate larger sample volumes and changes 
in the protocol than the use of the ball-bearing homogeniser. Further experiments 
were performed to optimise lysosome purification. These included varying cell 
number, the pressure used to disrupt cells, and the use of different 
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homogenisation buffers. In general, these variables did not significantly influence 
the intactness or recovery of purified lysosomes. When the time of the SPION 
pulse and chase periods was altered it was found that these had a large influence 
on lysosome latency and recovery suggesting that these were the most important 
variables when using this method. Biochemical analysis of purified lysosome 
fractions showed that they were enriched with LAMP-1 and Rab5 and Rab7, but 
had lesser amounts of EEA1. This is in agreement with previous analysis of 
purified lysosomes (Becken et al., 2010). Overall, it is difficult to know what 
variables may influence lysosome purification as published protocols do not give 
details on the development of the method, only the final outcome. Despite this, 
lysosomes were purified from cells with a latency of ~80 % latency and ~7 % 
recovery. 
6.2 Purification of phagosomes 
Phagosomes were purified from J774.2 cells using magnetic streptavidin beads. 
This method was chosen as it was rapid and avoided the use of density 
centrifugation. After lysate generation, streptavidin-bead phagosomes were 
isolated on a magnet and washed (approximately 10-15 min). In contrast, the 
centrifugation steps used in latex bead phagosome purification alone can take 
between 1 and 4 hours (Gotthardt et al., 2006, Desjardins et al., 1994). 
The uptake of beads was shown to be dependent upon the number of beads per 
cell used (multiplicity of infection; MOI). At a low MOI centrifuging beads onto cells 
helped to promote uptake but at a higher MOI centrifugation did not increase 
uptake. This suggests that promoting cell and bead contact is important when 
using low numbers of particles but not at higher particle:cell ratios. It is possible 
that higher ratios of particle uptake may influence the maturation of phagosomes. 
Although the phagosome isolation protocol aimed to synchronise bead uptake, it is 
likely that this can only go so far to try and yield phagosomes of the same 
composition. Within individual cells the composition of phagosomes will differ 
(Griffiths, 2004). When using a low number of particles, it is likely that a cell could 
take up several particles at once. With a high number of particles, a cell may need 
to divert extra membrane to the cell surface which could result in a delay in particle 
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internalisation. The end result would be a more heterogeneous population of 
organelles compared to lower ratios. 
Initial optimisation experiments suggested that nitrogen cavitation was not suitable 
to release phagosomes from cells as the majority of phagosomes were not intact 
when using this method. One possibility of this is that as the pressure within the 
nitrogen bomb was increased the phagosome membrane would have been forced 
tightly against the streptavidin bead. Any rough edges on the beads could have 
created weakness in the phagosomal membranes causes them to rupture. Ball-
bearing homogenisation was investigated and found to be a suitable method for 
releasing phagosomes from cells. This may have been because the release of 
phagosomes from cells involved mechanical disruption rather than gas expansion 
and the pressures involved would have been much lower. 
When phagosomes were analysed by western blotting markers of the early and 
late endocytic pathway could be seen. Phagosomes were generally enriched with 
LAMP1 and levels of LAMP1 increased the longer the phagosomes were given to 
mature. EEA1 was also found on phagosomes, as well as Rab5, Rab7 and α-
tubulin. This was not surprising given the fact that phagosomes are heterogeneous 
(Griffiths, 2004). Other studies have also found these proteins on isolated 
phagosomes (Garin et al., 2001, Becken et al., 2010) and it is not surprising given 
their roles in phagosome maturation (Vieira et al., 2002). Similarly, it was seen that 
levels of the lysosomal enzyme β-hexosaminidase increased as phagosomes 
were allowed to mature for increasing lengths of time, suggesting some were 
reaching lysosomes. This is also in agreement with previous data (Becken et al., 
2010). The final outcome was the purification of phagosomes that were 
approximately 75 % intact. The overall recovery of phagosomes was not 
determined. This study builds upon previous methods and presents an alternative 
and rapid method of isolating phagosomes from cells that can be optimised to 
produce phagosomes of different ages. 
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6.3 Fusion assay 
One aim of the thesis was to establish an in vitro phagosome-lysosome fusion 
assay. To this end, two protocols were successfully developed to purify both 
phagosomes and lysosomes from cells that were intact and biochemically 
characterised. To analyse phagosome-lysosome fusion it was necessary to 
analyse the transfer of a marker between the two compartments. This assay 
aimed to analyse the transfer of biotin-HRP from purified lysosomes to streptavidin 
bead-phagosomes. The assessment of transfer of biotin-HRP was performed 
using a highly sensitive substrate, Amplex Red. Control experiments showed that 
biotin-HRP fed to cells and isolated from lysosomes were still able to bind to 
streptavidin-phagosomes isolated from cells. Only around 30 % of the biotin-HRP 
from lysosomes was able to bind to beads suggesting that some was degraded. 
Moreover, the biotin-HRP binding capacity of phagosomes was often lower than 
that of a similar number of beads that had not passed through cells suggesting 
some degradation of the surface streptavidin. Despite this, the amount of biotin-
HRP that could be detected yielded a strong fluorescent signal when assayed 
using Amplex Red. 
Fusion of lysosomes and phagosomes was then attempted in vitro. Unfortunately, 
no fusion signal could be seen. The reasons for this were unclear, as biotin-HRP 
from lysosomes was able to give a fluorescent signal when incubated with Amplex 
Red, and likewise, phagosomes were able to bind biotin-HRP. One possibility was 
that the pig brain cytosol used to support vesicle fusion contained endogenous 
biotin and other factors which may have interfered with vesicle fusion when using 
biotin-HRP as a marker of fusion. Despite these challenges, the purification of 
phagosomes and lysosomes was successful and this thesis presents the 
framework on which to determine the conditions needed to see a fusion signal. 
It was demonstrated that biotin-HRP binding to beads that had been incubated in 
pig brain cytosol was reduced (Fig. 3.36). The next experiment that it would be 
important to perform would be an in vitro mixing assay between HRP-lysosomes 
and streptavidin-phagosomes in the presence of pig brain cytosol. These 
components could be mixed and vesicle membranes lysed with detergents to 
allow mixing of contents. Although this was in essence the control for the in vitro 
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fusion assay (conditions 5&6 Fig 3.35) it was performed at 4 ºC for 15 min which 
may not have been long enough to see transfer of biotin-HRP to streptavidin 
beads. Thus, performing this experiment at room temperature or overnight at 4 ºC 
may demonstrate if pig brain cytosol was responsible for a lack of a fusion signal. 
For the final fusion assay beads were opsonised with IgG before use. As 
previously discussed, this was done in an attempt to increase bead uptake and get 
a working fusion assay. This would undoubtedly change the kinetics of 
phagosome maturation. Thus, it would also be important to characterise the 
composition of these phagosomes. 
6.4 PEPSY screen 
The mechanisms by which Rhodococcus equi manipulates host cell membrane 
trafficking are not clear, but it is suggested that the R. equi phagosome is arrested 
at an early endosomal stage (Fernandez-Mora et al., 2005). The bacterial effector 
proteins that facilitate this are not known. To identify putative virulence factors, the 
R. equi genome was screened for proteins that disrupted membrane traffic in 
yeast. This was performed using pathogen effector screening in yeast (PEPSY), a 
previously established methodology in which a bacterial gene library is expressed 
in yeast and yeast are then screened for a VPS phenotype (Shohdy et al., 2005). 
This thesis is the first example of the generation of an R. equi gene library and 
expression of R. equi genes in yeast. Unfortunately, the screen failed to determine 
any virulence factors that altered membrane trafficking in yeast. This may have 
been due to a lack of similarity between the human targets of R. equi effector 
proteins and their yeast orthologues. Alternatively, R. equi effector proteins may 
have needed to be on the vacuolar side of the yeast lumen to see an effect on 
membrane trafficking. To test these hypotheses (and to take a targeted approach 
to investigating R. equi virulence) the essential R. equi virulence factor, VapA, was 
expressed in the yeast cytoplasm and also targeted to the yeast vacuole. When 
expressed in the yeast cytoplasm and targeted to the vacuole, VapA did not 
produce an observable membrane trafficking defect as no secretion of CPY was 
seen. However, VapA has been determined to be an essential virulence factor for 
R. equi intracellular survival (Jain et al., 2003). So, for completion, VapA was 
expressed in the cytoplasm of mammalian cells. VapA had no effect on membrane 
trafficking when expressed in the mammalian cell cytoplasm. Strikingly, when 
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VapA was recombinantly produced and introduced to the mammalian lysosome 
lumen (via fluid-phase endocytosis), it resulted in the swelling of lysosomes. This 
effect was then further characterised. 
 6.5 The role of VapA in the intracellular survival of Rhodococcus equi 
Recombinantly produced VapA caused swelling of lysosomes. This effect was 
time and dose dependent and was abrogated when VapA was heat denatured 
before feeding to cells. VapA selectively affected late endocytic (ciM6PR+) and 
lysosomal (LAMP1+) compartments and may have had an indirect effect on early 
endosomal compartments (but this was not clear). Given the similarity between the 
C-terminal core structure of the Vap proteins of R. equi, it was hypothesised that 
VapD and VapG may also induce lysosomal dysfunction but they had no 
observable effect. As the variability in the protein sequence of the Vaps is in their 
N-terminal regions, it was thought that this may be responsible for the activity of 
VapA. Experiments involving chimeric proteins of the VapD N terminus and VapA 
core or the core of VapA alone showed that the core of VapA is sufficient to cause 
lysosomal swelling and that the N-terminal region is not important. Moreover, the 
N-terminal regions of the other Vaps were not inhibitory to any potential activity 
that they possessed, as the addition of VapD N-terminal region to the VapA core 
did not prevent lysosomal swelling. As the swelling of the lysosomes by VapA was 
indicative of lysosomal dysfunction it hypothesised that VapA-affected 
compartments may have had reduced proteolytic activity or a disrupted pH. Using 
the fluorescent cathepsin B substrate, Magic Red, it was seen that this was not the 
case and that VapA-affected compartments contained active cathepsins (and were 
by proxy determined to still be acidic).  
The swelling of lysosomes was also seen in infection of J774.2 macrophage with 
R. equi. Both plasmid cured avirulent and plasmid positive strains of R. equi were 
found to reside in a LAMP1 positive compartment in agreement with previous data 
(Fernandez-Mora et al., 2005, Toyooka et al., 2005). This compartment was also 
found to colocalise with VapA produced by the bacterium. Additionally, VapA fed 
cells showed an upregulation of LAMP1 but VapD or VapG cells did not. This was 
suggestive of lysosome dysfunction and therefore lysosome biogenesis was 
increased, but this needs to be investigated further.  
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This study demonstrates that it is important to consider the subcellular localisation 
of a bacterial virulence factor, especially if it is not clear whether the bacterial 
effector is actively translocated into the host cell cytoplasm. This methodology 
could be used along with cytoplasmic expression of bacterial proteins to more 
thoroughly investigate their function. 
To understand the mechanism behind Vap-induced lysosomal swelling it was 
necessary to identify the mammalian target of VapA. This was attempted using 
two biochemical approaches; i) immunoprecipitation and ii) proximity-dependent 
biotinylation. Small amounts of myc-tagged VapA were immunoprecipitated but 
large scale experiments were unsuccessful. This may have also been due to the 
cytoplasmic expression of VapA or a lack of enough immunoprecipitated protein. 
The second approach was more successful and some potential VapA-interacting 
proteins (of endocytic origin) were identified. However, these experiments needed 
to be repeated and the protein hits validated.  
6.6 Conclusions 
In summary, the purification protocols presented within this thesis offer an 
alternative method of lysosome and phagosome purification, which could be used 
for further studies of phagosome and lysosome function. While the aim was to 
detect fusion of these organelles in vitro this was not seen. However, these 
protocols provide a basis of future work to achieve this aim. The second aim of the 
thesis was to investigate the pathogenesis of R. equi. This thesis presents the first 
characterisation of the effect of the R. equi virulence protein, VapA, on the 
mammalian endocytic system. VapA-induced disruption of lysosome function may 
be a mechanism by which R. equi prevents its delivery to the lysosome and 
survives intracellularly. This work also builds upon our knowledge of the function of 
the Vap proteins and has identified the region of the protein that is essential for its 
function.  
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6.7 Future Perspectives 
Further studies could aim to build upon this work in several ways. Firstly, the 
protocols described in this study could be adapted for different cell types and 
purposes. For example, this protocol could be used to purify pathogen-containing 
compartments for use in proteomic studies. Secondly, a working fusion assay 
would be a powerful tool to study the requirements of phagosome-lysosome 
fusion. While it is likely that these will be similar to the requirements of late 
endosome-lysosome fusion, such studies may discover novel proteins that are 
involved in this process. Should future work be successful in establishing in vitro 
fusion, the assay could be used to study the effect of bacterial effector proteins on 
phagosome-lysosome fusion. This raises the exciting prospect of using VapA-
containing lysosomes to determine if VapA disrupts phagosome-lysosome fusion.  
This study demonstrated a key role for VapA in the pathogenesis of R. equi. 
Future studies should also aim to identify the mammalian target of VapA in order 
to elucidate its function. Key to understanding the function of VapA will be the 
generation of mutated VapA proteins to uncover key residues that are necessary 
for its activity. The lysosomal swelling assay described in this thesis could be used 
for this purpose. This study has shown that despite their similarity in structure the 
Vap proteins appear to differ in their functions. Thus, structure is not a good 
indicator as to whether or not any of the remaining Vaps can disrupt lysosome 
function. Recombinantly producing the remaining Vap proteins and testing them 
will be key to understanding their functions. 
The fact that VapA alone is not sufficient to restore virulence to plasmid-cured 
strains suggests that R. equi may have other virulence factors that are used in 
conjunction with VapA to disrupt membrane trafficking. It has recently been shown 
that the presence of the virulence plasmid alters the transcription of 18 % of 
chromosomal genes, suggesting that R. equi may have the ability to grow 
intracellularly but this requires a large overhaul of its physiology (Coulson et al., 
2015). It would be interesting to know if any of these genes themselves are 
effector proteins that disrupt membrane trafficking. The role of lipids and the 
bacterial surface chemistry in the pathogenicity of R. equi has not been heavily 
investigated, but it has been shown that the length of mycolic acid changes is 
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important in preventing delivery of R. equi to the lysosome (Sydor et al., 2013). 
Conversely, an R. equi mutant lacking a polysaccharide capsule was not 
attenuated for virulence in a macrophage cell line or mouse model (Sydor et al., 
2008). It remains to be seen if any other lipids or surface molecules produced by 
Rhodococcus are involved in virulence. Finally, it may be interesting to discover 
the basis behind host tropism between VapA and VapB expressing strains of R. 
equi and determine if any of the untested Vap proteins have a similar effect to 
VapA. 
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Appendix 1.0 
BirA*-VapA LC MS raw data. Table shows the number of peptide matches and quantified relative abundance (molar %) of identified proteins 
(calculated by dividing the number of observed peptides by the number of observable peptides). Green boxes indicate proteins unique to the 
control sample; red boxes indicate proteins unique to BirA*-VapA.  
Protein BirA* Matches 
BirA*-
VapA 
Matches 
BirA* 
Molar % 
BirA*-
VapA 
Molar % 
BirA*/BirA
*-VapA 
Ratio 
P35527-Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 82 73 4.46 2.59 1.72 
P04264-Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 70 109 5.46 4.05 1.35 
P35908-Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 69 63 3.19 2.21 1.44 
P0CW18-Serine protease 56 OS=Homo sapiens GN=PRSS56 PE=1 SV=1 27   2.18   Bir A Only 
P62829-60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 27 60 17.56 38.28 -2.18 
Q14244-Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 26 12 2.10 0.49 4.31 
P13645-Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 21 54 2.48 3.05 -1.23 
P37802-Transgelin-2 OS=Homo sapiens GN=TAGLN2 PE=1 SV=3 17   7.97   Bir A Only 
P13647-Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 15 24 1.18 1.28 -1.09 
P08779-Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 13 12 1.74 1.16 1.50 
P02538-Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 12 25 1.24 1.34 -1.08 
Q8IVT5-Kinase suppressor of Ras 1 OS=Homo sapiens GN=KSR1 PE=1 SV=2 10 3 0.56 0.13 4.23 
Q6P1L8-39S ribosomal protein L14, mitochondrial OS=Homo sapiens GN=MRPL14 PE=1 SV=1 10 11 4.31 3.71 1.16 
P04259-Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5 10 28 1.03 1.34 -1.30 
P02533-Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 9 13 1.24 1.00 1.24 
A6NCM1-Putative IQ and AAA domain-containing protein 1-like OS=Homo sapiens GN=IQCA1P1 PE=5 SV=2 8 10 0.00 0.00 2.00 
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Q9Y618-Nuclear receptor corepressor 2 OS=Homo sapiens GN=NCOR2 PE=1 SV=2 7 2 0.21 0.03 7.01 
P15924-Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 6 2 0.15 0.03 5.01 
P08729-Keratin, type II cytoskeletal 7 OS=Homo sapiens GN=KRT7 PE=1 SV=5 5 7 0.56 0.28 2.00 
Q5TFE4-5'-nucleotidase domain-containing protein 1 OS=Homo sapiens GN=NT5DC1 PE=1 SV=1 5 4 0.18 0.09 2.00 
P63173-60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 5 13 2.83 4.18 -1.48 
Q5VTE0-Putative elongation factor 1-alpha-like 3 OS=Homo sapiens GN=EEF1A1P5 PE=5 SV=1 4 2 0.80 0.19 4.16 
P60709-Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 4 1 0.71 0.10 6.87 
Q14247-Src substrate cortactin OS=Homo sapiens GN=CTTN PE=1 SV=2 4   0.47   Bir A Only 
P62633-Cellular nucleic acid-binding protein OS=Homo sapiens GN=CNBP PE=1 SV=1 4 3 0.44 0.22 2.00 
Q6KB66-Keratin, type II cytoskeletal 80 OS=Homo sapiens GN=KRT80 PE=1 SV=2 4 6 0.35 0.18 2.00 
P62263-40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 4 4 2.07 1.52 1.36 
P62899-60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 4 5 1.45 1.81 -1.25 
P04792-Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 3 1 0.86 0.21 4.15 
Q15365-Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=1 SV=2 3   0.80   Bir A Only 
A6NMY6-Putative annexin A2-like protein OS=Homo sapiens GN=ANXA2P2 PE=5 SV=2 3   0.77   Bir A Only 
P08670-Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 3 1 0.53 0.09 6.01 
Q9NQ39-Putative 40S ribosomal protein S10-like OS=Homo sapiens GN=RPS10P5 PE=5 SV=1 3 1 0.47 0.24 2.00 
Q15797-Mothers against decapentaplegic homolog 1 OS=Homo sapiens GN=SMAD1 PE=1 SV=1 3 3 0.35 0.18 2.00 
Q02413-Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 3 2 0.24 0.07 3.21 
Q7Z2W4-Zinc finger CCCH-type antiviral protein 1 OS=Homo sapiens GN=ZC3HAV1 PE=1 SV=3 3 1 0.18 0.04 4.01 
P21333-Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 3   0.09   Bir A Only 
O75122-CLIP-associating protein 2 OS=Homo sapiens GN=CLASP2 PE=1 SV=2 3 3 0.06 0.03 2.00 
P25685-DnaJ homolog subfamily B member 1 OS=Homo sapiens GN=DNAJB1 PE=1 SV=4 3 3 0.50 0.38 1.31 
P62805-Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 2 3 1.95 0.97 2.00 
O15235-28S ribosomal protein S12, mitochondrial OS=Homo sapiens GN=MRPS12 PE=1 SV=1 2 1 1.33 0.31 N/A 
Q86WX3-Active regulator of SIRT1 OS=Homo sapiens GN=RPS19BP1 PE=1 SV=1 2 1 1.33 0.31 N/A 
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Q9Y5V0-Zinc finger protein 706 OS=Homo sapiens GN=ZNF706 PE=1 SV=1 2 3 1.12 1.34 -1.19 
P62701-40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 2 5 0.65 0.52 1.26 
O60783-28S ribosomal protein S14, mitochondrial OS=Homo sapiens GN=MRPS14 PE=1 SV=1 2 1 0.62 0.31 N/A 
P04406-Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 2   0.53   N/A 
P62750-60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 2 4 0.53 0.57 -1.08 
Q14919-Dr1-associated corepressor OS=Homo sapiens GN=DRAP1 PE=1 SV=3 2 1 0.41 0.21 N/A 
Q9BY77-Polymerase delta-interacting protein 3 OS=Homo sapiens GN=POLDIP3 PE=1 SV=2 2 4 0.41 0.31 1.34 
P13646-Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 2 4 0.38 0.40 -1.04 
Q96DF8-Protein DGCR14 OS=Homo sapiens GN=DGCR14 PE=1 SV=1 2 2 0.35 0.18 N/A 
Q96HC4-PDZ and LIM domain protein 5 OS=Homo sapiens GN=PDLIM5 PE=1 SV=5 2   0.30   N/A 
Q96EK4-THAP domain-containing protein 11 OS=Homo sapiens GN=THAP11 PE=1 SV=2 2 1 0.27 0.13 N/A 
P11498-Pyruvate carboxylase, mitochondrial OS=Homo sapiens GN=PC PE=1 SV=2 2   0.15   N/A 
P27816-Microtubule-associated protein 4 OS=Homo sapiens GN=MAP4 PE=1 SV=3 2 2 0.15 0.07 N/A 
P27448-MAP/microtubule affinity-regulating kinase 3 OS=Homo sapiens GN=MARK3 PE=1 SV=4 2 3 0.12 0.10 1.15 
P49790-Nuclear pore complex protein Nup153 OS=Homo sapiens GN=NUP153 PE=1 SV=2 2 4 0.12 0.09 1.34 
Q9HCD6-Protein TANC2 OS=Homo sapiens GN=TANC2 PE=1 SV=3 2 1 0.09 0.01 N/A 
Q5SW79-Centrosomal protein of 170 kDa OS=Homo sapiens GN=CEP170 PE=1 SV=1 2 3 0.06 0.06 1.00 
Q8WWI1-LIM domain only protein 7 OS=Homo sapiens GN=LMO7 PE=1 SV=3 2 1 0.06 0.03 N/A 
Q14980-Nuclear mitotic apparatus protein 1 OS=Homo sapiens GN=NUMA1 PE=1 SV=2 2 2 0.03 0.04 N/A 
Q5VTU8-ATP synthase subunit epsilon-like protein, mitochondrial OS=Homo sapiens GN=ATP5EP2 PE=3 SV=1 1 2 1.74 2.22 N/A 
Q71UM5-40S ribosomal protein S27-like OS=Homo sapiens GN=RPS27L PE=1 SV=3 1   1.00   N/A 
Q9GZT3-SRA stem-loop-interacting RNA-binding protein, mitochondrial OS=Homo sapiens GN=SLIRP PE=1 
SV=1 1 1 0.77 0.38 N/A 
O43920-NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 OS=Homo sapiens GN=NDUFS5 PE=1 SV=3 1 1 0.74 0.37 N/A 
P62318-Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV=1 1 2 0.68 0.34 N/A 
P62851-40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 1 2 0.68 0.34 N/A 
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Q5QNW6-Histone H2B type 2-F OS=Homo sapiens GN=HIST2H2BF PE=1 SV=3 1 2 0.68 0.77 N/A 
P37108-Signal recognition particle 14 kDa protein OS=Homo sapiens GN=SRP14 PE=1 SV=2 1   0.65   N/A 
P62249-40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 1 1 0.56 0.28 N/A 
P62979-Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 1 2 0.50 0.25 N/A 
Q14011-Cold-inducible RNA-binding protein OS=Homo sapiens GN=CIRBP PE=1 SV=1 1   0.50   N/A 
P0DI83-Ras-related protein Rab-34, isoform NARR OS=Homo sapiens GN=RAB34 PE=1 SV=1 1 2 0.44 0.47 N/A 
P61081-NEDD8-conjugating enzyme Ubc12 OS=Homo sapiens GN=UBE2M PE=1 SV=1 1   0.44   N/A 
P46782-40S ribosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 1   0.41   N/A 
Q06830-Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 1 2 0.41 0.21 N/A 
P23284-Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 1   0.38   N/A 
P23396-40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 1   0.35   N/A 
Q9BS40-Latexin OS=Homo sapiens GN=LXN PE=1 SV=2 1   0.35   N/A 
Q9NSI2-Protein FAM207A OS=Homo sapiens GN=FAM207A PE=1 SV=2 1 2 0.35 0.38 N/A 
A6NLX3-Speedy protein E4 OS=Homo sapiens GN=SPDYE4 PE=2 SV=2 1   0.32   N/A 
Q99943-1-acyl-sn-glycerol-3-phosphate acyltransferase alpha OS=Homo sapiens GN=AGPAT1 PE=1 SV=2 1 1 0.30 0.15 N/A 
P05089-Arginase-1 OS=Homo sapiens GN=ARG1 PE=1 SV=2 1 1 0.27 0.13 N/A 
P09486-SPARC OS=Homo sapiens GN=SPARC PE=1 SV=1 1   0.27   N/A 
Q8NG68-Tubulin--tyrosine ligase OS=Homo sapiens GN=TTL PE=1 SV=2 1   0.21   N/A 
P31930-Cytochrome b-c1 complex subunit 1, mitochondrial OS=Homo sapiens GN=UQCRC1 PE=1 SV=3 1   0.18   N/A 
P55010-Eukaryotic translation initiation factor 5 OS=Homo sapiens GN=EIF5 PE=1 SV=2 1   0.18   N/A 
Q8ND56-Protein LSM14 homolog A OS=Homo sapiens GN=LSM14A PE=1 SV=3 1   0.18   N/A 
Q9BR76-Coronin-1B OS=Homo sapiens GN=CORO1B PE=1 SV=1 1 1 0.18 0.09 N/A 
Q9BXS6-Nucleolar and spindle-associated protein 1 OS=Homo sapiens GN=NUSAP1 PE=1 SV=1 1 1 0.18 0.09 N/A 
P10809-60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 1   0.15   N/A 
P29353-SHC-transforming protein 1 OS=Homo sapiens GN=SHC1 PE=1 SV=4 1   0.15   N/A 
Q8N1N4-Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 1 1 0.15 0.07 N/A 
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Q9HCS2-Cytochrome P450 4F12 OS=Homo sapiens GN=CYP4F12 PE=1 SV=2 1   0.15   N/A 
Q9NY93-Probable ATP-dependent RNA helicase DDX56 OS=Homo sapiens GN=DDX56 PE=1 SV=1 1   0.15   N/A 
Q9UQ13-Leucine-rich repeat protein SHOC-2 OS=Homo sapiens GN=SHOC2 PE=1 SV=2 1 1 0.15 0.07 N/A 
O00571-ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 1 1 0.12 0.06 N/A 
P08107-Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 1   0.12   N/A 
P08238-Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 1   0.12   N/A 
P14923-Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 1 1 0.12 0.06 N/A 
Q14684-Ribosomal RNA processing protein 1 homolog B OS=Homo sapiens GN=RRP1B PE=1 SV=3 1   0.12   N/A 
Q7Z353-Highly divergent homeobox OS=Homo sapiens GN=HDX PE=1 SV=1 1   0.12   N/A 
Q96N16-Janus kinase and microtubule-interacting protein 1 OS=Homo sapiens GN=JAKMIP1 PE=1 SV=1 1   0.12   N/A 
Q9NZQ3-NCK-interacting protein with SH3 domain OS=Homo sapiens GN=NCKIPSD PE=1 SV=1 1   0.12   N/A 
Q6PJF5-Inactive rhomboid protein 2 OS=Homo sapiens GN=RHBDF2 PE=1 SV=2 1   0.09   N/A 
Q7KZI7-Serine/threonine-protein kinase MARK2 OS=Homo sapiens GN=MARK2 PE=1 SV=2 1 3 0.09 0.10 -1.16 
Q8IWC1-MAP7 domain-containing protein 3 OS=Homo sapiens GN=MAP7D3 PE=1 SV=2 1 1 0.09 0.04 N/A 
Q8N163-Cell cycle and apoptosis regulator protein 2 OS=Homo sapiens GN=CCAR2 PE=1 SV=2 1 3 0.09 0.13 -1.50 
Q9H0D6-5'-3' exoribonuclease 2 OS=Homo sapiens GN=XRN2 PE=1 SV=1 1 2 0.09 0.04 N/A 
Q9NRA8-Eukaryotic translation initiation factor 4E transporter OS=Homo sapiens GN=EIF4ENIF1 PE=1 SV=2 1 1 0.09 0.04 N/A 
Q9Y2X9-Zinc finger protein 281 OS=Homo sapiens GN=ZNF281 PE=1 SV=1 1   0.09   N/A 
A2RUR9-Coiled-coil domain-containing protein 144A OS=Homo sapiens GN=CCDC144A PE=1 SV=1 1   0.06   N/A 
O75339-Cartilage intermediate layer protein 1 OS=Homo sapiens GN=CILP PE=1 SV=4 1   0.06   N/A 
Q14432-cGMP-inhibited 3',5'-cyclic phosphodiesterase A OS=Homo sapiens GN=PDE3A PE=1 SV=3 1 1 0.06 0.03 N/A 
Q7Z2Y5-Nik-related protein kinase OS=Homo sapiens GN=NRK PE=1 SV=2 1   0.06   N/A 
Q86UR5-Regulating synaptic membrane exocytosis protein 1 OS=Homo sapiens GN=RIMS1 PE=1 SV=1 1 1 0.06 0.03 N/A 
Q86UU1-Pleckstrin homology-like domain family B member 1 OS=Homo sapiens GN=PHLDB1 PE=1 SV=1 1   0.06   N/A 
Q92878-DNA repair protein RAD50 OS=Homo sapiens GN=RAD50 PE=1 SV=1 1   0.06   N/A 
Q96EV2-RNA-binding protein 33 OS=Homo sapiens GN=RBM33 PE=1 SV=3 1 1 0.06 0.03 N/A 
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Q96RT1-Protein LAP2 OS=Homo sapiens GN=ERBB2IP PE=1 SV=2 1 1 0.06 0.03 N/A 
Q9H2P0-Activity-dependent neuroprotector homeobox protein OS=Homo sapiens GN=ADNP PE=1 SV=1 1 2 0.06 0.03 N/A 
Q9HAU0-Pleckstrin homology domain-containing family A member 5 OS=Homo sapiens GN=PLEKHA5 PE=1 
SV=1 1   0.06   N/A 
Q9P2J5-Leucine--tRNA ligase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 1   0.06   N/A 
Q9UPQ0-LIM and calponin homology domains-containing protein 1 OS=Homo sapiens GN=LIMCH1 PE=1 SV=4 1   0.06   N/A 
P20930-Filaggrin OS=Homo sapiens GN=FLG PE=1 SV=3 1   0.03   N/A 
Q15652-Probable JmjC domain-containing histone demethylation protein 2C OS=Homo sapiens GN=JMJD1C 
PE=1 SV=2 1   0.03   N/A 
Q86YA3-Uncharacterized protein C4orf21 OS=Homo sapiens GN=C4orf21 PE=2 SV=3 1   0.03   N/A 
Q86YZ3-Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 1 2 0.03 0.03 N/A 
Q8IZT6-Abnormal spindle-like microcephaly-associated protein OS=Homo sapiens GN=ASPM PE=1 SV=2 1   0.03   N/A 
Q9UPY3-Endoribonuclease Dicer OS=Homo sapiens GN=DICER1 PE=1 SV=3 1   0.03   N/A 
P04083-Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2   3   0.38 
BiravepA 
Only 
P0C0S5-Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2   4   1.99 
BiravepA 
Only 
P19013-Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4   10   0.34 
BiravepA 
Only 
P42677-40S ribosomal protein S27 OS=Homo sapiens GN=RPS27 PE=1 SV=3   11   4.82 
BiravepA 
Only 
P48681-Nestin OS=Homo sapiens GN=NES PE=1 SV=2   4   0.03 
BiravepA 
Only 
O75179-Ankyrin repeat domain-containing protein 17 OS=Homo sapiens GN=ANKRD17 PE=1 SV=3   1   0.01 N/A 
O75385-Serine/threonine-protein kinase ULK1 OS=Homo sapiens GN=ULK1 PE=1 SV=2   1   0.04 N/A 
O95168-NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 OS=Homo sapiens GN=NDUFB4 PE=1 
SV=3   1   0.31 N/A 
P07339-Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1   1   0.10 N/A 
P09669-Cytochrome c oxidase subunit 6C OS=Homo sapiens GN=COX6C PE=1 SV=2   1   0.56 N/A 
P11021-78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2   1   0.06 N/A 
P29372-DNA-3-methyladenine glycosylase OS=Homo sapiens GN=MPG PE=1 SV=3   1   0.13 N/A 
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P39019-40S ribosomal protein S19 OS=Homo sapiens GN=RPS19 PE=1 SV=2   2   0.65 N/A 
P41223-Protein BUD31 homolog OS=Homo sapiens GN=BUD31 PE=1 SV=2   1   0.27 N/A 
P48634-Protein PRRC2A OS=Homo sapiens GN=PRRC2A PE=1 SV=3   1   0.01 N/A 
P50454-Serpin H1 OS=Homo sapiens GN=SERPINH1 PE=1 SV=2   1   0.10 N/A 
P55042-GTP-binding protein RAD OS=Homo sapiens GN=RRAD PE=1 SV=2   1   0.13 N/A 
P62244-40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2   1   0.31 N/A 
P62269-40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3   1   0.27 N/A 
P62280-40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3   1   0.25 N/A 
P62847-40S ribosomal protein S24 OS=Homo sapiens GN=RPS24 PE=1 SV=1   1   0.31 N/A 
P62917-60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2   2   0.34 N/A 
P82979-SAP domain-containing ribonucleoprotein OS=Homo sapiens GN=SARNP PE=1 SV=3   1   0.19 N/A 
Q12947-Forkhead box protein F2 OS=Homo sapiens GN=FOXF2 PE=1 SV=2   1   0.10 N/A 
Q13464-Rho-associated protein kinase 1 OS=Homo sapiens GN=ROCK1 PE=1 SV=1   1   0.03 N/A 
Q13573-SNW domain-containing protein 1 OS=Homo sapiens GN=SNW1 PE=1 SV=1   1   0.07 N/A 
Q14978-Nucleolar and coiled-body phosphoprotein 1 OS=Homo sapiens GN=NOLC1 PE=1 SV=2   2   0.13 N/A 
Q15032-R3H domain-containing protein 1 OS=Homo sapiens GN=R3HDM1 PE=1 SV=3   1   0.04 N/A 
Q15054-DNA polymerase delta subunit 3 OS=Homo sapiens GN=POLD3 PE=1 SV=2   1   0.09 N/A 
Q15517-Corneodesmosin OS=Homo sapiens GN=CDSN PE=1 SV=3   1   0.09 N/A 
Q16527-Cysteine and glycine-rich protein 2 OS=Homo sapiens GN=CSRP2 PE=1 SV=3   1   0.21 N/A 
Q5JPF3-Ankyrin repeat domain-containing protein 36C OS=Homo sapiens GN=ANKRD36C PE=2 SV=3   1   0.03 N/A 
Q5M775-Cytospin-B OS=Homo sapiens GN=SPECC1 PE=1 SV=1   1   0.04 N/A 
Q5VWN6-Protein FAM208B OS=Homo sapiens GN=FAM208B PE=1 SV=1   1   0.01 N/A 
Q69YL0-Uncharacterized protein DKFZp762I1415 OS=Homo sapiens PE=4 SV=1   2   0.44 N/A 
Q6MZP7-Protein lin-54 homolog OS=Homo sapiens GN=LIN54 PE=1 SV=3   1   0.06 N/A 
Q6P0Q8-Microtubule-associated serine/threonine-protein kinase 2 OS=Homo sapiens GN=MAST2 PE=1 SV=2   2   0.04 N/A 
Q6PJT7-Zinc finger CCCH domain-containing protein 14 OS=Homo sapiens GN=ZC3H14 PE=1 SV=1   1   0.06 N/A 
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Q6UUV7-CREB-regulated transcription coactivator 3 OS=Homo sapiens GN=CRTC3 PE=1 SV=2   1   0.07 N/A 
Q7RTV0-PHD finger-like domain-containing protein 5A OS=Homo sapiens GN=PHF5A PE=1 SV=1   1   0.37 N/A 
Q8IY67-Ribonucleoprotein PTB-binding 1 OS=Homo sapiens GN=RAVER1 PE=1 SV=1   1   0.07 N/A 
Q8TAE8-Growth arrest and DNA damage-inducible proteins-interacting protein 1 OS=Homo sapiens 
GN=GADD45GIP1 PE=1 SV=1   1   0.18 N/A 
Q8TEQ8-GPI ethanolamine phosphate transferase 3 OS=Homo sapiens GN=PIGO PE=1 SV=3   1   0.04 N/A 
Q96BP2-Coiled-coil-helix-coiled-coil-helix domain-containing protein 1 OS=Homo sapiens GN=CHCHD1 PE=1 
SV=1   1   0.35 N/A 
Q96DZ1-Endoplasmic reticulum lectin 1 OS=Homo sapiens GN=ERLEC1 PE=1 SV=1   1   0.09 N/A 
Q96GD4-Aurora kinase B OS=Homo sapiens GN=AURKB PE=1 SV=3   1   0.12 N/A 
Q96NU1-Sterile alpha motif domain-containing protein 11 OS=Homo sapiens GN=SAMD11 PE=2 SV=3   1   0.06 N/A 
Q96PK6-RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2   1   0.06 N/A 
Q99741-Cell division control protein 6 homolog OS=Homo sapiens GN=CDC6 PE=1 SV=1   1   0.07 N/A 
Q9BQ48-39S ribosomal protein L34, mitochondrial OS=Homo sapiens GN=MRPL34 PE=1 SV=1   1   0.47 N/A 
Q9H496-Torsin-1A-interacting protein 2, isoform IFRG15 OS=Homo sapiens GN=TOR1AIP2 PE=2 SV=1   2   0.29 N/A 
Q9NX20-39S ribosomal protein L16, mitochondrial OS=Homo sapiens GN=MRPL16 PE=1 SV=1   1   0.16 N/A 
Q9P2N5-RNA-binding protein 27 OS=Homo sapiens GN=RBM27 PE=1 SV=2   1   0.04 N/A 
Q9UBV7-Beta-1,4-galactosyltransferase 7 OS=Homo sapiens GN=B4GALT7 PE=1 SV=1   1   0.12 N/A 
Q9UBZ4-DNA-(apurinic or apyrimidinic site) lyase 2 OS=Homo sapiens GN=APEX2 PE=1 SV=1   1   0.07 N/A 
Q9ULD9-Zinc finger protein 608 OS=Homo sapiens GN=ZNF608 PE=1 SV=4   1   0.03 N/A 
Q9ULE3-DENN domain-containing protein 2A OS=Homo sapiens GN=DENND2A PE=2 SV=4   1   0.04 N/A 
Q9UNX3-60S ribosomal protein L26-like 1 OS=Homo sapiens GN=RPL26L1 PE=1 SV=1   1   0.28 N/A 
Q9Y2D4-Exocyst complex component 6B OS=Homo sapiens GN=EXOC6B PE=1 SV=3   1   0.04 N/A 
Q9Y2H8-Zinc finger protein 510 OS=Homo sapiens GN=ZNF510 PE=2 SV=1   1   0.06 N/A 
Q9Y2R2-Tyrosine-protein phosphatase non-receptor type 22 OS=Homo sapiens GN=PTPN22 PE=1 SV=2   1   0.04 N/A 
Q9Y5Q5-Atrial natriuretic peptide-converting enzyme OS=Homo sapiens GN=CORIN PE=1 SV=2   1   0.04 N/A 
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Appendix 1.1 
VapA-BirA*-His LC MS raw data Table shows the number of peptide matches and quantified relative abundance (molar %) of identified 
proteins (calculated by dividing the number of observed peptides by the number of observable peptides). Red boxes indicate proteins unique 
to the control sample; green boxes indicate proteins unique to VapA-BirA*-His. 
Protein	  
BirA* 
Matches 
VapA-
BirA* 
Matches 
BirA* 
Molar % 
VapA-
BirA* 
Molar % 
BirA*/Vap
A-BirA* 
Ratio 
Pyruvate carboxylase, mitochondrial OS=Homo sapiens GN=PC PE=1 SV=2 - P11498 84 85 11.24 11.46 1.02 
Acetyl-CoA carboxylase 1 OS=Homo sapiens GN=ACACA PE=1 SV=2 - Q13085 74 78 0.87 0.92 1.06 
Protein SON OS=Homo sapiens GN=SON PE=1 SV=4 - P18583 53 61 0.63 0.66 1.04 
Propionyl-CoA carboxylase alpha chain, mitochondrial OS=Homo sapiens GN=PCCA PE=1 SV=4 - P05165 55 55 11.33 8.85 -1.28 
Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 - P35908 46 46 5.51 5.37 -1.03 
Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 PE=1 SV=2 - Q9BVP2 35 42 4.80 5.82 1.21 
Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - P04264 39 40 5.15 4.31 -1.20 
Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 - P13645 36 36 7.71 6.79 -1.14 
Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 - P35527 25 27 3.67 3.41 -1.07 
Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 - P13647 25 19 1.76 0.95 -1.84 
Arginine and glutamate-rich protein 1 OS=Homo sapiens GN=ARGLU1 PE=1 SV=1 - Q9NWB6 20 23 3.85 5.62 1.46 
Transcription termination factor 1 OS=Homo sapiens GN=TTF1 PE=1 SV=3 - Q15361 20 22 0.49 0.52 1.07 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial OS=Homo sapiens GN=MCCC1 PE=1 SV=3 - 
Q96RQ3 20 22 0.84 0.79 -1.07 
Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 SV=3 - P48668 21 17 1.33 0.93 -1.43 
Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 - P02538 20   1.24   BirA only 
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Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 - P16401 15 18 7.88 9.18 1.16 
E3 ubiquitin-protein ligase RBBP6 OS=Homo sapiens GN=RBBP6 PE=1 SV=1 - Q7Z6E9 11 17 0.12 0.17 1.36 
Treacle protein OS=Homo sapiens GN=TCOF1 PE=1 SV=3 - Q13428 12 16 0.17 0.22 1.30 
Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 SV=2 - P10412 12 13 4.06 4.85 1.19 
60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 - Q02878 7 12 0.79 1.23 1.57 
Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 - P16403 11 12 3.67 4.43 1.21 
Round spermatid basic protein 1-like protein OS=Homo sapiens GN=RSBN1L PE=1 SV=2 - Q6PCB5 10 12 0.29 0.25 -1.14 
Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2 - Q86YZ3 11 11 0.11 0.09 -1.21 
Keratin, type II cytoskeletal 79 OS=Homo sapiens GN=KRT79 PE=1 SV=2 - Q5XKE5 11 9 0.48 0.32 -1.48 
Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6 - Q00839 3 10 0.06 0.21 3.43 
Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4 - P02533 9 10 0.55 0.61 1.11 
Ribosomal RNA processing protein 1 homolog B OS=Homo sapiens GN=RRP1B PE=1 SV=3 - Q14684 10 9 0.27 0.21 -1.29 
Chromodomain-helicase-DNA-binding protein 4 OS=Homo sapiens GN=CHD4 PE=1 SV=2 - Q14839 10 8 0.09 0.07 -1.42 
Multiple myeloma tumor-associated protein 2 OS=Homo sapiens GN=MMTAG2 PE=1 SV=1 - Q9BU76 10 8 1.25 0.80 -1.55 
Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 SV=3 - P67809 10 5 0.81 0.28 -2.84 
Cell growth-regulating nucleolar protein OS=Homo sapiens GN=LYAR PE=1 SV=2 - Q9NX58 9 8 0.60 0.46 -1.31 
Keratin, type II cytoskeletal 1b OS=Homo sapiens GN=KRT77 PE=2 SV=3 - Q7Z794 6 8 0.25 0.30 1.21 
Lysine-rich nucleolar protein 1 OS=Homo sapiens GN=KNOP1 PE=1 SV=1 - Q1ED39 7 8 0.31 0.32 1.04 
Acetyl-CoA carboxylase 2 OS=Homo sapiens GN=ACACB PE=1 SV=3 - O00763 8 7 0.06 0.05 -1.02 
Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 - P08779 8 8 0.49 0.43 -1.14 
Keratin, type II cytoskeletal 7 OS=Homo sapiens GN=KRT7 PE=1 SV=5 - P08729   7   0.28 VapA only 
Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 - P08670 5 7 0.20 0.26 1.32 
Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - P60709 6 7 0.33 0.42 1.28 
40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 - P62241 3 6 0.27 0.73 2.66 
Probable ATP-dependent RNA helicase DDX46 OS=Homo sapiens GN=DDX46 PE=1 SV=2 - Q7L014 4 6 0.07 0.09 1.36 
DNA topoisomerase 1 OS=Homo sapiens GN=TOP1 PE=1 SV=2 - P11387 6 5 0.14 0.10 -1.39 
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Serine/threonine-protein kinase PRP4 homolog OS=Homo sapiens GN=PRPF4B PE=1 SV=3 - Q13523 6 4 0.11 0.06 -1.76 
Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=4 - P13646 5   0.38   BirA only 
60S ribosomal protein L23a OS=Homo sapiens GN=RPL23A PE=1 SV=1 - P62750 3 5 0.40 0.70 1.77 
Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1 - Q9BQE3 3 5 0.12 0.19 1.54 
Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 PE=1 SV=3 - O76021 3 5 0.11 0.17 1.52 
Ubiquitin carboxyl-terminal hydrolase 42 OS=Homo sapiens GN=USP42 PE=1 SV=3 - Q9H9J4 4 5 0.06 0.06 1.08 
AP-3 complex subunit delta-1 OS=Homo sapiens GN=AP3D1 PE=1 SV=1 - O14617 5 5 0.07 0.07 -1.14 
Probable rRNA-processing protein EBP2 OS=Homo sapiens GN=EBNA1BP2 PE=1 SV=2 - Q99848 5 3 0.33 0.16 -2.08 
Nucleolar protein 56 OS=Homo sapiens GN=NOP56 PE=1 SV=4 - O00567 5 2 0.19 0.05 -3.52 
Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 - P08238   4   0.09 VapA only 
Putative elongation factor 1-alpha-like 3 OS=Homo sapiens GN=EEF1A1P5 PE=5 SV=1 - Q5VTE0   4   0.15 VapA only 
40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=1 SV=1 - P62753 1 4 0.07 0.28 4.08 
Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 - P06733 2 4 0.08 0.16 1.96 
Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 - P14618 2 4 0.07 0.13 1.84 
Carbamoyl-phosphate synthase [ammonia], mitochondrial OS=Homo sapiens GN=CPS1 PE=1 SV=2 - P31327 2 4 0.02 0.04 1.76 
40S ribosomal protein S30 OS=Homo sapiens GN=FAU PE=1 SV=1 - P62861 3 4 1.52 2.29 1.51 
Elongation factor 1-alpha 2 OS=Homo sapiens GN=EEF1A2 PE=1 SV=1 - Q05639 3 4 0.12 0.15 1.25 
Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 - Q9NR30 3 4 0.07 0.08 1.20 
Peptidyl-prolyl cis-trans isomerase G OS=Homo sapiens GN=PPIG PE=1 SV=2 - Q13427 3 4 0.07 0.08 1.20 
A-kinase anchor protein 17A OS=Homo sapiens GN=AKAP17A PE=1 SV=2 - Q02040 3 4 0.07 0.09 1.17 
Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - P04406 4 4 0.24 0.21 -1.14 
Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 - P11142 4 4 0.12 0.10 -1.14 
Chromodomain-helicase-DNA-binding protein 3 OS=Homo sapiens GN=CHD3 PE=1 SV=3 - Q12873 4 4 0.03 0.03 -1.14 
Serine/arginine repetitive matrix protein 2 OS=Homo sapiens GN=SRRM2 PE=1 SV=2 - Q9UQ35 4 3 0.02 0.02 -1.52 
Nucleolar protein of 40 kDa OS=Homo sapiens GN=ZCCHC17 PE=1 SV=1 - Q9NP64 4 3 0.33 0.21 -1.58 
ADP-ribosylation factor-like protein 6-interacting protein 4 OS=Homo sapiens GN=ARL6IP4 PE=1 SV=1 - Q66PJ3 4 2 0.22 0.09 -2.41 
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G patch domain-containing protein 4 OS=Homo sapiens GN=GPATCH4 PE=1 SV=2 - Q5T3I0 4 1 0.17 0.03 -5.11 
Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3 - P15924 4 1 0.03 0.01 -5.68 
L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 - P00338   3   0.15 VapA only 
Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 SV=1 - P17844   3   0.08 VapA only 
Tubulin beta-2B chain OS=Homo sapiens GN=TUBB2B PE=1 SV=1 - Q9BVA1   3   0.11 VapA only 
Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=1 - P68104 3   0.12   BirA only 
Keratin, type II cytoskeletal 78 OS=Homo sapiens GN=KRT78 PE=2 SV=2 - Q8N1N4 3   0.11   BirA only 
Ubiquitin carboxyl-terminal hydrolase 36 OS=Homo sapiens GN=USP36 PE=1 SV=3 - Q9P275 1 3 0.01 0.04 3.52 
Filaggrin-2 OS=Homo sapiens GN=FLG2 PE=1 SV=1 - Q5D862 2 3 0.01 0.02 1.76 
Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=2 - P62805 2 3 0.41 0.62 1.51 
Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 - P69905 2 3 0.29 0.42 1.47 
Histone H2B type 2-F OS=Homo sapiens GN=HIST2H2BF PE=1 SV=3 - Q5QNW6 2 3 0.32 0.47 1.47 
40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 - P62266 2 3 0.27 0.40 1.46 
Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=1 SV=4 - P07910 2 3 0.12 0.16 1.39 
Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5 - P08107 2 3 0.06 0.08 1.37 
Transcription initiation factor TFIID subunit 3 OS=Homo sapiens GN=TAF3 PE=1 SV=1 - Q5VWG9 2 3 0.04 0.05 1.32 
Serine/arginine-rich splicing factor 11 OS=Homo sapiens GN=SRSF11 PE=1 SV=1 - Q05519 3 3 0.11 0.10 -1.14 
Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 - P07900 3 3 0.07 0.06 -1.14 
Splicing factor, arginine/serine-rich 19 OS=Homo sapiens GN=SCAF1 PE=1 SV=3 - Q9H7N4 3 3 0.04 0.04 -1.14 
60S ribosomal protein L29 OS=Homo sapiens GN=RPL29 PE=1 SV=2 - P47914 3 3 0.58 0.35 -1.65 
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 - P02768 3 2 0.09 0.05 -1.77 
40S ribosomal protein S2 OS=Homo sapiens GN=RPS2 PE=1 SV=2 - P15880 3 2 0.20 0.11 -1.79 
Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 - P13639 3 2 0.06 0.03 -1.89 
Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2 - P81605 3 2 0.69 0.35 -1.96 
60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 - P26373   2   0.15 VapA only 
60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=1 SV=2 - P62424   2   0.12 VapA only 
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A-kinase anchor protein 9 OS=Homo sapiens GN=AKAP9 PE=1 SV=3 - Q99996   2   0.01 VapA only 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo sapiens GN=RPN1 PE=1 
SV=1 - P04843   2   0.05 VapA only 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 - P21333   2   0.01 VapA only 
Golgin subfamily B member 1 OS=Homo sapiens GN=GOLGB1 PE=1 SV=2 - Q14789   2   0.01 VapA only 
Histone-lysine N-methyltransferase NSD2 OS=Homo sapiens GN=WHSC1 PE=1 SV=1 - O96028   2   0.02 VapA only 
Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2 - P62937   2   0.21 VapA only 
Titin OS=Homo sapiens GN=TTN PE=1 SV=4 - Q8WZ42 2 1 0.00 0.00 VapA only 
Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2 - P07437 2   0.08   BirA only 
Tubulin beta-4A chain OS=Homo sapiens GN=TUBB4A PE=1 SV=2 - P04350 2   0.08   BirA only 
Nuclear mitotic apparatus protein 1 OS=Homo sapiens GN=NUMA1 PE=1 SV=2 - Q14980 1 2 0.01 0.02 2.64 
ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3 - O00571 1 2 0.02 0.05 1.98 
Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 - P14174 1 2 0.16 0.32 1.96 
60S ribosomal protein L4 OS=Homo sapiens GN=RPL4 PE=1 SV=5 - P36578 1 2 0.04 0.07 1.91 
60S ribosomal protein L5 OS=Homo sapiens GN=RPL5 PE=1 SV=3 - P46777 1 2 0.06 0.10 1.86 
Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - P60174 1 2 0.06 0.11 1.85 
Eukaryotic translation initiation factor 5B OS=Homo sapiens GN=EIF5B PE=1 SV=4 - O60841 1 2 0.01 0.02 1.76 
Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 - P06748 1 2 0.06 0.11 1.76 
60S ribosomal protein L36a-like OS=Homo sapiens GN=RPL36AL PE=1 SV=3 - Q969Q0 2 2 0.35 0.31 -1.14 
ATP-binding cassette sub-family F member 1 OS=Homo sapiens GN=ABCF1 PE=1 SV=2 - Q8NE71 2 2 0.04 0.03 -1.14 
Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=4 - O75367 2 2 0.10 0.09 -1.14 
Filaggrin OS=Homo sapiens GN=FLG PE=1 SV=3 - P20930 1 2 0.01 0.01 -1.14 
Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 PE=1 SV=5 - P09651 2 2 0.11 0.09 -1.14 
Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP PE=1 SV=2 - O60506 2 2 0.06 0.05 -1.14 
Histone H2A type 1 OS=Homo sapiens GN=HIST1H2AG PE=1 SV=2 - P0C0S8 2 2 0.32 0.28 -1.14 
HMG box transcription factor BBX OS=Homo sapiens GN=BBX PE=1 SV=1 - Q8WY36 2 2 0.04 0.03 -1.14 
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Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 - P19338 2 2 0.05 0.04 -1.14 
Parathymosin OS=Homo sapiens GN=PTMS PE=1 SV=2 - P20962 2 2 0.40 0.35 -1.14 
Sp110 nuclear body protein OS=Homo sapiens GN=SP110 PE=1 SV=5 - Q9HB58 2 2 0.05 0.04 -1.14 
Argininosuccinate synthase OS=Homo sapiens GN=ASS1 PE=1 SV=2 - P00966 2 2 0.09 0.08 -1.14 
Desmoglein-1 OS=Homo sapiens GN=DSG1 PE=1 SV=2 - Q02413 2 2 0.03 0.03 -1.14 
Eukaryotic initiation factor 4A-I OS=Homo sapiens GN=EIF4A1 PE=1 SV=1 - P60842 2 2 0.09 0.08 -1.14 
Protein SREK1IP1 OS=Homo sapiens GN=SREK1IP1 PE=1 SV=1 - Q8N9Q2 2 2 0.23 0.20 -1.14 
RNA-binding protein 39 OS=Homo sapiens GN=RBM39 PE=1 SV=2 - Q14498 2 2 0.07 0.06 -1.14 
U2 snRNP-associated SURP motif-containing protein OS=Homo sapiens GN=U2SURP PE=1 SV=2 - O15042 2 2 0.03 0.03 -1.14 
Antigen KI-67 OS=Homo sapiens GN=MKI67 PE=1 SV=2 - P46013 2 1 0.01 0.01 -2.27 
Pre-mRNA-processing factor 40 homolog A OS=Homo sapiens GN=PRPF40A PE=1 SV=2 - O75400 2 1 0.04 0.02 -2.27 
pre-rRNA processing protein FTSJ3 OS=Homo sapiens GN=FTSJ3 PE=1 SV=2 - Q8IY81 2 1 0.04 0.02 -2.27 
NF-kappa-B-activating protein OS=Homo sapiens GN=NKAP PE=1 SV=1 - Q8N5F7 2 1 0.09 0.04 -2.27 
Propionyl-CoA carboxylase beta chain, mitochondrial OS=Homo sapiens GN=PCCB PE=1 SV=3 - P05166 2 1 0.07 0.03 -2.50 
40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 - P62249   1   0.10 VapA only 
40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 - P61247   1   0.05 VapA only 
40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 - P62081   1   0.08 VapA only 
60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 - P10809   1   0.03 VapA only 
60S ribosomal protein L15 OS=Homo sapiens GN=RPL15 PE=1 SV=2 - P61313   1   0.07 VapA only 
60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A PE=1 SV=2 - P18077   1   0.14 VapA only 
78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 - P11021   1   0.02 VapA only 
ADP/ATP translocase 4 OS=Homo sapiens GN=SLC25A31 PE=2 SV=1 - Q9H0C2   1   0.05 VapA only 
AP-4 complex subunit epsilon-1 OS=Homo sapiens GN=AP4E1 PE=1 SV=2 - Q9UPM8   1   0.01 VapA only 
AP-5 complex subunit zeta-1 OS=Homo sapiens GN=AP5Z1 PE=1 SV=2 - O43299   1   0.04 VapA only 
Arginase-1 OS=Homo sapiens GN=ARG1 PE=1 SV=2 - P05089   1   0.05 VapA only 
ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 - P06576   1   0.03 VapA only 
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ATPase family AAA domain-containing protein 3B OS=Homo sapiens GN=ATAD3B PE=1 SV=1 - Q5T9A4   1   0.02 VapA only 
ATP-dependent RNA helicase DDX24 OS=Homo sapiens GN=DDX24 PE=1 SV=1 - Q9GZR7   1   0.02 VapA only 
Bcl-2-associated transcription factor 1 OS=Homo sapiens GN=BCLAF1 PE=1 SV=2 - Q9NYF8   1   0.02 VapA only 
Calcium-binding mitochondrial carrier protein SCaMC-3 OS=Homo sapiens GN=SLC25A23 PE=1 SV=2 - Q9BV35   1   0.03 VapA only 
Calcium-independent phospholipase A2-gamma OS=Homo sapiens GN=PNPLA8 PE=1 SV=1 - Q9NP80   1   0.02 VapA only 
Cyclin-dependent kinase 11A OS=Homo sapiens GN=CDK11A PE=1 SV=4 - Q9UQ88   1   0.02 VapA only 
DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3 - P11388   1   0.01 VapA only 
Dynein heavy chain 17, axonemal OS=Homo sapiens GN=DNAH17 PE=1 SV=2 - Q9UFH2   1   0.01 VapA only 
E3 ubiquitin-protein ligase ARIH1 OS=Homo sapiens GN=ARIH1 PE=1 SV=2 - Q9Y4X5   1   0.03 VapA only 
Echinoderm microtubule-associated protein-like 6 OS=Homo sapiens GN=EML6 PE=2 SV=2 - Q6ZMW3   1   0.01 VapA only 
Envoplakin OS=Homo sapiens GN=EVPL PE=1 SV=3 - Q92817   1   0.01 VapA only 
Fascin OS=Homo sapiens GN=FSCN1 PE=1 SV=3 - Q16658   1   0.03 VapA only 
Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2 - P04792   1   0.08 VapA only 
Histone H1x OS=Homo sapiens GN=H1FX PE=1 SV=1 - Q92522   1   0.08 VapA only 
Homeobox protein NOBOX OS=Homo sapiens GN=NOBOX PE=1 SV=4 - O60393   1   0.02 VapA only 
HRAS-like suppressor 2 OS=Homo sapiens GN=HRASLS2 PE=1 SV=1 - Q9NWW9   1   0.10 VapA only 
Kinesin-like protein KIF22 OS=Homo sapiens GN=KIF22 PE=1 SV=5 - Q14807   1   0.02 VapA only 
Mediator of RNA polymerase II transcription subunit 25 OS=Homo sapiens GN=MED25 PE=1 SV=2 - Q71SY5   1   0.02 VapA only 
Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 - P26038   1   0.03 VapA only 
Nestin OS=Homo sapiens GN=NES PE=1 SV=2 - P48681   1   0.01 VapA only 
Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNAK PE=1 SV=2 - Q09666   1   0.00 VapA only 
Neuroepithelial cell-transforming gene 1 protein OS=Homo sapiens GN=NET1 PE=1 SV=1 - Q7Z628   1   0.03 VapA only 
NHS-like protein 1 OS=Homo sapiens GN=NHSL1 PE=1 SV=2 - Q5SYE7   1   0.01 VapA only 
Non-POU domain-containing octamer-binding protein OS=Homo sapiens GN=NONO PE=1 SV=4 - Q15233   1   0.03 VapA only 
Nuclear receptor coactivator 3 OS=Homo sapiens GN=NCOA3 PE=1 SV=1 - Q9Y6Q9   1   0.01 VapA only 
Olfactory receptor 2V1 OS=Homo sapiens GN=OR2V1 PE=3 SV=2 - Q8NHB1   1   0.05 VapA only 
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Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 - Q06830   1   0.08 VapA only 
Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SERBP1 PE=1 SV=2 - Q8NC51   1   0.08 VapA only 
Pogo transposable element with ZNF domain OS=Homo sapiens GN=POGZ PE=1 SV=2 - Q7Z3K3   1   0.01 VapA only 
Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 - P09874   1   0.02 VapA only 
Polypyrimidine tract-binding protein 1 OS=Homo sapiens GN=PTBP1 PE=1 SV=1 - P26599   1   0.03 VapA only 
Potassium channel subfamily K member 4 OS=Homo sapiens GN=KCNK4 PE=1 SV=2 - Q9NYG8   1   0.04 VapA only 
Potassium channel subfamily K member 9 OS=Homo sapiens GN=KCNK9 PE=1 SV=1 - Q9NPC2   1   0.04 VapA only 
Probable phosphoglycerate mutase 4 OS=Homo sapiens GN=PGAM4 PE=2 SV=1 - Q8N0Y7   1   0.06 VapA only 
Protein kinase C theta type OS=Homo sapiens GN=PRKCQ PE=1 SV=3 - Q04759   1   0.02 VapA only 
Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1 SV=1 - P06702   1   0.13 VapA only 
Putative charged multivesicular body protein 4B-like protein CHMP4BP1 OS=Homo sapiens GN=CHMP4BP1 
PE=5 SV=1 - P59074   1   0.09 VapA only 
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Homo sapiens GN=DHX15 PE=1 
SV=2 - O43143   1   0.02 VapA only 
Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 SV=2 - Q9Y383   1   0.04 VapA only 
Putative uncharacterized protein C11orf40 OS=Homo sapiens GN=C11orf40 PE=2 SV=1 - Q8WZ69   1   0.07 VapA only 
Rap guanine nucleotide exchange factor-like 1 OS=Homo sapiens GN=RAPGEFL1 PE=1 SV=2 - Q9UHV5   1   0.02 VapA only 
Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 - P61026   1   0.08 VapA only 
Ras-related protein Rab-21 OS=Homo sapiens GN=RAB21 PE=1 SV=3 - Q9UL25   1   0.07 VapA only 
Receptor-transporting protein 4 OS=Homo sapiens GN=RTP4 PE=2 SV=3 - Q96DX8   1   0.06 VapA only 
Rho guanine nucleotide exchange factor 12 OS=Homo sapiens GN=ARHGEF12 PE=1 SV=1 - Q9NZN5   1   0.01 VapA only 
Ribosome biogenesis protein BRX1 homolog OS=Homo sapiens GN=BRIX1 PE=1 SV=2 - Q8TDN6   1   0.04 VapA only 
RNA-binding motif protein, X-linked 2 OS=Homo sapiens GN=RBMX2 PE=1 SV=2 - Q9Y388   1   0.04 VapA only 
RNA-binding protein 26 OS=Homo sapiens GN=RBM26 PE=1 SV=3 - Q5T8P6   1   0.02 VapA only 
Serpin B12 OS=Homo sapiens GN=SERPINB12 PE=1 SV=1 - Q96P63   1   0.04 VapA only 
Sodium channel protein type 5 subunit alpha OS=Homo sapiens GN=SCN5A PE=1 SV=2 - Q14524   1   0.01 VapA only 
Stromal interaction molecule 2 OS=Homo sapiens GN=STIM2 PE=1 SV=2 - Q9P246   1   0.02 VapA only 
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Suprabasin OS=Homo sapiens GN=SBSN PE=2 SV=2 - Q6UWP8   1   0.03 VapA only 
Sushi, nidogen and EGF-like domain-containing protein 1 OS=Homo sapiens GN=SNED1 PE=2 SV=2 - Q8TER0   1   0.01 VapA only 
THO complex subunit 4 OS=Homo sapiens GN=ALYREF PE=1 SV=3 - Q86V81   1   0.07 VapA only 
Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 - P29401   1   0.02 VapA only 
Vacuolar protein sorting-associated protein 35 OS=Homo sapiens GN=VPS35 PE=1 SV=2 - Q96QK1   1   0.02 VapA only 
Zinc finger CCCH-type with G patch domain-containing protein OS=Homo sapiens GN=ZGPAT PE=1 SV=3 - 
Q8N5A5   1   0.03 VapA only 
Zinc finger protein 483 OS=Homo sapiens GN=ZNF483 PE=1 SV=3 - Q8TF39   1   0.02 VapA only 
26S proteasome non-ATPase regulatory subunit 14 OS=Homo sapiens GN=PSMD14 PE=1 SV=1 - O00487 1   0.06   BirA only 
40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 - P62701 1   0.06   BirA only 
60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 - Q07020 1   0.09   BirA only 
60S ribosomal protein L26 OS=Homo sapiens GN=RPL26 PE=1 SV=1 - P61254 1   0.12   BirA only 
Annexin A1 OS=Homo sapiens GN=ANXA1 PE=1 SV=2 - P04083 1   0.05   BirA only 
APC membrane recruitment protein 1 OS=Homo sapiens GN=AMER1 PE=1 SV=2 - Q5JTC6 1   0.01   BirA only 
Apoptosis-inducing factor 3 OS=Homo sapiens GN=AIFM3 PE=1 SV=1 - Q96NN9 1   0.03   BirA only 
ATP-dependent RNA helicase DDX25 OS=Homo sapiens GN=DDX25 PE=1 SV=2 - Q9UHL0 1   0.04   BirA only 
Basal body-orientation factor 1 OS=Homo sapiens GN=CCDC176 PE=2 SV=3 - Q8ND07 1   0.03   BirA only 
Branched-chain-amino-acid aminotransferase, cytosolic OS=Homo sapiens GN=BCAT1 PE=1 SV=3 - P54687 1   0.04   BirA only 
Bromodomain adjacent to zinc finger domain protein 2A OS=Homo sapiens GN=BAZ2A PE=1 SV=4 - Q9UIF9 1   0.01   BirA only 
Calponin-2 OS=Homo sapiens GN=CNN2 PE=1 SV=4 - Q99439 1   0.06   BirA only 
CAP-Gly domain-containing linker protein 2 OS=Homo sapiens GN=CLIP2 PE=1 SV=1 - Q9UDT6 1   0.02   BirA only 
Cathepsin D OS=Homo sapiens GN=CTSD PE=1 SV=1 - P07339 1   0.04   BirA only 
Collagen alpha-1(XXV) chain OS=Homo sapiens GN=COL25A1 PE=1 SV=2 - Q9BXS0 1   0.03   BirA only 
Decapping and exoribonuclease protein OS=Homo sapiens GN=DXO PE=2 SV=2 - O77932 1   0.04   BirA only 
Diacylglycerol kinase alpha OS=Homo sapiens GN=DGKA PE=1 SV=3 - P23743 1   0.02   BirA only 
DNA polymerase theta OS=Homo sapiens GN=POLQ PE=1 SV=2 - O75417 1   0.01   BirA only 
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DNA-directed RNA polymerase III subunit RPC4 OS=Homo sapiens GN=POLR3D PE=1 SV=2 - P05423 1   0.04   BirA only 
EMILIN-2 OS=Homo sapiens GN=EMILIN2 PE=1 SV=3 - Q9BXX0 1   0.02   BirA only 
Ensconsin OS=Homo sapiens GN=MAP7 PE=1 SV=1 - Q14244 1   0.02   BirA only 
Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens GN=EIF3A PE=1 SV=1 - Q14152 1   0.01   BirA only 
Fer-1-like protein 6 OS=Homo sapiens GN=FER1L6 PE=2 SV=2 - Q2WGJ9 1   0.01   BirA only 
Fez family zinc finger protein 1 OS=Homo sapiens GN=FEZF1 PE=2 SV=1 - A0PJY2 1   0.04   BirA only 
GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 - P62826 1   0.08   BirA only 
Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 SV=3 - P52272 1   0.02   BirA only 
Heterogeneous nuclear ribonucleoprotein U-like protein 2 OS=Homo sapiens GN=HNRNPUL2 PE=1 SV=1 - 
Q1KMD3 1   0.02   BirA only 
Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA2B1 PE=1 SV=2 - P22626 1   0.05   BirA only 
Histone deacetylase 9 OS=Homo sapiens GN=HDAC9 PE=1 SV=2 - Q9UKV0 1   0.02   BirA only 
Junction plakoglobin OS=Homo sapiens GN=JUP PE=1 SV=3 - P14923 1   0.02   BirA only 
Kinesin-like protein KIF21A OS=Homo sapiens GN=KIF21A PE=1 SV=2 - Q7Z4S6 1   0.01   BirA only 
Luc7-like protein 3 OS=Homo sapiens GN=LUC7L3 PE=1 SV=2 - O95232 1   0.04   BirA only 
Lysine-specific demethylase 3A OS=Homo sapiens GN=KDM3A PE=1 SV=4 - Q9Y4C1 1   0.01   BirA only 
Lysine-specific demethylase PHF2 OS=Homo sapiens GN=PHF2 PE=1 SV=4 - O75151 1   0.02   BirA only 
Monocarboxylate transporter 7 OS=Homo sapiens GN=SLC16A6 PE=1 SV=2 - O15403 1   0.03   BirA only 
Mortality factor 4-like protein 1 OS=Homo sapiens GN=MORF4L1 PE=1 SV=2 - Q9UBU8 1   0.04   BirA only 
Mucin-19 OS=Homo sapiens GN=MUC19 PE=1 SV=2 - Q7Z5P9 1   0.01   BirA only 
Myb-binding protein 1A OS=Homo sapiens GN=MYBBP1A PE=1 SV=2 - Q9BQG0 1   0.01   BirA only 
Neurogenic locus notch homolog protein 2 OS=Homo sapiens GN=NOTCH2 PE=1 SV=3 - Q04721 1   0.01   BirA only 
Neutral alpha-glucosidase AB OS=Homo sapiens GN=GANAB PE=1 SV=3 - Q14697 1   0.02   BirA only 
Nucleolar protein 58 OS=Homo sapiens GN=NOP58 PE=1 SV=1 - Q9Y2X3 1   0.03   BirA only 
Oxidoreductase NAD-binding domain-containing protein 1 OS=Homo sapiens GN=OXNAD1 PE=1 SV=1 - 
Q96HP4 1   0.06   BirA only 
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 - P32119 1   0.09   BirA only 
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Peroxiredoxin-4 OS=Homo sapiens GN=PRDX4 PE=1 SV=1 - Q13162 1   0.06   BirA only 
PHD and RING finger domain-containing protein 1 OS=Homo sapiens GN=PHRF1 PE=1 SV=3 - Q9P1Y6 1   0.01   BirA only 
Plexin-B2 OS=Homo sapiens GN=PLXNB2 PE=1 SV=3 - O15031 1   0.01   BirA only 
Prelamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 - P02545 1   0.02   BirA only 
Protein FAM9A OS=Homo sapiens GN=FAM9A PE=1 SV=1 - Q8IZU1 1   0.05   BirA only 
Protein Smaug homolog 1 OS=Homo sapiens GN=SAMD4A PE=1 SV=3 - Q9UPU9 1   0.02   BirA only 
Protein unc-45 homolog A OS=Homo sapiens GN=UNC45A PE=1 SV=1 - Q9H3U1 1   0.02   BirA only 
Putative 60S ribosomal protein L37a-like OS=Homo sapiens GN=RPL37L PE=5 SV=2 - A6NKH3 1   0.19   BirA only 
Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE=1 SV=1 - Q7L2E3 1   0.01   BirA only 
Putative uncharacterized protein encoded by LINC00478 OS=Homo sapiens GN=LINC00478 PE=5 SV=1 - 
A1L4M7 1   0.17   BirA only 
RAD52 motif-containing protein 1 OS=Homo sapiens GN=RDM1 PE=1 SV=1 - Q8NG50 1   0.06   BirA only 
Ras GTPase-activating protein 2 OS=Homo sapiens GN=RASA2 PE=1 SV=3 - Q15283 1   0.02   BirA only 
RNA-binding protein 34 OS=Homo sapiens GN=RBM34 PE=1 SV=2 - P42696 1   0.04   BirA only 
rRNA 2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 - P22087 1   0.06   BirA only 
Serine/threonine-protein kinase ULK1 OS=Homo sapiens GN=ULK1 PE=1 SV=2 - O75385 1   0.02   BirA only 
Serine/threonine-protein phosphatase 4 regulatory subunit 4 OS=Homo sapiens GN=PPP4R4 PE=1 SV=1 - 
Q6NUP7 1   0.02   BirA only 
Short transient receptor potential channel 5 OS=Homo sapiens GN=TRPC5 PE=1 SV=1 - Q9UL62 1   0.04   BirA only 
Spermatogenesis-associated protein 4 OS=Homo sapiens GN=SPATA4 PE=2 SV=1 - Q8NEY3 1   0.06   BirA only 
Spermatogenesis-associated protein 7 OS=Homo sapiens GN=SPATA7 PE=2 SV=3 - Q9P0W8 1   0.03   BirA only 
Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 - P10599 1   0.17   BirA only 
Thyroid hormone receptor-associated protein 3 OS=Homo sapiens GN=THRAP3 PE=1 SV=2 - Q9Y2W1 1   0.02   BirA only 
Transmembrane protein 2 OS=Homo sapiens GN=TMEM2 PE=1 SV=1 - Q9UHN6 1   0.01   BirA only 
Tripartite motif-containing protein 77 OS=Homo sapiens GN=TRIM77 PE=2 SV=2 - I1YAP6 1   0.04   BirA only 
Tyrosine-protein kinase ABL1 OS=Homo sapiens GN=ABL1 PE=1 SV=4 - P00519 1   0.01   BirA only 
Uncharacterized protein CXorf23 OS=Homo sapiens GN=CXorf23 PE=1 SV=1 - A2AJT9 1   0.02   BirA only 
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Unconventional myosin-Ih OS=Homo sapiens GN=MYO1H PE=2 SV=2 - Q8N1T3 1   0.02   BirA only 
Versican core protein OS=Homo sapiens GN=VCAN PE=1 SV=3 - P13611 1   0.01   BirA only 
Xaa-Pro aminopeptidase 2 OS=Homo sapiens GN=XPNPEP2 PE=1 SV=3 - O43895 1   0.00   BirA only 
Zinc finger protein 232 OS=Homo sapiens GN=ZNF232 PE=2 SV=1 - Q9UNY5 1   0.04   BirA only 
U4/U6.U5 tri-snRNP-associated protein 1 OS=Homo sapiens GN=SART1 PE=1 SV=1 - O43290 1 1 0.02 0.04 2.05 
Trypsin-1 OS=Homo sapiens GN=PRSS1 PE=1 SV=1 - P07477 1 1 0.07 0.13 1.76 
40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 - P62244 1 1 0.13 0.11 -1.14 
60S ribosomal protein L11 OS=Homo sapiens GN=RPL11 PE=1 SV=2 - P62913 1 1 0.09 0.08 -1.14 
60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=1 - P84098 1 1 0.08 0.07 -1.14 
Arginine/serine-rich protein PNISR OS=Homo sapiens GN=PNISR PE=1 SV=2 - Q8TF01 1 1 0.02 0.02 -1.14 
ATP-dependent RNA helicase DDX18 OS=Homo sapiens GN=DDX18 PE=1 SV=2 - Q9NVP1 1 1 0.02 0.02 -1.14 
Caspase recruitment domain-containing protein 14 OS=Homo sapiens GN=CARD14 PE=1 SV=2 - Q9BXL6 1 1 0.02 0.02 -1.14 
Chromodomain-helicase-DNA-binding protein 1 OS=Homo sapiens GN=CHD1 PE=1 SV=2 - O14646 1 1 0.01 0.01 -1.14 
Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 - P26641 1 1 0.04 0.03 -1.14 
Fatty acid synthase OS=Homo sapiens GN=FASN PE=1 SV=3 - P49327 1 1 0.01 0.01 -1.14 
Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 - P04075 1 1 0.05 0.04 -1.14 
INO80 complex subunit B OS=Homo sapiens GN=INO80B PE=1 SV=2 - Q9C086 1 1 0.05 0.04 -1.14 
Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 - Q12906 1 1 0.02 0.02 -1.14 
Lipoprotein lipase OS=Homo sapiens GN=LPL PE=1 SV=1 - P06858 1 1 0.04 0.03 -1.14 
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA OS=Homo sapiens GN=MAN1A1 PE=1 SV=3 - P33908 1 1 0.02 0.02 -1.14 
Mitochondrial uncoupling protein 3 OS=Homo sapiens GN=UCP3 PE=1 SV=1 - P55916 1 1 0.06 0.05 -1.14 
M-phase inducer phosphatase 3 OS=Homo sapiens GN=CDC25C PE=1 SV=2 - P30307 1 1 0.04 0.03 -1.14 
Paladin OS=Homo sapiens GN=PALD1 PE=1 SV=3 - Q9ULE6 1 1 0.02 0.02 -1.14 
PHD finger protein 14 OS=Homo sapiens GN=PHF14 PE=1 SV=2 - O94880 1 1 0.02 0.02 -1.14 
Polyhomeotic-like protein 2 OS=Homo sapiens GN=PHC2 PE=1 SV=1 - Q8IXK0 1 1 0.02 0.02 -1.14 
Protein LLP homolog OS=Homo sapiens GN=LLPH PE=2 SV=1 - Q9BRT6 1 1 0.13 0.11 -1.14 
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Putative IQ and AAA domain-containing protein 1-like OS=Homo sapiens GN=IQCA1P1 PE=5 SV=2 - A6NCM1 1 1 0.02 0.02 -1.14 
Retinitis pigmentosa 9 protein OS=Homo sapiens GN=RP9 PE=1 SV=2 - Q8TA86 1 1 0.07 0.07 -1.14 
Serine/Arginine-related protein 53 OS=Homo sapiens GN=RSRC1 PE=1 SV=1 - Q96IZ7 1 1 0.05 0.04 -1.14 
StAR-related lipid transfer protein 6 OS=Homo sapiens GN=STARD6 PE=2 SV=1 - P59095 1 1 0.07 0.07 -1.14 
Transcription elongation factor SPT6 OS=Homo sapiens GN=SUPT6H PE=1 SV=2 - Q7KZ85 1 1 0.01 0.01 -1.14 
Transcriptional adapter 2-beta OS=Homo sapiens GN=TADA2B PE=1 SV=2 - Q86TJ2 1 1 0.04 0.03 -1.14 
Ubiquitin-40S ribosomal protein S27a OS=Homo sapiens GN=RPS27A PE=1 SV=2 - P62979 1 1 0.11 0.09 -1.14 
Uncharacterized protein C11orf57 OS=Homo sapiens GN=C11orf57 PE=1 SV=2 - Q6ZUT1 1 1 0.06 0.05 -1.14 
Voltage-dependent L-type calcium channel subunit alpha-1S OS=Homo sapiens GN=CACNA1S PE=1 SV=4 - 
Q13698 1 1 0.01 0.01 -1.14 
ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 SV=1 - P25705 1 1 0.03 0.03 -1.14 
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A OS=Homo sapiens GN=PDE1A 
PE=2 SV=2 - P54750 1 1 0.06 0.05 -1.14 
Caspase-14 OS=Homo sapiens GN=CASP14 PE=1 SV=2 - P31944 1 1 0.07 0.06 -1.14 
Cyclic GMP-AMP synthase OS=Homo sapiens GN=MB21D1 PE=1 SV=2 - Q8N884 1 1 0.03 0.03 -1.14 
Heterogeneous nuclear ribonucleoprotein L OS=Homo sapiens GN=HNRNPL PE=1 SV=2 - P14866 1 1 0.03 0.03 -1.14 
Keratinocyte proline-rich protein OS=Homo sapiens GN=KPRP PE=1 SV=1 - Q5T749 1 1 0.03 0.03 -1.14 
Membrane-spanning 4-domains subfamily A member 10 OS=Homo sapiens GN=MS4A10 PE=2 SV=3 - Q96PG2 1 1 0.06 0.05 -1.14 
N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 OS=Homo sapiens GN=DDAH1 PE=1 SV=3 - O94760 1 1 0.06 0.05 -1.14 
Pre-mRNA-splicing factor 38B OS=Homo sapiens GN=PRPF38B PE=1 SV=1 - Q5VTL8 1 1 0.03 0.03 -1.14 
Proliferation-associated protein 2G4 OS=Homo sapiens GN=PA2G4 PE=1 SV=3 - Q9UQ80 1 1 0.04 0.04 -1.14 
Protein RIC-3 OS=Homo sapiens GN=RIC3 PE=1 SV=1 - Q7Z5B4 1 1 0.04 0.04 -1.14 
Splicing regulatory glutamine/lysine-rich protein 1 OS=Homo sapiens GN=SREK1 PE=1 SV=1 - Q8WXA9 1 1 0.03 0.03 -1.14 
Surfeit locus protein 6 OS=Homo sapiens GN=SURF6 PE=1 SV=3 - O75683 1 1 0.04 0.04 -1.14 
Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens GN=VDAC2 PE=1 SV=2 - P45880 1 1 0.06 0.05 -1.14 
Zinc finger protein 503 OS=Homo sapiens GN=ZNF503 PE=1 SV=1 - Q96F45 1 1 0.03 0.03 -1.14 
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List of definitions 
ADP   Adenosine diphosphate 
ALP Alkaline phosphatase 
ATP   Adenosine triphosphate 
BCA   Bicinchoninic acid 
β-Hex   β-Hexosaminidase 
bp Base pairs 
cdM6PR  cation-dependent mannose 6-phosphate receptor 
ciM6PR  cation-independent mannose 6-phosphate receptor 
CLEAR  Coordinated lysosomal expression and regulation 
CMA Chaperone-mediated autophagy 
co-IP   co-immunoprecipitation 
CPY   Carboxypeptidase Y 
CPY-Inv Carboxypeptidase Y- Invertase 
DAPI 4',6-diamidino 2-phenylindole 
DMSO Dimethylsulfoxide 
DNA   Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
EE   Early endosome 
EEA1   Early endosome antigen 1 
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ERC Endocytic recycling compartment 
ESCRT  Endosomal sorting complex required for transport 
FCS   Foetal calf serum 
GDP   Guanosine diphosphate 
GFP   Green fluorescent protein 
GTP   Guanosine triphosphate 
HeLa Henrietta Lacks’ cancer cell line 
HOPS   Homotypic fusion and protein sorting complex 
IgG Immunoglobulin G 
ILV   Intraluminal vesicle 
kbp Kilobase pairs 
kDa   Kilodaltons 
L   Litre 
LAMP1  Lysosomal-associated membrane protein 1 
LBPA   Lysobisphosphatidic acid  
LCV   Legionella containing vacuole 
LE   Late endosome 
LIMP   Lysosome integral membrane protein 
LPS   Lipopolysaccharide 
LSD   Lysosomal storage disorder 
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M   Molar 
mg   Milligram 
mL   Millilitre 
mM   Millimolar 
mRNA Messenger ribonucleic acid 
MVB   Multivesicular body 
ng   Nanomolar 
nm   Nanometre 
nM   Nanomolar 
n.s. Non-significant 
NSF   N-ethylmaleimide-sensitive factor 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline 
PCR   Polymerase Chain Reaction 
PEPSY  Pathogen effector protein screening in yeast 
PRR Pattern recognition receptor 
PtdIns[3]P  Phosphatidylinositol 3-phosphate 
PtdIns[3,5]P2  Phosphatidylinositol 3,5-bisphosphate 
PtdIns[4,5]P2  Phosphatidylinositol 4,5-bisphosphate 
RCV   Rhodococcus containing vacuole 
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RILP Rab-interacting lysosomal protein 
RNA   Ribonucleic acid 
RPM Revolutions per minute 
SCV   Salmonella containing vacuole 
SDS Sodium dodecyl sulfate 
SNARE Soluble-NSF attachment protein receptor 
TES 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-
yl]amino]ethanesulfonic acid 
TFEB   Transcription factor EB 
TGN   trans Golgi network 
Tris Trisaminomethane 
µg   Microgram 
µl   Microlitre 
µm   Micrometer 
µM   Micromolar 
Vap   Virulence associated protein 
vATPase  Vacuolar ATPase 
VPS   Vacuole protein sorting 
W.B.   Western blot 
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